Document:

Reseach & License Agreement

 Exhibit 10.1 

  
 [CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 

 

 RESEARCH AND LICENSE AGREEMENT 

This Research and License Agreement is made and entered into as of February 3, 2011 (the “Effective Date”) by and between

 DEBIOPHARM S.A., a stock company duly established under the laws of Switzerland, with registered company number CH-550-0173350-8,
whose registered office is at Forum “après-demain”, Chemin Messidor 5-7, 1006 Lausanne, Switzerland (“DEBIOPHARM”), 
 And 
 MARINA BIOTECH, INC., a company duly established under the laws of the State of
Delaware, whose registered office is at 3830 Monte Villa Parkway, Bothell, Washington 98021, U.S.A. (“COMPANY”), 
 WITNESSETH: 
 WHEREAS, DEBIOPHARM is a pharmaceutical company that possesses
expertise in the research, regulatory, development, manufacturing and, through sublicensees, commercialization of pharmaceutical products on a worldwide basis; 
 WHEREAS, COMPANY has certain expertise and experience in the research, discovery, and development of certain pharmaceuticals based on RNA interference; 

WHEREAS, COMPANY and DEBIOPHARM would like to conduct a Joint Research Plan for the discovery and research of a Lead Compound which will be
developed by DEBIOPHARM as a therapeutic product for use in superficial bladder cancer; 
 WHEREAS DEBIOPHARM wishes to obtain from
COMPANY all of the intellectual property rights owned or controlled by COMPANY which is necessary for the discovery and research of the Lead Compound, whether existing prior the Effective Date or being created after the Effective Date so as to
develop and commercialize pharmaceutical products making use of the Lead Compound, and COMPANY wishes to license out to DEBIOPHARM such intellectual property rights; 
 NOW, THEREFORE, in consideration of the foregoing and the covenants and obligations set forth in this Agreement, DEBIOPHARM and COMPANY agree as follows: 

 

	1.	DEFINITIONS AND INTERPRETATION 

  

	1.1	Unless the context otherwise requires, the terms in this Agreement, when used with initial capital letters, shall have the meanings set forth below or at their first
use in this Agreement: 

  

	 “Accounting Standards” 
	means, with respect to COMPANY, GAAP (Generally Accepted Accounting Principles), and, with respect to DEBIOPHARM, DEBIOPHARM’s accounting policies as consistently applied.

  

	 “Affiliate” 
	 means any corporation or other legal entity controlled by, controlling, or under common control with DEBIOPHARM or COMPANY. For this purpose, the term “control” means direct or
indirect beneficial ownership of at least fifty percent (50%) of the voting stock of a corporation or other legal entity, or to hold 

  
 1 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
the effective power to appoint or dismiss members of the management. 

  

	 “Agreement” 
	means this written license agreement, including its exhibits (the “Exhibit(s)”). 

  

	 “API” 
	means an active pharmaceutical ingredient. 

  

	 “Applicable Laws”  
	means the applicable laws, rules and regulations, including any rules, regulations, guidelines or other requirements of any Governmental Authorities (including any Regulatory Authorities) that
may be in effect from time to time in any country or jurisdiction of the Territory. 

  

	 “Backup Compounds” 
	means all Collaboration Candidates, Collaboration Molecules and Collaboration Compounds, except the selected Lead Compound and Backup Lead. 

 

	 “Backup Lead” 
	means a Collaboration Compound selected at the same time as the Lead Compound and reserved exclusively for DEBIOPHARM by COMPANY for [***] months after its selection. 

 

	 “Business Day” 
	means any day other than a Saturday, a Sunday or a day on which commercial banks located in Lausanne, Switzerland, and Bothell, Washington, are authorized or required by law to remain closed.

  

	 “Change of Control” 
	means any of the following events: (a) any Third Party (or group of Third Parties acting in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent
(50%) of the total voting power of the stock then outstanding of a Party normally entitled to vote in election of directors (however, for DEBIOPHARM any change of control within the family members of the current beneficial owner shall not be
considered as a Change of Control); (b) a Party consolidates with or merges into another corporation or entity, or any corporation or entity consolidates with or merges into a Party, in either event pursuant to a transaction in which more than
fifty percent (50%) of the total voting power of the stock outstanding of the surviving entity normally entitled to vote in elections of directors is not held by the parties holding at least fifty percent (50%) of the outstanding shares of
a Party preceding such consolidation or merger; or (c) a Party conveys, transfers or leases all or substantially all of its assets to any Third Party. 

 

	 “Claim” 
	means any claim, demand, law suit and/or cause of action (whether criminal or civil, in contract, tort or otherwise) for losses or damages. 

  
 2 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 “Collaboration Candidates” 
	means up to [***] UNA (unlocked nucleic acid) modified Collaboration Molecules (UsiRNA) per Collaboration Target. 

 

	 “Collaboration Compounds”  
	means up to [***] Collaboration Candidates ([***]) formulated in a specific synthetic liposomal formulation for in vivo delivery. 

 

	 “Collaboration Molecules” 
	means up to [***] siRNAs (small interfering ribonucleic acid) directed to a target gene for each of the Collaboration Targets. 

 

	 “Collaboration Targets”  
	means the [***] target genes identified in Exhibit 1 plus [***] additional ones selected by DEBIOPHARM within [***] months after the Effective Date. 

 

	 “Combination Product” 
	means a Product combining a Lead Compound together with another API. 

  

	 “Commercialization” or
 “Commercialize” 
	
means the commercial manufacture, marketing, promotion, sale, offering for sale, distribution, and/or commercial importation and exportation of the Product. 

 

	 “COMPANY Background
 IP” 
	
means the Intellectual Property owned or Controlled by COMPANY and/or its Affiliates and existing as of the Effective Date for the Formulation Technology IP, the UNA Platform Technology IP
and COMPANY UsiRNA Technology IP. 

  

	 “COMPANY Patents” 
	means all Patents covering the COMPANY Background IP as set forth in Exhibit 3. 

  

	 “COMPANY UsiRNA
 Technology IP” 
	
means all Intellectual Property Controlled by COMPANY and/or its Affiliates which cover the specific UsiRNA (i.e., the Collaboration Molecules, Collaboration Candidates and Collaboration
Compounds for the HRAS and FGFR3 Collaboration Targets) existing as of the Effective Date, the Patents for which are set forth in Exhibit 3(c) it being understood that all future related filings with regard to [***] and [***] if chosen as a
Lead Compound or Backup Lead shall be considered to belong to Exhibit 3(c). For the avoidance of doubt, inclusion of Collaboration Compounds in this definition does not grant any additional rights to the Formulation Technology IP beyond the
rights granted in the Licensed Rights. 

  

	 “Competing Product” 
	means any compound or product in the Exclusive Field. 

  

	 “Confidential Information” 
	 means any information of a confidential or proprietary nature disclosed by a Party or its Affiliates (the 

  
 3 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
“Disclosing Party”) to the other Party or its Affiliates (the “Receiving Party”), including but not limited to each Party’s or its Affiliates’
invention disclosures, proprietary materials, data, including any Data, know-how, including any Know-How, technologies, trade secrets, and/or manufacturing, marketing, personnel and other business information and plans, whether in oral, written,
graphic or electronic form. Information shall not be deemed “Confidential Information” hereunder, and the Receiving Party shall have no obligation with respect to any information if it is: 

 

	 	(i) known by the Receiving Party prior to disclosure by the Disclosing Party, as evidenced by internal records or documentation of the Receiving Party; or

  

	 	(ii) information which is in the public domain or subsequently enters the public domain through no fault of the Receiving Party; or 

 

	 	(iii) information that is received by the Receiving Party from an independent Third Party with the lawful right to disclose; or 

 

	 	(iv) information that the Receiving Party can establish was independently developed by its (or its Affiliates’) employees or contractors without the use of or
reference to Confidential Information of the Disclosing Party. 

  

	 “Control” or “Controlled”  
	means with respect to any Know-How, Patents, or other Intellectual Property, the legal authority or right (whether by ownership, license or otherwise) of a Party to grant a license or a
sublicense of or under such Know-How, Patents, or other Intellectual Property, to another Person, or to otherwise disclose such proprietary or trade secret information to another Person, without breaching the terms of any agreement with a Third
Party, or misappropriating the proprietary or trade secret information of a Third Party. 

  

	 “Copyrights”  
	means, collectively, all works of authorship, mask works and any and all other registered and unregistered copyrights and copyrightable works, and all applications, registrations, extensions,
and renewals thereof. 

  

	 “CTA” 
	means a clinical trial application. 

  

	 “Data” 
	 means any and all research data, technical data, test and development data, pre-clinical and clinical data, formulations, processes, protocols, regulatory files and the like which are
developed by either Party prior to the Effective Date or during the Term and in connection with the Collaboration Molecules, the 

  
 4 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
Collaboration Candidates, the Collaboration Compounds, the Lead Compound, the Backup Lead or the Product. 

 

	 “Data/Market Exclusivity” 
	means, with respect to any country of the Territory, an additional market protection, beyond Patents, granted by a Regulatory Authority in such country which confers an exclusive
Commercialization period during which DEBIOPHARM, its Affiliates and/or Sublicensees have the exclusive right to market, price and sell a Product in such country through a regulatory exclusivity right such as new chemical entity exclusivity, new use
or indication exclusivity, new formulations exclusivity, orphan drug exclusivity, pediatric exclusivity and any applicable data exclusivity. 

  

	 “DEBIOPHARM Background
 IP” 
	
means any and all of DEBIOPHARM IP existing as at the Effective Date. 

  

	 “DEBIOPHARM IP” 
	means Intellectual Property owned or Controlled by DEBIOPHARM. 

  

	 “DEBIOPHARM Know-How” 
	means the Know-How which is generated by DEBIOPHARM or its Affiliates (or Third Parties which will have assigned such Know-How to DEBIOPHARM and/or its Affiliates) as of the Effective Date and
during the Term of this Agreement. 

  

	 “DEBIOPHARM Patent” 
	means any Patent covering the DEBIOPHARM Background IP or DEBIOPHARM’s Inventions conceived and reduced to practice by employees of DEBIOPHARM or its Affiliates (or Third Parties which will
have assigned their rights to DEBIOPHARM and/or its Affiliates) as of the Effective Date and during the Term of this Agreement. 

  

	 “DEBIOPHARM Trademarks” 
	means the Trademarks used by DEBIOPHARM to register, sell, license, distribute and promote the Product in any country of the Territory. 

 

	 “Development Costs” 
	 means fixed and variable unreimbursed costs incurred by DEBIOPHARM for its activities regarding the development of the Lead Compound and/or the Product, calculated in accordance with the
Accounting Standards applicable to DEBIOPHARM. Subject to the foregoing sentence, such costs shall include (i) direct, out-of-pocket external cost, e.g., clinical grants, clinical laboratory fees, patent and trademark prosecution, maintenance
and litigation, and the cost of studies conducted and services provided by contract research organizations and individuals, consultants, toxicology contractors, and manufacturers necessary or useful for the purpose of obtaining a Marketing
Authorization for the Product in any country, (ii) amount paid with 

  
 5 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
respect to the development of the Lead Compound, and/or the Product directly relating to pre-clinical and clinical trials, including quality control and quality assurance, (iii) costs
related to Data management, statistical designs and studies, document preparation and related expenses associated with the clinical testing program for a Lead Compound and/or the Product, and (iv) cost of labor, raw materials, supplies and
other resources directly consumed in the conduct of the research, development and manufacture of the Lead Compound and/or Product for use in preclinical and clinical trials. 

 

	 “Development Plan” 
	means plans for the development of the Lead Compound as outlined in Exhibit 4 hereto. 

  

	 “Diagnostic Tool” 
	means any companion diagnostic and/or any diagnostic assay relating to the Product. 

  

	 “Effective Date” 
	means the date shown at the beginning of this Agreement. 

  

	 “EMEA” 
	means the European Medicines Agency of the European Union, or a successor agency thereto. 

  

	 “Exclusive Field” 
	means all uses in humans and animals for the prevention and treatment of superficial bladder cancer. 

 

	 “Expert” 
	means a mutually acceptable, disinterested, conflict-of-interest-free individual not affiliated with either Party or any of its Affiliates who, with respect to a dispute concerning a financial,
scientific, technical or regulatory matter, possesses appropriate expertise to resolve such dispute. 

  

	 “FDA” 
	means the United States Food and Drug Administration, or a successor federal agency thereto. 

  

	 “Field” 
	means collectively the Exclusive Field and Other Field. 

  

	 “Fifth Patient In” 
	means in respect of a clinical trial, the time a fifth
(5th) volunteer or patient recruited for that
particular clinical trial is administered a dose of a Product. 

  

	 “First Commercial Sale” 
	means the first commercial sale by DEBIOPHARM, its Affiliates and/or its Sublicensees to a Third Party of a Product for value in any country in the Territory following receipt of a Marketing
Authorization to market such Product in the applicable country. 

  

	 “Formulation Technology IP” 
	 means the IP owned or Controlled by COMPANY and/or its Affiliates which cover the liposomal formulations (including the DiLA2 technology) as of the 

  
 6 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
Effective Date, the Patents for which are set forth in Exhibit 3(a). 

  

	 “Generic Product” 
	means any marketed product which is bioequivalent to the Product and/or which is substitutable with the Product in the country in which it is sold. 

 

	 “GMP Manufacturer” 
	means the Party that is responsible for ensuring that the Product is manufactured in accordance with GMP. 

 

	 “Good Clinical Practices” or
 “GCP” 
	
means all applicable good clinical practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials, including, as
applicable, (a) as set forth in the European Commission Directive 2001/20/EC relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, and brought into law by the European
Commission Directive 2005/28/EC laying down the principles and detailed guidelines for good clinical practice for investigational medicinal products; (b) the International Conference on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (“ICH”), Harmonised Tripartite Guideline for Good Clinical Practice (CMP/ICH/135/95) and any other guidelines for good clinical practice for clinical trials on medicinal products in the EU;
(c) the Declaration of Helsinki (2004) as last amended at the 52nd World Medical Association in October 2008 and any further amendments or clarifications thereto; (d) US CFR Title 21, Parts 50 (Protection of Human Subjects), 56 (IRBs) and 312 (Investigational New
Drug Application), as may be amended from time to time; and (e) the equivalent Applicable Laws in any relevant country or jurisdiction, each as may be amended and applicable from time to time and in each case, that provide for, among other
things, assurance that the clinical data and reports results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects. 

 

	 “Good Manufacturing
 Practices” or “GMP” 
	 
means all applicable good manufacturing practices including, as applicable, (a) the applicable part of quality assurance to ensure that products are consistently produced and
controlled in accordance with the quality standards appropriate for their intended use, as defined in the European Commission Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practices; (b) the principles
detailed in United States Current Good Manufacturing Practices, 21 CFR Sections 210, 211, 601 and 610; (c) the rules Governing Medicinal Products in the European Community, Volume IV

  
 7 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
Good Manufacturing Practice for Medicinal Products; (d) the principles detailed in ICH Q7A guidelines; and (e) the equivalent Applicable Laws in any relevant country or jurisdiction,
each as may be amended and applicable from time to time. 

  

	 “Governmental Authority”  
	means any supranational, national, federal, state or local court, agency, authority, department, regulatory body or other governmental instrumentality. 

 

	 “ICC” 
	means the International Chamber of Commerce. 

  

	 “ICC Rules” 
	means the arbitration rules of the International Chamber of Commerce. 

  

	 “IMPD” 
	means an “Investigational Medicinal Product Dossier” application or any foreign equivalent thereof. 

 

	 “Improvements”  
	means any improvement of the Product as well as improvements of manufacturing processes. 

  

	 “IND” 
	means an “Investigational New Drug” application as defined in the United States Federal Food, Drug and Cosmetic Act, as amended and applicable regulations promulgated thereunder by the
FDA, or an equivalent application submitted to an equivalent Regulatory Authority in any other country or jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such country or
jurisdiction, including a CTA. 

  

	 “Intellectual Property” (“IP”) 
	means all intellectual property and industrial property rights of any kind or nature throughout the world, including all (a) Patents; (b) Trademarks; (c) Copyrights;
(d) rights in computer programs (whether in source code, object code, or other form) algorithms, databases, compilations and data, technology supporting the foregoing, and all documentation, including user manuals related to any of the
foregoing; (e) trade secrets and all other confidential information, Know-How, inventions, proprietary processes, formulae, models and methodologies; (f) rights of publicity, privacy and rights to personal information; (g) all rights
in the foregoing and in other similar intangible assets; and (h) and all applications and registrations for the foregoing. 

  

	 “Inventions” 
	means any discovery, whether or not patentable, made as a result of the research or development activities of a Party. 

 

	 “Joint IP” 
	means the Intellectual Property jointly owned by both Parties as set forth in Section 10.1. 

  

	 “Joint Patents” 
	means any and all Patents claiming any Joint IP. 

  
 8 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 “Joint Research Period” 
	means the time from the Effective Date until the last research task (i.e., until completion of Task no 13 of the Joint Research Plan) performed by COMPANY, which shall not exceed [***] months
after Effective Date. 

  

	 “Joint Research Plan”  
	means the discovery and research of the Lead Compound for the use in the Exclusive Field in accordance with the research plan agreed upon by the Parties and attached hereto as Exhibit 2.

  

	 “Joint UsiRNA Technology IP” 
	means all Joint IP on the sequence-specific UsiRNA (i.e., the Collaboration Molecules, Collaboration Candidates and Collaboration Compounds) excluding the COMPANY UsiRNA Technology IP. For the
avoidance of doubt, inclusion of Collaboration Compounds in this definition does not grant any additional rights to the Formulation Technology IP beyond the rights granted in the Licensed Rights 

 

	 “JSC” 
	means the joint steering committee created by the Parties in accordance with Section 4.1 hereof. 

 

	 “Know-How” 
	means technical and other information, including information comprising or relating to concepts, discoveries, designs, formulae, ideas, inventions, methods, models, assays, research plans,
procedures, designs for experiments and tests and results of experimentation and testing (including results of research or development or other developments), formulations, processes (including manufacturing processes, specifications and
techniques), and Data including documents containing any of the above which is non-patentable or non-patented and which is secret. 

  

	 “Lead Compound”  
	means a Collaboration Compound selected for development as a Product. 

  

	 “Licensed Rights” 
	means the exclusive and non-exclusive rights under the Formulation Technology IP, UNA Platform Technology IP, COMPANY UsiRNA Technology IP, and Joint IP granted by COMPANY to DEBIOPHARM under
Section 2.1 hereof. 

  

	 “Marketing Authorization” 
	means, in respect of any country or jurisdiction in the Territory, receipt from the applicable Regulatory Authority of the final authorisation required (in compliance with Applicable Laws) to
place any pharmaceutical product on the market in such country or jurisdiction in the Territory for sale for any purpose (excluding any pricing or reimbursement approval). 

 

	 “Milestone Payment”  
	has the meaning given in Section 8.3 hereof. 

  
 9 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 “NDA” 
	means a “New Drug Application” (as more fully defined in United States Code of Federal Regulations, Title 21, Section 314.5 et seq.) filed with the FDA or the equivalent
application filed with any other Regulatory Authority to obtain a Marketing Authorization for a Product in a country or jurisdiction in the Territory. 

  

	 “Net Sales” 
	means, with respect to a Product, the gross amount billed or invoiced by Sublicensees for sales of Products to Third Parties (excluding sales of Products to Sublicensees for resale), less the
following items, as allocable to such Products (if not previously deducted in calculating the amount invoiced): 

  

	 	(i)	[***], 

  

	 	(ii)	[***], 

  

	 	(iii)	[***], and 

  

	 	(iv)	[***], 

  

	 	it being specified that disposal of Product for, or use of Product in, pre-clinical or clinical trials, including for compassionate use, or distribution of Product as
free samples (such samples to be in quantities common in the industry for this type of pharmaceutical products) shall not give rise to any deemed sales under this definition. 

 

	 	In the event the Product is sold as a Combination Product, the Net Sales of the Product, for the purposes of determining royalty payments, shall be determined by
multiplying the Net Sales of the Combination Product by the fraction, A/(A+B) where A is the weighted (by sales volume) average sale price in a particular country of the Product when sold separately in finished form and B is the weighted average
sale price in that country of the other product(s) sold separately in finished form. In the event that such average sale price cannot be determined for both the Product and the other product(s) in combination, Net Sales for purposes of determining
royalty payments shall be agreed by the Parties based on the relative value contributed by each component, such agreement not to be unreasonably withheld. 

 

	 “Other Field” 
	means all uses in humans and animals, including but not limited to the prevention and treatment of diseases and other conditions in all indications excluding the Exclusive Field.

  
 10 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 “Party” or “Parties” 
	means either DEBIOPHARM or COMPANY, as the context requires, and, when used in plural, shall mean DEBIOPHARM and COMPANY. 

 

	 “Patents” 
	means all rights under any patent and patent application in any country, including any substitution, extension, patent term restoration, supplementary protection certificate, reissue,
re-examination, renewal, division, continuation or continuation-in-part thereof. 

  

	 “Person” 
	means any individual, corporation, general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, or other entity or Governmental Authority.

  

	 “Phase I Clinical Trial” 
	means a clinical trial consistent with United States Code of Federal Regulations, Title 21, Section 312.21 (a), or any foreign counterpart of it. Any possible expansion of a Phase I
Clinical Trial in specific indications under a phase I protocol, which might follow the dose escalation phase, is considered as the same Phase I Clinical Trial. 

 

	 “Phase II Clinical Trial” 
	means a clinical trial consistent with United States Code of Federal Regulations, Title 21, Section 312.21 (b), or any foreign counterpart of it. 

 

	 “Phase III Clinical Trial” 
	means a clinical trial consistent with United States Code of Federal Regulations, Title 21, Section 312.21 (c), or any foreign counterpart of it. 

 

	 “Pivotal Enabling Study
 Phase II Clinical Trial”  
	
means a Phase II Clinical Trial, based on the result of which the start of a Phase III Clinical Trial as a pivotal study intended to lead to a Marketing Authorization shall be permitted.

  

	 “Product” 
	means a product which contains a Lead Compound or Backup Lead, whether or not as the sole API (i.e., including any Combination Product), in any dosage form, formulation and mode of
administration and for all present and future indications in the Field as set forth in Exhibit 5. 

  

	 “Reasonable Commercial
 Efforts” 
	
means those efforts and resources consistent with the usual practice of DEBIOPHARM in pursuing the development or commercialization of its own pharmaceutical products that are of similar
development stage and market potential as the Product, taking into account all relevant factors, including present and future market potential, and DEBIOPHARM’s own pharmaceutical products that are of similar market potential, financial return,
medical and clinical considerations, present and future 

  
 11 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
regulatory environment and competitive market conditions, all as measured by the facts and circumstances at the time such efforts are due. 

 

	 “Regulatory Authority” 
	means, in a particular country or jurisdiction in the Territory, any applicable Governmental Authority involved in granting approval to initiate or conduct clinical testing in humans, for
regulatory approval and/or, to the extent required in such country or jurisdiction, for pricing or reimbursement approval for a Product in such country or jurisdiction, including (a) the FDA; (b) the EMEA; (c) the European Commission;
(d) the Japanese Ministry of Health, Labour and Welfare (“MHLW”); and (e) the Japanese Pharmaceuticals and Medical Devices Agency (“PMDA”), and for each of the foregoing (a) through (e) including
any successor thereto. 

  

	 “Regulatory Filings” 
	means, with respect to the Lead Compound or Product, any submission to a Regulatory Authority of any appropriate regulatory application, and shall include any scientific advice request,
submission to a Regulatory Authority, MA applications, and any supplement or amendment thereto. For the avoidance of doubt, Regulatory Filings shall include any IND, NDA, CTA, MA applications or the corresponding application in any country or
jurisdiction of the Territory. 

  

	 “Royalty” or “Royalties” 
	means the royalties to be paid by DEBIOPHARM to COMPANY in connection with the license to Commercialize the Product and that are calculated on Sublicensee Royalties (received by DEBIOPHARM),
less Third Party Royalties in accordance with Section 8.7. 

  

	 “Royalty Term” 
	means, on a country-by-country basis the period beginning upon the First Commercial Sale of a Product in a country of the Territory and ending upon the later of: (a) expiration of the
last-to-expire Valid Claim of the COMPANY UsiRNA Technology IP (but only if the Product is covered by such Patents) or the Joint UsiRNA Technology IP (but only if the Product is covered by such Patents), which Valid Claim covers the composition of
matter or use of such Product in such country; or (b) the [***] anniversary of the First Commercial Sale of such Product in such country. 

  

	 “Sublicense Agreement” 
	 means any agreement entered into by DEBIOPHARM or any of its Affiliates with a Sublicensee whereby such Sublicensee is granted a sublicense under this Agreement, or such Sublicensee is
granted an option to acquire a sublicense under this Agreement, for the Commercialization of the Product. Notwithstanding anything expressed or implied in the foregoing provisions of this definition, the term “Sublicense

  
 12 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
Agreement” shall include any agreement entered into with a Sublicensee whereby such Sublicensee is granted the right or option to purchase its supply of Products in finished form from
DEBIOPHARM or its Affiliates for resale unto to the market (distribution agreement). For the avoidance of doubt, the term “Sublicense Agreement” shall exclude (i) any agreement between DEBIOPHARM or its Affiliate and a Third Party
service provider under which a sublicense is granted to such Third Party for the sole purpose of enabling such Third Party to perform contract services on behalf of DEBIOPHARM or its Affiliate (e.g., contract research or development organizations,
clinical sites performing clinical trials, universities and scientific institutes), and (ii) contracts with manufacturing companies pertaining to any manufacturing process for a Lead Compound, the Backup Lead or a Product.

  

	 “Sublicensee” 
	means a Third Party that has entered into a Sublicense Agreement. 

  

	 “Sublicensing Payments”  
	means a share of the Sublicensing Revenues which shall be paid by DEBIOPHARM to COMPANY. 

  

	 “Sublicensing Revenues” 
	means any payment due to DEBIOPHARM or its Affiliates by a Sublicensee in consideration for the sublicense granted to such a Sublicensee pursuant to this Agreement, including without limitation
any option fee, upfront fee, milestone payment and also including without limitation the fair market value of any equity instruments issued by the Sublicensee to DEBIOPHARM or its Affiliates in consideration for such sublicense, but to the exclusion
of (i) all Sublicensee Royalties and (ii) purchase prices paid by a Sublicensee corresponding to manufacturing and delivery costs for Product supplied to it by DEBIOPHARM or its Affiliates. 

 

	 “Sublicensee Royalties” 
	means the royalties assessed on Net Sales of the Product on the market effectively paid to DEBIOPHARM and its Affiliates by Sublicensees in connection with their right to Commercialize the
Product in accordance with the Sublicense Agreement, including without limitation running royalties less taxes, levies or government withholdings on such royalties effectively paid by Sublicensees on such royalties. 

 

	 	For clarity, Sublicensee Royalties do not include (i) Sublicensing Revenues, or (ii) purchase prices paid by a Sublicensee corresponding to manufacturing and
delivery costs for Products supplied to it by DEBIOPHARM or its Affiliates. 

  

	 “Term” 
	shall have the meaning given in Section 11.1 hereof. 

  
 13 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 “Territory” 
	means [***]. 

  

	 “Third Party” 
	means any Person other than (i) DEBIOPHARM or COMPANY or (ii) an Affiliate of DEBIOPHARM or COMPANY. 

 

	 “Third Party Intellectual
 Property Rights” 
	
means any and all Intellectual Property controlled by a Third Party, inasmuch as such Intellectual Property is necessary or reasonably required to develop, make use of the Lead Compound, the
Backup Lead (if chosen as the Lead Compound), the Diagnostic Tool and/or the Product. 

  

	 “Third Party Royalties” 
	means the royalties (including running royalties), milestones and/or other consideration payable by DEBIOPHARM, its Affiliates or Sublicensees to a Third Party in consideration for the license
to DEBIOPHARM, its Affiliates or Sublicensees in and to the Third Party Intellectual Property Rights with respect to developing, making, having made, using, selling, offering to sell and/or importing the Lead Compound or the Product.

  

	 “Trademarks” 
	means collectively, all registered and unregistered marks, trade names, trade dress rights, logos, taglines, slogans, Internet domain names, web addresses, and other indicia of origin, together
with the goodwill associated with any of the foregoing, and all applications, registrations, extensions and renewals thereof, selected for use on the Product. 

 

	 “UNA Platform Technology IP” 
	means the IP owned or Controlled by COMPANY and/or its Affiliates which cover the UNA technology and generic UsiRNA schemes as of the Effective Date, the Patents for which are set forth in
Exhibit 3(b). 

  

	 “Valid Claim” 
	means: 

  

	 	(a) a claim of an issued patent that has not expired or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent
jurisdiction in a final and non appealable judgment (or judgment from which no appeal was taken within the allowable time period), and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or in any other way; or

  

	 	 (b) a claim within a patent application that has not been revoked, cancelled, withdrawn, abandoned, or held unpatentable or invalid by a patent office, court or
other governmental agency of competent jurisdiction in a final and non appealable judgment (or judgment from which no appeal was taken within the allowable time period), and which has not been admitted to be invalid

  
 14 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
or unenforceable through reissue, disclaimer or in any other way, and which has not been pending for more than [***] years from its first priority filing date anywhere in the world.

  

	1.2	For purposes of this Agreement (i) words in the singular shall be held to include the plural and vice versa as the context requires, (ii) the words
“including” and “include” shall mean “including, without limitation”, unless otherwise specified; (iii) the terms “hereof”, “herein”, “herewith”, and “hereunder”, and words
of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement; and (iv) all references to “Section” and “Exhibit”, unless otherwise
specified, are intended to refer to a Section or Exhibit of or to this Agreement. 

  

	2.	GRANT OF RIGHTS 

  

	2.1	Grants of rights to DEBIOPHARM 

2.1.1     As of the Effective Date and until selection of the Lead Compound and Backup Lead, COMPANY grants to DEBIOPHARM the
following licenses: 
  

	 	(a)	A [***] license under the COMPANY UsiRNA Technology IP and Joint UsiRNA Technology IP to search, have searched, develop, have developed, improve, and have improved the
Collaboration Targets, the Collaboration Molecules, the Collaboration Candidates and the Collaboration Compounds in the Field and in the Territory; and 

  

	 	(b)	A [***] license under the COMPANY Formulation Technology IP, UNA Platform Technology IP, and any improvement thereof made by COMPANY related to the Collaboration
Molecules, Collaboration Candidates and/or Collaboration Compounds, to use, have used, develop, have developed, improve, and have improved DEBIOPHARM’s synthesis process, process development and manufacturing process in accordance with the
Joint Research Plan in the Field and in the Territory. 

 2.1.2     After selection of the Lead Compound
and the Backup Lead, COMPANY grants to DEBIOPHARM the following licenses: 
  

	 	(a)	A [***] license under the COMPANY UsiRNA Technology IP, and any improvement thereof made by COMPANY, and Joint UsiRNA Technology IP to search, have searched, develop,
have developed, improve, have improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Lead Compound and Backup Lead in a Product in the Field in the Territory; and

  

	 	(b)	A [***] license under the COMPANY Formulation Technology IP and UNA Platform Technology IP, and any improvement thereof related to the Lead Compound, Backup Lead and/or
Product made by COMPANY through DEBIOPHARM’s completion of the Development Plan, to use, have used, develop, have developed, improve, and have improved DEBIOPHARM’s synthesis process, process development and manufacturing process and to
make, have made, use, have used, manufacture, have manufactured, sell, distribute, export and/or import the Product anywhere in the Territory in the Field. 

 

	 	(c)	 A [***] license under the COMPANY’s rights and interest in the Joint UsiRNA Technology IP to search, have searched, develop, have developed,
improve, 

  
 15 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
have improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Backup Compounds, in the Exclusive Field in the
Territory. 

  

	 	(d)	A [***] license under the COMPANY’s rights and interest in the Joint UsiRNA Technology IP to search, have searched, develop, have developed, improve, have
improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Backup Compounds in the Other Field in the Territory. 

 

	 	(e)	A [***] license under the COMPANY UsiRNA Technology IP and any improvement thereof made by COMPANY to search, have searched, develop, have developed, improve, have
improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Backup Compounds, in the Exclusive Field in the Territory during the Non-Compete Period.

  

	2.1.3	Diagnostic Tool 

  

	 	(a)	COMPANY shall not prohibit DEBIOPHARM from developing any Diagnostic Tool in the Field in the Territory. 

 

	 	(b)	COMPANY grants to DEBIOPHARM a [***] license to develop, have developed, register, have registered, commercialize and have commercialized a Diagnostic Tool solely to
the siRNA sequences disclosed in the COMPANY UsiRNA Technology IP, in the Field and in the Territory. For purposes of clarity, such [***] license shall not include any rights to the UNA Platform Technology IP. 

 

	 	(c)	COMPANY grants to DEBIOPHARM a [***] license under the COMPANY’s rights and interest in the Joint UsiRNA Technology IP to develop, have developed, register, have
registered, commercialize and have commercialized a Diagnostic Tool, in the Field and in the Territory. For purposes of clarity, such [***] license shall not include any rights to the UNA Platform Technology IP. 

 

	 	(d)	Should DEBIOPHARM be required to pay any royalty or consideration to any Third Party under any COMPANY IP in relation to the development, registration or
commercialisation of the Diagnostic Tool, such royalty shall be considered as a Third Party Royalty and be deductible as per Section 8.7. 

  

	2.1.4	Additional Terms Regarding the Licensed Rights to DEBIOPHARM 

  

	 	(a)	With regard to manufacturing, the Licensed Rights shall include the [***] right of DEBIOPHARM to manufacture and/or have manufactured the Lead Compound, the Backup Lead
and/or the Product [***] for the Territory. 

  

	 	(b)	Where exclusive, the Licensed Rights are granted to DEBIOPHARM on an exclusive basis even as to COMPANY, which shall not develop, have developed, improve, have
improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Lead Compound, the Backup Lead, or the Product in the Field and in the Territory. 

 

	 	(c)	 The License Rights shall include the right to grant sublicenses under the Licensed Rights and shall also include the right to grant to a Sublicensee
the right to grant further sublicenses to the extent of the Licensed Rights. If DEBIOPHARM or any of its Affiliates enters into a Sublicense Agreement or any agreement with a Third

  
 16 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
Party service provider or manufacturer, DEBIOPHARM shall ensure that the applicable terms and conditions of this Agreement shall apply to the applicable Sublicensee, service provider or
manufacturer to the same extent as they apply to DEBIOPHARM with respect to, and to the extent of the Licensed Rights. DEBIOPHARM shall assume full responsibility for the performance of all its obligations under this Agreement and any breach of any
Sublicense Agreement by a Sublicensee. 

  

	 	(d)	all Licensed Rights concerning the Backup Lead shall exist only for [***] months after selection of the Backup Lead unless such Backup Lead is selected as the Lead
Compound. For the sake of clarity, after the [***] months period, should the Backup Lead not be selected as the Lead Compound, it shall be considered as a Backup Compound. Furthermore, DEBIOPHARM may, during the [***] month period, perform research
and develop the Backup Lead in conjunction with the Lead Compound in accordance with the Joint Research Plan and Development Plan. All such costs shall be borne by DEBIOPHARM. 

 

	 	(e)	For the purposes of clarification, the rights provided in this Agreement allow for one Lead Compound to be Commercialized in DEBIOPHARM’s Product(s), Rights to the
Backup Compounds are provided to DEBIOPHARM as alternatives to the Lead Compound and/or Backup Lead. 

  

	2.1.5	Transfer of COMPANY Know-How and materials: As soon as possible after the Effective Date, COMPANY shall use its Reasonable Commercial Efforts to transfer, at no
costs to DEBIOPHARM (with the exception of COMPANY’s out-of-pocket travel expenses for travel requested by DEBIOPHARM, which travel costs shall be paid for by DEBIOPHARM), all Know-How, as well as any and all information and Data specifically
related to the Exclusive Field on the COMPANY Background IP and materials, including UsiRNAs, formulation components and formulated UsiRNAs, which shall be transferred under task No 17, that is necessary for DEBIOPHARM to perform assay development
of the Joint Research Plan in the most efficient and effective manner, and in accordance with the Joint Research Plan. 

  

	2.2	Grants of rights to COMPANY: DEBIOPHARM hereby grants to COMPANY a [***] license, with the right to grant sublicenses, under Intellectual Property created by
DEBIOPHARM during the performance of the Joint Research Plan directly relating to the COMPANY Formulation Technology IP and UNA Platform Technology IP. 

  

	3.	JOINT RESEARCH PLAN AND FURTHER DEVELOPMENT 

  

	3.1	Joint Research Plan 

  

	3.1.1	The Parties have agreed on the Joint Research Plan; COMPANY shall be responsible for the activities listed from No 1 through 13 and partially No 17; DEBIOPHARM shall be
responsible for the activities listed from No 14 through 25. 

  

	3.1.2	 The cost for each of the activities (No 1 through 13 and partially No 17) to be carried out by COMPANY is described in the Joint Research Plan; the
total shall not exceed USD [***]; any excess shall be for the account of the COMPANY; the COMPANY undertakes to carry out the activities listed in No 1 through 13 and partially 17; should the costs of the activities for No 1 through 13, and
partially No 17 exceed USD [***], the excess will be for the account of the COMPANY; the payment shall be made in [***] instalments of USD [***] by DEBIOPHARM to COMPANY; COMPANY shall send to DEBIOPHARM an original invoice covering the first
payment and such payment shall be made within [***] working days of the signature of the Licence Agreement, the second instalment shall be made 

  
 17 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
within [***] months of the signature of the Licence Agreement and every [***] months thereafter until the last instalment to be made within [***] months after the Effective Date. DEBIOPHARM shall
approve in writing via e-mail the commencement of each task before COMPANY starts such task. Parties, through the JSC, will negotiate and amend the Joint Research Plan, including an amendment to this Agreement (in accordance with Section 19.6)
to cover new costs to COMPANY for performance of such amended Joint Research Plan, should a Party require new or additional work not covered in the present Joint Research Plan. COMPANY is under no obligation to provide any new or additional work.
DEBIOPHARM reserves the right to have any new or additional work under the amended Joint Research Plan performed by a Third Party as discussed by the JSC and approved by DEBIOPHARM in writing via e-mail. 

 

	3.1.3	DEBIOPHARM shall select the Lead Compound and the Backup Lead concurrently from the Collaboration Compounds. DEBIOPHARM may at any time during the [***]-month period
after selection, and without justification to COMPANY, decide to abandon the development of the Lead Compound and choose to develop the Backup Lead instead; in such case, the Backup Lead becomes automatically the Lead Compound; at any time,
DEBIOPHARM may decide without justification to COMPANY to abandon the Backup Lead and may request, at no additional cost to DEBIOPHARM a Backup Compound from COMPANY on a [***] basis as set forth in Sections 2.1.2(c) and (e); if such Backup Compound
selected by DEBIOPHARM as the new Lead Compound is still [***] available in the Field, all the Licensed Rights that apply to the Lead Compound shall apply to the chosen Backup Compound. 

 

	3.1.4	COMPANY and DEBIOPHARM shall use their best commercial efforts to perform the activities with reasonable care and professional skills and to deliver the deliverables
described in the Joint Research Plan; COMPANY shall perform the Joint Research Plan in accordance with the standard applicable in the pharmaceutical industry, and in all applicable laws and regulations. 

 

	3.1.5	COMPANY shall regularly, and in any event upon DEBIOPHARM’S request, provide DEBIOPHARM with full information and shall at any time give DEBIOPHARM any and all
information which could have an impact (i) on DEBIOPHARM’s decision to continue or terminate the Joint Research Plan and/or (ii) on DEBIOPHARM’s selection of the Lead Compound and the Backup Lead. During the Joint Research
Period, COMPANY shall provide to DEBIOPHARM with reports, the content of such reports to be agreed upon by the JSC, in writing and in electronic format (word) as provided in the Joint Research Plan but in any event at the end of each of the tasks
(No 1 through 13) set forth in the Joint Research Plan. 

  

	3.1.6	COMPANY shall keep complete and accurate records of all work conducted by it in the course of the Joint Research Plan. All such records will be kept in sufficient
details and in a manner consistent with the standard practices in the pharmaceutical industry. Furthermore, COMPANY shall keep in its archive all the results of the Joint Research Plan for a period of minimum [***] years following the completion of
the Joint Research Plan and will keep such results and Data available to DEBIOPHARM upon DEBIOPHARM’s request. 

  

	3.2	Further Development  

  

	3.2.1	Development Responsibilities. After the Joint Research Period, DEBIOPHARM shall be solely responsible for the development of the Product in the Territory and for
any communication with Regulatory Authorities in the Territory. 

  
 18 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	3.2.2	Development Obligations. DEBIOPHARM shall have the sole responsibility to undertake the development of the Lead Compound, at its sole cost and expense, and shall
retain final decision making authority on all development and regulatory matters relating to the Lead Compound and the Product in the Field in the Territory. Notwithstanding the foregoing, DEBIOPHARM shall use Reasonable Commercial Efforts to
develop and Commercialize the Product in accordance with the Development Plan. For the sake of clarity, DEBIOPHARM may, at its discretion, cost and responsibility, subcontract any development activity to a third party. 

 

	3.2.3	Decision-making Authority. DEBIOPHARM shall have final decision-making authority regarding adjustments to the Development Plan, provided however that such
adjustments shall not result in DEBIOPHARM disrupting the development of the Lead Compound for more than [***] consecutive months. 

  

	3.2.4	Reports. DEBIOPHARM shall provide to COMPANY within ninety (90) days as of the end of each calendar year a report detailing the progress made with respect
to the development of the Lead Compound. 

  

	4.	JOINT STEERING COMMITTEE 

  

	4.1	Establishment of the Joint Steering Committee. Within a reasonable period of time after the Effective Date, the Parties shall establish a JSC of four
(4) committee members, consisting of two (2) representatives designated by each Party, to oversee and control the implementation of this Agreement between the Parties and the development and Commercialization of Product in the Territory.
Either Party shall also choose one of its representatives to serve as a co-chair of the JSC who will be responsible, along with the other co-chair, for the preparation and distribution of agendas and for coordinating the drafting of minutes. Each
Party may replace its JSC representative at any time upon written notice to the other. A Party’s representative on the JSC shall be authorized to act on behalf of such Party until written notice of the removal of such representative is received
by the other Party. If a representative of a Party is unable to attend a meeting, such Party may designate an alternate representative to attend such meeting. A Party may change one or more of its representatives to the JSC at any time upon notice
to the other Party. 

  

	4.2	Duration, Scope of Authority and Responsibilities of the Joint Steering Committee. The JSC shall continue in existence until the termination or expiration of
this Agreement or until the Parties mutually agree in writing to disband or alter the activities of the JSC. The JSC shall (i) review and comment on the results of each task set forth in the Joint Research Plan and address any issues that may
arise under the Joint Research Plan, (ii) review and comment the Development Plan, (iii) address and coordinate resolution of issues that may arise relating to the transfer of Know-How, materials and other technology between the Parties,
(iv) address issues that may arise relating to the Commercialization of Product, (v) perform general oversight of any other issues arising out of this Agreement or the subject matter contained herein, and (vi) address such other
issues and matters as are expressly specified in this Agreement or as the Parties may agree from time to time. 

  

	4.3	 Meeting of the Joint Steering Committee. The JSC shall meet no less frequently than twice per calendar year during the Joint Research Period and
once per year thereafter; in any event, the JSC may meet at such other times as deemed appropriate by the JSC. A quorum of the JSC shall exist whenever there is present at a meeting at least one representative appointed by each Party. The meetings
of the JSC shall take place alternately in Lausanne and Bothell, or any other places as are mutually agreed. For clarity, during the Joint Research Period, the JSC shall meet in person for two meetings.

  
 19 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
Thirty (30) days’ prior written notice of each meeting shall be provided to the representatives, unless such notice is waived in writing by the representatives. The JSC may also
convene, or be polled or consulted, from time to time by means of communications, video conferencing or written (including electronic) correspondence, as deemed necessary or appropriate. In addition, either Party may, at its discretion, invite a
reasonable number of non-voting employees, consultants or scientific advisors to attend the meeting of the JSC, provided that such invitees are bound by appropriate confidentiality obligations. In addition, the Parties’ scientific teams shall
meet on a monthly basis via videoconference or teleconference to discuss the progress of the research and results received under the Joint Research Plan. 

 

	4.4	Decisions of the Joint Steering Committee. All decisions of the JSC shall be made by consensus. Notwithstanding the foregoing, [***]. 

 

	5.	MANUFACTURING 

DEBIOPHARM shall have the [***] right to manufacture, or have manufactured the Lead Compound, the Backup Lead and the Product. DEBIOPHARM
will, at its own discretion, determine the sites for the manufacture, release and supply of the Lead Compound, the Backup Lead and the Product. 
  

	6.	COMMERCIALIZATION 

DEBIOPHARM shall be solely responsible for the Commercialization of the Product in the Territory, including without limitation the
pricing and reimbursement strategy. 
  

	7.	COMPETING PRODUCT 

COMPANY agrees that it will not research, have researched, develop, have developed, register, have registered, manufacture, have
manufactured, market, promote, sell, offer for sale, or distribute in the Territory any Competing Product from the Effective Date until [***] years after the date of the First Commercial Sale of the Product in any country of the Territory (the
“Non Compete Period”). For the avoidance of doubt, this Section does not restrict or prohibit COMPANY from licensing or sublicensing any Formulation Technology IP, UNA Platform Technology IP, or other Intellectual Property owned or
Controlled by COMPANY and not subject to this Agreement, to a Third Party in any field except as set forth in the Licensed Rights; until selection of the Collaboration Targets or [***] months from execution of this Agreement, whichever occurs first,
this Section prohibits COMPANY from granting any license under the COMPANY IP (except the Formulation Technology IP, UNA Platform Technology IP and IP specifically covering [***] and [***]) to a Third Party; any information disclosed by DEBIOPHARM
in relation to the Collaboration Targets to be selected shall be considered as Confidential Information and may not be used in any manner by COMPANY. [***]. 
  

	8.	CONSIDERATION 

  

	8.1	Consideration. As consideration for the Licensed Rights, DEBIOPHARM shall pay to COMPANY the amounts set forth in this Article 8. 

 

	8.2	Joint Research Plan: the costs of performance by each Party of the Joint Research Plan shall be borne by DEBIOPHARM as described in Section 3.1.2.

  

	8.3	 Milestones. DEBIOPHARM shall pay the non-refundable Milestone Payments set forth in this Section 8.3, for each of the following milestone
events, whether such milestone event is achieved by DEBIOPHARM, its Affiliates or Sublicensees, or any Third Party acting on 

  
 20 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
behalf of DEBIOPHARM, its Affiliates or Sublicensees. Milestone Payments shall be paid only once regardless of how many times a Product achieves the corresponding milestone event, and no payment
shall be due for any milestone event which is not achieved, except as set forth in the last sentence of this Section 8.3. For clarity, there shall be no additional Milestone Payments even if the Product is developed in more than one indication
in the Field, and there shall be no additional Milestone Payments even if DEBIOPHARM develops more than one Product within the Field. 

  

			
	Milestone events	  	Milestone Payments
payable to 
COMPANY
in USD
	 Research Milestone
Payments
	  	 
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 Development Milestone
Payments
	  	 
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

DEBIOPHARM shall provide COMPANY with written notice within [***] Business Days of the occurrence of any of the foregoing milestone
events and the Milestone Payments are payable by DEBIOPHARM to COMPANY within [***] days from receipt of an invoice issued by COMPANY. In the event that a given milestone event is realized and becomes payable but any milestone event(s) that
constitutes a prior step was never realized and was never paid to COMPANY, such prior milestone event(s) shall automatically be deemed to have occurred and become due and payable simultaneously with such occurring milestone event. 

 

	8.4	Credit against the Milestone Payments. The Milestone Payments shall be credited against the Sublicensing Payments to be paid to COMPANY in accordance with
Section 8.5 hereof, provided that the overall amount of the Sublicensing Payments exceeds the aggregate of the Milestone Payments actually paid to COMPANY in accordance with Section 8.3 hereof. 

 

	8.5	Sublicensing Payments. COMPANY shall receive [***] percent ([***]%) of all Sublicensing Revenues received by DEBIOPHARM and its Affiliates subject to the credits
set forth in Section 8.4 hereof. Payment of Sublicensing Payments shall be made to COMPANY within [***] days as of receipt by DEBIOPHARM or its Affiliate of Sublicensing Revenues. 

 

	8.6	Royalties. COMPANY shall receive as Royalties the following amounts in those countries of the Territory during the Royalty Term: 

 

					
	Net Sales per calendar year by
Sublicensees	  	Royalty Sharing	 	  
	 <USD [***]
	  	[***]%	 	 

  
 21 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

					
	 between
USD [***] and USD [***]
	  	            [***]%  
          	 	 
	 >USD [***]
	  	[***]%	 	 

  

	8.7	Third Party Royalties. If during the Term, DEBIOPHARM, its Affiliate or Sublicensee obtains a license from a Third Party, or continues in effect any license in
existence as of the Effective Date with any Third Party in order to avoid infringing such Third Party Intellectual Property Rights in the course of the sale of Product by DEBIOPHARM, its Affiliate or Sublicensee in a country, the Milestones and
Royalties payable with respect to such Product in such country shall be reduced by an amount equal to the Third Party Royalties paid by DEBIOPHARM, its Affiliate or Sublicensee, but in no case will the Milestones and the Royalties be reduced to less
than [***] percent ([***]%) of the Milestones or the Royalty. Upon request from COMPANY, DEBIOPHARM will provide evidence of payments of such Third Party Royalties. 

 

	8.8	Generic Products. It is agreed that the royalties payable to COMPANY shall be at the rates shown above on the condition that, during the applicable period, no
third party will enter the market in the relevant country with Generic Products. If and when it is determined by DEBIOPHARM based on a reference database such as IMS, that (i) Generic Products have entered a market and (ii) such
penetration of Generics exceeds a market share of [***] percent ([***]%) of the aggregate unit sales of such Product in a country and in a calendar quarter, the royalty to be paid to COMPANY for that market will be reduced by the same percentage as
the royalty reduction or percentage reduction of royalties received from the Sublicensee by DEBIOPHARM. 

  

	9.	PAYMENTS 

  

	9.1	Royalties. Royalties shall be paid by DEBIOPHARM to COMPANY [***], within [***] days as of the end of each [***] in which Sublicensee Royalties are received by
DEBIOPHARM or its Affiliates. 

  

	9.2	Sublicensing Payments. Sublicensing Payments shall be paid by DEBIOPHARM to COMPANY within [***] days from receipt of Sublicensing Revenues by DEBIOPHARM or its
Affiliates. 

  

	9.3	Payments. Payments shall be made in US Dollars to the bank account indicated by COMPANY. If Net Sales or payments to DEBIOPHARM and its Affiliates of Sublicensee
Royalties and/or Sublicensing Revenues are made in another currency than US Dollars, DEBIOPHARM shall convert such amounts in US Dollars for the purpose of the calculation of the Royalties and Sublicensing Payments by applying the average interbank
exchange rate as published on www.oanda.com for the last day of each month within the Calendar Quarter for which payment to COMPANY is due. All costs associated with payments to COMPANY, including the costs of wire transfers, shall be paid by
DEBIOPHARM and shall not be deducted from the payments to COMPANY. 

  

	9.4	Late Payments. Any payment under this Agreement that is not timely paid shall bear interest at the annual rate of [***] percent ([***]%) or the maximum amount
allowed by Applicable Law, whichever is less; provided, however, that DEBIOPHARM shall have a grace period of ten (10) Business Days after the payment is due in order to make the payment, and interest shall not be applied until expiration of
such grace period. 

  

	9.5	Taxes. Either Party shall pay all income, revenue, value added, and other taxes on account of payments accruing or made under this Agreement.

  
 22 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	9.6	Audits. DEBIOPHARM shall maintain and shall cause its Affiliates and Sublicensees to maintain full, true and accurate books of account containing all particulars
that may be necessary for the purpose of calculating all Royalties and Sublicensing Payments due under this Agreement. Such books of account shall be kept at their principal place of business. DEBIOPHARM, its Affiliates and Sublicensees shall permit
COMPANY, by independent qualified public accountants selected by COMPANY and reasonably acceptable to DEBIOPHARM, to examine such books and records at any reasonable time, but not later than [***] years following the rendering of any corresponding
reports, accountings and payments pursuant to this Agreement. The foregoing right of review may be exercised only once during each calendar year. Such accountants may be required by DEBIOPHARM, its Affiliates and Sublicensees to enter into
reasonably acceptable confidentiality agreements, and in no event shall such accountants disclose to COMPANY any information other than such as relates to the accuracy of reports and payments made or due hereunder. The opinion of said independent
accountants regarding such reports, accountings and payments shall be binding on the Parties other than in the case of manifest error. COMPANY shall bear the cost of any such examination and review; provided that if the inspection and audit show an
underpayment of Royalties or Sublicensing Payments due to COMPANY of more than [***] percent ([***]%) of the amount due for the applicable accounting period, then DEBIOPHARM shall promptly reimburse COMPANY for all costs incurred in connection with
such examination and review. DEBIOPHARM shall promptly pay to COMPANY the amount of such underpayment revealed by an examination and review. 

  

	10.	INTELLECTUAL PROPERTY RIGHTS AND INFRINGEMENT 

  

	10.1	Inventions.  

  

	10.1.1	Ownership 

  

	 	(a)	Intellectual Property generated by COMPANY under tasks no. 1 through 13 of the Joint Research Plan shall be Joint IP except for COMPANY UsiRNA Technology IP, which
shall remain vested in COMPANY. 

  

	 	(b)	Intellectual Property generated by COMPANY and DEBIOPHARM under task no. 17 of the Joint Research Plan shall be Joint IP. 

 

	 	(c)	Intellectual Property generated by DEBIOPHARM under tasks no. 14 through 25 (excluding task no. 17) shall be solely owned by DEBIOPHARM. In the event that DEBIOPHARM
develops such IP on COMPANY Formulation Technology IP and/or UNA Platform Technology IP, DEBIOPHARM shall promptly notify COMPANY and provide COMPANY any information and documents necessary for COMPANY to understand and use DEBIOPHARM IP directly
relating to the COMPANY Formulation Technology IP and UNA Platform Technology IP. 

  

	 	(d)	All other Intellectual Property generated by each Party during the Term of this Agreement but not under the Joint Research Plan shall be solely owned by the Party that
generated such Intellectual Property. 

  

	 	(e)	Determination of inventorship shall be made in accordance with US patent laws. 

 

	10.1.2	Rights to and Use of Joint IP. 

  

	 	(a)	COMPANY’s rights in any Joint IP shall be included within the Licensed Rights. 

  
 23 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	(b)	After selection of the Lead Compound and Backup Lead, COMPANY may: 

  

	 	(i)	use for internal research purposes in the Other Field any Joint IP for any purpose, except for the Lead Compound, the Backup Lead (during the [***]-month period) and
Product, in the Territory, without accounting to or obtaining the approval of DEBIOPHARM. 

  

	 	(ii)	[***] license its interest in any Joint IP outside of the Lead Compound, Backup Lead and Product to a Third Party in the Other Field. As soon as it becomes publicly
available, written notice will be provided by COMPANY to DEBIOPHARM, and, in compliance with SEC requirements, COMPANY shall disclose to DEBIOPHARM material information concerning the license, including the field of use and indication, and may
provide a copy of the redacted [***] license. 

  

	 	(iii)	[***] license its interest in any Joint IP directly related to Formulation Technology IP and/or UNA Platform Technology IP outside of the Lead Compound, Backup Lead and
Product to a Third Party in the Field. As soon as it becomes publicly available, written notice will be provided by COMPANY to DEBIOPHARM, and, in compliance with SEC requirements, COMPANY shall disclose to DEBIOPHARM material information concerning
the license, including the field of use and indication, and may provide a copy of the redacted [***] license. 

  

	 	(iv)	Except for any rights in the Joint IP expressly granted to COMPANY under this Agreement, no further right to use, exploit, or license in any manner the COMPANY’s
interest in any Joint IP is hereby granted to COMPANY. For the avoidance of doubt, COMPANY may not grant any [***] license in any Joint UsiRNA Technology IP to a Third Party in the Other Field, nor grant any license in any Joint UsiRNA Technology IP
covering the Lead Compound or Backup Lead to a Third Party in the Field. 

  

	 	(c)	After selection of the Lead Compound and Backup Lead, and except for the Lead Compound, the Backup Lead and the Product, DEBIOPHARM may [***] license its interest in
any Joint IP to a Third Party in the Other Field. As soon as it becomes publicly available, written notice will be provided by DEBIOPHARM to COMPANY, and DEBIOPHARM shall disclose to COMPANY material information concerning the license, including the
field of use and indication, and may provide a copy of the redacted [***] license. For the avoidance of doubt, DEBIOPHARM may not grant any [***] licence in any Joint IP not covering Lead Compound or Backup Lead to a Third Party in the Other Field.

  

	10.2	Patent Prosecution : 

  

	 	(i)	 Formulation Technology IP and UNA Platform Technology IP: at all time during this Agreement, all pending patent applications and issued patents
included in Formulation Technology IP and UNA Platform Technology IP shall be prepared, prosecuted, filed and maintained, at COMPANY’s costs, by outside patent counsel chosen by COMPANY. COMPANY shall, or shall instruct patent counsel to, keep
DEBIOPHARM regularly informed of the progress of the prosecution, issuance and maintenance of all such patent applications and patents and be available to discuss any issues and answer any questions DEBIOPHARM may have. COMPANY will not finally
abandon any patent application or patent rights included in the Formulation Technology IP and UNA Platform Technology IP without first notifying DEBIOPHARM in writing; should DEBIOPHARM fail to

  
 24 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
respond in writing within [***] days of such notice, DEBIOPHARM shall be deemed to have given its approval to COMPANY’s course of action. 

 

	 	(ii)	COMPANY UsiRNA Technology IP: 

  

	 	(a)	until DEBIOPHARM’s selection of the Lead Compound and the Backup Lead, all pending patent applications and issued patents included in the COMPANY UsiRNA Technology
IP shall be prepared, prosecuted, filed and maintained, at COMPANY’s costs, by outside patent counsel chosen by COMPANY, provided that if COMPANY changes outside patent counsel, COMPANY shall first seek approval of DEBIOPHARM, such approval not
to be unreasonably withheld. COMPANY shall, or shall instruct patent counsel, to keep DEBIOPHARM regularly informed of the progress of the prosecution, issuance and maintenance of all such patent applications and patents, and be available to discuss
any issues and answer any questions DEBIOPHARM may have and take reasonable comments made by DEBIOPHARM into consideration. If COMPANY decides to finally abandon or not to maintain any patent application or patent included in the COMPANY UsiRNA
Technology IP, COMPANY shall provide DEBIOPHARM with [***] days’ prior written notice of such determination (or, at COMPANY’s sole discretion such other period of time reasonably necessary to allow DEBIOPHARM to assume such
responsibilities). In such event, DEBIOPHARM shall have the right, at its option, to control the filing, prosecution and/or maintenance of any such COMPANY UsiRNA Technology IP at its own expense in the name of COMPANY. DEBIOPHARM shall have the
sole right, in good faith, to determine whether to seek or obtain any patent term extension(s), restoration(s) or the like that may be available in the future with respect to the COMPANY UsiRNA Technology IP in any part of the Territory.

  

	 	(b)	 After selection of the Lead Compound and Backup Lead, DEBIOPHARM shall take over and assume the sole responsibility for the preparation, prosecution,
filing and maintenance, at DEBIOPHARM’s costs, by outside patent counsel chosen by DEBIOPHARM of all pending patent applications and issued patents included in the COMPANY UsiRNA Technology IP for the sole purpose of covering and protecting the
Lead Compound and/or the Backup Lead as used in the Product provided that such rights shall be expressly subject to the obligations of DEBIOPHARM to (i) keep COMPANY regularly and timely informed of the filing, progress, issuance and
maintenance of all such patent applications and patents, including the provision to COMPANY of copies of counsel’s invoices directly related to the COMPANY UsiRNA Technology IP covering the Lead Compound and/or the Backup Lead; (ii) give
COMPANY reasonable opportunity to comment on the type and scope of useful claims and the nature of supporting disclosures and as soon as DEBIOPHARM is of summon receipt of prior written notice of all meetings and material communications with any
patent authorities concerning the COMPANY UsiRNA Technology IP and covering the Lead Compound and/or the Backup Lead; (iii) consider in good faith comments received from COMPANY or its outside patent counsel; (vi) not to finally abandon
any patent application or patent included in the COMPANY UsiRNA Technology IP covering the Lead Compound and/or the Backup Lead without COMPANY’s prior written consent. For purposes of clarity, COMPANY shall have the right, but without
negatively impacting DEBIOPHARM’s rights under this Section 10.2(ii)(b), and with the prior written agreement of DEBIOPHARM, to prepare, prosecute, file and maintain, at COMPANY’s costs, by outside patent counsel chosen by COMPANY,
any and all Inventions on COMPANY UsiRNA 

  
 25 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
Technology IP not covering and protecting the Lead Compound and/or Backup Lead. 

 DEBIOPHARM shall have no obligation to prepare, prosecute, file and maintain any of pending patent applications and issued patents included in the COMPANY UsiRNA Technology IP not covering and protecting
the Lead Compound, the Backup Lead or the Product, which shall continue to be ruled by Section 10.2(ii)(a). 
  

	 	(iii)	Prosecution and Maintenance of Joint Patents. DEBIOPHARM shall control the filing, prosecution and maintenance of the Joint Patents in the Territory including,
but not limited to, filing applications for, and obtaining, patent term extensions, supplemental protection certificates and the like. DEBIOPHARM shall bear any and all Joint Patents costs. All applications and filings shall be made in the name of
DEBIOPHARM and COMPANY. Any material decision (e.g. decisions resulting in a limitation of the scope of the claims, abandonment of one or more countries, and the like) to be made in connection with filing, prosecution and maintenance of the Joint
Patents shall be made by DEBIOPHARM after consultation with COMPANY. DEBIOPHARM will reasonably consider COMPANY’s input. If DEBIOPHARM determines not to file, to abandon or not to maintain any Joint Patent in the Territory, then DEBIOPHARM
shall provide COMPANY with [***] days’ prior written notice of such determination (or, at DEBIOPHARM’s sole discretion, such other period of time reasonably necessary to allow COMPANY to assume such responsibilities). In such event,
COMPANY shall have the right, at its option, to control the filing, prosecution and/or maintenance of any such Joint Patent at its own expense in the name of DEBIOPHARM and COMPANY. In such event, such Joint Patent shall be ruled by
Section 10.2(ii)(a). 

  

	 	(iv)	DEBIOPHARM and COMPANY each hereby disclaims any representations or warranties, express or implied, as to whether a patent is granted or not or held valid or not. Each
Party shall use commercially reasonable standards for prosecution of Patents under Section 10.2. 

  

	 	(v)	Prosecution and Maintenance of DEBIOPHARM Patents. DEBIOPHARM shall have the right to prepare, file, prosecute and maintain all DEBIOPHARM Patents at its own
expense, by outside patent counsel chosen by DEBIOPHARM, in the name of DEBIOPHARM, in the world. DEBIOPHARM shall, or shall instruct patent counsel, to keep COMPANY regularly informed of the progress of the prosecution, issuance and maintenance of
all patent applications and patents within the DEBIOPHARM Patents that are specifically related to the Formulation Technology IP and UNA Platform Technology IP, and shall be available to discuss any issues and answer any questions COMPANY may have
and take reasonable comments made by COMPANY into consideration. If DEBIOPHARM decides to finally abandon or not to maintain any such patent application or patent within the DEBIOPHARM Patents that are specifically related to the Formulation
Technology IP and UNA Platform Technology IP, DEBIOPHARM shall provide COMPANY with [***] days’ prior written notice of such determination (or, at DEBIOPHARM’s sole discretion, such other period of time reasonably necessary to allow
COMPANY to assume such responsibilities). In such event, COMPANY shall have the right, at its option, to control the filing, prosecution and/or maintenance of any such DEBIOPHARM Patents and patent applications specifically related to the
Formulation Technology IP and UNA Platform Technology IP at its own expense in the name of DEBIOPHARM. 

  

	10.3	Patent Infringement. 

  
 26 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	(a)	Notice: Either Party shall promptly notify the other Party in writing if it reasonably believes that any Patent included in the Licensed Rights or a Joint Patent
is being, or has been, infringed or misappropriated by a Third Party in any country of the world. 

  

	 	(b)	Prosecution of Patent Infringement. The Party responsible for Patent prosecution as set forth in Section 10.2 shall have the first right, but not the
obligation, to prosecute infringement in the Territory. In the case of infringement of a Joint Patent (DEBIOPHARM being the responsible party under Section 10.2(iii)), it is agreed that COMPANY may not prevent DEBIOPHARM from starting and
conducting a lawsuit. In each such case, the responsible Party shall bear all costs and expenses with respect to any such prosecution and shall retain all related recoveries. The responsible Party shall notify the other Party of such infringement
and keep the other Party reasonably informed with respect to the disposition of any action taken in connection therewith and shall reasonably consider the other Party’s comments on any such action. Any damages or recovery from such action,
including any settlement therefrom, shall be allocated first to the reimbursement of any costs and expenses incurred in conducting such litigation, with the remainder of any such recoveries to be retained by the responsible Party provided that, if
the responsible Party is DEBIOPHARM, DEBIOPHARM shall pay Royalties to COMPANY in accordance with Section 8.6 hereof with respect to the lost sales of Product represented by such recovery; if such lost sales amount is not ascertainable, then
Royalties shall be calculated on the remainder of any such recovery amount itself. The responsible Party shall not settle any claim involving the Patents that would limit or compromise the scope, validity or enforceability of any Patent included in
the Licensed Rights or a Joint Patent without the consent of the other Party, which consent shall not be unreasonably withheld. If the responsible Party does not bring action to prosecute infringement of a Patent included in the Licensed Rights or a
Joint Patent in the Territory within [***] days after notification thereof to or by the responsible Party pursuant to this Section, then the other Party shall have the right to initiate an action against any Third Party engaged in such infringement
directly or contributorily in the Territory. In such case, the other Party shall bear all costs and expenses with respect to any such prosecution and shall retain all related recoveries. In any action for infringement of the Patents included in the
Licensed Rights or a Joint Patent by a Third Party in the Territory, the Parties shall provide each other with reasonable cooperation and assistance and if required by law that each owner of a Joint Patent must be plaintiff, the non prosecuting
Party shall be obliged to participate into the proceedings as plaintiff, each Party bearing its own costs. 

  

	10.4	DEBIOPHARM Trademarks. DEBIOPHARM shall identify and select one or more DEBIOPHARM Trademarks to be used to register, sell, license, distribute and promote the
Product in the Territory. DEBIOPHARM shall own all DEBIOPHARM Trademarks and the corresponding goodwill and, at its cost, shall be responsible for procurement, registration, maintenance and enforcement of any of the DEBIOPHARM Trademarks. Unless
otherwise agreed in writing between the Parties, COMPANY shall not avail itself of any license on any DEBIOPHARM Trademark or any other trademark of DEBIOPHARM, shall not register or use any trademark of DEBIOPHARM and shall not license, register or
use any trademark or trade name which is the same as, or confusingly similar to, any trademark of DEBIOPHARM. COMPANY shall not use any trade dress used by DEBIOPHARM or confusingly similar to any trade dress used by DEBIOPHARM.

  

	10.5	 Infringement of DEBIOPHARM Trademarks. COMPANY shall promptly notify DEBIOPHARM in writing of any infringement of a DEBIOPHARM Trademark in the

  
 27 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
Territory that comes to its knowledge. DEBIOPHARM shall have the sole right, but not the obligation, to initiate proceedings against, or defend Claims made by, any person in connection with any
of the DEBIOPHARM Trademarks. The commencement, strategies, termination, settlement or defense of any action relating to the validity of the DEBIOPHARM Trademarks shall be decided by DEBIOPHARM. Any such proceedings shall be at the expense of
DEBIOPHARM. Any damages or costs recovered by DEBIOPHARM as a result of any such proceedings or Claims shall be at the sole benefit and account of DEBIOPHARM. 

 

	11.	TERM, EXPIRY AND TERMINATION 

  

	11.1	Term. This Agreement shall enter in force as of the Effective Date and remain in effect until the expiry of the Royalty Term, unless earlier terminated in
accordance with this Article 11 or as otherwise agreed in writing by the Parties. 

  

	11.2	Termination by Either Party. Either Party may terminate this Agreement by written notice to the other Party if the other Party: 

 

	 	(i)	is in material breach of any of its obligations under this Agreement which is not remediable, or if remediable, has not been remedied within sixty (60) days of
written notice requiring it to be remedied; or 

  

	 	(ii)	the other Party ceases or threatens to cease to trade or becomes or is deemed insolvent, is unable to pay its debts as they fall due, files for bankruptcy, has a
receiver, administrative receiver, administrator or manager appointed over the whole or any part of its assets or business, makes any composition or arrangement with its creditors or an order of resolution is made for its dissolution or liquidation
(other than for the purpose of solvent amalgamation or reconstruction), or takes or suffers any similar or analogous procedure, action or event in consequence of debt in any jurisdiction. 

 

	11.3	Termination by DEBIOPHARM in its Sole Discretion: 

  

	 	(a)	during the Joint Research Period, DEBIOPHARM may terminate the Agreement and the activities under the Joint Research Plan without cause and at any time by giving sixty
(60) days’ written notice to COMPANY, and with no further payments to COMPANY (aside from any previously accrued payment obligation); upon termination of the Agreement, COMPANY shall send a final invoice with the total fees and expenses
incurred during the Joint Research Period until the effective date of termination of the Agreement and the balance shall be either paid by DEBIOPHARM to COMPANY or reimbursed by COMPANY to DEBIOPHARM; and 

 

	 	(b)	 after the Joint Research Period, and until the grant of the first Marketing Authorization for the Product in the Territory, DEBIOPHARM may terminate
this Agreement at any time by giving ninety (90) days’ written notice to COMPANY, and with no further payments to COMPANY (aside from any previously accrued payment obligation), if DEBIOPHARM determines in its sole discretion that
scientific, technical, regulatory or economic reasons provide grounds for DEBIOPHARM to cease further pursuit of the development. After the grant of the first Marketing Authorization for the Product in the Territory, DEBIOPHARM may terminate this
Agreement at any time by giving one hundred and eighty (180) days’ written notice to COMPANY, and with no further payments to COMPANY (aside from any previously accrued payment obligation), if DEBIOPHARM determines in its sole discretion
that scientific, technical, regulatory or economic 

  
 28 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
reasons provide grounds for DEBIOPHARM to cease further pursuit of the purposes and objectives of this Agreement. 

 

	12.	EFFECT OF EXPIRY AND TERMINATION 

  

	12.1	No Impact on Prior Rights. Any termination or expiry of this Agreement shall be without prejudice to any rights or obligations which have accrued to either
Party. 

  

	12.2	Perpetual License. If this Agreement expires due to the expiry of the Royalty Term under Section 11.1 hereof, and is not earlier terminated, DEBIOPHARM
shall have, with effect from the date of expiry of this Agreement in a country of the Territory, a [***] license under the Licensed Rights to develop, have developed, improve, have improved, register, have registered, make, have made, use, have
used, market, store, package, label, sell, distribute, export and import the Lead Compound and/or the Product in the Field in such country of the Territory. 

 

	12.3	Termination by DEBIOPHARM for COMPANY’s Breach or Bankruptcy. If this Agreement is terminated by DEBIOPHARM pursuant to Section 11.2 hereof, DEBIOPHARM
shall retain a [***] license under the Licensed Rights to develop, have developed, improve, have improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Lead
Compound and/or the Product in the Field in the Territory. DEBIOPHARM shall also have the option, in its sole discretion, (i) to keep its inventory of Product in order to sell or to otherwise dispose of it or (ii) to require that COMPANY
repurchase such inventory of Product at cost from DEBIOPHARM. 

  

	12.4	Termination by COMPANY for DEBIOPHARM’s Breach or Bankruptcy. If this Agreement is terminated by COMPANY pursuant to Section 11.2 hereof, all licenses
granted to DEBIOPHARM under this Agreement shall terminate and all License Rights shall revert to COMPANY at no cost to COMPANY. DEBIOPHARM shall promptly make an accounting to COMPANY of the inventory of the Product it has in its stock as at the
date of such termination. COMPANY shall have the option, in its sole discretion, (i) to repurchase or to cause a Third Party or an Affiliate designated by COMPANY to repurchase DEBIOPHARM’s inventory of Product at cost from DEBIOPHARM, or
(ii) to authorize DEBIOPHARM to continue selling its inventory of Product for a period not to exceed six (6) months after such termination. DEBIOPHARM shall, at its cost, promptly assign or reassign to COMPANY or to a Third Party or
Affiliate designated by COMPANY the then existing Marketing Authorizations for the Product. 

  

	12.5	Termination by DEBIOPHARM. If this Agreement is terminated by DEBIOPHARM pursuant to Section 11.3 hereof, all licenses granted to DEBIOPHARM under this
Agreement shall terminate and all License Rights shall revert to COMPANY at no cost to COMPANY. DEBIOPHARM shall promptly make an accounting to COMPANY of the inventory of the Product it has in its stock as at the date of such termination. COMPANY
shall have the option, in its sole discretion, (i) to repurchase or to cause a Third Party or an Affiliate designated by COMPANY to repurchase DEBIOPHARM’s inventory of Product at cost from DEBIOPHARM, or (ii) to authorize DEBIOPHARM
to continue selling its existing inventory of Product for a period not to exceed [***] months after such termination. DEBIOPHARM shall, at its cost, promptly assign or reassign to COMPANY or to a Third Party or Affiliate designated by COMPANY the
then existing Marketing Authorizations for the Product. 

  

	12.6	 In the event this Agreement is terminated by DEBIOPHARM in accordance with Section 11.3 hereof, upon COMPANY request and undertaking to pay to
DEBIOPHARM [***]% of 

  
 29 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
all income and considerations received by COMPANY from any sublicensees for the Product in the Field: 

 

	 	(a)	the Data developed by DEBIOPHARM shall be transferred to COMPANY; and/or 

  

	 	(b)	DEBIOPHARM’s rights and interest in the Joint IP, created under the Joint Research Plan shall be exclusively licensed to COMPANY; and/or 

 

	 	(c)	DEBIOPHARM’s rights and interest in its sole IP created under the Joint Research Plan (tasks 14 through 25 except task 17) shall be [***] licensed to COMPANY, in
the Field and in the Territory, 

  

	    	it being understood that the obligation to pay [***]% of all income and considerations shall apply even if COMPANY requests for the transfer of only one of (a),
(b) or (c). 

  

	12.7	Other Consequences of an Early Termination. In the event of an early termination of this Agreement, 

 

	 	(a)	Either Party shall: 

  

	 	(i)	make its personnel reasonably available to the other Party as necessary to effect an orderly transition of development and commercial responsibilities, with the
reasonable cost of such personnel to be borne by the transferring Party for such services, and 

  

	 	(ii)	assign and transfer to the other Party, and execute all such documents as may be reasonably required to transfer hereunder, at no expense to the other Party, all of the
Party’s right, title and interest in the following to the extent they pertain to the Product and all Regulatory Filings, Marketing Authorizations and clinical trial agreements (to the extent assignable and not cancelled).

  

	 	(b)	No compensation or refund shall be due by either Party to the other Party, otherwise than damages for a material breach of this Agreement as determined by a court of
competent jurisdiction. 

  

	 	(c)	Unless otherwise agreed in writing by the Parties, the termination of this Agreement shall cause the automatic termination of all ancillary agreements related hereto
executed at any time as of the Effective Date, to the exception of non-disclosure agreements. 

  

	13.	WARRANTIES 

  

	13.1	Mutual Representations and Warranties. Either Party hereby represents and warrants as follows: 

 

	 	(a)	It is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power
and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement. 

 

	 	(b)	 On the Effective Date, (i) it has the full right and authority to enter into this Agreement and perform its obligations hereunder, (ii) is
not aware of any impediment that would prevent it from entering into this Agreement or that would 

  
 30 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
inhibit its ability to perform its obligations under this Agreement, (iii) it has taken all necessary corporate actions on its part required to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder, and (iv) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party that is enforceable against it
in accordance with its terms. 

  

	 	(c)	It has not entered into any agreement with any Third Party that is in conflict with the rights granted to the other Party under this Agreement, and has not taken any
action that would in any way prevent it from granting the rights granted to the other Party under this Agreement, or that would otherwise materially conflict with or materially adversely affect the rights granted to the other Party under this
Agreement. The performance and execution of this Agreement will not result in a breach of any other contract to which it is a party. 

  

	 	(d)	On the Effective Date, it is not aware of any action, suit, inquiry or investigation instituted by any Third Party that questions or threatens the validity of this
Agreement. 

  

	 	(e)	To the best of its knowledge, either Party has, on the Effective Date, the right to grant to the other Party the rights and licenses granted by such Party to the other
Party pursuant to this Agreement. 

  

	 	(f)	Either Party has, on the Effective Date, the necessary qualified personnel, equipment, Know-How and other means to perform its duties under this Agreement in a timely
manner in accordance with the terms hereof. 

  

	 	(g)	All necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be obtained by such Party in connection with the
execution, delivery and performance of this Agreement have been obtained. 

  

	13.2	COMPANY Representations and Warranties. COMPANY hereby represents and warrants that as of the Effective Date: 

 

	 	(a)	COMPANY has the right to grant to DEBIOPHARM the rights that COMPANY purports to grant DEBIOPHARM hereunder; COMPANY is the owner of, or Controls, the Licensed Rights
to the COMPANY Background IP, free and clear of all liens or security interests. 

  

	 	(b)	COMPANY has the right to grant to DEBIOPHARM the rights that COMPANY purports to grant DEBIOPHARM hereunder; COMPANY is the owner of, or Controls [***] the Licensed
Rights to the COMPANY UsiRNA Technology IP, free and clear of all liens or security interests. 

  

	 	(c)	COMPANY does not own or Control any other patents, know-how or intellectual property rights or otherwise have the right to use or practice any rights under any patents
that are not included in the Licensed Rights and that would be necessary for the development, manufacture, marketing, promotion, use, sale, import or export of the Lead Compound, the Backup Lead or the Product. 

 

	 	(d)	COMPANY is not aware of or has not received any claim or threat from Third Parties regarding infringement of the rights of any Third Party by the Licensed Rights.

  
 31 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	(e)	COMPANY is not aware of or has not given any notice to any Third Party about infringement by such Third Party of all or any portion of the Licensed Rights.

  

	 	(f)	COMPANY has disclosed to DEBIOPHARM the results of all preclinical and clinical testing and other Data relevant to the bladder cancer in its possession or control or
that are known to COMPANY on the Effective Date. COMPANY has not withheld any information, including Data that, in COMPANY’s reasonable judgement, is material to treatment of bladder cancer and to the performance of the Joint Research Plan. All
information and Data disclosed by COMPANY to DEBIOPHARM are complete and accurate in all material respects. 

  

	 	(g)	There is no litigation pending against COMPANY with respect to all or any portion of the Licensed Rights. 

 

	 	(h)	COMPANY has not received any research grant from, or entered into any agreement with, any governmental body with regard to the Collaboration Target, the Collaboration
Molecules or the Collaboration Candidates. 

  

	 	(i)	Exhibit 3 sets forth an accurate and complete list of all COMPANY Patents at the Effective Date. 

 

	 	(j)	COMPANY has not committed any act, or omitted to commit any act, that may cause the Patents to expire prematurely or be declared invalid or unenforceable.

  

	 	(k)	All documents and materials provided by COMPANY to DEBIOPHARM do not contain any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, are not misleading, and COMPANY has not failed to disclose to DEBIOPHARM any material and relevant fact or circumstance known to COMPANY relating to any of
the COMPANY Background IP that would be reasonably material to DEBIOPHARM in connection with this Agreement. 

  

	13.3	No Other Representations or Warranties. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT OR IN ANY OTHER WRITTEN AGREEMENT BETWEEN THE PARTIES, THE FOREGOING
REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF, AND EITHER PARTY EXPRESSLY DISCLAIMS, ANY AND ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF DESIGN, MERCHANTABILITY, AND FITNESS FOR A
PARTICULAR PURPOSE. 

  

	13.4	COMPANY’s covenants. 

  

	 	(a)	It will not grant any interest in the COMPANY Patents and in COMPANY’s interest in any Joint IP which is inconsistent with the terms and conditions of this
Agreement. 

  

	 	(b)	It will not transfer or assign, in all or in parts, its right, title or interest in or to the COMPANY Intellectual Property Rights or the Joint IP to any Third Party
without DEBIOPHARM’s prior written consent, which consent shall not be unreasonably withheld, except under a Change of Control event. 

  

	 	(c)	COMPANY covenants that COMPANY shall use its best efforts not to commit any act nor fail to perform any act that would negatively impact the rights granted to
DEBIOPHARM under the Licensed Rights or performance of this Agreement. 

  
 32 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	13.5	Mutual Covenants. Either Party covenants the following: 

  

	 	(a)	That it shall comply in all material respects with all Applicable Laws applicable to the license, development, manufacture or Commercialization of the Lead Compound,
the Backup Lead and the Product. 

  

	 	(b)	That it shall disclose promptly to the other Party all information in its possession or control and as to which it becomes aware concerning side effects, injury,
toxicity or sensitivity reaction and incidents or severity thereof with respect to the Lead Compound and the Product. 

  

	14.	INDEMNIFICATION 

  

	14.1	Indemnification by DEBIOPHARM. DEBIOPHARM agrees to indemnify, hold harmless and defend COMPANY and its Affiliates and their respective directors, officers,
employees and agents (collectively the “COMPANY Indemnitees”) from and against any and all Claims, expenses and/or loss, cost of defense (including without limitation reasonable attorneys’ fees, court costs, witness fees,
damages, judgments, fines and amounts paid in settlement) and any other amounts (collectively “Losses”) that any COMPANY Indemnitee becomes legally obligated to pay to a Third Party, because of any Claim or Claims against such
COMPANY Indemnitee to the extent that such Claim or Claims arise out of or results from (i) a material breach by DEBIOPHARM of its obligations under this Agreement; or (ii) the gross negligence or wilful misconduct of DEBIOPHARM, or its
Affiliates, or any of their respective officers, employees or agents, provided, however, that DEBIOPHARM shall not be required to indemnify the COMPANY Indemnitees for any Losses pursuant to this Section 14.1 to the extent that (i) such
Losses arise from a material breach by COMPANY or any of its Affiliates, directors, officers, employees or agents, of any of its obligations under this Agreement, (ii) such Losses arise or result from the gross negligence or wilful misconduct
of COMPANY or any of its Affiliates, directors, officers, employees or agents or (iii) DEBIOPHARM’s liability for such Losses is limited pursuant to Section 14.4 hereof. 

 

	14.2	Indemnification by COMPANY. COMPANY agrees to indemnify, hold harmless and defend DEBIOPHARM and its Affiliates and their respective directors, officers,
employees and agents (collectively the “DEBIOPHARM Indemnitees”) from and against any and all Claims, expenses and/or loss, cost of defense (including without limitation reasonable attorneys’ fees, court costs, witness fees,
damages, judgments, fines and amounts paid in settlement) and any other amounts (collectively “Losses”) that any DEBIOPHARM Indemnitee becomes legally obligated to pay to a Third Party, because of any Claim or Claims against such
DEBIOPHARM Indemnitee to the extent that such Claim or Claims arise out of or results from (i) a material breach by COMPANY of its obligations under this Agreement; or (ii) the gross negligence or wilful misconduct of COMPANY, or its
Affiliates, or any of their respective officers, employees or agents, provided, however, that COMPANY shall not be required to indemnify the DEBIOPHARM Indemnitees for any Losses pursuant to this Section 14.2 to the extent that (i) such
Losses arise from a material breach by DEBIOPHARM or any of its Affiliates, directors, officers, employees or agents, of any of its obligations under this Agreement, (ii) such Losses arise or result from the gross negligence or wilful
misconduct of DEBIOPHARM or any of its Affiliates, directors, officers employees or agents or (iii) COMPANY’s liability for such Losses is limited pursuant to Section 14.4 hereof. 

 

	14.3	 Claim. In the event of a Claim by a Third Party against either Party or any person entitled to indemnifications under this Agreement
(“Indemnified Party”), the Indemnified Party shall promptly notify the other Party having the indemnification obligation under this 

  
 33 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
Agreement with respect to such Claim (such Party, the “Indemnifying Party”) in writing of the Claim. The Indemnifying Party shall have the right to assume the defense of any such
Third Party Claim for which it is obligated to indemnify the Indemnified Party under this Article 14. The Indemnified Party shall cooperate with the Indemnifying Party (and its insurer) as the Indemnifying Party may reasonably request, and at the
Indemnifying Party’s sole cost and expense. The Indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any Claim that has been assumed by the Indemnifying Party. The
Indemnifying Party shall have no obligation to indemnify an Indemnified Party in connection with any settlement made without the Indemnifying Party’s prior written consent. If the Parties cannot agree as to the application of this Article 14 to
any Third Party Claim, the Parties may conduct separate defenses of such Claim, with each Party retaining the right to claim indemnification from the other in accordance with this Article 14 upon resolution of the underlying Claim.

  

	14.4	Exclusions. NOTWITHSTANDING ANYTHING EXPRESSED OR IMPLIED IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR LOSS
OF PROFITS, SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT. 

  

	15.	CONFIDENTIALITY 

  

	15.1	The Receiving Party agrees to keep confidential Confidential Information disclosed to it by the Disclosing Party, not to disclose the Confidential Information to any
Third Party unless it first obtains the written consent of the Disclosing Party and not to use the Confidential Information other than as permitted by the terms of this Agreement. DEBIOPHARM may disclose Confidential Information, without
COMPANY’s prior written consent, to its consultants, experts, (potential) subcontractors and manufacturers and business partners who have a legitimate need to have access to said Confidential Information, who shall be bound by confidentiality
and non-use commitments no less restrictive than those of this Agreement, and who shall have been made aware of the confidential nature of the Confidential Information. 

 

	15.2	The Receiving Party may disclose Confidential Information where disclosure is required by Applicable Laws, a court of competent jurisdiction, a Regulatory Authority or
stock exchange with authority over its business or securities, provided that the Receiving Party shall give the Disclosing Party as much notice of the disclosure as is permitted and practicable and, where possible, shall give the Disclosing Party an
opportunity to make representations in relation to the proposed disclosure. 

  

	15.3	In the event of the termination or expiry of this Agreement for any reason, the Receiving Party shall, within [***] Business Days of receipt of a written request from
the other Party at any time, return to the Disclosing Party or destroy copies of all Confidential Information received by it from the Disclosing Party, to the exception of (i) general electronic back-up copies not easily accessible and of
(ii) one (1) copy to ensure the performance by the Receiving Party of its obligations of confidentiality and non use. 

  

	15.4	The obligations of confidentiality set forth in this Article 15 shall survive the expiry or termination of this Agreement for a period of [***] years as of the date of
disclosure of such confidential information to the Receiving Party. 

  

	16.	PUBLICATIONS 

  

	16.1	 Publications: As of Effective Date and except as required by applicable law, neither Party shall publish any Data or results relating to the
Joint Research Plan and development of the Product without DEBIOPHARM’s prior written approval. COMPANY also agrees that 

  
 34 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
DEBIOPHARM has a valuable interest not to have Know-How published and therefore shall refrain from such publication, without DEBIOPHARM’s express prior agreement. DEBIOPHARM shall have the
right to publish pre-clinical and clinical data and results without prior approval of COMPANY as long as these data and results are not detrimental to the Product. For clarity, COMPANY has the right to publish on Formulation Technology IP and UNA
Platform Technology IP if such publication does not use or reference any Data, Joint IP or Inventions that arise under the Joint Research Plan; and further, COMPANY has the right to publish on COMPANY UsiRNA Technology if such publication is outside
of the Exclusive Field and does not use or reference any Data, Joint IP or Inventions that arise under the Joint Research Plan. DEBIOPHARM acknowledges that as of the Effective Date, two manuscripts, one on [***] and one on [***], have been
submitted by COMPANY for publication. 

  

	16.2	Clinical Trials. Notwithstanding the terms of Section 16.1 hereof, the Parties recognize that independent investigators, hospitals and universities may be
entrusted with the conduct of clinical trials of the Product. Such independent investigators, hospitals and universities are understood to operate in an academic environment and shall be allowed to release information regarding such clinical trials
of the Product in a manner consistent with academic standards. 

  

	16.3	Press Release. The Parties shall issue a mutually agreed upon joint press release within seventy-two (72) hours following the execution of this Agreement in
accordance with SEC regulations. The Parties will jointly discuss and agree in writing on any statement to the public regarding this Agreement or any of its terms, subject in each case to disclosure otherwise required by law or regulation as
determined in good faith by either Party. When either Party elects to make any such statement, it will give the other Party at least [***] Business Days’ notice to the other Party to review and comment on such statement.

  

	17.	NOTICES 

  

	17.1	Save as otherwise provided in this Agreement, any notice, demand or other communication (“Notice”) to be given by either Party under, or in connection
with, this Agreement shall be in writing and signed by, on behalf of, the Party giving it. Any Notice shall be served by sending it by fax to the number set out in Section 17.2 hereof, and delivering it by hand or by registered mail to the
address set out in Section 17.2 hereof and in each case marked for the attention of the relevant Party set out in Section 17.2 hereof (or as otherwise notified from time to time in accordance with the provisions of Section 17.3
hereof). Any Notice so served by fax or hand shall be deemed to have been duly given or made as follows: 

  

	 	(a)	if sent by fax, at the time of transmission; or 

  

	 	(b)	in the case of delivery by hand, when delivered, 

 provided that in each case where delivery by fax or by hand occurs after 6pm on a Business Day or on a day which is not a Business Day, service shall be deemed to occur at 9am on the next following
Business Day. References to time in this Section 17.1 are to local time in the country of the addressee. 
  

	17.2	The addressees and fax numbers of the Parties for the purpose of Section 17.1 hereof are as follows: 

 

	 	(a)	DEBIOPHARM 

  

							
		 	Address:	 	Debiopharm S.A.	 	

  
 35 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

							
		 		 	Forum “après-demain”	 	
		 		 	Chemin Messidor 5-7	 	
		 		 	CP 5911	 	
		 		 	1002 Lausanne	 	
		 		 	Switzerland	 	
				
		 	Fax:	 		 	
				
		 	To the attention of:	 		 	
				
		 	with a copy to	 		 	

  

	 	(b)	COMPANY 

  

							
		 	Address:	 	Marina Biotech, Inc.	 	
		 		 	3830 Monte Villa Parkway	 	
		 		 	Bothell, WA 98021	 	
		 		 	U.S.A.	 	
				
		 	Fax:	 		 	
				
		 	To the attention of:	 		 	
				
		 	With a copy to	 		 	

  

	17.3	A Party may notify the other Party of a change to its name, relevant addressee, address or fax number for the purposes of this Article 17, provided that such notice
shall only be effective on: 

  

	 	(a)	the date specified in the notification as the date on which the change is to take place; or 

 

	 	(b)	if no date is specified or the date is less than five (5) Business Days after the date on which notice is given, the date following five (5) Business Days
after notice of any change has been given. 

  

	17.4	In providing service it shall be sufficient to prove that the envelope containing such Notice was properly addressed and delivered to the address shown thereon or that
the facsimile transmission was made and a facsimile confirmation report was received, as the case may be. 

  

	18.	GOVERNING LAW AND DISPUTE RESOLUTION 

  

	18.1	This Agreement shall be governed by and construed under the laws of England and Wales, without regard to conflict of law principles. 

 

	18.2	The Parties agree that, except as set forth in Section 18.4 hereof, the procedures set forth in Sections 18.3 through 18.8 hereof shall be the exclusive mechanism
for resolving any dispute, disagreement, controversy or Claim arising under, out of or relating to this Agreement and any subsequent amendments to this Agreement, including without limitation its formation, validity, binding effect, interpretation,
performance, breach or termination, as well as non contractual Claims arising out of the subject matter of this Agreement. 

  
 36 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	18.3	Unless otherwise set forth in this Agreement, in the event of a dispute, the Parties shall remain bound by the terms of this Agreement. The dispute shall be submitted
to the other Party by written Notice in accordance with Article 17 hereof, prior to any action under Sections 18.6 and 18.7 hereof. The appropriate executive officers of the Parties shall attempt in good faith to resolve the dispute within [***]
days as of receipt by the other Party of the aforementioned Notice. 

  

	18.4	All disputes between the Parties relating to scientific matters arising out of this Agreement shall be referred to a scientific Expert agreed by the executive officers
of the Parties. If there is no agreement as to the selection of a scientific Expert within [***] days as of receipt by the other Party of the written notice regarding the dispute, or the dispute is not resolved by the executive officers of the
Parties with the assistance of such a scientific Expert within [***] days of the matter being referred to him/her, then the dispute shall be settled in accordance with Section 18.6 and 18.7 hereof. 

 

	18.5	If the Parties are unable to resolve a given dispute pursuant to Section 18.3 hereof within [***] days of notifying such dispute to the other Party, either Party
shall have the dispute settled by mediation and binding arbitration in accordance with Sections 18.6 and 18.7 hereof. 

  

	18.6	The parties shall provided they have exhausted the mechanisms under 18.3 or 18.4 in the event of a scientific matter, and 18.5, without prejudice to any other
proceedings, seek to settle any dispute arising out of or in connection with the present contract in accordance with the ICC ADR Rules in London, UK. If the dispute is not resolved by the Parties with the assistance of mediation within [***] days of
the matter being referred to mediation, then the dispute shall be settled by arbitration as set out in Section 18.7 hereof. 

  

	18.7	Provided the Parties have exhausted the mechanisms under 18.3 (or 18.4) and 18.6, any dispute arising out of or in connection with this Agreement, including any
question or dispute regarding its existence, validity or termination, shall be referred to and finally settled by arbitration under the Rules of the International Chamber of Commerce (the “ICC Rules”). The arbitral tribunal shall
consist of three (3) arbitrators. Either Party shall nominate one (1) arbitrator. The third arbitrator, who shall act as the chairman of the tribunal, may be nominated by those two arbitrators within [***] Business Days of the nomination
of the second arbitrator. If the arbitrators nominated by the Parties fail to nominate the third arbitrator within this period of [***] Business Days, the ICC shall proceed with the appointment of the third arbitrator in accordance with the ICC
Rules. The seat, or legal place, of arbitration shall be London. The language to be used in the arbitral proceedings shall be English. The arbitration proceedings shall be kept confidential and shall not be disclosed to the public.

  

	18.8	Without resulting in the waiver of any remedy under this Agreement, Sections 18.6 and 18.7 hereof shall not preclude either Party from seeking injunctive relief from
any court of competent jurisdiction pending the commencement of arbitral proceedings. 

  

	19.	MISCELLANEOUS 

  

	19.1	 Independent Contractor. Neither Party shall be deemed an agent or representative of the other Party for any purpose, and this Agreement shall
not create or establish an agency. Except as may be specifically provided herein, neither Party shall have any right, power, or authority, nor shall they represent themselves as having authority to assume, create or incur any expense, liability or
obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other Party for any purpose. The Parties agree that the relationship of DEBIOPHARM and COMPANY established by this Agreement is that

  
 37 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	 	 
of an independent licensee and licensor. This Agreement does not, is not intended to, and shall not be construed to, establish a partnership or joint venture. 

 

	19.2	Third Parties. This Agreement is neither expressly nor impliedly made for the benefit of any entity other than the Parties, and neither any Third Party nor any
Affiliate shall have any claim against either Party on the basis of this Agreement. 

  

	19.3	Further Actions. From time to time during the Term, either Party shall at the reasonable request of the other Party (i) deliver to such other Party such
records, data or other documents consistent with the provisions of this Agreement, (ii) execute and deliver, or cause to be delivered, all such assignments, consents, documents or further instruments of transfer or license, and (iii) take
or cause to be taken all such other actions, as such other Party may reasonably deem necessary or desirable in order for such Party to obtain the full benefits of this Agreement and the transactions contemplated thereby, including without limitation
registration of the license granted under this Agreement. 

  

	19.4	Government Approvals. Either Party shall cooperate with the other Party and use Reasonable Commercial Efforts to make all registrations, filings and
applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, permits and waivers, if required, and to do all other things necessary or desirable for the consummation of the
transaction as contemplated hereby. 

  

	19.5	Entire Agreement. This Agreement, including all the Exhibits, sets forth the entire understanding of the Parties with respect to the subject matter hereof and
cancels and supersedes all previous communications, representations or understandings, and agreements, whether oral or written, between the Parties relating to the subject matter hereof. The Non-disclosure Agreement entered into by and between
DEBIOPHARM and COMPANY on February 2, 2010 (the “Non-disclosure Agreement”) is hereby terminated on the Effective Date, but any provision of the Non-disclosure Agreement that is intended to survive termination shall survive
such termination with regard to any Confidential Information disclosed by either Party under the Non-disclosure Agreement. Should there be any conflict in any of the terms set forth in this Agreement and any of the Exhibits, the terms of this
Agreement shall control. 

  

	19.6	Amendment. No modification or amendment of any provision of this Agreement shall be valid or effective unless made in writing and signed by duly authorized
officers of each Party. 

  

	19.7	Assignment. Except to the extent otherwise expressly provided elsewhere in this Agreement, neither Party to this Agreement may assign, transfer, charge or
otherwise encumber this Agreement or any right, benefit or interest under it, nor transfer it without the prior written consent of the other Party provided that a Party may assign this Agreement to any Affiliate or as a result of Change of Control,
provided that such successor agrees in writing to be bound by the terms of this Agreement as if it were the assigning Party. This Agreement shall be binding upon the successors and permitted assigns of the Parties. 

 

	19.8	Performance by Affiliates. Either Party acknowledges that obligations under this Agreement may be performed by Affiliates of DEBIOPHARM and COMPANY. Either Party
guarantees and warrants any performance of this Agreement by its Affiliates. Wherever in this Agreement the Parties delegate responsibility to Affiliates, the Parties agree that such Affiliates may not make decisions inconsistent with this
Agreement, amend the terms of this Agreement or act contrary to its terms in any way. 

  
 38 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

	19.9	Force Majeure. Any prevention, delay or interruption of performance (collectively “Delay”) by either Party under this Agreement shall not be a
breach of this Agreement if and to the extent caused by occurrences beyond the reasonable control of the Party affected by the force majeure, including but not limited to acts of God, embargoes, governmental restrictions, terrorism, general strike,
fire, flood, earthquake, explosion, riots, wars (declared or undeclared), civil disorder, rebellion or sabotage. The affected Party shall immediately notify the other Party upon the commencement and end of the Delay. During the Delay, any time for
performance hereunder by either Party shall be extended by the actual time of Delay. If the Delay resulting from the force majeure exceeds six (6) months, the other Party, upon written notice to the affected Party, may extend the Term for an
amount of time equal to the Delay. 

  

	19.10	Severability. If any of the provisions of this Agreement are held to be void or unenforceable by a court of competent jurisdiction, then such void or
unenforceable provisions shall be replaced by valid and enforceable provisions which will achieve as far as possible the economic business intentions of the Parties. However, the remainder of this Agreement will remain in full force and effect,
provided that the material interests of the Parties are not affected i.e., the Parties would presumably have concluded this Agreement without the unenforceable provisions. 

 

	19.11	Waiver. A waiver of any default, breach or non-compliance under this Agreement is not effective unless signed by the Party to be bound by the waiver. No waiver
will be inferred from or implied by any failure to act or delay in acting by a Party in respect of any default, breach, non-observance or by anything done or omitted to be done by the other Party. The waiver by a Party of any default, breach or
non-compliance under this Agreement will not operate as a waiver of that Party’s rights under this Agreement in respect of any continuing or subsequent default, breach or non-compliance. 

 

	19.12	No Right to Use Names. Except as otherwise provided herein, this Agreement provides no grant of right to a Party, express or implied, to use in any manner the
corporate or business names or trademarks of the other Party or its Affiliates. 

  

	19.13	Legal Compliance. Either Party shall observe any and all Applicable Laws in the conduct of its activities under this Agreement, and undertakes to make and fulfil
any and all formalities in connection with all such activities which may be required under Applicable Laws. The Parties further agree to comply in all means with the current applicable Good Laboratory Practices, Good Clinical Practices and Good
Manufacturing Practices, and apply a high standard of ethics in the conduct of its activities under this Agreement. 

  

	19.14	Language. This Agreement has been drafted in the English language, and the English language shall control its interpretation. Any translation shall be for
convenience purposes only and shall not be legally binding. 

  

	19.15	Interpretation. The Parties agree that the terms and conditions of this Agreement are the result of negotiations between the Parties and that this Agreement
shall not be construed in favour of or against either Party by reason of the extent to which such a Party participated in the preparation of this Agreement. 

 

	19.16	Counterparts. The Parties shall execute this Agreement in two (2) counterparts, either of which the Parties shall deem an original, but which together shall
constitute one and the same instrument. 

 [SIGNATURE PAGE FOLLOWS] 

  
 39 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives as of the Effective Date. 
  

											
	DEBIOPHARM S.A.	  		  	MARINA BIOTECH, INC.	  	
				
	 /s/ Dr. R.Y. Mauvernay
	  		  	 /s/ J. Michael French
	  	
	Name:	  	Dr. R.Y. Mauvernay	  		  	Name:	  	J. Michael French	  	
	Title:	  	President	  		  	Title:	  	President and CEO	  	
		  		  		  		  		  	
	Date:	  	 February 3, 2011
	  		  	Date:	  	 3 February 2011
	  	

  

			
	 Exhibits:
	 	 
		
	Exhibit 1:	 	Collaboration Targets
	Exhibit 2:	 	Joint Research Plan
	Exhibit 3:	 	COMPANY Patents
	Exhibit 3(a):	 	Formulation Technology IP
	Exhibit 3(b)	 	UNA Platform Technology IP
	Exhibit 3(c)	 	COMPANY UsiRNA Technology IP
	Exhibit 4:	 	Development Plan (to be inserted upon selection of Lead Compound)
	Exhibit 5:	 	Product (to be inserted upon selection of Lead Compound)

  
 40 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

 Exhibit 1 
 Collaboration Targets 
 [***] 
 [***] 
 [***] others (to be identified by Debiopharm and included in this Exhibit) 

  
 41 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

 Exhibit 2 
 Joint Research Plan 
 Debiopharm – Marina Biotech Collaboration

 Clinical Development of Formulated UsiRNA for 

Treatment of Bladder Cancer 
 [***] 

  
 42 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

 Exhibit 3 
 COMPANY Patents 
 Exhibit 3a (Formulation Technology IP): 

 

					
	Serial No.	 	Filing date	 	COMPANY ref
	 [***]
	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]
	 To be completed if
applicable
	 	 	 	 

 It is to be noted that the formulation to be used in the Product is not known at the Effective Date. The Parties agree to review and complete this Exhibit 3a with all relevant Formulation Technology IP
after the Lead Compound and Backup Lead are identified by DEBIOPHARM. 
 Exhibit 3b (UNA Platform Technology IP): 

 

					
	Serial No.	 	Filing date	 	COMPANY ref
	 [***]
	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]
	 To be completed if
applicable
	 	 	 	 

 Exhibit 3c (COMPANY UsiRNA Technology IP): 
  

					
	Serial No.	 	Filing date	 	COMPANY ref
	 [***]
	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]
	 To be completed if
applicable
	 	 	 	 

 * The sequences specific to the [***] gene target are contained in the [***] patent application, which covers other gene targets not included in this Agreement. This application will be used as a priority
document for two to-be-filed PCT patent applications. One PCT application will be specific to the [***] target and the second PCT application will cover the dual UsiRNA approach specific to the combination of [***] and [***]. Exhibit 3c will be
revised after such filing and after agreement between the Parties. 

  
 43 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

 Exhibit 4 
 Development Plan 
 (to be inserted upon selection of Lead Compound ) 

  
 44 

 [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
  

 Exhibit 5 
 Product 
 (To be inserted upon selection of Lead Compound) 

  
 45Credit Agreement

 Exhibit 10.1 
 EXECUTION COPY 
  

 
  

CREDIT AGREEMENT 
 Dated as of May 10, 2011 
 among 

iGATE CORPORATION, 
 as Borrower, 
 DBS BANK LTD., SINGAPORE, 

as Administrative Agent, 
 and 
 THE OTHER LENDERS PARTY HERETO, 

and 
 DBS BANK
LTD., BANGALORE BRANCH, 
 as Lead Arranger 
  

 

 Table of Contents 

 

							
	 	  	 	  	Page	 
	ARTICLE I	  
	
	DEFINITIONS AND ACCOUNTING TERMS	  
			
	 Section 1.01
	  	Defined Terms	  	 	1	  
	 Section 1.02
	  	Other Interpretive Provisions	  	 	44	  
	 Section 1.03
	  	Accounting Terms	  	 	44	  
	 Section 1.04
	  	Rounding	  	 	45	  
	 Section 1.05
	  	References to Agreements, Laws, Etc.	  	 	45	  
	 Section 1.06
	  	Times of Day	  	 	45	  
	 Section 1.07
	  	Timing of Payment or Performance	  	 	45	  
	 Section 1.08
	  	Currency Equivalents Generally	  	 	45	  
	
	ARTICLE II	  
	
	THE COMMITMENTS AND BORROWINGS	  
			
	 Section 2.01
	  	The Loans	  	 	46	  
	 Section 2.02
	  	Borrowings, Conversions and Continuations of Loans	  	 	46	  
	 Section 2.03
	  	[Reserved]	  	 	47	  
	 Section 2.04
	  	[Reserved]	  	 	47	  
	 Section 2.05
	  	Prepayments	  	 	47	  
	 Section 2.06
	  	Termination or Reduction of Commitments	  	 	48	  
	 Section 2.07
	  	Repayment of Loans	  	 	49	  
	 Section 2.08
	  	Interest	  	 	49	  
	 Section 2.09
	  	Fees	  	 	50	  
	 Section 2.10
	  	Computation of Interest and Fees	  	 	50	  
	 Section 2.11
	  	Evidence of Indebtedness	  	 	50	  
	 Section 2.12
	  	Payments Generally	  	 	51	  
	 Section 2.13
	  	Sharing of Payments	  	 	53	  
	 Section 2.14
	  	[Reserved]	  	 	53	  
	
	ARTICLE III	  
	
	TAXES, INCREASED COSTS PROTECTION AND ILLEGALITY	  
			
	 Section 3.01
	  	Taxes	  	 	53	  
	 Section 3.02
	  	Illegality	  	 	55	  
	 Section 3.03
	  	Inability to Determine Rates	  	 	56	  
	 Section 3.04
	  	Increased Cost and Reduced Return; Capital Adequacy; Reserves on Eurocurrency Rate Loans	  	 	56	  
	 Section 3.05
	  	Funding Losses	  	 	57	  
	 Section 3.06
	  	Matters Applicable to All Requests for Compensation	  	 	58	  
	 Section 3.07
	  	Replacement of Lenders Under Certain Circumstances	  	 	59	  
	 Section 3.08
	  	Survival	  	 	59	  

  
 -i-

							
	 	  	 	  	Page	 
	ARTICLE IV	  
	
	CONDITIONS PRECEDENT	  
			
	 Section 4.01
	  	Conditions of Initial Borrowing	  	 	60	  
	 Section 4.02
	  	Conditions to All Borrowings	  	 	61	  
	 Section 4.03
	  	Closing Date	  	 	61	  
	
	ARTICLE V	  
	
	REPRESENTATIONS AND WARRANTIES	  
			
	 Section 5.01
	  	Existence, Qualification and Power; Compliance with Laws	  	 	61	  
	 Section 5.02
	  	Authorization; No Contravention	  	 	62	  
	 Section 5.03
	  	Governmental Authorization; Other Consents	  	 	62	  
	 Section 5.04
	  	Binding Effect	  	 	62	  
	 Section 5.05
	  	Financial Statements; No Material Adverse Effect	  	 	62	  
	 Section 5.06
	  	Litigation	  	 	63	  
	 Section 5.07
	  	Ownership of Property; Liens	  	 	63	  
	 Section 5.08
	  	Environmental Compliance	  	 	63	  
	 Section 5.09
	  	Taxes	  	 	64	  
	 Section 5.10
	  	Compliance with ERISA	  	 	64	  
	 Section 5.11
	  	Subsidiaries; Equity Interests	  	 	64	  
	 Section 5.12
	  	Margin Regulations; Investment Company Act	  	 	64	  
	 Section 5.13
	  	Disclosure	  	 	65	  
	 Section 5.14
	  	Intellectual Property; Licenses, Etc.	  	 	65	  
	 Section 5.15
	  	Solvency	  	 	65	  
	 Section 5.16
	  	Designation of Senior Debt	  	 	65	  
	
	ARTICLE VI	  
	
	AFFIRMATIVE COVENANTS	  
			
	 Section 6.01
	  	Financial Statements	  	 	65	  
	 Section 6.02
	  	Certificates; Other Information	  	 	66	  
	 Section 6.03
	  	Notices	  	 	67	  
	 Section 6.04
	  	Reserved	  	 	68	  
	 Section 6.05
	  	Maintenance of Existence	  	 	68	  
	 Section 6.06
	  	Maintenance of Properties	  	 	68	  
	 Section 6.07
	  	Maintenance of Insurance	  	 	68	  
	 Section 6.08
	  	Compliance with Laws	  	 	68	  
	 Section 6.09
	  	Books and Records	  	 	68	  
	 Section 6.10
	  	Inspection Rights	  	 	68	  
	 Section 6.11
	  	Covenant to Guarantee Obligations	  	 	69	  
	 Section 6.12
	  	Use of Proceeds	  	 	70	  
	 Section 6.13
	  	[Reserved]	  	 	70	  
	 Section 6.14
	  	Designation of Subsidiaries	  	 	70	  
	 Section 6.15
	  	Payment of Taxes	  	 	70	  
	 Section 6.16
	  	Post-Closing Obligations	  	 	70	  

  
 -ii-

							
	 	  	 	  	Page	 
	ARTICLE VII	  
	
	NEGATIVE COVENANTS	  
	 Section 7.01
	  	Liens	  	 	71	  
	 Section 7.02
	  	[RESERVED]	  	 	71	  
	 Section 7.03
	  	Indebtedness	  	 	71	  
	 Section 7.04
	  	Fundamental Changes	  	 	75	  
	 Section 7.05
	  	Dispositions	  	 	76	  
	 Section 7.06
	  	Restricted Payments	  	 	77	  
	 Section 7.07
	  	[RESERVED]	  	 	79	  
	 Section 7.08
	  	Transactions with Affiliates	  	 	79	  
	 Section 7.09
	  	Limitation on Restrictions on Distributions from Restricted Subsidiaries	  	 	81	  
	
	ARTICLE VIII	  
	
	EVENTS OF DEFAULT AND REMEDIES	  
			
	 Section 8.01
	  	Events of Default	  	 	83	  
	 Section 8.02
	  	Remedies upon Event of Default	  	 	85	  
	 Section 8.03
	  	Exclusion of Immaterial Subsidiaries	  	 	85	  
	 Section 8.04
	  	Application of Funds	  	 	86	  
	
	ARTICLE IX	  
	
	ADMINISTRATIVE AGENT AND OTHER AGENTS	  
			
	 Section 9.01
	  	Appointment and Authorization of Agents	  	 	86	  
	 Section 9.02
	  	[Reserved].	  	 	87	  
	 Section 9.03
	  	Delegation of Duties	  	 	87	  
	 Section 9.04
	  	Liability of Agents	  	 	87	  
	 Section 9.05
	  	Reliance by Agents	  	 	87	  
	 Section 9.06
	  	Notice of Default	  	 	88	  
	 Section 9.07
	  	Credit Decision; Disclosure of Information by Agents	  	 	88	  
	 Section 9.08
	  	Indemnification of Agents and Expense Reimbursement	  	 	88	  
	 Section 9.09
	  	Agents in Their Individual Capacities	  	 	89	  
	 Section 9.10
	  	Successor Agents	  	 	89	  
	 Section 9.11
	  	Administrative Agent May File Proofs of Claim	  	 	89	  
	 Section 9.12
	  	Guaranty Matters	  	 	90	  
	 Section 9.13
	  	Other Agents; Arrangers and Managers	  	 	90	  
	 Section 9.14
	  	Appointment of Supplemental Administrative Agents	  	 	91	  
	 Section 9.15
	  	Withholding Tax	  	 	91	  
	
	ARTICLE X	  
	
	MISCELLANEOUS	  
			
	 Section 10.01
	  	Amendments, Etc.	  	 	92	  
	 Section 10.02
	  	Notices and Other Communications; Facsimile Copies	  	 	93	  
	 Section 10.03
	  	No Waiver; Cumulative Remedies	  	 	94	  
	 Section 10.04
	  	Attorney Costs and Expenses	  	 	94	  

  
 -iii-

							
	 	  	 	  	Page	 
	 Section 10.05
	  	Indemnification by the Borrower	  	 	94	  
	 Section 10.06
	  	Payments Set Aside	  	 	95	  
	 Section 10.07
	  	Successors and Assigns	  	 	96	  
	 Section 10.08
	  	Confidentiality	  	 	99	  
	 Section 10.09
	  	Setoff	  	 	99	  
	 Section 10.10
	  	Counterparts	  	 	100	  
	 Section 10.11
	  	Integration	  	 	100	  
	 Section 10.12
	  	Survival of Representations and Warranties	  	 	100	  
	 Section 10.13
	  	Severability	  	 	100	  
	 Section 10.14
	  	GOVERNING LAW	  	 	100	  
	 Section 10.15
	  	WAIVER OF RIGHT TO TRIAL BY JURY	  	 	101	  
	 Section 10.16
	  	Binding Effect	  	 	101	  
	 Section 10.17
	  	Judgment Currency	  	 	101	  
	 Section 10.18
	  	Lender Action	  	 	101	  
	 Section 10.19
	  	USA PATRIOT Act	  	 	102	  

									
		
	SCHEDULES	  			
				
	 1
	 	 —
	    	Closing Date Guarantors	  			
	 1.01A
	 	 —
	    	[Reserved]	  			
	 1.01B
	 	 —
	    	[Reserved]	  			
	 1.01C
	 	 —
	    	Excluded Subsidiaries	  			
	 1.01D
	 	 —
	    	Material Real Property	  			
	 2.01
	 	 —
	    	Revolving Credit Commitment	  			
	 5.06
	 	 —
	    	Litigation	  			
	 5.10(a)
	 	 —
	    	Compliance with ERISA	  			
	 5.11
	 	 —
	    	Subsidiaries	  			
	 7.02
	 	 —
	    	[Reserved]	  			
	 7.05
	 	 —
	    	[Reserved]	  			
	 7.08
	 	 —
	    	[Reserved]	  			
	 7.13
	 	 —
	    	[Reserved]	  			
	 10.02
	 	 —
	    	Administrative Agent’s Office, Certain Addresses for Notices	  			
		
	EXHIBITS	  			
		
	 Form of
	  			
				
	 A
	 	 —
	    	Committed Loan Notice	  			
	 B
	 	 —
	    	[Reserved]	  			
	 C
	 	 —
	    	Revolving Credit Note	  			
	 D
	 	 —
	    	Compliance Certificate	  			
	 E
	 	 —
	    	Assignment and Assumption	  			
	 F
	 	 —
	    	Guaranty	  			
	 G
	 	 —
	    	[Reserved]	  			
	 H
	 	 —
	    	Opinion Matters — New York Counsel to Loan Parties	  			
	 I
	 	 —
	    	[Reserved]	  			
	 J
	 	 —
	    	Officer’s Certificate	  			

  
 -iv-

 CREDIT AGREEMENT 

This CREDIT AGREEMENT (this “Agreement”) is entered into as of May 10, 2011, among iGATE CORPORATION, a
Pennsylvania corporation (the “Borrower”), the banks, financial institutions and other institutional lenders party hereto (each, a “Lender”; together with any other person that becomes a Lender hereunder pursuant to
Section 10.07, the “Lenders”), DBS BANK LTD., SINGAPORE (“DBS”), as administrative agent (or any successor appointed pursuant to Section 9.10, the “Administrative Agent”) for
the Lenders and the other Secured Parties (each as hereinafter defined), and DBS BANK LTD., BANGALORE BRANCH, as lead arranger (the “Lead Arranger”). 
 PRELIMINARY STATEMENTS 
 1. The Borrower intends to acquire indirectly (the
“Acquisition”) 60.2%, on a fully diluted basis, of the Equity Interests (as this and other capitalized terms used in these preliminary statements are defined in Section 1.01 below) of Patni Computer Systems Limited (the
“Company”) pursuant to (a) that certain Share Purchase Agreement dated January 10, 2011 among Pan-Asia iGATE Solutions, a company incorporated under the laws of Mauritius and a wholly-owned Subsidiary of the Borrower
(“iGATE Mauritius”), and iGATE Global Solutions Limited, a company incorporated under the laws of India, and certain sellers acting through each of Mr. Gajendra K. Patni, Mr. Ashok K. Patni and
Mr. Narendra K. Patni, (b) that certain Share Purchase Agreement dated January 10, 2011 between iGATE Mauritius and General Atlantic Mauritius Limited and (c) that certain Securities Purchase Agreement dated January 10,
2011 between iGATE Mauritius and General Atlantic Mauritius Limited. 
 2. The Borrower has requested that, concurrently with
the consummation of the Transactions, the Lenders extend credit to the Borrower in the form of Revolving Credit Commitments in an aggregate principal amount of the Dollar Equivalent of $50,000,000 (the “Revolving Credit Facility”).

 3. The proceeds of Revolving Credit Loans will be used for working capital and other general corporate purposes of the
Borrower, the Company and their Subsidiaries. 
 4. The Lenders have indicated their willingness to lend on the terms and
subject to the conditions set forth herein. 
 In consideration of the mutual covenants and agreements herein contained, the
parties hereto covenant and agree as follows: 
 ARTICLE I 

Definitions and Accounting Terms 

Section 1.01 Defined Terms. As used in this Agreement, the following terms shall have the
meanings set forth below: 
 “Acquired Indebtedness” means Indebtedness (a) of a Person or any of its
Subsidiaries existing at the time such Person becomes a Restricted Subsidiary, or (b) assumed in connection with the acquisition of assets from such Person, in each case whether or not Incurred by such Person in connection with such Person
becoming a Restricted Subsidiary of the Borrower or such acquisition or (c) of a Person at the time such Person merges with or into or consolidates or otherwise combines with the Borrower or any Restricted Subsidiary. Acquired Indebtedness
shall be deemed to have been Incurred, with respect to clause (a) of the preceding sentence, on the date such Person becomes a Restricted Subsidiary and, with 

 
respect to clause (b) of the preceding sentence, on the date of consummation of such acquisition of assets and, with respect to clause (c) of the preceding sentence, on the date of the
relevant merger, consolidation or other combination. 
 “Acquisition” has the meaning specified in the
preliminary statements of this Agreement. 
 “Additional Assets” means (a) any property or assets (other
than cash and Capital Stock) used or to be used by the Borrower, a Restricted Subsidiary or otherwise useful in a Similar Business (it being understood that capital expenditures on property or assets already used in a Similar Business or to replace
any property or assets that are the subject of such Disposition shall be deemed an investment in Additional Assets); (b) the Capital Stock of a Person that is engaged in a Similar Business and becomes a Restricted Subsidiary as a result of the
acquisition of such Capital Stock by the Borrower or a Restricted Subsidiary of the Borrower; or (c) Capital Stock constituting a minority interest in any Person that at such time is a Restricted Subsidiary of the Borrower. 

“Administrative Agent” means, subject to Section 9.13, DBS, in its capacity as administrative agent under
the Loan Documents, or any successor administrative agent appointed in accordance with Section 9.10. 

“Administrative Agent’s Office” means, with respect to any currency, the Administrative Agent’s address and,
as appropriate, account as set forth on Schedule 10.02 with respect to such currency, or such other address or account as the Administrative Agent may from time to time notify the Borrower and the Lenders. 

“Administrative Questionnaire” means an Administrative Questionnaire in a form supplied by the Administrative Agent.

 “Affiliate” of any specified Person means any other Person, directly or indirectly, controlling or
controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, “control” when used with respect to any Person means the power to direct the management and policies of such Person,
directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 

“Agent-Related Persons” means the Agents, together with their respective Affiliates, and the officers, directors,
employees, agents and attorneys-in-fact of such Persons and Affiliates. 
 “Agents” means, collectively, the
Administrative Agent and the Supplemental Administrative Agents (if any). 
 “Aggregate Commitments” means the
Commitments of all the Lenders. 
 “Agreement” means this Credit Agreement. 

“Agreement Currency” has the meaning specified in Section 10.17. 

“Apax” means Apax Partners LLP and funds or partnerships related, managed or advised by any of them or any Affiliate of
any of them. 
 “Applicable Lending Office” means for any Lender, such Lender’s office, branch or
affiliate designated for Eurocurrency Rate Loans or Base Rate Loans, as applicable, as notified to the 

  
 -2-

 
Administrative Agent and the Borrower or as otherwise specified in the Assignment and Assumption pursuant to which such Lender became a party hereto, any of which offices may, subject to
Section 3.01(e) and Section 3.02, be changed by such Lender upon 10 days’ prior written notice to the Administrative Agent and the Borrower; provided that for the purposes of the definition of “Excluded
Taxes” and Section 3.01, any such change shall be deemed an assignment made pursuant to an Assignment and Assumption. 
 “Applicable Rate” means a percentage per annum equal to (A) for Eurocurrency Rate Loans, 2.80% and (B) for Base Rate Loans, 1.80%. 

“Approved Fund” means, with respect to any Lender, any Fund that is administered, advised or managed by (a) such
Lender, (b) an Affiliate of such Lender or (c) an entity or an Affiliate of an entity that administers, advises or manages such Lender. 
 “Assignees” has the meaning specified in Section 10.07(b). 
 “Assignment and Assumption” means an Assignment and Assumption substantially in the form of Exhibit E. 

“Associate” means (i) any Person engaged in a Similar Business of which the Borrower or its Restricted Subsidiaries
are the legal and beneficial owners of between 20% and 50% of all outstanding Voting Stock and (ii) any joint venture entered into by the Borrower or any Restricted Subsidiary of the Borrower. 

“Attorney Costs” means and includes all reasonable fees, expenses and disbursements of any law firm or other external
legal counsel. 
 “Audited Financial Statements” means the audited balance sheets of the Borrower for the
fiscal years ended December 31, 2007, December 31, 2008 and December 31, 2009 and the related audited statements of income and cash flows of the Borrower for the fiscal years ended December 31, 2007, December 31,
2008 and December 31, 2009. 
 “Base Rate” means with respect to Dollar-denominated
Loans, a fluctuating interest rate per annum in effect from time to time, which rate per annum shall at all times be equal to the highest of (a) 1% per annum above the one-month LIBOR Rate (as determined pursuant to clause
(a) of the definition thereof), (b) the Prime Rate, and (c) the Federal Funds Effective Rate plus  1/2 of 1%. 
 “Base Rate Loan” means a
Loan that bears interest at a rate based on the Base Rate. 
 “Board of Directors” means (a) with respect
to the Borrower or any corporation, the board of directors or managers, as applicable, of the corporation, or any duly authorized committee thereof; (b) with respect to any partnership, the board of directors or other governing body of the
general partner of the partnership or any duly authorized committee thereof; and (c) with respect to any other Person, the board or any duly authorized committee of such Person serving a similar function. Whenever any provision requires any
action or determination to be made by, or any approval of, a Board of Directors, such action, determination or approval shall be deemed to have been taken or made if approved by a majority of the directors on any such Board of Directors (whether or
not such action or approval is taken as part of a formal board meeting or as a formal board approval). 

“Borrower” has the meaning set forth in the recitals to this Agreement. 

  
 -3-

 “Borrowing” means Loans of the same Type, made, converted or continued on
the same date in the same currency and, in the case of Eurocurrency Rate Loans, as to which a single Interest Period is in effect. 
 “Business Day” means any day that is not a Saturday, Sunday or other day on which commercial banks in New York City and Toronto are authorized or required by law to remain closed;
provided that when used in connection with a Eurocurrency Rate Loan denominated in Dollars, the term “Business Day” shall also exclude any day on which banks are not open for dealings in Dollar deposits in the London interbank
market. 
 “Capital Stock” of any Person means any and all shares of, rights to purchase, warrants, options or
depositary receipts for, or other equivalents of or partnership or other interests in (however designated), equity of such Person, including any Preferred Stock, but excluding any debt securities convertible into such equity. 

“Capitalized Lease Obligations” means an obligation that is required to be classified and accounted for as a capitalized
lease for financial reporting purposes on the basis of GAAP. The amount of Indebtedness represented by such obligation will be the capitalized amount of such obligation at the time any determination thereof is to be made as determined on the basis
of GAAP, and the Stated Maturity thereof will be the date of the last payment of rent or any other amount due under such lease prior to the first date such lease may be terminated without penalty. 

“Cash Equivalents” means: 
 (1)(a) United States dollars, euro, or any national currency of any member state of the European Union or the Republic of India; or (b) any other foreign currency held by the Borrower and the
Restricted Subsidiaries in the ordinary course of business; 
 (2) securities issued or insured by the United States or Canadian
governments, a member state of the European Union, the Republic of India or, in each case, any agency or instrumentality of thereof. or in respect of which the United States or Canadian governments, a member state of the European Union, the Republic
of India or, in each case, any agency or instrumentality of thereof has a full and direct Guarantee Obligation (provided that the full faith and credit of such country or such member state is pledged in support thereof), having maturities of
not more than two years from the date of acquisition; 
 (3) certificates of deposit, time deposits, eurodollar time deposits,
overnight bank deposits or bankers’ acceptances having maturities of not more than one year from the date of acquisition thereof issued by any Lender or by any bank or trust company (a) whose commercial paper is rated at least
“A-2” or the equivalent thereof by S&P or at least “P-2” or the equivalent thereof by Moody’s (or if at the time neither is issuing comparable ratings, then a comparable rating of another Nationally Recognized
Statistical Rating Organization) or (b) (in the event that the bank or trust company does not have commercial paper which is rated) having combined capital and surplus in excess of $100,000,000; 

(4) repurchase obligations for underlying securities of the types described in clauses (2) and (3) entered into with any bank
meeting the qualifications specified in clause (3) above; 
 (5) commercial paper rated at the time of acquisition thereof
at least “A-2” or the equivalent thereof by S&P or “P-2” or the equivalent thereof by Moody’s or carrying an equivalent rating by a Nationally Recognized Statistical Rating Organization, if both of the two named rating
agencies cease publishing ratings of investments or, if no rating is available in respect of the commercial paper, the issuer 

  
 -4-

 
of which has an equivalent rating in respect of its long-term debt, and in any case maturing within one year after the date of acquisition thereof; 

(6) readily marketable direct obligations issued by any state of the United States of America, any province of Canada, any member of the
European Union, the Republic of India or any political subdivision thereof, in each case, having one of the two highest rating categories obtainable from either Moody’s or S&P (or, if at the time, neither is issuing comparable ratings, then
a comparable rating of a rating agency reasonably acceptable to the Administrative Agent) with maturities of not more than two years from the date of acquisition; 
 (7) Indebtedness or Preferred Stock issued by Persons with a rating of “BBB-” or higher from S&P or “Baa3” or higher from Moody’s (or, if at the time, neither is issuing
comparable ratings, then a comparable rating of another Nationally Recognized Statistical Rating Organization) with maturities of 12 months or less from the date of acquisition; 

(8) bills of exchange issued in the United States, Canada, a member state of the European Union, the Republic of India, or Japan eligible
for rediscount at the relevant central bank and accepted by a bank (or any dematerialized equivalent); 
 (9) interests in any
investment company, money market or enhanced high yield fund which invests 95% or more of its assets in instruments of the type specified in clauses (1) through (7) above; and 

(10) for purposes of clause (2) of the definition of “Disposition”, the marketable securities portfolio owned by
the Borrower and its Subsidiaries on the Closing Date. 
 Notwithstanding the foregoing, Cash Equivalents shall include amounts
denominated in currencies other than those set forth in clause (1) above, provided that such amounts are converted into any currency listed in clause (1) as promptly as practicable and in any event within 10 Business Days following
the receipt of such amounts. 
 “Cash Management Services” means any of the following to the extent not
constituting a line of credit (other than an overnight draft facility that is not in default): ACH transactions, treasury and/or cash management services, including, without limitation, controlled disbursement services, overdraft facilities, foreign
exchange facilities, deposit and other accounts and merchant services. 
 “Change in Law” shall mean
(a) the adoption of any law, treaty, order, policy, rule or regulation after the Closing Date, (b) any change in any law, treaty, order, policy, rule or regulation or in the interpretation or application thereof by any Governmental
Authority after the Closing Date or (c) compliance by a Lender with any guideline, request or directive issued or made after the Closing Date by any central bank or other governmental or quasi-governmental authority(whether or not having the
force of law); provided that notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection
therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory
authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted, adopted or issued, in each case other than any rules, regulations, orders, requests, guidelines or
directives thereunder that Lenders are required to comply with prior to the Closing Date. 
 “Change of
Control” means: (a) the Borrower becomes aware of (by way of a report or any other filing pursuant to Section 13(d) of the Exchange Act, proxy, vote, written notice or otherwise) any

  
 -5-

 
“person” or “group” of related persons (as such terms are used in Sections 13(d) and 14(d) of the Exchange Act as in effect on the Closing Date), other than one or more
Permitted Holders, is or becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act as in effect on the Closing Date), directly or indirectly, of more than 50% of the total voting power of the Voting
Stock of the Borrower or (b) the direct or indirect sale, lease, transfer, conveyance or other disposition, in one or a series of related transactions, of all or substantially all of the assets of the Borrower and its Restricted Subsidiaries
taken as a whole to a Person, other than a Restricted Subsidiary or one or more Permitted Holders. 
 “Closing
Date” means May 10, 2011. 
 “Code” means the U.S. Internal Revenue Code of 1986, as amended from
time to time, and Treasury regulations promulgated thereunder. 
 “Commitment” means a Revolving Credit
Commitment. 
 “Commitment Fee” means an amount per annum equal to 0.40%. 

“Committed Loan Notice” means a notice of (a) a Revolving Credit Borrowing, (b) a conversion of Loans from one
Type to the other, or (c) a continuation of Eurocurrency Rate Loans, pursuant to Section 2.02(a), which, if in writing, shall be substantially in the form of Exhibit A. 

“Company” has the meaning set forth in the preliminary statements to this Agreement 

“Compensation Period” has the meaning specified in Section 2.12(c)(ii). 

“Compliance Certificate” means a certificate substantially in the form of Exhibit D. 

“Consolidated Depreciation and Amortization Expense” means, with respect to any Person for any period, the total amount
of depreciation and amortization expense, including amortization of deferred financing fees of such Person and its Restricted Subsidiaries for such period on a consolidated basis and otherwise determined in accordance with GAAP. 

“Consolidated EBITDA” for any period means the Consolidated Net Income for such period: 

 

	 	(1)	increased (without duplication) by the following, in each case (other than clause (h) to the extent deducted (and not added back) with respect to Consolidated Net
Income: 

 (a) provision for taxes based on income or profits or capital, including, without
limitation, state, franchise and similar taxes and foreign withholding taxes of such Person paid or accrued during such period deducted; plus 
 (b) Fixed Charges of such Person for such period (including (x) net losses on Hedging Obligations or other derivative instruments entered into for the purpose of hedging interest rate risk and
(y) costs of surety bonds in connection with financing activities, plus amounts excluded from the definition of “Consolidated Interest Expense” pursuant to clauses (w), (x) and (y) in clause (1) thereof); plus

 (c) Consolidated Depreciation and Amortization Expense of such Person for such period; plus 

  
 -6-

 (d) any expenses or charges (other than depreciation or amortization
expense) related to any Equity Offering, Permitted Investment, acquisition, disposition, recapitalization or the Incurrence of Indebtedness permitted to be Incurred by this Agreement (including a refinancing thereof) (whether or not successful),
including (i) such fees, expenses or charges related to the offering of the Senior Notes and this Agreement and any Securitization Fees, and (ii) any amendment or other modification of the Senior Notes, this Agreement and any
Securitization Fees; plus 
 (e) the amount of any restructuring charge or reserve, integration cost or
other business optimization expense or cost associated with establishing new facilities, including any one-time costs incurred in connection with acquisitions and costs related to the closure and/or consolidation of facilities; 

(f) any other non-cash charges, write-downs, expenses, losses or items reducing Consolidated Net Income for such period
including any impairment charges or the impact of purchase accounting, (excluding any such non-cash charge, write-down or item to the extent it represents an accrual or reserve for a cash expenditure for a future period) or other items classified by
the Borrower as special items, less other non-cash items of income increasing Consolidated Net Income (excluding any such non-cash item of income to the extent it represents a receipt of cash in any future period); plus 

(g) the amount of management, monitoring, consulting and advisory fees (including termination fees) and related
indemnities and expenses paid or accrued in such period to Apax to the extent otherwise permitted under the covenants described under Sections 7.06 and 7.08; provided, however that such fees do not exceed $2,500,000 per any
consecutive four quarter period; plus 
 (h) the amount of net cost savings projected by the Borrower in
good faith to be realized as a result of specified actions either taken or initiated prior to or during such period (calculated on a pro forma basis as though such cost savings had been realized on the first day of such period), net of the
amount of actual benefits realized or expected to be realized prior to or during such period from such actions; provided that (x) such cost savings are reasonably identifiable and factually supportable, (y) such actions have been
taken or initiated no later than eighteen months after the Closing Date, and (z) the aggregate amount of cost savings added pursuant to this clause (h) shall not exceed 10% of EBITDA for any period of four consecutive fiscal quarters;
plus 
 (i) the amount of loss on sale of Securitization Assets and related assets to the Securitization
Subsidiary in connection with a Qualified Securitization Financing; plus 
 (j) management equity plan or
stock option plan or any other management or employee benefit plan or agreement or any stock subscription or shareholder agreement, to the extent that such costs or expenses are funded with cash proceeds contributed to the capital of the Borrower or
net cash proceeds of an issuance of Capital Stock of the Borrower (other than Disqualified Stock, Designated Preferred Stock or Excluded Contributions) solely to the extent that such Net Cash Proceeds are excluded from the calculation set forth in
Section 7.06(c); plus 
 (k) cash receipts (or any netting arrangements resulting in reduced
cash expenditures) not representing Consolidated EBITDA or Consolidated Net Income in any period to the extent non-cash gains relating to such income were deducted in the calculation of Consolidated EBITDA pursuant to clause (2) below for any
previous period and not added back; plus 

  
 -7-

 (l) rent expense as determined in accordance with GAAP not actually paid in
cash during such period (net of rent expense paid in cash during such period over and above rent expense as determined in accordance with GAAP); plus 
 (m) realized foreign exchange losses resulting from the impact of foreign currency changes on the valuation of assets or liabilities on the balance sheet of the Borrower and its Restricted Subsidiaries;
and 
 (n) net realized losses from Hedging Obligations or embedded derivatives that require similar accounting
treatment and the application of Accounting Standard Codification Topic 815 and related pronouncements; 
  

	 	(2)	decreased (without duplication) by: (a) non-cash gains increasing Consolidated Net Income of such Person for such period, excluding any non-cash gains to the
extent they represent the reversal of an accrual or reserve for a potential cash item that reduced Consolidated EBITDA in any prior period and any non-cash gains with respect to cash actually received in a prior period so long as such cash did not
increase Consolidated EBITDA in such prior period; plus (b) realized foreign exchange income or gains resulting from the impact of foreign currency changes on the valuation of assets or liabilities on the balance sheet of the Borrower
and its Restricted Subsidiaries; plus (c) any net realized income or gains from Hedging Obligations or embedded derivatives that require similar accounting treatment and the application of Accounting Standard Codification Topic 815 and
related pronouncements, plus (d) rent expense actually paid in cash during such period (net of rent expense paid in cash during such period in an amount equal to rent expense determined in accordance with GAAP) and

  

	 	(3)	increased or decreased (without duplication) by, as applicable, any adjustments resulting for the application of Accounting Standards Codification Topic 460 or any
comparable regulation. 

 “Consolidated Income Taxes” means taxes or other payments, including
deferred taxes, based on income, profits or capital (including, without limitation, withholding taxes) and franchise taxes of any of the Borrower and its Restricted Subsidiaries, whether or not paid, estimated, accrued or required to be remitted to
any Governmental Authority. 
 “Consolidated Interest Expense” means, with respect to any Person for any
period, without duplication, the sum of: 
 (1) consolidated interest expense of such Person and its Restricted Subsidiaries for
such period, to the extent such expense was deducted (and not added back) in computing Consolidated Net Income (including (a) amortization of original issue discount resulting from the issuance of Indebtedness at less than par, (b) all
commissions, discounts and other fees and charges owed with respect to letters of credit or bankers acceptances, (c) non-cash interest payments (but excluding any non-cash interest expense attributable to the movement in the mark to market
valuation of Hedging Obligations or other derivative instruments pursuant to GAAP), (d) the interest component of Capitalized Lease Obligations, and (e) net payments, if any, pursuant to interest rate Hedging Obligations with respect to
Indebtedness, and excluding (v) accretion or accrual of discounted liabilities other than Indebtedness, (w) any expense resulting from the discounting of any Indebtedness in connection with the application of purchase accounting in
connection with any acquisition, (x) amortization of deferred financing fees, debt issuance costs, commissions, fees and expenses, (y) any expensing of bridge, commitment and other financing fees, and (z) interest with respect to
Indebtedness of any Parent of such Person appearing upon the balance sheet of such Person solely by reason of push-down accounting under GAAP; plus 

  
 -8-

 (2) consolidated capitalized interest of such Person and its Restricted Subsidiaries for
such period, whether paid or accrued; less 
 (3) interest income for such period. 

For purposes of this definition, interest on a Capitalized Lease Obligation shall be deemed to accrue at an interest rate reasonably
determined by such Person to be the rate of interest implicit in such Capitalized Lease Obligation in accordance with GAAP. 

“Consolidated Net Income” means, for any period, the net income (loss) of the Borrower and its Restricted Subsidiaries
determined on a consolidated basis on the basis of GAAP; provided, however, that there will not be included in such Consolidated Net Income: 
  

	 	(1)	subject to the limitations contained in clause (3) below, any net income (loss) of any Person if such Person is not a Restricted Subsidiary, except that the
Borrower’s equity in the net income of any such Person for such period will be included in such Consolidated Net Income up to the aggregate amount of cash or Cash Equivalents actually distributed by such Person during such period to the
Borrower or a Restricted Subsidiary as a dividend or other distribution or return on investment or could have been distributed, as reasonably determined by an Officer of the Borrower (subject, in the case of a dividend or other distribution or
return on investment to a Restricted Subsidiary, to the limitations contained in clause (2) below); 

  

	 	(2)	solely for the purpose of determining the amount available for Restricted Payments under Section 7.06(3)(i) any net income (loss) of any Restricted
Subsidiary (other than Guarantors) if such Subsidiary is subject to restrictions, directly or indirectly, on the payment of dividends or the making of distributions by such Restricted Subsidiary, directly or indirectly, to the Borrower or a
Guarantor by operation of the terms of such Restricted Subsidiary’s charter or any agreement, instrument, judgment, decree, order, statute or governmental rule or regulation applicable to such Restricted Subsidiary or its shareholders (other
than restrictions that have been waived or otherwise released), except that the Borrower’s equity in the net income of any such Restricted Subsidiary for such period will be included in such Consolidated Net Income up to the aggregate amount of
cash or Cash Equivalents actually distributed or that could have been distributed by such Restricted Subsidiary during such period to the Borrower or another Restricted Subsidiary as a dividend or other distribution (subject, in the case of a
dividend to another Restricted Subsidiary, to the limitation contained in this clause); 

  

	 	(3)	any net after tax gain (or loss) realized upon the sale or other disposition of any asset or disposed operations of the Borrower or any Restricted Subsidiaries
(including pursuant to any sale/leaseback transaction) which is not sold or otherwise disposed of in the ordinary course of business (as determined in good faith by an Officer or the Board of Directors of the Borrower); 

 

	 	(4)	any net after tax extraordinary, exceptional, unusual or nonrecurring gain, loss, charge or expense or any charges, expenses or reserves in respect of any
restructuring, redundancy or severance expense; 

  

	 	(5)	the cumulative effect of a change in accounting principles; 

  
 -9-

	 	(6)	any non-cash compensation charge or expense arising from any grant of stock, stock options or other equity based awards and any non-cash deemed finance charges in
respect of any pension liabilities or other provisions; 

  

	 	(7)	all deferred financing costs written off and premiums paid or other expenses incurred directly in connection with any early extinguishment of Indebtedness and any net
after tax gain (loss) from any write-off or forgiveness of Indebtedness or Hedging Obligations or other debt instruments; 

  

	 	(8)	any unrealized gains or losses in respect of Hedging Obligations or any ineffectiveness recognized in earnings related to qualifying hedge transactions or the fair
value of changes therein recognized in earnings for derivatives that do not qualify as hedge transactions, in each case, in respect of Hedging Obligations; 

 

	 	(9)	any unrealized foreign currency translation or transaction gains or losses in respect of Indebtedness or other obligations of (i) any Person denominated in a
currency other than the functional currency of such Person and any unrealized foreign exchange gains or losses relating to translation of assets and liabilities denominated in foreign currencies or (ii) the Borrower or any Restricted Subsidiary
owing to the Borrower or any Restricted Subsidiary; 

  

	 	(10)	any purchase accounting effects, net of taxes, including, but not limited to, adjustments to inventory, property and equipment, software and other intangible assets and
deferred revenue in component amounts required or permitted by GAAP and related authoritative pronouncements (including the effects of such adjustments pushed down to the Borrower and the Restricted Subsidiaries), as a result of any consummated
acquisition, or the amortization or write-off of any amounts thereof (including any write-off of in process research and development); 

  

	 	(11)	any goodwill or other intangible asset impairment charge or write-off; 

  

	 	(12)	solely for the purpose of determining the amount available for Restricted Investments (but not other Restricted Payments) under Section 7.06(3)(i)
(x) only to the extent not otherwise added back to Consolidated Net Income, depreciation and amortization expense to the extent in excess of capital expenditures on property, plant and equipment and (y) Consolidated Income Taxes to the
extent in excess of cash payments made in respect of such Consolidated Income Taxes; and 

  

	 	(13)	accruals and reserves that are established within twelve months after the release date of the escrow proceeds under the documentation in respect of the Senior Notes in
accordance with GAAP shall be excluded. 

 “Consolidated Priority Debt” means, at any date of
determination, the sum, without duplication, of (1) the aggregate outstanding Secured Indebtedness of the Borrower and the Restricted Subsidiaries and (2) the aggregate outstanding Indebtedness for borrowed money of the Restricted
Subsidiaries that are not Guarantors. 
 “Consolidated Priority Debt Leverage Ratio” means as of
any date of determination, the ratio of (x) the sum of (i) the aggregate outstanding Consolidated Priority Debt plus (ii) $125,000,000 less the amount of outstanding Consolidated Priority Debt incurred pursuant to clause (a)(i) of
Section 7.03 to (y) the aggregate amount of Consolidated EBITDA for the period of the most recent four consecutive fiscal quarters ending prior to the date of such determination for which internal consolidated financial

  
 -10-

 
statements of the Borrower are available, in each case with such pro forma adjustments as are appropriate and consistent with the pro forma adjustments set forth in the definition of “Fixed
Charge Coverage Ratio.” 
 “Consolidated Total Indebtedness” means, as of any date of determination,
(a) the aggregate amount of Indebtedness of the Borrower and the Restricted Subsidiaries outstanding on such date, determined on a consolidated basis in accordance with GAAP (but excluding the effects of any discounting of Indebtedness
resulting from the application of purchase accounting in connection with the Transactions or any acquisition permitted hereunder or other Investment permitted hereunder) consisting only of Indebtedness for borrowed money, unreimbursed obligations
under letters of credit, obligations in respect of Capitalized Leases and debt obligations evidenced by promissory notes or similar instruments, minus (b) the aggregate amount of cash and Cash Equivalents (in each case, free and clear of all
Liens, other than Liens permitted by Section 7.01, excluding cash and Cash Equivalents to the extent the use thereof for the application to payment of Indebtedness is not prohibited by law or any contract to which Borrower or any
Restricted Subsidiary is a party). 
 “Contingent Obligations” means, with respect to any Person, any
obligation of such Person guaranteeing in any manner, whether directly or indirectly, any operating lease, dividend or other obligation that does not constitute Indebtedness (“primary obligations”) of any other Person (the
“primary obligor”), including any obligation of such Person, whether or not contingent: 
  

	 	(1)	to purchase any such primary obligation or any property constituting direct or indirect security therefor; 

 

	 	(2)	to advance or supply funds: 

  

	 	(a)	for the purchase or payment of any such primary obligation; or 

  

	 	(b)	to maintain the working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor; or

  

	 	(3)	to purchase property, securities or services primarily for the purpose of assuring the owner of any such primary obligation of the ability of the primary obligor to
make payment of such primary obligation against loss in respect thereof. 

 “Credit Facility”
means, with respect to the Borrower or any of its Subsidiaries, one or more debt facilities, indentures or other arrangements (including this Agreement or commercial paper facilities and overdraft facilities) with banks, other financial institutions
or investors providing for revolving credit loans, term loans, notes, receivables financing (including through the sale of receivables to such institutions or to special purpose entities formed to borrow from such institutions against such
receivables), letters of credit or other Indebtedness, in each case, as amended, restated, modified, renewed, refunded, replaced, restructured, refinanced, repaid, increased or extended in whole or in part from time to time (and whether in whole or
in part and whether or not with the original administrative agent and lenders or another administrative agent or agents or other banks or institutions and whether provided under this Agreement or one or more other credit or other agreements,
indentures, financing agreements or otherwise) and in each case including all agreements, instruments and documents executed and delivered pursuant to or in connection with the foregoing (including any notes and letters of credit issued pursuant
thereto and any Guarantee Obligations and collateral agreement, patent and trademark security agreement, mortgages or letter of credit applications and other Guarantee Obligations, pledges, agreements, security agreements and collateral documents).
Without limiting the generality of the foregoing, the term “Credit Facility” shall include any agreement or instrument (1) changing the maturity of any Indebtedness Incurred thereunder or contemplated thereby, (2) adding
Subsidiaries of the Borrower 

  
 -11-

 
as additional borrowers or guarantors thereunder, (3) increasing the amount of Indebtedness Incurred thereunder or available to be borrowed thereunder; provided that such increase in
borrowings is permitted by Section 7.03 or (4) otherwise altering the terms and conditions thereof. 

“Debtor Relief Laws” means the Bankruptcy Code of the United States, and all other liquidation, conservatorship,
bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect and affecting
the rights of creditors generally and any general principles, reservations or qualifications as to matters of law set out in any legal opinion delivered in connection with a Loan Document. 

“Default” means any event or condition that constitutes an Event of Default or that, with the giving of any notice, the
passage of time, or both, would be an Event of Default. 
 “Default Rate” means an interest rate equal to
(a) the Base Rate, plus (b) the Applicable Rate applicable to Base Rate Loans, plus (c) 2.0% per annum. 

“Defaulting Lender” shall mean any Lender that has (a) failed to fund its portion of any Borrowing within one
Business Day of the date on which it shall have been required to fund the same, unless the subject of a good faith dispute between Borrower and such Lender related hereto, (b) notified Borrower, the Administrative Agent or any other Lender in
writing that it does not intend to comply with any of its funding obligations under this Agreement or has made a public statement to the effect that it does not intend to comply with its funding obligations under this Agreement or under agreements
in which it commits to extend credit generally, (c) failed, within one Business Day after written request by tile Administrative Agent or Borrower, to confirm that it will comply with the terms of this Agreement relating to its obligations to
fund prospective Loans (unless the subject of a good faith dispute between Borrower and such Lender); provided that any such Lender shall cease to be a Defaulting Lender under this clause (c) upon receipt of such confirmation by the
Administrative Agent or Borrower, (d) otherwise failed to pay over to Borrower, the Administrative Agent or any other Lender any other amount required to be paid by it hereunder within one Business Day of the date when due (unless the subject
of a good faith dispute), or (e) (i) become or is or has a direct or indirect parent company become or is insolvent or (ii) become or has a direct or indirect parent company that become the subject of a bankruptcy or insolvency
proceeding, or has had a receiver, conservator, trustee, or custodian or appointed for it, or has taken any action in furtherance of, or indicating its consent to, approval of or acquiescence in any such proceeding or appointment (for the avoidance
of doubt, a Lender shall not be deemed to be a Defaulting Lender solely by virtue of the ownership or acquisition of any Equity Interest in such Lender or its parent by a Governmental Authority); provided that, as of any date of
determination, the determination of whether any Lender is a Defaulting Lender hereunder shall not take into account, and shall not otherwise impair, any amounts funded by such Lender which have been assigned by such Lender to an SPC pursuant to
Section 10.07(h). Any determination by the Administrative Agent that a Lender is a Defaulting Lender under clauses (a) through (e) above shall be conclusive and binding absent manifest error, and such Lender shall be deemed to
be a Defaulting Lender upon delivery of written notice of such determination to the Borrower and each Lender. 

“Designated Non-Cash Consideration” means the fair market value (as determined in good faith by the Borrower) of
non-cash consideration received by the Borrower or one of its Restricted Subsidiaries in connection with an Disposition that is so designated as Designated Non-Cash Consideration pursuant to an Officer’s Certificate, setting forth the basis of
such valuation, less the amount of cash or Cash Equivalents received in connection with a subsequent payment, redemption, retirement, sale or other disposition of such Designated Non-Cash Consideration. A particular item of Designated Non-Cash

  
 -12-

 
Consideration will no longer be considered to be outstanding when and to the extent it has been paid, redeemed or otherwise retired or sold or otherwise disposed of in compliance with
Section 7.05. 
 “Designated Preferred Stock” means, with respect to the Borrower, Preferred Stock
(other than Disqualified Stock) (a) that is issued for cash (other than to the Borrower or a Subsidiary of the Borrower or an employee stock ownership plan or trust established by the Borrower or any such Subsidiary for the benefit of their
employees to the extent funded by the Borrower or such Subsidiary) and (b) that is designated as “Designated Preferred Stock” pursuant to an Officer’s Certificate of the Borrower at or prior to the issuance thereof, the Net Cash
Proceeds of which are excluded from the calculation set forth in Section 7.08(3)(ii). 
 “Disinterested
Director” means, with respect to any Affiliate Transaction, a member of the Board of Directors of the Borrower having no material direct or indirect financial interest in or with respect to such Affiliate Transaction. A member of the Board
of Directors of the Borrower shall be deemed not to have such a financial interest by reason of such member’s holding Capital Stock of the Borrower or any options, warrants or other rights in respect of such Capital Stock. 

“Disposition” means: (a) the sale, conveyance, transfer or other disposition, whether in a single
transaction or a series of related transactions, of property or assets (including by way of a Sale and Leaseback Transaction) of the Borrower (other than Capital Stock of the Borrower) or any of its Restricted Subsidiaries (each referred to in this
definition as a “disposition”); or (b) the issuance or sale of Capital Stock of any Restricted Subsidiary (other than Preferred Stock of Restricted Subsidiaries issued in compliance with Section 7.03 or
directors’ qualifying shares and shares issued to foreign nationals as required under applicable law), whether in a single transaction or a series of related transactions; in each case, other than: 

(1) a disposition by a Restricted Subsidiary to the Borrower or by the Borrower or a Restricted Subsidiary to a Restricted Subsidiary;

 (2) a disposition of cash, Cash Equivalents or Investment Grade Securities; 

(3) a disposition of inventory or other assets in the ordinary course of business; 

(4) a disposition of obsolete, surplus or worn out equipment or other assets or equipment or other assets that are not useful in the
conduct of the business of the Borrower and its Restricted Subsidiaries; 
 (5) transactions permitted under
Section 7.04 or a transaction that constitutes a Change of Control; 
 (6) an issuance of Capital Stock by a
Restricted Subsidiary to the Borrower or to another Restricted Subsidiary or as part of or pursuant to an equity incentive or compensation plan approved by the Board of Directors; 

(7) any dispositions of Capital Stock, properties or assets in a single transaction or series of related transactions with a fair market
value (as determined in good faith by the Borrower) of less than $10,000,000; 
 (8) any Restricted Payment that is permitted to
be made, and is made, under Section 7.06 and the making of any Permitted Payment or Permitted Investment or, solely for purposes of 

  
 -13-

 
Section 7.05(c), asset sales, the proceeds of which are used to make such Restricted Payments or Permitted Investments; 

(9) dispositions in connection with Permitted Liens; 
 (10) dispositions of receivables in connection with the compromise, settlement or collection thereof in the ordinary course of business or in bankruptcy or similar proceedings and exclusive of factoring
or similar arrangements; 
 (11) the licensing or sub-licensing of intellectual property or other general intangibles and
licenses, sub-licenses, leases or subleases of other property, in each case, in the ordinary course of business; 
 (12)
foreclosure, condemnation or any similar action with respect to any property or other assets; 
 (13) the sale or discount (with
or without recourse, and on customary or commercially reasonable terms and for credit management purposes) of accounts receivable or notes receivable arising in the ordinary course of business, or the conversion or exchange of accounts receivable
for notes receivable; 
 (14) any disposition of Capital Stock, Indebtedness or other securities of an Unrestricted Subsidiary;

 (15) any disposition of Capital Stock of a Restricted Subsidiary pursuant to an agreement or other obligation with or to a
Person (other than the Borrower or a Restricted Subsidiary) from whom such Restricted Subsidiary was acquired, or from whom such Restricted Subsidiary acquired its business and assets (having been newly formed in connection with such acquisition),
made as part of such acquisition and in each case comprising all or a portion of the consideration in respect of such sale or acquisition; 
 (16) to the extent allowable under Section 1031 of the Code, any exchange of like property (excluding any boot thereon) for use in a Similar Business; 

(17) any disposition of Securitization Assets, or participations therein, in connection with any Qualified Securitization Financing;

 (18) any financing transaction with respect to property constructed, acquired, replaced, repaired or improved (including any
reconstruction, refurbishment, renovation and/or development of real property) by the Borrower or any Restricted Subsidiary, including Sale and Leaseback Transactions and asset securitizations, permitted by this Agreement; and 

(19) any surrender or waiver of contract rights or the settlement, release or surrender of contract, tort or other claims of any kind.

 “Disqualified Stock” means, with respect to any Person, any Capital Stock of such Person which by its terms
(or by the terms of any security into which it is convertible or for which it is exchangeable) or upon the happening of any event: 
  

	 	(1)	matures or is mandatorily redeemable for cash or in exchange for Indebtedness pursuant to a sinking fund obligation or otherwise; or 

  
 -14-

	 	(2)	is or may become (in accordance with its terms) upon the occurrence of certain events or otherwise redeemable or repurchasable for cash or in exchange for Indebtedness
at the option of the holder of the Capital Stock in whole or in part, 

 in each case on or prior to the earlier of (a) the
Stated Maturity of the Senior Notes or (b) the date on which there are no Senior Notes outstanding; provided, however, that (i) only the portion of Capital Stock which so matures or is mandatorily redeemable, is so
convertible or exchangeable or is so redeemable at the option of the holder thereof prior to such date will be deemed to be Disqualified Stock and (ii) any Capital Stock that would constitute Disqualified Stock solely because the holders
thereof have the right to require the Borrower to repurchase such Capital Stock upon the occurrence of a change of control or asset sale (howsoever defined or referred to) shall not constitute Disqualified Stock if any such redemption or repurchase
obligation is subject to compliance by the relevant Person with Section 7.06; provided, however, that if such Capital Stock is issued to any plan for the benefit of employees of the Borrower or its Subsidiaries or by any
such plan to such employees, such Capital Stock shall not constitute Disqualified Stock solely because it may be required to be repurchased by the Borrower or its Subsidiaries in order to satisfy applicable statutory or regulatory obligations.

 “Dollar” and “$” mean lawful money of the United States. 

“Dollar Equivalent” means, on any date of determination, with respect to any amount denominated in Dollars, such amount.
In making any determination of the Dollar Equivalent (for purposes of calculating the amount of Loans to be borrowed from the respective Lenders on any date or for any other purpose), the Administrative Agent shall use the relevant Exchange Rate in
effect on the date on which the Borrower delivers a Committed Loan Notice (which, in accordance with Section 2.02(a), may be telephonic) with respect to such Borrowing or on such other date upon which a Dollar Equivalent is required to
be determined pursuant to the provisions of this Agreement. As appropriate, amounts specified herein as amounts in Dollars shall be or include any relevant Dollar Equivalent amount. 

“Eligible Assignee” means (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund and
(d) any other Person (other than the Loan Parties and those Persons identified by the Borrower to DBS prior to the Closing Date in a written instrument acknowledged by the Lead Arranger as ineligible to be a Lender. 

“Environmental Laws” means any and all Laws relating to pollution, the protection of the environment, natural resources
or to the release of any Hazardous Materials into the environment, or, to the extent relating to exposure to Hazardous Materials, human health. 
 “Environmental Liability” means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities) of any
Loan Party or any of their respective Subsidiaries directly or indirectly resulting from or based upon (a) violation of any Environmental Law, (b) the generation, use, handling, transportation, storage, treatment or disposal of any
Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or (e) any contract, agreement or other consensual arrangement pursuant to which
liability is assumed or imposed with respect to any of the foregoing. 
 “Equity Contribution” means the
contribution by the Sponsor to Borrower, directly or indirectly, of an aggregate amount of cash equal to, when taken together with the proceeds of the Senior Notes, cash on the Borrower’s balance sheet and other sources of funding, shall not be
less than $250,000,000. 

  
 -15-

 “Equity Interests” means, with respect to any Person, all of the shares,
interests, rights, participations or other equivalents (however designated) of capital stock of (or other ownership or profit interests or units in) such Person and all of the warrants, options or other rights for the purchase, acquisition or
exchange from such Person of any of the foregoing (including through convertible securities). 
 “Equity
Offering” means (x) a sale of Capital Stock of the Borrower (other than Disqualified Stock) other than offerings registered on Form S-8 (or any successor form) under the Securities Act or any similar offering in other
jurisdictions, or (y) the sale of Capital Stock or other securities, the proceeds of which are contributed to the equity (other than through the issuance of Disqualified Stock or Designated Preferred Stock or through an Excluded Contribution)
of the Borrower or any of its Restricted Subsidiaries. 
 “ERISA” means the Employee Retirement Income Security
Act of 1974, as amended from time to time. 
 “ERISA Affiliate” means any trade or business (whether or not
incorporated) that is under common control with any Loan Party and is treated as a single employer within the meaning of Section 414 of the Code or Section 4001 of ERISA. 

“ERISA Event” means (a) a Reportable Event with respect to a Pension Plan; (b) a withdrawal by any Loan Party
or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which it was a substantial employer (as defined in Section 4001(a)(2) of ERISA) or a cessation of operations that is treated as a termination
under Section 4062(a) of ERISA; (c) a complete or partial withdrawal by any Loan Party or any ERISA Affiliate from a Multiemployer Plan, notification of any Loan Party or ERISA Affiliate concerning the imposition of withdrawal liability or
notification that a Multiemployer Plan is insolvent or is in reorganization within the meaning of Title IV of ERISA (or, after the effectiveness of the Pension Act, that is in endangered or critical status, within the meaning of Section 305 of
ERISA); (d) the filing of a notice of intent to terminate, the treatment of a Plan amendment as a termination under Sections 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Pension Plan or Multiemployer
Plan; (e) an event or condition which constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan or Multiemployer Plan; (f) the imposition of any liability
under Title IV of ERISA, other than for PBGC premiums due but not delinquent under Section 4007 of ERISA, upon any Loan Party or any ERISA Affiliate; or (g) on or after the effectiveness of the Pension Act, a determination that any Pension
Plan is, or is expected to be, in “at-risk” status (within the meaning of Section 303(i)(4)(A) of ERISA or Section 430(i)(4)(A) of the Code). 
 “Eurocurrency Rate Loan” means any Loan denominated in Dollars bearing interest at a rate based on the LIBOR Rate. 

“Event of Default” has the meaning specified in Section 8.01. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Exchange Rate” means on any day for purposes of determining the Dollar Equivalent of any amount denominated in a
currency other than Dollars, the rate at which such other currency may be exchanged into Dollars at approximately 12:00 noon, New York City time on such day as set forth on the Reuters World Currency Page for such currency, and, in the event that
such rate does not appear on any Reuters World Currency Page, the Exchange Rate shall be determined by reference to such other publicly available service for displaying exchange rates as may be agreed upon by the Administrative Agent and

  
 -16-

 
the Borrower, or, in the absence of such an agreement, such Exchange Rate shall instead be the arithmetic average of the spot rates of exchange of the Administrative Agent in the market where its
foreign currency exchange operations in respect of such currency are then being conducted, at or about 12:00 noon, New York City time on such date for the purchase of Dollars for delivery two Business Days later; provided that, if at the time
of any such determination, for any reason, no such spot rate is being quoted, the Administrative Agent may use any reasonable method it deems appropriate to determine such rate, and such determination shall be conclusive absent manifest error.

 “Excluded Contribution” means Net Cash Proceeds or property or assets received by the Borrower as capital
contributions to the equity (other than through the issuance of Disqualified Stock or Designated Preferred Stock) of the Borrower after the Closing Date or from the issuance or sale (other than to a Restricted Subsidiary or an employee stock
ownership plan or trust established by the Borrower or any Subsidiary of the Borrower for the benefit of its employees to the extent funded by the Borrower or any Restricted Subsidiary) of Capital Stock (other than Disqualified Stock or Designated
Preferred Stock) of the Borrower, in each case, to the extent designated as an Excluded Contribution pursuant to an Officer’s Certificate of the Borrower. 
 “Excluded Subsidiary” means (a) each Subsidiary listed on Schedule 1.01C hereto, (b) any Subsidiary that is prohibited by applicable Law or contractual obligation from
guaranteeing the Obligations, (c) any Immaterial Subsidiary, (d) any Subsidiary which would require consent, approval, license or authorization from a Governmental Authority to provide a Guarantee unless such consent, approval, license or
authorization has been received or if such Subsidiary becoming a Guarantor would result in a material adverse tax consequence to the Borrower or any of their Subsidiaries (including as a result of the operation of Section 956 of the Code or any
similar law or regulation in ay applicable jurisdiction) (as reasonably determined by the Borrower with the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed)), and (e) any other Subsidiary with
respect to which the Administrative Agent and the Borrower reasonably agree in writing that the cost or other consequences (including any adverse tax consequences) of providing a Guarantee shall be excessive in view of the benefits to be obtained by
the Lenders therefrom. 
 “Excluded Taxes” means (a) with respect to each Agent and each Lender, taxes
(including any additions to tax, penalties and interest) imposed on its overall net income or net profits (including any franchise taxes imposed in lieu thereof) by the jurisdiction (or any political subdivision thereof) under the Laws of which such
Agent or such Lender, as the case may be, is resident or deemed to be resident, is organized, maintains an Applicable Lending Office, or carries on business or is deemed to carry on business to which such payment relates (other than a business
deemed to arise solely from such person having executed, delivered, become party to, performed its obligations or received a payment under, enforced and/or engaged in activities contemplated by this Agreement or any other Loan Document), and
(b) any withholding tax that is imposed on amounts payable to a Lender that would not have been imposed but for such Lender’s failure to comply with Section 3.01(f). 

“Facility” means the Revolving Credit Facility. 

“Federal Funds Effective Rate” means, for any day, the rate per annum equal to the weighted average of the rates on
overnight federal funds transactions with members of the Federal Reserve System arranged by federal funds brokers on such day, as published by the Federal Reserve Bank on the Business Day next succeeding such day; provided that (a) if
such day is not a Business Day, the Federal Funds Effective Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day, and (b) if no such rate is so
published on such next succeeding Business Day, the Federal Funds Effective Rate for such day shall be the average rate (rounded upward, if necessary, to a whole multiple of 1/100 of 1%) of the quotations for the day of such

  
 -17-

 
transactions received by the Administrative Agent from three federal funds brokers of recognized standing selected by it. 
 “Fee Letter” means the Fee Letter dated May 10, 2011 (or as of such date) between the Borrower and DBS, as amended, supplemented or otherwise modified from time to time. 

“Fixed Charge Coverage Ratio” means, with respect to any Person on any determination date, the ratio of
Consolidated EBITDA of such Person for the most recent four consecutive fiscal quarters ending immediately prior to such determination date for which internal consolidated financial statements are available to the Fixed Charges of such Person for
four consecutive fiscal quarters. In the event that the Borrower or any Restricted Subsidiary Incurs, assumes, redeems, defeases, retires or extinguishes any Indebtedness or becomes subject to a Guarantee Obligation in respect of any Indebtedness
(other than, in each case, Indebtedness incurred under any revolving credit facility unless such Indebtedness has been permanently repaid and has not been replaced) or issues or redeems Disqualified Stock or Preferred Stock subsequent to the
commencement of the period for which the Fixed Charge Coverage Ratio is being calculated but prior to or simultaneously with the event for which the calculation of the Fixed Charge Coverage Ratio is made (the “Fixed Charge Coverage Ratio
Calculation Date”), then the Fixed Charge Coverage Ratio shall be calculated giving pro forma effect to such Incurrence, assumption, guarantee, redemption, defeasance, retirement or extinguishment of Indebtedness, or such issuance or
redemption of Disqualified Stock or Preferred Stock, as if the same had occurred at the beginning of the applicable four-quarter period. For purposes of making the computation referred to above, any Investment, acquisitions, dispositions, mergers,
consolidations and disposed operations that have been made by the Borrower or any of its Restricted Subsidiaries, during the four-quarter reference period or subsequent to such reference period and on or prior to or simultaneously with the Fixed
Charge Coverage Ratio Calculation Date shall be calculated on a pro forma basis assuming that all such Investments, acquisitions, dispositions, mergers, consolidations and disposed or discontinued operations (and the change in any associated fixed
charge obligations and the change in Consolidated EBITDA resulting therefrom) had occurred on the first day of the four-quarter reference period. If since the beginning of such period any Person that subsequently became a Restricted Subsidiary or
was merged with or into the Borrower or any of its Restricted Subsidiaries since the beginning of such period shall have made any Investment, acquisition, disposition, merger, consolidation or disposed or discontinued operation that would have
required adjustment pursuant to this definition, then the Fixed Charge Coverage Ratio shall be calculated giving pro forma effect thereto for such period as if such Investment, acquisition, disposition, merger, consolidation or disposed operation
had occurred at the beginning of the applicable four-quarter period. 
 For purposes of this definition, whenever pro forma
effect is to be given to a transaction, the pro forma calculations shall be made in good faith by a responsible financial or chief accounting officer of the Borrower (including cost savings and synergies). If any Indebtedness bears a floating rate
of interest and is being given pro forma effect, the interest on such Indebtedness shall be calculated as if the rate in effect on the Fixed Charge Coverage Ratio Calculation Date had been the applicable rate for the entire period (taking into
account any Hedging Obligations applicable to such Indebtedness). Interest on a Capitalized Lease Obligation shall be deemed to accrue at an interest rate reasonably determined by a responsible financial or accounting officer of the Borrower to be
the rate of interest implicit in such Capitalized Lease Obligation in accordance with GAAP. For purposes of making the computation referred to above, interest on any Indebtedness under a revolving credit facility computed with a pro forma basis
shall be computed based upon the average daily balance of such Indebtedness during the applicable period except as set forth in the first paragraph of this definition. Interest on Indebtedness that may optionally be determined at an interest rate
based upon a factor of a prime or similar rate, a eurocurrency interbank offered rate, or other rate, shall be determined to have been based upon the rate actually chosen, or if none, then based upon such optional rate chosen as the Borrower may
designate. 

  
 -18-

 “Fixed Charges” means, with respect to any Person for any period, the sum
of (a) Consolidated Interest Expense of such Person for such period; (b) all cash dividends or other distributions paid (excluding items eliminated in consolidation) on any series of Preferred Stock of any Subsidiary of such Person during
such period; and (c) all cash dividends or other distributions paid (excluding items eliminated in consolidation) on any series of Disqualified Stock during this period. 
 “Foreign Plan” means any employee benefit plan, program, policy, arrangement or agreement maintained or contributed to or by, or entered into with, any Loan Party or any Subsidiary with
respect to employees outside the United States. 
 “Foreign Subsidiary” means, with respect to any Person, any
Subsidiary of such Person that is not organized or existing under the laws of the United States, any state thereof, or the District of Columbia, and any Subsidiary of such Subsidiary. 

“FRB” means the Board of Governors of the Federal Reserve System of the United States. 

“Fund” means any Person (other than a natural person) that is engaged in making, purchasing, holding or otherwise
investing in commercial loans and similar extensions of credit in the ordinary course. 
 “GAAP” means
generally accepted accounting principles in the United States of America as in effect on the date of any calculation or determination required hereunder. Except as otherwise set forth in this Agreement, all ratios and calculations based on GAAP
contained in this Agreement shall be computed in accordance with GAAP. At any time after the Closing Date, the Borrower may elect to establish that GAAP shall mean the GAAP as in effect on or prior to the date of such election; provided that
any such election, once made, shall be irrevocable. At any time after the Closing Date, the Borrower may elect to apply IFRS accounting principles in lieu of GAAP and, upon any such election, references herein to GAAP shall thereafter be construed
to mean IFRS (except as otherwise provided in this Agreement), including as to the ability of the Borrower to make an election pursuant to the previous sentence; provided that any such election, once made, shall be irrevocable;
provided, further, that any calculation or determination in this Agreement that require the application of GAAP for periods that include fiscal quarters ended prior to the Borrower’s election to apply IFRS shall remain as
previously calculated or determined in accordance with GAAP. The Borrower shall give notice of any such election made in accordance with this definition to the Administrative Agent and the Lenders. 

“Governmental Authority” means any nation, sovereign or government, any state, provincial, territorial or other
political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, administrative tribunal, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory, self-regulatory or administrative
powers or functions of or pertaining to government, including a central bank or stock exchange. 
 “Granting
Lender” has the meaning specified in Section 10.07(h). 
 “Guarantee Obligations” means
any obligation, contingent or otherwise, of any Person directly or indirectly guaranteeing any Indebtedness of any other Person, including any such obligation, direct or indirect, contingent or otherwise, of such Person: 

(1) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness of such other Person
(whether arising by virtue of partnership arrangements, or by agreements to keep-well, to purchase assets, goods, securities or services, to take-or-pay or to maintain financial statement conditions or otherwise); or 

  
 -19-

 (2) entered into primarily for purposes of assuring in any other manner the
oblige of such Indebtedness of the payment thereof or to protect such oblige against loss in respect thereof (in whole or in part); 

provided, however, that the term “Guarantee Obligations” shall not include endorsements for collection or deposit in the ordinary
course of business. The amount of any Guarantee Obligation shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee Obligation is made or, if
not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith. 
 “Guarantees” has the meaning specified in the definition of “Guarantee Requirement.” The term “Guarantee” used as a verb has a corresponding meaning. 

“Guarantee Requirement” means, at any time, the requirement that: 

(a) all Obligations shall have been unconditionally guaranteed (the “Guarantees”) by each domestic Wholly
Owned Subsidiary (other than any Unrestricted Subsidiary and any Excluded Subsidiary); 
 The foregoing definition shall not
require the granting of guarantees if and for so long as (a) the Administrative Agent and the Borrower reasonably agree in writing the cost of granting such guarantee shall be excessive in view of the benefits to be obtained by the Lenders
therefrom; (b) with respect to any assets of the Borrower’s general statutory limitations, financial assistance, corporate benefit, fraudulent preference, “earnings stripping” or “thin capitalization” rules and similar
rules prohibit the granting of a guarantee (or where they require that it be limited as to amount or otherwise, the same shall be limited accordingly); provided that the Borrower uses commercially reasonable efforts to overcome such
obstacles; and (c) with respect to the Borrower it is not within the legal capacity of the Borrower or if the same would breach the fiduciary duties of directors of any Loan Party or contravene any legal prohibition or regulatory requirement or
result in a material risk of personal or criminal liability for any officer of any Loan Party; provided that the Borrower shall use commercially reasonable efforts to overcome any such obstacle. 

“Guarantors” means each Person that becomes a party to a Guaranty pursuant to clause (b) of the definition
of “Guarantee Requirement” and any other Restricted Subsidiary that becomes a party to a Guaranty. 

“Guaranty” means, collectively, (a) the Guarantees and (b) each other guaranty and guaranty supplement
delivered pursuant to Section 6.11. 
 “Hazardous Materials” means all explosive or radioactive
substances or wastes and all hazardous or toxic substances, wastes or pollutants, including petroleum or petroleum distillates, asbestos or asbestos-containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all
other substances or wastes of any nature regulated pursuant to any applicable Environmental Law. 
 “Hedging
Obligations” means, with respect to any person, the obligations of such Person under any interest rate swap agreement, interest rate cap agreement, interest rate collar agreement, commodity swap agreement, commodity cap agreement, commodity
collar agreement, foreign exchange contracts, currency swap agreement or similar agreement providing for the transfer or mitigation of interest rate, commodity price or currency risks either generally or under specific contingencies. 

  
 -20-

 “IFRS” means International Financial Reporting Standards, as issued by the
International Accounting Standards Board. 
 “Immaterial Subsidiary” means any Restricted Subsidiary that
(i) has not guaranteed any other Indebtedness of the Borrower and (ii) has Total Assets (as determined in accordance with GAAP) and Consolidated EBITDA of less than 5.0% of the Borrower’s Total Assets and Consolidated EBITDA
(measured, in the case of Total Assets, at the end of the most recent fiscal period for which internal financial statements are available and, in the case of Consolidated EBITDA, for the four quarters ended most recently for which internal financial
statements are available, in each case measured on a pro forma basis giving effect to any acquisitions or depositions of companies, division or lines of business since such balance sheet date or the start of such four quarter period, as applicable,
and on or prior to the date of acquisition of such Subsidiary); provided that if all Immaterial Subsidiaries collectively have Total Assets and Consolidated EBITDA of 5.0% or more of the Borrower’s Total Assets and Consolidated EBITDA,
then the Borrower shall take all action necessary or reasonably requested by the Administrative Agent as required pursuant to Section 6.11 with respect to such Restricted Subsidiaries such that the aggregate Total Assets and aggregate
Consolidated EBITDA are less than 5.0% of the Borrower’s Total Assets and Consolidated EBITDA. 
 “Incur”
means issue, create, assume, have any Guarantee Obligation in respect of, incur, extend or otherwise become directly or indirectly liable for, contingently or otherwise; provided, however, that any Indebtedness or Capital Stock of a
Person existing at the time such Person becomes a Restricted Subsidiary (whether by merger, consolidation, acquisition or otherwise) will be deemed to be Incurred by such Restricted Subsidiary at the time it becomes a Restricted Subsidiary and the
terms “Incurred” and “Incurrence” have meanings correlative to the foregoing and any Indebtedness pursuant to any revolving credit or similar facility shall only be “Incurred” at the time any funds are borrowed
thereunder. 
 “Indebtedness” means, with respect to any Person on any date of determination (without
duplication): 
  

	 	(1)	the principal of indebtedness of such Person for borrowed money; 

  

	 	(2)	the principal of obligations of such Person evidenced by bonds, debentures, notes or other similar instruments; 

 

	 	(3)	all reimbursement obligations of such Person in respect of letters of credit, bankers’ acceptances or other similar instruments (the amount of such obligations
being equal at any time to the aggregate then undrawn and unexpired amount of such letters of credit or other instruments plus the aggregate amount of drawings thereunder that have been reimbursed) (except to the extent such reimbursement
obligations relate to trade payables and such obligations are satisfied within 30 days of Incurrence); 

  

	 	(4)	the principal component of all obligations of such Person to pay the deferred and unpaid purchase price of property (except trade payables), which purchase price is due
more than one year after the date of placing such property in service or taking final delivery and title thereto; 

  

	 	(5)	Capitalized Lease Obligations of such Person; 

  

	 	(6)	the principal component of all obligations, or liquidation preference, of such Person with respect to any Disqualified Stock or, with respect to any Restricted
Subsidiary, any Preferred Stock (but excluding, in each case, any accrued dividends); 

  
 -21-

	 	(7)	the principal component of all Indebtedness of other Persons secured by a Lien on any asset of such Person, whether or not such Indebtedness is assumed by such Person;
provided, however, that the amount of such Indebtedness will be the lesser of (a) the fair market value of such asset at such date of determination (as determined in good faith by the Borrower) and (b) the amount of such
Indebtedness of such other Persons; 

  

	 	(8)	Guarantee Obligations of such Person in respect of the principal component of Indebtedness of other Persons; and 

 

	 	(9)	to the extent not otherwise included in this definition, net obligations of such Person under Hedging Obligations (the amount of any such obligations to be equal at any
time to the net payments under such agreement or arrangement giving rise to such obligation that would be payable by such Person at the termination of such agreement or arrangement). 

The term “Indebtedness” shall not include any lease, concession or license of property (or Guarantee Obligation in respect
thereof) which would be considered an operating lease under GAAP as in effect on the Closing Date, any prepayments of deposits received from clients or customers in the ordinary course of business, or obligations under any license, permit or other
approval (or Guarantee Obligations in respect of such obligations) Incurred prior to the Closing Date or in the ordinary course of business. 
 The amount of Indebtedness of any Person at any time in the case of any revolving credit or similar facility shall be the total amount of funds borrowed and then outstanding. The amount of Indebtedness of
any Person at any date shall be determined as set forth above or otherwise provided in this Agreement, and (other than with respect to letters of credit or Guarantee Obligations or Indebtedness specified in the foregoing clauses (7),
(8) or (9)) shall equal the amount thereof that would appear on a balance sheet of such Person (excluding any notes thereto) prepared on the basis of GAAP. 
 Notwithstanding the above provisions, in no event shall the following constitute Indebtedness: 
  

	 	(i)	Contingent Obligations Incurred in the ordinary course of business; 

  

	 	(ii)	in connection with the purchase by the Borrower or any Restricted Subsidiary of any business, any post-closing payment adjustments to which the seller may become
entitled to the extent such payment is determined by a final closing balance sheet or such payment depends on the performance of such business after the closing; provided, however, that, at the time of closing, the amount of any such
payment is not determinable and, to the extent such payment thereafter becomes fixed and determined, the amount is paid within 30 days; or 

  

	 	(iii)	for the avoidance of doubt, any obligations in respect of workers’ compensation claims, early retirement or termination obligations, pension fund obligations or
contributions or similar claims, obligations or contributions or social security or wage Taxes. 

“Indemnified Liabilities” has the meaning specified in Section 10.05. 

“Indemnitees” has the meaning specified in Section 10.05. 

“Indenture” means the Indenture relating to the Senior Notes, dated as of April 29, 2011, between the Borrower as
issuer, iGate Technologies, Inc., as guarantor and Wilmington Trust FSB as the trustee for the holders of the Senior Notes. 

  
 -22-

 “Information” has the meaning specified in Section 10.08.

 “Initial Revolving Borrowing” means the initial borrowing of Revolving Credit Loans hereunder. 

“Interest Payment Date” means, as to any Loan other than a Base Rate Loan, the last day of each Interest Period
applicable to such Loan and the Maturity Date of the Facility under which such Loan was made; provided that if any Interest Period for a Eurocurrency Rate Loan exceeds three months, the respective dates that fall every three months after the
beginning of such Interest Period shall also be Interest Payment Dates and (b) as to any Base Rate Loan, the last Business Day of each March, June, September and December and the Maturity Date of the Facility under which such Loan was made.

 “Interest Period” means, as to each Eurocurrency Rate Loan, the period commencing on the date such
Eurocurrency Rate Loan is disbursed or converted to or continued as a Eurocurrency Rate Loan, and ending on the date one, two, three or six months thereafter, or to the extent available to each Lender of such Eurocurrency Rate Loan, nine or twelve
months thereafter or, any earlier date as selected by the Borrower in its Committed Loan Notice; provided that: 
 (a) any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless such Business Day falls in another calendar month, in
which case such Interest Period shall end on the next preceding Business Day; 
 (b) any Interest Period that
begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of
such Interest Period; and 
 (c) no Interest Period shall extend beyond the Maturity Date of the Facility under
which such Loan was made. 
 “Investment” means, with respect to any Person, all investments by such Person in
other Persons (including Affiliates) in the form of any direct or indirect advance, loan or other extensions of credit (other than advances or extensions of credit to customers, suppliers, directors, officers or employees of any Person in the
ordinary course of business, and excluding any debt or extension of credit represented by a bank deposit other than a time deposit) or capital contribution to (by means of any transfer of cash or other property to others or any payment for property
or services for the account or use of others), or the Incurrence of a Guarantee Obligation in respect of any obligation of, or any purchase or acquisition of Capital Stock, Indebtedness or other similar instruments issued by, such other Persons and
all other items that are or would be classified as investments on a balance sheet prepared on the basis of GAAP; provided, however, that endorsements of negotiable instruments and documents in the ordinary course of business will not
be deemed to be an Investment. If the Borrower or any Restricted Subsidiary issues, sells or otherwise disposes of any Capital Stock of a Person that is a Restricted Subsidiary such that, after giving effect thereto, such Person is no longer a
Restricted Subsidiary, any Investment by the Borrower or any Restricted Subsidiary in such Person remaining after giving effect thereto will be deemed to be a new Investment at such time. 

For purposes of Section 7.06: 
  

	 	(1)	 “Investment” will include the portion (proportionate to the Borrower’s equity interest in a Restricted Subsidiary to be
designated as an Unrestricted Subsidiary) of the fair market value of the net assets of such Restricted Subsidiary of the Borrower at the time that such Restricted Subsidiary is designated an Unrestricted Subsidiary; provided, however,
that 

  
 -23-

	 	 
upon a redesignation of such Subsidiary as a Restricted Subsidiary, the Borrower will be deemed to continue to have a permanent “Investment” in an Unrestricted Subsidiary in an amount
(if positive) equal to (a) the Borrower’s “Investment” in such Subsidiary at the time of such redesignation less (b) the portion (proportionate to the Borrower’s equity interest in such Subsidiary) of the fair market
value of the net assets (as conclusively determined by the Board of Directors of the Borrower in good faith) of such Subsidiary at the time that such Subsidiary is so re-designated a Restricted Subsidiary; and 

 

	 	(2)	any property transferred to or from an Unrestricted Subsidiary will be valued at its fair market value at the time of such transfer, in each case as determined in good
faith by the Board of Directors of the Borrower. 

 “Investment Grade Securities” means:

  

	 	(1)	securities issued or insured by the United States or Canadian government or any agency or instrumentality thereof, or in respect of which the United States or Canadian
government or any agency or instrumentality of thereof has a full and direct Guarantee Obligation (other than, in each case, Cash Equivalents); 

  

	 	(2)	securities issued or directly and fully guaranteed or insured by a member of the European Union, or any agency or instrumentality thereof (other than Cash Equivalents);

  

	 	(3)	debt securities or debt instruments with a rating of “A—” or higher from S&P or “A3” or higher by Moody’s or the equivalent of such
rating by such rating organization or, if no rating of Moody’s or S&P then exists, the equivalent of such rating by another Nationally Recognized Statistical Rating Organization, but excluding any debt securities or instruments constituting
loans or advances among the Borrower and its Subsidiaries; and 

  

	 	(4)	investments in any fund that invests exclusively in investments of the type described in clauses (1), (2) and (3) above which fund may also hold cash and Cash
Equivalents pending investment or distribution. 

 “IP Rights” has the meaning specified in
Section 5.14. 
 “Judgment Currency” has the meaning specified in Section 10.17.

 “Laws” means, collectively, all international, foreign, federal, state, provincial and local statutes,
treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation
or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority. 

“Lead Arranger” has the meaning set forth in the recitals to this Agreement. 

“Lender” has the meaning specified in the introductory paragraph to this Agreement and their respective successors and
assigns as permitted hereunder, each of which is referred to herein as a “Lender.” 
 “LIBOR Rate”
means, in relation to any Loan or Unpaid Sum, (a) the applicable Screen Rate or (b) if no Screen Rate is available for US Dollars for the Interest Period of that Loan or Unpaid Sum, the rates (rounded upwards to four decimal places) quoted
by the Administrative Agent or an Affiliate thereof 

  
 -24-

 
to leading banks in the London interbank market, as of 11:00 a.m. (London time) on the Quotation Day for which an interest rate is to be determined for the offering of deposits in US Dollars and
for a period comparable to the Interest Period for that Loan or Unpaid Sum. 
 “Lien” means any mortgage,
pledge, security interest, encumbrance, lien or charge of any kind (including any conditional sale or other title retention agreement or lease in the nature thereof). 
 “Loan” means an extension of credit by a Lender to the Borrower under Article II in the form of a Revolving Credit Loan. 

“Loan Documents” means, collectively, (a) this Agreement, (b) the Notes, (c) the Guaranty and
(d) the Fee Letter, in each case as amended. 
 “Loan Parties” means, collectively, (a) the Borrower
and (b) each other Guarantor. 
 “Management Advances” means loans or advances made to, or Guarantee
Obligations in respect of loans or advances made to, directors, officers, employees or consultants of any Parent, the Borrower or any Restricted Subsidiary not exceeding $5,000,000 in the aggregate outstanding at any time: 

 

	 	(1)	(a) in respect of travel, entertainment or moving related expenses Incurred in the ordinary course of business or (b) for purposes of funding any such
person’s purchase of Capital Stock (or similar obligations) of the Borrower, its Subsidiaries or any Parent with (in the case of this sub-clause (b)) the approval of the Board of Directors; 

 

	 	(2)	in respect of moving related expenses Incurred in connection with any closing or consolidation of any facility or office; or 

 

	 	(3)	other loans, advances or Guarantee Obligations. 

 “Material Adverse Effect” means (a) a material adverse effect on the business, operations, assets, liabilities (actual or contingent) or financial condition of the Borrower and its
Restricted Subsidiaries, taken as a whole, (b) a material adverse effect on the ability of the Loan Parties (taken as a whole) to perform their respective payment obligations under any Loan Document to which any of the Loan Parties is a party
or (c) a material adverse effect on the rights and remedies of the Lenders or the Agents under any Loan Document. 

“Material Real Property” means any real property owned by any Loan Party with a book value in excess of $2,000,000 and
each parcel of real property listed on Schedule 1.01D. 
 “Material Subsidiary” means, at any date of
determination, each Subsidiary of the Borrower that is not an Immaterial Subsidiary (but including, in any case, any Subsidiary that has been designated as a Material Subsidiary as provided in, or has been designated as an Immaterial Subsidiary in a
manner that does not comply with, the definition of “Immaterial Subsidiary”). 
 “Maturity
Date” means May 10, 2016; provided that, if such day is not a Business Day, the Maturity Date shall be the Business Day immediately preceding such day. 
 “Moody’s” means Moody’s Investors Service, Inc. and any successor thereto. 
 “Multiemployer Plan” means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which any Loan Party or any ERISA Affiliate makes or is obligated to

  
 -25-

 
make contributions, or during the period since January 1, 2003, has made or been obligated to make contributions. 
 “Nationally Recognized Statistical Rating Organization” means a nationally recognized statistical rating organization within the meaning of Rule 436 of the Securities Act. 

“Net Available Cash” from an Disposition means cash payments received (including any cash payments received by way of
deferred payment of principal pursuant to a note or installment receivable or otherwise and net proceeds from the sale or other disposition of any securities received as consideration, but only as and when received, but excluding any other
consideration received in the form of assumption by the acquiring person of Indebtedness or other obligations relating to the properties or assets that are the subject of such Disposition or received in any other non-cash form) therefrom, in each
case net of: 
 (1) all legal, accounting, investment banking, title and recording tax expenses, commissions and other fees and
expenses Incurred, and all Taxes paid or required to be paid or accrued as a liability under GAAP (after taking into account any available tax credits or deductions and any tax sharing agreements), as a consequence of such Disposition; 

(2) all payments made on any Indebtedness which is secured by any assets subject to such Disposition, in accordance with the terms of any
Lien upon such assets, or which by applicable law be repaid out of the proceeds from such Disposition; 
 (3) all distributions
and other payments required to be made to minority interest holders (other than any Parent, the Borrower or any of their respective Subsidiaries) in Subsidiaries or joint ventures as a result of such Disposition; and 

(4) the deduction of appropriate amounts required to be provided by the seller as a reserve, on the basis of GAAP, against any
liabilities associated with the assets disposed of in such Disposition and retained by the Borrower or any Restricted Subsidiary after such Disposition. 
 “Net Cash Proceeds” with respect to any issuance or sale of Capital Stock, means the cash proceeds of such issuance or sale net of attorneys’ fees, accountants’ fees,
underwriters’ or placement agents’ fees, listing fees, discounts or commissions and brokerage, consultant and other fees and charges actually Incurred in connection with such issuance or sale and net of taxes paid or payable as a result of
such issuance or sale (after taking into account any available tax credit or deductions and any tax sharing arrangements). 

“Non-Guarantor” means any Restricted Subsidiary that is not a Guarantor. 

“Non-Consenting Lender” has the meaning specified in Section 3.07(d). 

“Non-Loan Party” means any Subsidiary of the Borrower that is not a Loan Party. 

“Non-U.S. Subsidiary” means a subsidiary of the Borrower organized in a jurisdiction other than the United States or
Canada, any state or territory thereof, or the District of Columbia. 
 “Note” means a Revolving Credit Note.

 “Obligations” means all advances to, and debts, liabilities, obligations, covenants and duties of, any Loan
Party or other Subsidiary arising under any Loan Document or otherwise with respect to any Loan, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and
including interest and fees that accrue after the 

  
 -26-

 
commencement by or against any Loan Party or any other Subsidiary of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such
interest and fees are allowed claims in such proceeding. Without limiting the generality of the foregoing, the Obligations of the Loan Parties under the Loan Documents (and of any of their Subsidiaries to the extent they have obligations under the
Loan Documents) include (i) the obligation (including guarantee obligations) to pay principal, interest, reimbursement obligations, charges, expenses, fees, Attorney Costs, indemnities and other amounts payable by any Loan Party or any other
Subsidiary under any Loan Document and (ii) the obligation of any Loan Party or any other Subsidiary to reimburse any amount in respect of any of the foregoing that any Lender, in its sole discretion, may elect to pay or advance on behalf of
such Loan Party or such Subsidiary. 
 “Officer” means, with respect to any Person, (1) the Chairman of
the Board of Directors, the Chief Executive Officer, the President, the Chief Financial Officer, any Vice President, the Treasurer, any Managing Director, or the Secretary (a) of such Person or (b) if such Person is owned or managed by a
single entity, of such entity, or (2) any other individual designated as an “Officer” for the purposes of this Agreement by the Board of Directors of such Person. 

“Officer’s Certificate” means, with respect to any Person, a certificate signed by one Officer of such Person.

 “Organization Documents” means (a) with respect to any corporation, the certificate or articles of
incorporation and the bylaws; (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement; and (c) with respect to any partnership, joint venture, trust or other form
of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, declaration, instrument, filing or notice with respect thereto filed in connection with its formation or organization
with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity. 

“Other Taxes” has the meaning specified in Section 3.01(b). 

“Outstanding Amount” means with respect to the Revolving Credit Loans on any date, the outstanding principal amount
thereof after giving effect to any borrowings and prepayments or repayments of Revolving Credit Loans occurring on such date. 

“Packing Credit Facility” means the revolving packing credit facility, as described in and pursuant to the
terms of the Facility Letter, dated as of April 1, 2011, between iGATE Global Solutions Limited and Standard Chartered Bank, together with the related documents thereto (including the revolving loans thereunder, any letters of credit and
reimbursement obligations related thereto, any related Guarantee Obligations and security documents), as amended, extended, renewed, restated, refunded, replaced, refinanced, supplemented, modified or otherwise changed (in whole or in part, and
without limitation as to amount, terms, conditions, covenants and other provisions) from time to time, and any one or more agreements (and related documents) governing Indebtedness, including indentures, incurred to refinance, substitute,
supplement, replace or add to (including increasing the amount available for borrowing or adding or removing any Person as a borrower, issuer or guarantor thereunder; provided that such increase in borrowings is permitted by
Section 7.03 in whole or in part, the borrowings and commitments then outstanding or permitted to be outstanding under such Packing Credit Facility or one or more successors to the Packing Credit Facility or one or more new credit
agreements. 
 “Parent” means any Person of which the Borrower at any time is or becomes a Subsidiary after the
Closing Date. 

  
 -27-

 “Pari Passu Indebtedness” means Indebtedness of the Borrower which ranks
equally in right of payment to the Senior Notes under the Indenture. 
 “Participant” has the meaning specified
in Section 10.07(e). 
 “PBGC” means the Pension Benefit Guaranty Corporation. 

“Pension Act” means the Pension Protection Act of 2006, as amended. 

“Pension Plan” means any “employee pension benefit plan” (as such term is defined in Section 3(2) of
ERISA) other than a Multiemployer Plan, that is subject to Title IV of ERISA and is sponsored or maintained by any Loan Party or any ERISA Affiliate or to which any Loan Party or any ERISA Affiliate contributes or has an obligation to contribute, or
in the case of a multiple employer or other plan described in Section 4064(a) of ERISA, has made contributions at any time since January 1, 2003. 
 “Permitted Asset Swap” means the concurrent purchase and sale or exchange of assets used or useful in a Similar Business or a combination of such assets and cash, Cash Equivalents between
the Borrower or any of its Restricted Subsidiaries and another Person; provided that any cash or Cash Equivalents received in excess of the value of any cash or Cash Equivalents sold or exchanged must be applied in accordance with
Section 7.05. 
 “Permitted Holders” means, collectively, (1) Apax, (2) any one or more
Persons whose beneficial ownership constitutes or results in a Change of Control in respect of which a Change of Control Offer is made in accordance with (and as defined in) the requirements of the Indenture and Affiliates of such Persons,
(3) Senior Management, (4) any Person who is acting as an underwriter in connection with a public or private offering of Capital Stock of any Parent or the Borrower, acting in such capacity, and (5) any group (within the meaning of
Section 13(d)(3) or Section 14(d)(2) of the Exchange Act or any successor provision) of which any of the foregoing are members; provided that, in the case of such group and without giving effect to the existence of such group or any
other group, Apax and Senior Management, collectively, have beneficial ownership of more than 50% of the total voting power of the Voting Stock of the Borrower. 
 “Permitted Investment” means (in each case, by the Borrower or any of its Restricted Subsidiaries): 
  

	 	(1)	Investments in (a) a Restricted Subsidiary (including the Capital Stock of a Restricted Subsidiary) or the Borrower or (b) a Person (including the Capital
Stock of any such Person) that is engaged in a Similar Business that will, upon the making of such Investment, become a Restricted Subsidiary; 

  

	 	(2)	Investments in another Person if such Person is engaged in any Similar Business and as a result of such Investment such other Person is merged, consolidated or
otherwise combined with or into, or transfers or conveys all or substantially all its assets to, the Borrower or a Restricted Subsidiary; 

  

	 	(3)	Investments in Cash Equivalents or Investment Grade Securities; 

  

	 	(4)	Investments in payroll, travel and similar advances to cover matters that are expected at the time of such advances ultimately to be treated as expenses for accounting
purposes and that are made in the ordinary course of business; 

  
 -28-

	 	(5)	Management Advances; 

  

	 	(6)	Investments in Capital Stock, obligations or securities received in settlement of debts created in the ordinary course of business and owing to the Borrower or any
Restricted Subsidiary, or as a result of foreclosure, perfection or enforcement of any Lien, or in satisfaction of judgments or pursuant to any plan of reorganization or similar arrangement including upon the bankruptcy or insolvency of a debtor;

  

	 	(7)	Investments made as a result of the receipt of non-cash consideration from a sale or other disposition of property or assets, including an Disposition;

  

	 	(8)	Investments existing or pursuant to agreements or arrangements in effect on the Closing Date and any modification, replacement, renewal or extension thereof, provided
that the amount of any such Investments may not be increased; 

  

	 	(9)	Hedging Obligations, which transactions or obligations are Incurred in compliance with Section 7.03; 

 

	 	(10)	additional Investments having an aggregate fair market value, taken together with all other Investments made pursuant to this clause (10) that are at that time
outstanding, not to exceed the greater of $50,000,000 and 2.5% of Total Assets (with the fair market value of each Investment being measured at the time made and without giving effect to subsequent changes in value) plus the amount of any
distributions, dividends, payments or other returns in respect of such Investments (without duplication for purposes of the covenant described in Section 7.06(c) any amounts applied pursuant to clause (c) of the first paragraph of
such covenant); provided that if such Investment is in Capital Stock of a Person that subsequently becomes a Restricted Subsidiary, such Investment shall thereafter be deemed permitted under the foregoing clause (1) or (2) and shall
not be included as having been made pursuant to this clause (10); 

  

	 	(11)	pledges or deposits with respect to leases or utilities provided to third parties in the ordinary course of business or Liens otherwise described in the definition of
“Permitted Liens” or made in connection with Liens permitted under Section 7.01; 

  

	 	(12)	any Investment to the extent made using Capital Stock of the Borrower (other than Disqualified Stock) or Capital Stock of any Parent (other than Disqualified Stock) as
consideration; 

  

	 	(13)	any transaction to the extent constituting an Investment that is permitted and made in accordance with the provisions of Section 7.08 (except those
described in clauses (1), (3), (5), (7), (8), (11) and (13) of such Section); 

  

	 	(14)	Investments consisting of purchases and acquisitions of inventory, supplies, materials and equipment or licenses or leases of intellectual property, in any case, in the
ordinary course of business and in accordance with this Agreement; 

  

	 	(15)	(i) Guarantee Obligations in respect of Indebtedness of the Borrower and its Restricted Subsidiaries not prohibited by Section 7.03 and (other than
with respect to Indebtedness) guarantees, keepwells and similar arrangements in the ordinary course of business, and (ii) performance guarantees with respect to obligations incurred by the Borrower or any of its Restricted Subsidiaries that are
permitted by this Agreement; 

  
 -29-

	 	(16)	Investments consisting of earnest money deposits required in connection with a purchase agreement, or letter of intent, or other acquisitions to the extent not
otherwise prohibited by this Agreement; 

  

	 	(17)	Investments of a Restricted Subsidiary acquired after the Closing Date or of an entity merged into the Borrower or merged into or consolidated with a Restricted
Subsidiary after the Closing Date to the extent that such Investments were not made in contemplation of or in connection with such acquisition, merger or consolidation and were in existence on the date of such acquisition, merger or consolidation;

  

	 	(18)	Investments consisting of licensing of intellectual property pursuant to joint marketing arrangements with other Persons; 

 

	 	(19)	contributions to a “rabbi” trust for the benefit of employees or other grantor trust subject to claims of creditors in the case of a bankruptcy of the
Borrower; and 

  

	 	(20)	any transaction to the extent constituting an Investment in connection with any disposition of Capital Stock of a Restricted Subsidiary pursuant to Indian regulatory or
shareholding requirements, including, without limitation, the ability to invest proceeds received from the disposition of such Capital Stock to create an escrow account, the ability to pass the control of such escrow account to a third party and the
entry into put or call arrangements with third parties. 

 “Permitted Liens” means, with respect
to any Person: 
  

	 	(1)	Liens on (a) assets or property of a Restricted Subsidiary that is not a Guarantor securing Indebtedness of any Restricted Subsidiary that is not a Guarantor and
(b) assets or property of the Borrower or any Restricted Subsidiary securing Obligations in respect of Indebtedness of the Borrower or a Guarantor; provided that at the time of Incurrence and after giving pro forma effect thereto, the
Consolidated Priority Debt Leverage Ratio would be no greater than 1.50 to 1.00; 

  

	 	(2)	pledges, deposits or Liens under workmen’s compensation laws, unemployment insurance laws, social security laws or similar legislation, or insurance related
obligations (including pledges or deposits securing liability to insurance carriers under insurance or self-insurance arrangements), or in connection with bids, tenders, completion guarantees, contracts (other than for borrowed money) or leases, or
to secure utilities, licenses, public or statutory obligations, or to secure surety, indemnity, judgment, appeal or performance bonds, guarantees of government contracts (or other similar bonds, instruments or obligations), or as security for
contested taxes or import or customs duties or for the payment of rent, or other obligations of like nature, in each case Incurred in the ordinary course of business; 

 

	 	(3)	Liens imposed by law, including carriers’, warehousemen’s, mechanics’, landlords’, materialmen’s and repairmen’s or other like Liens, in
each case for sums not yet overdue for a period of more than 60 days or that are bonded or being contested in good faith by appropriate proceedings; 

  

	 	(4)	Liens for taxes, assessments or other governmental charges not yet delinquent or which are being contested in good faith by appropriate proceedings; provided
that appropriate reserves required pursuant to GAAP have been made in respect thereof; 

  
 -30-

	 	(5)	Liens in favor of the Borrower of surety, performance or other bonds, guarantees or letters of credit or bankers’ acceptances (not issued to support Indebtedness
for borrowed money) issued pursuant to the request of and for the account of the Borrower or any Restricted Subsidiary in the ordinary course of its business; 

 

	 	(6)	encumbrances, ground leases, easements (including reciprocal easement agreements), survey exceptions, or reservations of, or rights of others for, licenses, rights of
way, sewers, electric lines, telegraph and telephone lines and other similar purposes, or zoning, building codes or other restrictions (including minor defects or irregularities in title and similar encumbrances) as to the use of real properties or
Liens incidental to the conduct of the business of the Borrower and its Restricted Subsidiaries or to the ownership of its properties which do not in the aggregate materially adversely affect the value of said properties or materially impair their
use in the operation of the business of the Borrower and its Restricted Subsidiaries; 

  

	 	(7)	Liens on assets or property of the Borrower or any Restricted Subsidiary securing Hedging Obligations permitted under this Agreement; 

 

	 	(8)	leases, licenses, subleases and sublicenses of assets (including real property and intellectual property rights), in each case entered into in the ordinary course of
business; 

  

	 	(9)	Liens arising out of judgments, decrees, orders or awards not giving rise to an Event of Default so long as any appropriate legal proceedings which may have been duly
initiated for the review of such judgment, decree, order or award have not been finally terminated or the period within which such proceedings may be initiated has not expired; 

 

	 	(10)	Liens to secure Indebtedness permitted by Section 7.03(a)(i); 

  

	 	(11)	Liens that are contractual rights of set-off or, in the case of clause (i) or (ii) below, other bankers’ Liens (i) relating to treasury, depository
and Cash Management Services or any automated clearing house transfers of funds in the ordinary course of business and not given in connection with the issuance of Indebtedness, (ii) relating to pooled deposit or sweep accounts to permit
satisfaction of overdraft or similar obligations incurred in the ordinary course of business of the Borrower or any Subsidiary or (iii) relating to purchase orders and other agreements entered into with customers of the Borrower or any
Restricted Subsidiary in the ordinary course of business; 

  

	 	(12)	Liens existing on the Closing Date; 

  

	 	(13)	Liens on property, other assets or shares of stock of a Person at the time such Person becomes a Restricted Subsidiary (or at the time the Borrower or a Restricted
Subsidiary acquires such property, other assets or shares of stock, including any acquisition by means of a merger, consolidation or other business combination transaction with or into the Borrower or any Restricted Subsidiary); provided,
however, that such Liens are not created, Incurred or assumed in anticipation of or in connection with such other Person becoming a Restricted Subsidiary (or such acquisition of such property, other assets or stock); provided,
further, that such Liens are limited to all or part of the same property, other assets or stock (plus improvements, accession, proceeds or dividends or distributions in connection with the original property, other assets or stock) that
secured (or, under the written arrangements under which such Liens arose, could secure) the obligations to which such Liens relate; 

  
 -31-

	 	(14)	Liens on assets or property of the Borrower or any Restricted Subsidiary securing Indebtedness or other obligations of the Borrower or such Restricted Subsidiary owing
to the Borrower or another Restricted Subsidiary, or Liens in favor of the Borrower or any Guarantor; 

  

	 	(15)	Liens securing Refinancing Indebtedness Incurred to refinance Indebtedness that was previously so secured, and permitted to be secured under this Agreement;
provided that any such Lien is limited to all or part of the same property or assets (plus improvements, accessions, proceeds or dividends or distributions in respect thereof) that secured (or, under the written arrangements under which the
original Lien arose, could secure) the Indebtedness being refinanced or is in respect of property that is or could be the security for or subject to a Permitted Lien hereunder; 

 

	 	(16)	(a) mortgages, liens, security interests, restrictions, encumbrances or any other matters of record that have been placed by any government, statutory or
regulatory authority, developer, landlord or other third party on property over which the Borrower or any Restricted Subsidiary of the Borrower has easement rights or on any leased property and subordination or similar arrangements relating thereto
and (b) any condemnation or eminent domain proceedings affecting any real property; 

  

	 	(17)	any encumbrance or restriction (including put and call arrangements) with respect to Capital Stock of any joint venture or similar arrangement pursuant to any joint
venture or similar agreement; 

  

	 	(18)	Liens on property or assets under construction (and related rights) in favor of a contractor or developer or arising from progress or partial payments by a third party
relating to such property or assets; 

  

	 	(19)	Liens on escrowed proceeds in respect of the Senior Notes for the benefit of the related holders of debt securities or other Indebtedness (or the underwriters or
arrangers thereof) or on cash set aside at the time of the Incurrence of any Indebtedness or government securities purchased with such cash, in either case to the extent such cash or government securities prefund the payment of interest on such
Indebtedness and are held in an escrow account or similar arrangement to be applied for such purpose; 

  

	 	(20)	Liens securing or arising by reason of any netting or set-off arrangement entered into in the ordinary course of banking or other trading activities, or liens over cash
accounts securing cash pooling arrangements; 

  

	 	(21)	Liens arising out of conditional sale, title retention, hire purchase, consignment or similar arrangements for the sale of goods entered into in the ordinary course of
business; 

  

	 	(22)	Liens securing Indebtedness and other obligations in an aggregate principal amount not to exceed $35,000,000 at any one time outstanding; 

 

	 	(23)	Liens on Capital Stock or other securities or assets of any Unrestricted Subsidiary that secure Indebtedness of such Unrestricted Subsidiary; 

 

	 	(24)	any security granted over the marketable securities portfolio described in clause (9) of the definition of “Cash Equivalents” in connection with the
disposal thereof to a third party; 

  
 -32-

	 	(25)	Liens on equipment of the Borrower or any Restricted Subsidiary and located on the premises of any client or supplier in the ordinary course of business;

  

	 	(26)	Liens on assets or securities deemed to arise in connection with and solely as a result of the execution, delivery or performance of contracts to sell such assets or
securities if such sale is otherwise permitted by this Agreement; 

  

	 	(27)	Utility and other similar deposits made in the ordinary course of business; and 

 

	 	(28)	Liens in connection with any disposition of Capital Stock of a Restricted Subsidiary pursuant to Indian regulatory or shareholding requirements, including, without
limitation, the ability to invest proceeds received from the disposition of such Capital Stock to create an escrow account, the ability to pass the control of such escrow account to a third party and the entry into put or call arrangements with
third parties. 

 For purposes of this definition, the term Indebtedness shall be deemed to include interest on such Indebtedness
including interest which increases the principal amount of such Indebtedness. 
 “Permitted Payment” means:

  

	 	(a)	the payment of any dividend or distribution within 60 days after the date of declaration thereof, if at the date of declaration such payment would have complied with
the provisions of this Agreement or the redemption, repurchase or retirement of Indebtedness if, at the date of any irrevocable redemption notice, such payment would have complied with the provisions of this Agreement; 

 

	 	(b)	any purchase, repurchase, redemption, defeasance or other acquisition or retirement of Capital Stock or Subordinated Indebtedness made by exchange (including any such
exchange pursuant to the exercise of a conversion right or privilege in connection with which cash is paid in lieu of the issuance of fractional shares) for, or out of the proceeds of the substantially concurrent sale of, Capital Stock of the
Borrower (other than Disqualified Stock or Designated Preferred Stock) (“Refunding Capital Stock”) or a substantially concurrent contribution to the equity (other than through the issuance of Disqualified Stock or
Designated Preferred Stock or through an Excluded Contribution) of the Borrower; provided, however, that to the extent so applied, the Net Cash Proceeds, or fair market value of property or assets or of marketable securities, from such sale
of Capital Stock or such contribution will be excluded from Section 7.06(3); 

  

	 	(c)	any purchase, repurchase, redemption, defeasance or other acquisition or retirement of Subordinated Indebtedness made by exchange for, or out of the proceeds of the
substantially concurrent sale of, Refinancing Indebtedness permitted to be Incurred pursuant to Section 7.03; 

  

	 	(d)	any purchase, repurchase, redemption, defeasance or other acquisition or retirement of Preferred Stock of the Borrower or a Restricted Subsidiary made by exchange for
or out of the proceeds of the substantially concurrent sale of Preferred Stock of the Borrower or a Restricted Subsidiary, as the case may be, that, in each case, is permitted to be Incurred pursuant to Section 7.03, and that in each
case, constitutes Refinancing Indebtedness; 

  
 -33-

	 	(e)	any purchase, repurchase, redemption, defeasance or other acquisition or retirement of Subordinated Indebtedness or Disqualified Stock or Preferred Stock of a
Restricted Subsidiary: 

  

	 	(i)	from Net Available Cash to the extent permitted under Section 7.05, but only if the Borrower shall have first complied with Section 7.05 and purchased all
Senior Notes tendered pursuant to any offer to repurchase all the Senior Notes required by the Indenture, prior to purchasing, repurchasing, redeeming, defeasing or otherwise acquiring or retiring such Subordinated Indebtedness;

  

	 	(ii)	to the extent required by the agreement governing such Subordinated Indebtedness, following the occurrence of a Change of Control (as defined in the Indenture) (or
other similar event described therein as a “change of control”), but only if the Borrower shall have first complied with the applicable terms of such Indenture and purchased all Senior Notes tendered pursuant to the offer to repurchase all
of the Senior Notes required thereby prior to purchasing, repurchasing, redeeming, defeasing or otherwise acquiring or retiring such Subordinated Indebtedness; 

 

	 	(iii)	consisting of Acquired Indebtedness (other than Indebtedness Incurred (A) to provide all or any portion of the funds utilized to consummate the transaction or
series of related transactions pursuant to which such Person became a Restricted Subsidiary or was otherwise acquired by the Borrower or a Restricted Subsidiary or (B) otherwise in connection with or contemplation of such acquisition);
provided, however, that such Acquired Indebtedness shall have a maturity date prior to the stated maturity of the Senior Notes; 

  

	 	(f)	a Restricted Payment to pay for the repurchase, retirement or other acquisition or retirement for value of Capital Stock (other than Disqualified Stock) of the Borrower
or any of its Parents held by any future, present or former employee, director or consultant of the Borrower, any of its Subsidiaries or any of its Parents (or permitted transferees, assigns, estates, trusts or heirs of such employee, director or
consultant) pursuant to any management equity plan or stock option plan or any other management or employee benefit plan or agreement; provided, however, that the aggregate Restricted Payments made under this clause do not exceed
$5,000,000 in any calendar year (with unused amounts in any calendar year being carried over to succeeding calendar years subject to a maximum of $10,000,000 in any calendar year); provided further that such amount in any calendar year may be
increased by an amount not to exceed: 

  

	 	(i)	the cash proceeds from the sale of Capital Stock (other than Disqualified Stock or Designated Preferred Stock) of the Borrower and, to the extent contributed to the
capital of the Borrower (other than through the issuance of Disqualified Stock or Designated Preferred Stock or an Excluded Contribution), Capital Stock of any of the Borrower’s Parents, in each case to members of management, directors or
consultants of the Borrower, any of its Subsidiaries or any of its Parents that occurred after the Closing Date, to the extent the cash proceeds from the sale of such Capital Stock have not otherwise been applied to the payment of Restricted
Payments by virtue of Section 7.06(3); plus 

  
 -34-

	 	(ii)	the cash proceeds of key man life insurance policies received by the Borrower and its Restricted Subsidiaries after the Closing Date; less 

 

	 	(iii)	the amount of any Restricted Payments made in previous calendar years pursuant to clauses (a) and (b) of this clause; 

and provided further that cancellation of Indebtedness owing to the Borrower or any Restricted Subsidiary from members of
management, directors, employees or consultants of the Borrower, any of the Borrower’s Parents or any of its Restricted Subsidiaries in connection with a repurchase of Capital Stock of the Borrower or any of its Parents will not be deemed to
constitute a Restricted Payment for purposes of this covenant or any other provision of this Agreement; 
  

	 	(g)	the declaration and payment of dividends to holders of any class or series of Disqualified Stock, or of any Preferred Stock of a Restricted Subsidiary, Incurred in
accordance with Section 7.03; 

  

	 	(h)	purchases, repurchases, redemptions, defeasances or other acquisitions or retirements of Capital Stock deemed to occur upon the exercise of stock options, warrants or
other rights in respect thereof if such Capital Stock represents a portion of the exercise price thereof; 

  

	 	(i)	so long as no Default or Event of Default has occurred and is continuing (or would result from), the declaration and payment by the Borrower of, dividends on the common
stock or common equity interests of the Borrower, in an amount not to exceed an annual rate of $0.15 per share (such amount to be appropriately adjusted to reflect any stock split, reverse stock split, stock dividend or similar transaction occurring
after the Closing Date so that the aggregate amount of dividends permitted after such transaction is the same as the amount permitted immediately prior to such transaction); 

 

	 	(j)	so long as no Default or Event of Default has occurred and is continuing (or would result from), Restricted Payments (including loans or advances) in an aggregate
amount outstanding at the time made not to exceed $30,000,000; 

  

	 	(k)	payments by the Borrower, or loans, advances, dividends or distributions to any Parent to make payments, to holders of Capital Stock of the Borrower or any Parent in
lieu of the issuance of fractional shares of such Capital Stock, provided, however, that any such payment, loan, advance, dividend or distribution shall not be for the purpose of evading any limitation of this covenant or otherwise to
facilitate any dividend or other return of capital to the holders of such Capital Stock (as determined in good faith by the Board of Directors); 

  

	 	(l)	Restricted Payments that are made with Excluded Contributions; 

  

	 	(m)	 the declaration and payment of dividends to holders of any class or series of Designated Preferred Stock of the Borrower issued after the Closing Date;
provided, however, that the amount of all dividends declared or paid pursuant to this clause shall not exceed the Net Cash Proceeds received by the Borrower or the aggregate amount contributed in cash to the equity (other than through
the issuance of Disqualified Stock or an Excluded Contribution of the Borrower, from the issuance or sale of such Designated Preferred Stock; provided further, that for the most recently ended four fiscal quarters for which internal financial
statements are available immediately preceding the date of 

  
 -35-

	 	 
issuance of such Designated Preferred Stock, after giving effect to such issuance on a pro forma basis the Borrower would be permitted to Incur at least $1.00 of additional Indebtedness pursuant
to the test set forth in Section 7.03; 

  

	 	(n)	dividends or other distributions of Capital Stock of, or Indebtedness owed to the Borrower or a Restricted Subsidiary by, Unrestricted Subsidiaries (unless the
Unrestricted Subsidiary’s principal asset is cash and Cash Equivalents); 

  

	 	(o)	so long as no Default or Event of Default has occurred and is continuing (or would result from), Investments in joint ventures and Unrestricted Subsidiaries having an
aggregate fair market value, when taken together with all other Investments made pursuant to this clause that are at the time outstanding, not to exceed the greater of $50,000,000 and 2.5% of Total Assets at the time of such Investment (with the
fair market value of each Investment being measured at the time made and without giving effect to subsequent changes in value); 

  

	 	(p)	distributions or payments of Securitization Fees, sales contributions and other transfers of Securitization Assets and purchases of Securitization Assets pursuant to a
Securitization Repurchase Obligation, in each case in connection with a Qualified Securitization Financing; and 

  

	 	(q)	any Restricted Payment made in connection with the Transactions and the fees and expenses related thereto or used to fund amounts owed to Affiliates (including
dividends to any Parent of the Borrower to permit payment by such parent of such amounts), in each case to the extent permitted by (or, in the case of a dividend to fund such payment, to the extent such payment, if made by the Borrower, would be
permitted by) Section 7.08(5) or (12). 

 “Person” means any natural person,
corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity. 
 “Plan” means any “employee benefit plan” (as such term is defined in Section 3(3) of ERISA) other than a Foreign Plan, established by any Loan Party or, with respect to any
such plan that is subject to Section 412 of the Code or Title IV of ERISA, any ERISA Affiliate. 
 “Preferred
Stock” as applied to the Capital Stock of any Person, means Capital Stock of any class or classes (however designated) which is preferred as to the payment of dividends or as to the distribution of assets upon any voluntary or involuntary
liquidation or dissolution of such Person, over shares of Capital Stock of any other class of such Person. 
 “Prime
Rate” shall mean, for any day, the prime rate published in The Wall Street Journal for such day; provided that if The Wall Street Journal ceases to publish for any reason such rate of interest, “Prime
Rate” shall mean the prime lending rate as set forth on the Bloomberg page PRIMBB Index (or successor page) for such day (or such other service as determined by the Administrative Agent from time to time for purposes of providing quotations
of prime lending interest rates); each change in the Prime Rate shall be effective on the date such change is effective. The prime rate is not necessarily the lowest rate charged by any financial institution to its customers. 

“Pro Rata Share” means, with respect to each Lender at any time a fraction (expressed as a percentage, carried out to
the ninth decimal place), the numerator of which is the amount of the Commitments of such Lender under the Facility at such time and the denominator of which is the amount 

  
 -36-

 
of the Aggregate Commitments under the Facility at such time; provided that at any time any Revolving Credit Lender shall be a Defaulting Lender, “Pro Rata Share” shall mean a
fraction the numerator of which is each Lender’s Revolving Credit Commitment and the denominator of which is the aggregate amount of the Revolving Credit Commitments (disregarding any such Defaulting Lender’s Revolving Credit Commitment).
If the Commitments have been terminated, then the Pro Rata Share of each Lender shall be determined based on the Pro Rata Share of such Lender immediately prior to such termination and after giving effect to any subsequent assignments made pursuant
to the terms hereof. 
 “Purchase Money Obligations” means any Indebtedness Incurred to finance or refinance
the acquisition, leasing, construction or improvement of property (real or personal) or assets (including Capital Stock) used or acquired in connection with the business of the Borrower or any of its Restricted Subsidiaries, and whether acquired
through the direct acquisition of such property or assets or the acquisition of the Capital Stock of any Person owning such property or assets, or otherwise. 
 “Qualified Securitization Financing” means any Securitization Facility of a Securitization Subsidiary that meets the following conditions: (i) the board of directors of the Borrower
shall have determined in good faith that such Qualified Securitization Financing (including financing terms, covenants, termination events and other provisions) is in the aggregate economically fair and reasonable to the Borrower and its Restricted
Subsidiaries, (ii) all sales of Securitization Assets and related assets by the Borrower or any Restricted Subsidiary to the Securitization Subsidiary or any other Person are made at fair market value (as determined in good faith by the
Borrower), (iii) the financing terms, covenants, termination events and other provisions thereof shall be market terms (as determined in good faith by the Borrower) and may include Standard Securitization Undertakings and (iv) the
Obligations under such Securitization Facility are non-recourse (except for customary representations, warranties, covenants and indemnities made in connection with such facilities) to the Borrower or any of its Restricted Subsidiaries (other than a
Securitization Subsidiary). The grant of a security interest in any Securitization Assets of the Borrower or any of its Restricted Subsidiaries (other than a Securitization Subsidiary) to secure Indebtedness under this Agreement shall not be deemed
a Qualified Securitization Financing. 
 “Quotation Day” means with respect to Dollars for any Interest Period,
two Business Days prior to the first day of such Interest Period, unless market practice differs in the London interbank market for any such currency, in which case the Quotation Day for such currency shall be determined by the Administrative Agent
in accordance with market practice in the London interbank market (and if quotations would normally be given by leading banks in the London interbank market on more than one day, the Quotation Day shall be the last of those days). 

“Reference Bank” shall be one or more Revolving Lenders designated from time to time by the Administrative Agent with
the approval (not to be unreasonably withheld) of the Borrower. 
 “Refinance” means refinance, refund,
replace, renew, repay, modify, restate, defer, substitute, supplement, reissue, resell, extend or increase (including pursuant to any defeasance or discharge mechanism) and the terms “refinances,” “refinanced” and
“refinancing” as used for any purpose in this Agreement shall have a correlative meaning. 
 “Refinancing
Indebtedness” means Indebtedness that is Incurred to refund, refinance, replace, exchange, renew, repay or extend (including pursuant to any defeasance or discharge mechanism) any Indebtedness existing on the date hereof or Incurred in
compliance with this Agreement including Indebtedness that refinances Refinancing Indebtedness; provided, however, that (a) if the Indebtedness being refinanced constitutes Subordinated Indebtedness, Disqualified Stock or
Preferred Stock, the Refinancing Indebtedness has a final Stated Maturity at the time such Refinancing Indebtedness is Incurred that is the same as or later than the final Stated Maturity of the Indebtedness being refinanced or,

  
 -37-

 
if shorter, the outstanding Loan and such Refinancing Indebtedness is subordinated to the outstanding Loans on terms at least as favorable to the Lenders as those contained in the documentation
governing the Indebtedness being refinanced and if Disqualified Stock, Subordinated Indebtedness or Preferred Stock is being refinanced, such Refinanced Indebtedness shall be Disqualified Stock, Subordinated Indebtedness or Preferred Stock, as the
case may be; and (b) such Refinancing Indebtedness is Incurred in an aggregate principal amount (or if issued with original issue discount, an aggregate issue price) that is equal to or less than the sum of the aggregate principal amount (or if
issued with original issue discount, the aggregate accreted value) then outstanding of the Indebtedness being refinanced (plus, without duplication, any additional Indebtedness Incurred to pay interest or premiums required by the instruments
governing such existing Indebtedness and costs, expenses and fees Incurred in connection therewith); provided, however, that Refinancing Indebtedness shall not include (x) Indebtedness of the Borrower or a Restricted Subsidiary
that refinances Indebtedness of an Unrestricted Subsidiary or (y) Indebtedness of a Restricted Subsidiary that is not a Guarantor that refinances Indebtedness of the Borrower or a Guarantor. 

“Register” has the meaning specified in Section 10.07(d). 

“Reportable Event” means with respect to any Plan any of the events set forth in Section 4043(c) of ERISA or the
regulations issued thereunder, other than events for which the thirty (30) day notice period has been waived. 

“Request for Borrowing” means with respect to a Borrowing, conversion or continuation of Revolving Credit Loans, a
Committed Loan Notice. 
 “Required Lenders” means, as of any date of determination, Lenders having more than
50% of the sum of the (a) Total Outstandings, (b) aggregate unused Term Commitments and (c) aggregate unused Revolving Credit Commitments; provided that the unused Revolving Credit Commitment of, and the portion of the Total
Outstandings held or deemed held by any Defaulting Lender or Lenders that are the Sponsor or any of its Affiliates shall be excluded for purposes of making a determination of Required Lenders. 

“Responsible Officer” means (a) any director, the chief executive officer, president, vice president, chief
financial officer, treasurer or assistant treasurer or other similar officer of a Loan Party and, as to any document delivered on the Closing Date, any director, secretary or assistant secretary of a Loan Party and (b) solely with respect to
Requests for Borrowings, any other director, officer or employee of the applicable Loan Party so designated by any of the foregoing officers of such Loan Party in a notice to the Administrative Agent. Any document delivered hereunder that is signed
by a Responsible Officer of a Loan Party shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of such Loan Party and such Responsible Officer shall be conclusively presumed to
have acted on behalf of such Loan Party. 
 “Restricted Investment” means any Investment other than a Permitted
Investment. 
 “Restricted Payment” has the meaning specified in Section 7.06. 

“Restricted Subsidiary” means any Subsidiary of the Borrower other than an Unrestricted Subsidiary. 

“Revolving Credit Borrowing” means a borrowing consisting of Revolving Credit Loans of the same Type and, in the case of
Eurocurrency Rate Loans, having the same Interest Period made by each of the Revolving Credit Lenders pursuant to Section 2.01. 

  
 -38-

 “Revolving Credit Commitment” means, as to each Revolving Credit Lender,
its obligation to make Revolving Credit Loans to the Borrower pursuant to Section 2.01, in an aggregate principal amount at any one time outstanding not to exceed the amount set forth, and opposite such Lender’s name on Schedule
2.01 under the caption “Revolving Credit Commitment” or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with this
Agreement. The aggregate Revolving Credit Commitments of all Revolving Credit Lenders shall be $50,000,000 on the Closing Date, as such amount may be adjusted from time to time in accordance with the terms of this Agreement. 

“Revolving Credit Exposure” means, as to each Revolving Credit Lender at any time, the outstanding principal amount of
all Revolving Credit Loans held by such Revolving Credit Lender (or its Applicable Lending Office). 
 “Revolving Credit
Facility” has the meaning specified in the preliminary statements to this Agreement. 
 “Revolving Credit
Lender” means, at any time, any Lender that has a Revolving Credit Commitment or that holds Revolving Credit Loans at such time. 
 “Revolving Credit Loan” has the meaning specified in Section 2.01. 
 “Revolving Credit Note” means a promissory note of the Borrower payable to any Revolving Credit Lender or its registered assigns, in substantially the form of Exhibit C
hereto, evidencing the aggregate Indebtedness of the Borrower to such Revolving Credit Lender resulting from the Revolving Credit Loans made by such Revolving Credit Lender. 
 “S&P” means Standard & Poor’s Ratings Services, a division of The McGraw-Hill Companies, Inc., and any successor thereto. 

“Sale and Leaseback Transaction” means any arrangement providing for the leasing by the Borrower or any of its
Restricted Subsidiaries of any real or tangible personal property, which property has been or is to be sold or transferred by the Borrower or such Restricted Subsidiary to a third Person in contemplation of such leasing 

“Screen Rate” means in relation to the LIBOR Rate, the British Bankers Association Interest Settlement Rate for the
relevant currency and period. 
 “SEC” means the Securities and Exchange Commission, or any Governmental
Authority succeeding to any of its principal functions. 
 “Secured Indebtedness” means any Indebtedness
secured by a Lien. 
 “Secured Parties” means, collectively, the Administrative Agent, the Collateral Agent,
the Lenders, the Supplemental Administrative Agent and each co-agent or sub-agent appointed by the Administrative Agent from time to time pursuant to Section 9.14(a). 
 “Securities Act” means the Securities Act of 1933, as amended. 

“Securitization Asset” means any accounts receivable subject to a Securitization Facility. 

  
 -39-

 “Securitization Facility” means any of one or more securitization financing
facilities as amended, supplemented, modified, extended, renewed, restated or refunded from time to time, pursuant to which the Borrower or any of its Restricted Subsidiaries sells its Securitization Assets to either (a) Person that is not a
Restricted Subsidiary or (b) a Securitization Subsidiary that in turn sells Securitization Assets to a person that is not a Restricted Subsidiary. 
 “Securitization Fees” means distributions or payments made directly or by means of discounts with respect to any Securitization Asset or participation interest therein issued or sold in
connection with, and other fees paid to a person that is not a Restricted Subsidiary in connection with, any Qualified Securitization Financing. 
 “Securitization Repurchase Obligation” means any obligation of a seller of Securitization Assets in a Qualified Securitization Financing to repurchase Securitization Assets arising as a
result of a breach of a representation, warranty or covenant or otherwise, including, without limitation, as a result of a receivable or portion thereof becoming subject to any asserted defense, dispute, offset or counterclaim of any kind as a
result of any action taken by, any failure to take action by or any other event relating to the seller. 

“Securitization Subsidiary” means any Subsidiary in each case formed for the purpose of and that solely engages in one
or more Qualified Securitization Financings and other activities reasonably related thereto and that is designated by the Borrower’s Board of Directors (as provided below) as a Securitization Subsidiary and: 

 

	 	(a)	no portion of the Indebtedness or any other obligations (contingent or otherwise) of which (i) is guaranteed by the Borrower or any Restricted Subsidiary
(excluding Guarantee Obligations (other than the principal of, and interest on, Indebtedness) pursuant to Standard Securitization Undertakings), (ii) is recourse to or obligates the Borrower or any Restricted Subsidiary (other than such
Securitization Subsidiary) in any way other than pursuant to Standard Securitization Undertakings, or (iii) subjects any property or asset of the Borrower or any Restricted Subsidiary (other than such Securitization Subsidiary), directly or
indirectly, contingently or otherwise, to the satisfaction thereof, other than pursuant to Standard Securitization Undertakings; 

  

	 	(b)	with which neither the Borrower nor any Restricted Subsidiary (other than such Securitization Subsidiary) has any material contract, agreement, arrangement or
understanding other than on terms not materially less favorable to the Borrower or such Restricted Subsidiary than those that might be obtained at the time from Persons that are not Affiliates of the Borrower, other than fees payable in the ordinary
course of business in connection with servicing accounts receivable of such entity; and 

  

	 	(c)	to which neither the Borrower nor any Restricted Subsidiary (other than such Securitization Subsidiary) has any obligation to maintain or preserve such entity’s
financial condition or cause such entity to achieve certain levels of operating results. 

 Any designation of a
Subsidiary as a Securitization Subsidiary shall be evidenced to the Administrative Agent by delivering to Administrative Agent a certified copy of the resolution of the Board of Directors of the Borrower giving effect to the designation and an
Officer’s Certificate certifying that the designation complied with the preceding conditions and was permitted by this Agreement. 

  
 -40-

 “Senior Management” means the officers, directors, and other members of
senior management of the Borrower or any of its Subsidiaries, who on the Closing Date beneficially own or have the right to acquire, directly or indirectly, Capital Stock of the Borrower or any Parent. 

“Senior Notes” means the $770,000,000 aggregate principal amount of 9% Senior Notes due 2016 issued by the Borrower
under the Indenture. 
 “Similar Business” means (a) any businesses, services or activities engaged in by
the Borrower or any of its Subsidiaries or any Associates on the Closing Date and (b) any businesses, services and activities engaged in by the Borrower or any of its Subsidiaries or any Associates that are related, complementary, incidental,
ancillary or similar to any of the foregoing or are extensions or developments of any thereof. 
 “Solvent” and
“Solvency” mean, with respect to any Person on any date of determination, that on such date (i) the fair value of the property (for the avoidance of doubt, calculated to include goodwill and other intangibles) of such Person is
greater than the total amount of liabilities, including contingent liabilities, of such Person, (ii) the present fair salable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of
such Person on its debts as they become absolute and matured, (iii) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability to pay such debts and liabilities as they mature
and (iv) such Person is not engaged in business or a transaction, and is not about to engage in business or a transaction, for which such Person’s property would constitute an unreasonably small capital; the amount of contingent
liabilities at any time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability. 

“SPC” has the meaning specified in Section 10.07(h). 

“Specified Transaction” means, with respect to any period, any Disposition, incurrence or repayment of Indebtedness,
Restricted Payment, Subsidiary designation or other event that by the terms of this Agreement requires “pro forma compliance” with a test or covenant hereunder or requires such test or covenant to be calculated on a “Pro
Forma Basis.” 
 “Sponsor” means each of Apax Partners, L.L.P. and its Affiliates and funds or
partnerships managed by it or any of its Affiliates, but not including, however, any of their portfolio companies. 

“Standard Securitization Undertakings” means representations, warranties, covenants and indemnities entered into by the
Borrower or any Subsidiary of the Borrower which the Borrower has determined in good faith to be customary in a Securitization Facility, including, without limitation, those relating to the servicing of the assets of a Securitization Subsidiary, it
being understood that any Securitization Repurchase Obligation shall be deemed to be a Standard Securitization Undertaking. 

“Stated Maturity” means, with respect to any security, the date specified in such security as the fixed date on which
the payment of principal of such security is due and payable, including pursuant to any mandatory redemption provision, but shall not include any contingent obligations to repay, redeem or repurchase any such principal prior to the date originally
scheduled for the payment thereof. 
 “Subordinated Indebtedness” means, with respect to any person, any
Indebtedness (whether outstanding on the Closing Date or thereafter Incurred) which is expressly subordinated in right of payment to any Loans outstanding hereunder. 

  
 -41-

 “Subsidiary” means, with respect to any Person, (i) any corporation,
association, or other business entity (other than a partnership, joint venture, limited liability company or similar entity) of which more than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of
any contingency) to vote in the election of directors, managers or trustees thereof is at the time of determination owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of that Person or a combination
thereof; or (ii) any partnership, joint venture, limited liability company or similar entity of which (a) more than 50% of the capital accounts, distribution rights, total equity and voting interests or general or limited partnership
interests, as applicable, are owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of that Person or a combination thereof whether in the form of membership, general, special or limited partnership
interests or otherwise; and (b) such Person or any Subsidiary of such Person is a controlling general partner or otherwise controls such entity. Unless otherwise specified, all references herein to a “Subsidiary” or to
“Subsidiaries” shall refer to a Subsidiary or Subsidiaries of the Borrower. 
 “Subsidiary Guarantor”
means, collectively, the Subsidiaries of the Borrower that are Guarantors. 
 “Successor Borrower” has the
meaning specified in Section 7.04(f). 
 “Supplemental Administrative Agent” has the meaning
specified in Section 9.14(a) and “Supplemental Administrative Agents” shall have the corresponding meaning. 
 “Tax Deduction” means a deduction or withholding for or on account of Tax from a payment under a Loan Document. 
 “Taxes” has the meaning specified in Section 3.01(a). 

“Test Period” means, at any date of determination, the most recently completed four consecutive fiscal quarters of the
Borrower ending on or prior to such date. 
 “Threshold Amount” means $50,000,000. 

“Total Outstandings” means the aggregate Outstanding Amount of all Loans. 

“Total Assets” mean, as of any date, the total consolidated assets of the Borrower and its Restricted Subsidiaries on a
consolidated basis, as shown on the most recent consolidated balance sheet of the Borrower and its Restricted Subsidiaries, determined on a pro forma basis in a manner consistent with the pro forma basis contained in the
definition of Fixed Charge Coverage Ratio. 
 “Transactions” means, collectively, (a) the Acquisition,
(b) the funding of the Initial Revolving Borrowing on the Closing Date, (c) the consummation of any other transactions in connection with the foregoing, and (d) the payment of the fees and expenses incurred in connection with any of
the foregoing. 
 “Transaction Expenses” means any fees or expenses incurred or paid by the Borrower, or any
Restricted Subsidiary in connection with the Transactions, this Agreement and the other Loan Documents and the transactions contemplated hereby and thereby. 
 “Type” means, with respect to a Loan, its character as a Base Rate Loan or a Eurocurrency Rate Loan. 
 “United States” and “U.S.” mean the United States of America. 

  
 -42-

 “Unpaid Sum” means any sum due and payable but unpaid by a Loan Party under
the Loan Documents. 
 “Unrestricted Subsidiary” means: 

 

	 	(1)	any Subsidiary of the Borrower that at the time of determination is an Unrestricted Subsidiary (as designated by the Board of Directors of the Borrower in the manner
provided below); and 

  

	 	(2)	any Subsidiary of an Unrestricted Subsidiary. 

 The Board of Directors of the Borrower may designate any Subsidiary of the Borrower (including any newly acquired or newly formed Subsidiary or a Person becoming a Subsidiary through merger, consolidation
or other business combination transaction, or Investment therein) to be an Unrestricted Subsidiary only if: 
  

	 	(1)	such Subsidiary or any of its Subsidiaries does not own any Capital Stock or Indebtedness of, or own or hold any Lien on any property of, the Borrower or any other
Subsidiary of the Borrower which is not a Subsidiary of the Subsidiary to be so designated or otherwise an Unrestricted Subsidiary; and 

  

	 	(2)	such designation and the Investment of the Borrower in such Subsidiary comply with Section 7.06. 

Any such designation by the Board of Directors of the Borrower shall be evidenced to the Administrative Agent by filing with the
Administrative Agent a resolution of the Board of Directors of the Borrower giving effect to such designation and an Officer’s Certificate certifying that such designation complies with the foregoing conditions. 

The Board of Directors of the Borrower may designate any Unrestricted Subsidiary to be a Restricted Subsidiary; provided that
immediately after giving effect to such designation (1) no Default or Event of Default would result therefrom and (2) the Borrower or the relevant Restricted Subsidiary would be able to Incur such Indebtedness pursuant to
Section 7.03, on a pro forma basis taking into account such designation. Any such designation by the Board of Directors shall be evidenced to the Administrative Agent by promptly delivering to the Administrative Agent a
copy of the resolution of the Board of Directors giving effect to such designation or an Officer’s Certificate certifying that such designation complied with the foregoing provisions. 

“USA PATRIOT Act” means The Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and
Obstruct Terrorism Act of 2001 (Title III of Pub. L. No. 107-56 (signed into law October 26, 2001)), as amended or modified from time to time. 
 “Voting Stock” of a Person means all classes of Capital Stock of such Person then outstanding and normally entitled to vote in the election of directors. 

“Weighted Average Life to Maturity” means, when applied to any Indebtedness, Disqualified Stock or Preferred Stock, as
the case may be, at any date, the quotient obtained by dividing (a) the sum of the products of the number of years from the date of determination to the date of each successive scheduled principal payment of such Indebtedness or redemption or
similar payment with respect to such Disqualified Stock or Preferred Stock multiplied by the amount of such payment, by (b) the sum of all such payments. 

  
 -43-

 “Wholly Owned Subsidiary” means a Restricted Subsidiary of the Borrower,
all of the Capital Stock of which (other than directors’ qualifying shares or shares required by any applicable law or regulation to be held by a Person other than the Borrower or another Wholly Owned Subsidiary) is owned by the Borrower or
another Wholly Owned Subsidiary. 
 “Withdrawal Liability” means the liability of a Multiemployer Plan as a
result of a complete or partial withdrawal from such Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA. 
 Section 1.02 Other Interpretive Provisions. With reference to this Agreement and each other Loan Document, unless otherwise specified herein or in such other Loan
Document: 
 (a) The meanings of defined terms are equally applicable to the singular and plural forms of the
defined terms. 
 (b)(i) The words “herein,” “hereto,” “hereof” and
“hereunder” and words of similar import when used in any Loan Document shall refer to such Loan Document as a whole and not to any particular provision thereof. 

(ii) Article, Section, Exhibit and Schedule references are to the Loan Document in which such reference appears.

 (iii) The term “including” is by way of example and not limitation. 

(iv) The term “documents” includes any and all instruments, documents, agreements, certificates, notices,
reports, financial statements and other writings, however evidenced, whether in physical or electronic form. 

(c) In the computation of periods of time from a specified date to a later specified date, the word “from” means
“from and including”; the words “to” and “until” each mean “to but excluding”; and the word “through” means “to and including.” 

(d) Section headings herein and in the other Loan Documents are included for convenience of reference only and shall not
affect the interpretation of this Agreement or any other Loan Document. 
 Section 1.03
Accounting Terms. 
 (a) All accounting terms not specifically or completely defined herein shall be construed in
conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP, applied in a manner consistent with that used in
preparing the Audited Financial Statements, except as otherwise specifically prescribed herein. 
 (b) [Reserved]. 

(c) Where reference is made to “the Borrower and its Restricted Subsidiaries on a consolidated basis” or similar language, such
consolidation shall not include any Subsidiaries of the Borrower other than Restricted Subsidiaries. 

  
 -44-

 Section 1.04 Rounding. Any financial ratios
required to be satisfied in order for a specific action to be permitted under this Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which
such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number). 
 Section 1.05 References to Agreements, Laws, Etc. Unless otherwise expressly provided herein, (a) references to Organization Documents, agreements (including
the Loan Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto, but only to the extent that such amendments, restatements, extensions,
supplements and other modifications are permitted by any Loan Document; and (b) references to any Law shall include all statutory and regulatory provisions consolidating, amending, replacing, supplementing or interpreting such Law. 

Section 1.06 Times of Day. Unless otherwise specified, all references herein to times of day
shall be references to New York City time. 
 Section 1.07 Timing of Payment or
Performance. When the payment of any obligation or the performance of any covenant, duty or obligation is stated to be due or performance required on a day which is not a Business Day, the date of such payment (other than as described in the
definition of Interest Period) or performance shall extend to the immediately succeeding Business Day. 
 
Section 1.08 Currency Equivalents Generally. 
 (a) The Administrative Agent shall determine the Dollar
Equivalent of any Borrowing denominated in a currency other than Dollars (i) as of the date of the commencement of the initial Interest Period therefor and as of the date of the commencement of each subsequent Interest Period therefor, in each
case using the Exchange Rate for such currency in relation to Dollars in effect on the date that is three Business Days prior to the date on which the applicable Interest Period shall commence and (ii) during the continuance of an Event of
Default, as reasonably requested by the Administrative Agent. Each amount determined as aforesaid shall, except as provided in subsections (b) and (c) of this Section 1.08, be the Dollar Equivalent of the applicable Borrowing
until the next required calculation thereof pursuant to the preceding sentences of this subsection. The Administrative Agent shall notify Borrower, the Borrower and the applicable Lenders of each calculation of the Dollar Equivalent of each
Borrowing denominated in a currency other than Dollars. 
 (b) Any amount specified in this Agreement (other than in
Article II, Article IX and Article X or as set forth in the other paragraphs of this Section) or any of the other Loan Documents to be in Dollars shall also include the equivalent of such amount in any currency
other than Dollars, such equivalent amount to be determined at the rate of exchange quoted by the Reuters World Currency Page for the applicable currency at 12:00 noon (New York City time) on such day (or, in the event such rate does not appear on
any Reuters World Currency Page, by reference to such other publicly available service for displaying exchange rates as may be agreed upon by the Administrative Agent and Borrower, or, in the absence of such agreement, such rate shall instead be the
arithmetic average of the spot rates of exchange of the Administrative Agent in the market where its foreign currency exchange operations in respect of such currency are then being conducted, at or about 12:00 noon (New York City time) on such date
for the purchase of Dollars for delivery two (2) Business Days later). Notwithstanding the foregoing, (i) for purposes of determining compliance with Article VII with respect to any amount of Indebtedness, Investment,
Disposition or Restricted Payment in a currency other than Dollars, no Default shall be deemed to have occurred solely as a result of changes in rates of exchange occurring after the time such Indebtedness, Investment, Disposition or Restricted
Payment is incurred or made; provided that for the 

  
 -45-

 
avoidance of doubt, the foregoing provisions of this Section 1.08 shall otherwise apply to such Sections, including with respect to determining whether any Indebtedness, Investment,
Disposition or Restricted Payment may be incurred or made at any time under such Sections and (ii) for the avoidance of doubt, the Exchange Rate shall be used for purposes of calculating the amount of any Loans, interest or fees payable
hereunder rather than the rates described in the immediately preceding sentence. 
 (c) For purposes of determining Consolidated
Total Indebtedness as of any date or Consolidated EBITDA for any Test Period, any amount in a currency other than Dollars will be converted to Dollars in a manner using the same weighted average exchange rates used in preparing the financial
statements of the Borrower for such Test Period. 
 ARTICLE II 

The Commitments and Borrowings 

Section 2.01 The Loans. 

(a) The Revolving Credit Borrowings. Subject to the terms and conditions set forth herein each Revolving Credit Lender severally
agrees to make (or cause its Applicable Lending Office to make) loans denominated in US Dollars (each such loan, a “Revolving Credit Loan”) from time to time, on any Business Day after the Closing Date until the Maturity Date with
respect to the Revolving Credit Facility (provided that each Revolving Credit Lender agrees to make the Initial Revolving Borrowing, at the request of the Borrower, on the Closing Date), in an aggregate principal amount not to exceed at any
time outstanding the amount of such Lender’s Revolving Credit Commitment; provided that, after giving effect to any such Revolving Credit Borrowing, the aggregate Outstanding Amount of the Revolving Credit Loans of any Lender shall not
exceed such Lender’s Revolving Credit Commitment. Within the limits of each Lender’s Revolving Credit Commitment, and subject to the other terms and conditions hereof, the Borrower may borrow under this Section 2.01, prepay
under Section 2.05, and reborrow under this Section 2.01. Revolving Credit Loans denominated in US Dollars shall be Eurocurrency Rate Loans unless required to be converted to Base Rate Loans, as further provided herein.

 Section 2.02 Borrowings, Conversions and Continuations of Loans. 

(a) Each Revolving Credit Borrowing, each conversion of Base Rate Loans to Eurocurrency Rate Loans, and each continuation of Eurocurrency
Rate Loans shall be made upon the Borrower’s irrevocable notice to the Administrative Agent. Each such notice must be received by the Administrative Agent (i) not later than noon, New York City time, three (3) Business Days prior to
the requested date of any Borrowing of Eurocurrency Rate Loans or any conversion to or continuation of Eurocurrency Rate Loans or of any conversion of Eurocurrency Rate Loans to Base Rate Loans, and (ii) not later than 1:00 p.m., New York City
time, one (1) Business Day prior to the requested date of any Borrowing of Base Rate Loans. Each Borrowing of, conversion to or continuation of Eurocurrency Rate Loans shall be in a principal amount of $1,000,000 or a whole multiple of $100,000
in excess thereof. Each Borrowing of or conversion to Base Rate Loans shall be in a principal amount of less than $1,000,000 or a whole multiple of $100,000 in excess thereof. Each Committed Loan Notice (whether telephonic or written) shall specify
(i) whether a Revolving Credit Borrowing, a conversion of Revolving Credit Loans from one Type to another or a continuation of Eurocurrency Rate Loans is requested, (ii) the requested date of the Borrowing, conversion or continuation, as
the case may be (which shall be a Business Day), (iii) the currency and principal amount of Loans to be borrowed, converted or continued, (iv) the Type of Loans to be borrowed or to which existing Loans denominated in Dollars, are to be
converted and (v) if applicable, the duration of the Interest Period with respect thereto. If the Borrower fails to specify a Type of Loan in a Committed Loan Notice or fails to give a timely notice requesting a conversion or

  
 -46-

 
continuation, then the applicable Loans shall be made as, or converted to, Base Rate Loans. Any such automatic conversion to Base Rate Loans shall be effective as of the last day of the Interest
Period then in effect with respect to the applicable Eurocurrency Rate Loans. If the Borrower requests a Borrowing of, conversion to, or continuation of Eurocurrency Rate Loans in any such Committed Loan Notice, but fails to specify an Interest
Period, it will be deemed to have specified an Interest Period of one (1) month. For the avoidance of doubt, the Borrower and Lenders acknowledge and agree that any conversion or continuation of an existing Loan shall be deemed to be a
continuation of that Loan with a converted interest rate methodology and not a new Loan. 
 (b) Following receipt of a Committed
Loan Notice, the Administrative Agent shall promptly notify each Lender of the amount of its Pro Rata Share of the Loans, and if no timely notice of a conversion or continuation is provided by the Borrower, the Administrative Agent shall notify each
Lender of the details of any automatic conversion to Base Rate Loans or continuation described in Section 2.02(a). In the case of each Borrowing, each Lender shall make (or cause its Applicable Lending Office to make) the amount of its
Loan available to the Administrative Agent in immediately available funds in Dollars according to the relevant Committed Loan Notice, at the Administrative Agent’s Office on the Business Day specified in the applicable Committed Loan Notice.
Upon satisfaction of the applicable conditions set forth in Section 4.02 (and, if such Borrowing is the initial Borrowing, Section 4.01), the Administrative Agent shall make all funds so received available to the Borrower in
Dollars according to the relevant Committed Loan Notice, either by (i) crediting the account of the Borrower on the books of the Administrative Agent with the amount of such funds or (ii) wire transfer of such funds, in each case in
accordance with instructions provided to (and reasonably acceptable to) the Administrative Agent by the Borrower. 
 (c) Except
as otherwise provided herein, a Eurocurrency Rate Loan may be continued or converted only on the last day of an Interest Period for such Eurocurrency Rate Loan unless the Borrower pays the amount due, if any, under Section 3.05 in
connection therewith. During the existence of an Event of Default, the Administrative Agent or the Required Lenders may require that no Loans denominated in Dollars may be converted to or continued as Eurocurrency Rate Loans. 

(d) The Administrative Agent shall promptly notify the Borrower and the Lenders of the interest rate applicable to any Interest Period
for Eurocurrency Rate Loans upon determination of such interest rate. The determination of the LIBOR Rate by the Administrative Agent shall be conclusive in the absence of manifest error. 

(e) Anything in subsection (a) to (d) above to the contrary notwithstanding, after giving effect to all Revolving Credit
Borrowings and all continuations of Revolving Credit Loans as the same Type, there shall not be more than ten (10) Interest Periods in effect for Revolving Credit Borrowings. 

Section 2.03 [Reserved]. 

Section 2.04 [Reserved]. 

Section 2.05 Prepayments. 

(a) Optional Prepayments. 
 (i) The Borrower may, upon notice to the Administrative Agent, at any time or from time to time voluntarily prepay Revolving Credit Loans in whole or in part without premium or penalty; provided
that (A) such notice must be received by the Administrative Agent not later than 12:00 noon, New York City time, (1) two (2) Business Days prior to any date of prepayment of Eurocurrency Rate

  
 -47-

 
Loans and (2) on the date of prepayment of Base Rate Loans; (B) any prepayment of Eurocurrency Rate Loans shall be in a principal amount of $1,000,000 or a whole multiple of $100,000 in
excess thereof; and (C) any prepayment of Base Rate Loans shall be in a principal amount of $1,000,000 or a whole multiple of $100,000, in excess thereof or, in each case, if less, the entire principal amount thereof then outstanding. Each such
notice shall specify the date and amount of such prepayment and the currency, Type(s) of Loans to be prepaid and, if Eurocurrency Rate Loans are to be prepaid, the Interest Period(s) of such Loans. The Administrative Agent will promptly notify each
Lender of its receipt of each such notice, and of the amount of such Lender’s ratable portion of such prepayment (based on such Lender’s Pro Rata Share of such prepayment). If such notice is given by the Borrower, the Borrower shall make
such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein. Any prepayment of a Eurocurrency Rate Loan shall be accompanied by all accrued interest on the amount prepaid, together with any
additional amounts required pursuant to Section 3.05. Each prepayment of the Loans pursuant to this Section 2.05(a) shall be applied to the Loans and installments thereof as directed by the Borrower and shall be paid to the
Lenders in accordance with their respective Pro Rata Shares. At the Borrower’s election in connection with any prepayment pursuant to this Section 2.05, such prepayment shall not be applied to any Revolving Credit Loan of a
Defaulting Lender and shall be allocated ratably among the relevant non-Defaulting Lenders. 
 (ii) [Reserved]. 

(iii) Notwithstanding anything to the contrary contained in this Agreement, a notice of optional prepayment may state that such notice is
conditional upon the effectiveness of other credit facilities or the receipt of the proceeds from the issuance of other Indebtedness or the occurrence of some other identifiable event or condition, in which case such notice of prepayment may be
revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified date of prepayment) if such condition is not satisfied. Promptly following receipt of any such notice, the Administrative Agent shall advise the Lenders of
the contents thereof. 
 Section 2.06 Termination or Reduction of Commitments.

 (a) The Borrower may, upon written notice to the Administrative Agent, terminate the unused Commitments of any Loans, or from
time to time permanently reduce the unused Commitments of any Loans; provided that (i) any such notice shall be received by the Administrative Agent three (3) Business Days prior to the date of termination or reduction and
(ii) any such partial reduction shall be in an aggregate amount of $1,000,000 or any whole multiple of $100,000 in excess thereof. Notwithstanding the foregoing, a notice of optional prepayment may state that such notice is conditional upon the
effectiveness of other credit facilities or the receipt of the proceeds from the issuance of other Indebtedness or the occurrence of some other identifiable event or condition, in which case such notice of prepayment may be revoked by the Borrower
(by notice to the Administrative Agent on or prior to the specified date of prepayment) if such condition is not satisfied. Promptly following receipt of any such notice, the Administrative Agent shall advise the Lenders of the contents thereof.

 (b) Mandatory. The Revolving Credit Commitments shall terminate on the Maturity Date. Notwithstanding the foregoing,
in the event that (i) the outstanding aggregate principal amount of the Senior Notes is equal to or less than $100,000,000 or (ii) any Refinancing Indebtedness is Incurred in respect of the Senior Notes, the Revolving Credit Commitments
shall terminate automatically. 
 (c) Application of Commitment Reductions; Payment of Fees. The Administrative Agent
will promptly notify the Lenders of any termination or reduction of the unused Commitments of any Loans under this Section 2.06. Upon any reduction of unused Commitments of any Loans, the Commitment of each Lender of such Loans shall be
reduced by such Lender’s Pro Rata Share of the 

  
 -48-

 
amount by which such Commitments are reduced (other than the termination of the Commitment of any Lender as provided in Section 3.07). All Commitment Fees accrued until the effective
date of any termination of the Revolving Credit Commitments shall be paid on the effective date of such termination. 
 
Section 2.07 Repayment of Loans. 
 (a) Revolving Credit Loans. The Borrower shall repay to the
Administrative Agent for the ratable account of the Lenders on the Maturity Date for the Revolving Credit Facility the aggregate principal amount of all of its Revolving Credit Loans outstanding on such date. 

(b) [Reserved]. 
 (c) Currency. Notwithstanding anything to the contrary contained herein, the Borrower shall repay each Loan in the currency in which it was advanced and in an amount equal to the Dollar Equivalent
of the original principal amount of such Loan, plus any reasonable foreign exchange costs, fees or expenses incurred by any Lender, acting through the Administrative Agent, if any, in respect of the conversion of such amount into Dollars.

 Section 2.08 Interest. 

(a) Subject to the provisions of Section 2.08(b), (i) each Eurocurrency Rate Loan shall bear interest on the outstanding
principal amount thereof for each Interest Period at a rate per annum equal to the LIBOR Rate for such Interest Period plus the Applicable Rate; and (ii) each Base Rate Loan shall bear interest on the outstanding principal amount thereof from
the applicable borrowing date at a rate per annum equal to the Base Rate plus the Applicable Rate. 
 (b) The Borrower shall pay
interest on past due amounts hereunder at a fluctuating interest rate per annum at all times equal to (x) with respect to past due principal of any Loan, the rate of interest otherwise applicable to such Loan plus 2.00% per annum
and (y) with respect to any other past due amount, the Default Rate to the fullest extent permitted by applicable Laws. Accrued and unpaid interest on past due amounts (including interest on past due interest) shall be due and payable upon
demand; provided that no amount shall be payable pursuant to this Section 2.08(b) to a Revolving Credit Lender that is a Defaulting Lender so long as such Revolving Credit Lender shall be a Defaulting Lender; provided
further that no amounts shall accrue pursuant to this Section 2.08(b) on any overdue amount or other amount payable to a Defaulting Lender so long as such Lender shall be a Defaulting Lender. 

(c) Interest on each Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as
may be specified herein. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law. 

(d) The amount of interest due and payable to each Lender shall be determined by the Administrative Agent. Interest shall be paid to each
Lender by the Administrative Agent, in accordance with Section 2.12. 
 (e) Notwithstanding anything to the contrary
contained herein, (i) the Borrower shall pay interest under this Section 2.08 in the currency in which the Loan relating to such interest payment was advanced, (ii) interest with respect to any Loan shall be calculated based on the
Dollar Equivalent of the original principal amount of such Loan, and (iii) each payment of interest shall be in an amount equal to the Dollar Equivalent of the amount of such interest payment calculated in accordance with this
Section 2.08, plus any reasonable foreign exchange costs, fees or expenses incurred by any Lender, acting through 

  
 -49-

 
the Administrative Agent, if any, in respect of the conversion of such amount into Dollars; provided that the Administrative Agent’s failure to give the notice specified in this
Section 2.08(e) shall not relieve the Borrower of its obligation to pay interest hereunder. 

Section 2.09 Fees. 

(a) Commitment Fee. The Borrower shall pay to the Administrative Agent for the account of each (i) Revolving
Credit Lender in accordance with its Pro Rata Share, the Commitment Fee on the actual daily amount by which the aggregate Revolving Credit Commitment exceeds the Outstanding Amount of Revolving Credit Loans; provided that any Commitment Fee
accrued with respect to any of the Revolving Credit Commitments of a Defaulting Lender during the period prior to the time such Lender became a Defaulting Lender and unpaid at such time shall not be payable by the Borrower so long as such Lender
shall be a Defaulting Lender except to the extent that such Commitment Fee shall otherwise have been due and payable by the Borrower prior to such time; and provided further that no Commitment Fee shall accrue on any of the Revolving
Credit Commitments of a Defaulting Lender so long as such Lender shall be a Defaulting Lender. The Commitment Fees shall accrue at all times from the Closing Date until the Maturity Date for the Revolving Credit Facility, including at any time
during which one or more of the conditions in Article IV is not met, and shall be due and payable quarterly in arrears on the last Business Day of each March, June, September and December, commencing with the first such date to occur
after the Closing Date, and on the Maturity Date for the Revolving Credit Facility. The Commitment Fee shall be calculated quarterly in arrears. 
 (b) Other Fees. The Borrower shall pay to the Agents such fees as shall have been separately agreed upon in writing in the amounts and at the times so specified. Such fees shall be fully earned
when paid and shall not be refundable for any reason whatsoever (except as expressly agreed between the Borrower and the applicable Agent). 
 Section 2.10 Computation of Interest and Fees. All computations of fees and interest for Base Rate Loans shall be made on the basis of a year of three hundred
sixty-five (365) days or three hundred sixty-six (366) days, as the case may be, and actual days elapsed. All other computations of fees and interest shall be made on the basis of a three hundred and sixty (360) day year and actual
days elapsed. Interest shall accrue on each Loan for the day on which such Loan is made, and shall not accrue on such Loan, or any portion thereof, for the day on which such Loan or such portion is paid; provided that any such Loan that is
repaid on the same day on which it is made shall, subject to Section 2.12(a), bear interest for one (1) day. Each determination by the Administrative Agent of an interest rate or fee hereunder shall be conclusive and binding for all
purposes, absent manifest error. For the purposes of the Interest Act (Canada), (i) whenever any interest or fees under this Agreement or any other Loan Document is calculated using a rate based on a year of 360 days, the rate determined
pursuant to such calculation, when expressed as an annual rate, is equivalent to (x) the applicable rate, (y) multiplied by the actual number of days in the calendar year in which the period for which such interest is payable (or
compounded) ends, and (z) divided by 360, (ii) the principle of deemed reinvestment of interest does not apply to any interest calculation under this Agreement, and (iii) the rates of interest stipulated in this Agreement are intended
to be nominal rates and not effective rates or yields. 
 Section 2.11 Evidence of
Indebtedness. 
 (a) The Borrowings made by each Lender shall be evidenced by one or more accounts or records maintained by
such Lender and evidenced by one or more entries in the Register maintained by the Administrative Agent, acting solely for purposes of Treasury Regulation Section 5f.103-1(c), as agent for the Borrower, in each case in the ordinary course of
business. The accounts or records maintained by 

  
 -50-

 
the Administrative Agent and each Lender shall be prima facie evidence absent manifest error of the amount of the Borrowings made by the Lenders to the Borrower and the interest and
payments thereon. Any failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrower hereunder to pay any amount owing with respect to the Obligations. In the event of any conflict between
the accounts and records maintained by any Lender and the accounts and records of the Administrative Agent in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of manifest error. Upon the
request of any Lender made through the Administrative Agent, the Borrower shall execute and deliver to such Lender (through the Administrative Agent) a Note payable to such Lender, which shall evidence such Lender’s Loans in addition to such
accounts or records. Each Lender may attach schedules to its Note and endorse thereon the date, Type (if applicable), amount and maturity of its Loans and payments with respect thereto. 

(b) [Reserved]. 

(c) Entries made in good faith by the Administrative Agent in the Register pursuant to Section 2.11(a) and (b), and by
each Lender in its account or accounts pursuant to Section 2.11(a) and (b), shall be prima facie evidence of the amount of principal and interest due and payable or to become due and payable from the Borrower to, in the
case of the Register, each Lender and, in the case of such account or accounts, such Lender, under this Agreement and the other Loan Documents, absent manifest error; provided that the failure of the Administrative Agent or such Lender to
make an entry, or any finding that an entry is incorrect, in the Register or such account or accounts shall not limit or otherwise affect the obligations of the Borrower under this Agreement and the other Loan Documents. 

Section 2.12 Payments Generally. 

(a) All payments to be made by the Borrower shall be made without condition or deduction for any counterclaim, defense, recoupment or
setoff. Except as otherwise expressly provided herein, all payments by the Borrower hereunder shall be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the applicable Administrative
Agent’s Office and in immediately available funds not later than 3:00 p.m. (New York City time) on the date specified herein. The Administrative Agent will promptly distribute to each Lender its Pro Rata Share (or other applicable share as
provided herein) of such payment in like funds as received by wire transfer to such Lender’s Applicable Lending Office. All payments received by the Administrative Agent after 3:00 p.m., New York City time, shall be deemed received on the next
succeeding Business Day and any applicable interest or fee shall continue to accrue. 
 (b) If any payment to be made by the
Borrower shall come due on a day other than a Business Day, payment shall be made on the next following Business Day, and such extension of time shall be reflected in computing interest or fees, as the case may be; provided that if such
extension would cause payment of interest on or principal of Eurocurrency Rate Loans, to be made in the next succeeding calendar month, such payment shall be made on the immediately preceding Business Day. 

(c) Unless the Borrower or any Lender has notified the Administrative Agent, prior to the date any payment is required to be made by it
to the Administrative Agent hereunder, that the Borrower or such Lender, as the case may be, will not make such payment, the Administrative Agent may assume that the Borrower or such Lender, as the case may be, has timely made such payment and may
(but shall not be so required to), in reliance thereon, make available a corresponding amount to the Person entitled thereto. If and to the extent that such payment was not in fact made to the Administrative Agent in immediately available funds,
then: 

  
 -51-

 (i) if the Borrower failed to make such payment, each Lender shall forthwith
on demand repay to the Administrative Agent the portion of such assumed payment that was made available to such Lender in immediately available funds, together with interest thereon in respect of each day from and including the date such amount was
made available by the Administrative Agent to such Lender to the date such amount is repaid to the Administrative Agent in immediately available funds at in the case of any such amount denominated in Dollars, the Federal Funds Effective Rate; and

 (ii) if any Lender failed to make such payment, such Lender shall forthwith on demand pay to the
Administrative Agent the amount thereof in immediately available funds, together with interest thereon for the period from the date such amount was made available by the Administrative Agent to the Borrower to the date such amount is recovered by
the Administrative Agent (the “Compensation Period”) at a rate per annum equal to in the case of any such amount denominated in Dollars, the Federal Funds Effective Rate. When such Lender makes payment to the Administrative Agent
(together with all accrued interest thereon), then such payment amount (excluding the amount of any interest which may have accrued and been paid in respect of such late payment) shall constitute such Lender’s Loan included in the applicable
Borrowing. If such Lender does not pay such amount forthwith upon the Administrative Agent’s demand therefor, the Administrative Agent may make a demand therefor upon the Borrower, and the Borrower shall pay such amount to the Administrative
Agent, together with interest thereon for the Compensation Period at a rate per annum equal to the rate of interest applicable to the applicable Borrowing. Nothing herein shall be deemed to relieve any Lender from its obligation to fulfill its
Commitment or to prejudice any rights which the Administrative Agent or the Borrower may have against any Lender as a result of any default by such Lender hereunder. 
 A notice of the Administrative Agent to any Lender or the Borrower with respect to any amount owing under this Section 2.12(c) shall be conclusive, absent manifest error. 

(d) If any Lender makes available to the Administrative Agent funds for any Loan to be made by such Lender as provided in the foregoing
provisions of this Article II, and such funds are not made available to the Borrower by the Administrative Agent because the conditions to the applicable Borrowing set forth in Article IV are not satisfied or waived in
accordance with the terms hereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest. 
 (e) The obligations of the Lenders hereunder to make Loans are several and not joint. The failure of any Lender to make any Loan or to fund any such participation on any date required hereunder shall not
relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan or purchase its participation. 

(f) Nothing herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to
constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner. 
 (g) Whenever any payment received by the Administrative Agent under this Agreement or any of the other Loan Documents is insufficient to pay in full all amounts due and payable to the Administrative Agent
and the Lenders under or in respect of this Agreement and the other Loan Documents on any date, such payment shall be distributed by the Administrative Agent and applied by the Administrative Agent and the Lenders in the order of priority set forth
in Section 8.04. If the Administrative Agent receives funds for application to the Obligations of the Loan Parties under or in respect of the Loan Documents under circumstances for which the Loan Documents do not specify the

  
 -52-

 
manner in which such funds are to be applied, the Administrative Agent may, but shall not be obligated to, elect to distribute such funds to each of the Lenders in accordance with such
Lender’s Pro Rata Share of the Outstanding Amount of all Loans outstanding at such time, in repayment or prepayment of such of the outstanding Loans or other Obligations then owing to such Lender. 

Section 2.13 Sharing of Payments. If, other than as expressly provided elsewhere herein, any
Lender shall obtain on account of the Loans made by it, any payment (whether voluntary, involuntary, through the exercise of any right of setoff, or otherwise) in excess of its ratable share (or other share contemplated hereunder) thereof, such
Lender shall immediately (a) notify the Administrative Agent of such fact, and (b) purchase from the other Lenders such participations in the Loans made by them, as the case may be, as shall be necessary to cause such purchasing Lender to
share the excess payment in respect of such Loans or such participations, as the case may be, pro rata with each of them; provided that (x) if all or any portion of such excess payment is thereafter recovered from the
purchasing Lender under any of the circumstances described in Section 10.06 (including pursuant to any settlement entered into by the purchasing Lender in its discretion), such purchase shall to that extent be rescinded and each other
Lender shall repay to the purchasing Lender the purchase price paid therefor, together with an amount equal to such paying Lender’s ratable share (according to the proportion of (i) the amount of such paying Lender’s required
repayment to (ii) the total amount so recovered from the purchasing Lender) of any interest or other amount paid or payable by the purchasing Lender in respect of the total amount so recovered, without further interest thereon and (y) the
provisions of this paragraph shall not be construed to apply to (A) any payment made by the Borrower pursuant to and in accordance with the express terms of this Agreement, (B) any payment obtained by a Lender as consideration for the
assignment of or sale of a participation in any of its Loans to any assignee or participant or (C) any disproportionate payment obtained by a Lender of any Loans as a result of the extension by Lenders of the maturity date or expiration date of
some but not all Loans or Revolving Credit Commitments of those Loans or any increase in the Applicable Rate in respect of Loans of Lenders that have consented to any such extension. The Borrower agrees that any Lender so purchasing a participation
from another Lender may, to the fullest extent permitted by applicable Law, exercise all its rights of payment (including the right of setoff, but subject to Section 10.09) with respect to such participation as fully as if such Lender
were the direct creditor of the Borrower in the amount of such participation. The Administrative Agent will keep records (which shall be conclusive and binding in the absence of manifest error) of participations purchased under this
Section 2.13 and will in each case notify the Lenders following any such purchases or repayments. Each Lender that purchases a participation pursuant to this Section 2.13 shall from and after such purchase have the right to
give all notices, requests, demands, directions and other communications under this Agreement with respect to the portion of the Obligations purchased to the same extent as though the purchasing Lender were the original owner of the Obligations
purchased. 
 Section 2.14 [Reserved]. 

ARTICLE III 
 Taxes, Increased Costs Protection and Illegality 
 Section 3.01 Taxes. 
 (a) Except as
provided in this Section 3.01, any and all payments by any Loan Party to or for the account of any Agent or any Lender under any Loan Document shall be made free and clear of and without deduction for any and all present or future taxes,
duties, levies, imposts, deductions, assessments, fees, withholdings or similar charges, and all liabilities (including additions to tax, penalties and interest) with respect thereto, excluding the Excluded Taxes (all such non-excluded taxes,
duties, levies, imposts, deductions, assessments, fees, withholdings or similar charges, and liabilities being hereinafter referred to 

  
 -53-

 
as “Taxes”). If the Borrower, any Guarantor or another applicable withholding agent shall be required by any Laws to deduct any Taxes from or in respect of any sum payable under
any Loan Document to any Agent or any Lender, (i) the sum payable by the applicable Loan Party shall be increased as necessary so that after all required deductions have been made (including deductions applicable to additional sums payable
under this Section 3.01), each of such Agent and such Lender receives an amount equal to the sum it would have received had no such deductions been made, (ii) the Borrower, such Guarantor or the applicable withholding agent shall
make such deductions, (iii) the applicable withholding agent shall pay the full amount deducted to the relevant taxation authority or other authority in accordance with applicable Laws, and (iv) within thirty (30) days after the date
of such payment (or, if receipts or evidence are not available within thirty (30) days, as soon as possible thereafter), the Borrower, such Guarantor or the applicable withholding agent shall furnish to such Agent or Lender (as the case may be)
the original or a facsimile copy of a receipt evidencing payment thereof to the extent such a receipt is issued therefor, or other written proof of payment thereof that is reasonably satisfactory to the Administrative Agent. If the Borrower, any
Guarantor or an applicable withholding agent fails to pay any Taxes when due to the appropriate Governmental Authority or fails to remit to any Agent or any Lender the required receipts or other required documentary evidence, the Borrower shall
indemnify such Agent and such Lender for any Taxes that may become payable by such Agent or such Lender arising out of such failure. 
 (b) In addition, the Borrower agrees to pay any and all present or future stamp, court or documentary taxes and any other excise, property or intangible taxes or charges or similar levies which arise from
any payment made under any Loan Document or from the execution, delivery, performance, enforcement or registration of, or otherwise with respect to, any Loan Document excluding, in each case, such amounts that result from an Assignment and
Assumption, transfer or assignment to or designation of a new Applicable Lending Office or other office for receiving payments under any Loan Document, except to the extent that any such change is requested in writing by the Borrower (all such
non-excluded taxes described in this Section 3.01(b) being hereinafter referred to as “Other Taxes”). 
 (c) The Borrower agrees to indemnify each Agent and each Lender for (i) the full amount of Taxes and Other Taxes (including any Taxes or Other Taxes imposed or asserted by any jurisdiction on amounts
payable and paid under this Section 3.01) payable by such Agent or such Lender and (ii) any reasonable expenses arising therefrom or with respect thereto, in each case whether or not such Taxes or Other Taxes were correctly or
legally imposed or asserted by the relevant Governmental Authority. Such Agent or Lender, as the case may be, will, at the Borrower’s request, (A) provide the Borrower with a written statement thereof setting forth in reasonable detail the
basis and calculation of such amounts or (B) have the amount of such Taxes or Other Taxes verified by an independent accountant. Payment under this Section 3.01(c) shall be made within ten (10) days after the date such Lender
or such Agent makes a demand therefor. 
 (d) If any Lender or Agent determines, in its reasonable discretion, that it has
received a refund in respect of any Taxes or Other Taxes as to which indemnification or additional amounts have been paid to it by any Loan Party pursuant to this Section 3.01, it shall promptly remit such refund as soon as practicable
after it is determined that such refund pertains to Taxes or Other Taxes (but only to the extent of indemnity payments made, or additional amounts paid, by the applicable Loan Party under this Section 3.01 with respect to the Taxes or
Other Taxes giving rise to such refund plus any interest included in such refund by the relevant Governmental Authority attributable thereto) to the applicable Loan Party, net of all reasonable out-of-pocket expenses (including taxes) of the Lender
or Agent, as the case may be, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund); provided that the applicable Loan Party, upon the request of the Lender or Agent, as the
case may be, agrees promptly to return the amounts refunded to the applicable Loan Party (plus any penalties, interest or other charges imposed by the relevant Governmental Authority, excluding any penalties and interest resulting from an
unreasonable delay on the part of the Lender or Agent to 

  
 -54-

 
respond to the relevant Governmental Authority after receiving notice from such Governmental Authority that such refund is required to be returned) to the applicable Lender or Agent in the event
such party is required to repay such refund to the relevant Governmental Authority. Such Lender or Agent, as the case may be, shall, at the applicable Loan Party’s request, provide the applicable Loan Party with a copy of any notice of
assessment or other evidence of the requirement to repay such refund received from the relevant Governmental Authority (provided that such Lender or Agent may delete any information therein that such Lender or Agent deems confidential).
Nothing herein contained shall interfere with the right of a Lender or Agent to arrange its tax affairs in whatever manner it thinks fit nor oblige any Lender or Agent to claim any tax refund or to make available its tax returns or disclose any
information relating to its tax affairs or any computations in respect thereof or require any Lender or Agent to do anything that would prejudice its ability to benefit from any other refunds, credits, reliefs, remissions or repayments to which it
may be entitled. 
 (e) Each Lender agrees that, upon the occurrence of any event giving rise to the operation of
Section 3.01(a) or (c) with respect to such Lender it will, if requested by the Borrower, use commercially reasonable efforts (subject to legal and regulatory restrictions) to designate another Applicable Lending Office for
any Loan affected by such event; provided that such efforts are made on terms that, in the judgment of such Lender, cause such Lender and its Applicable Lending Office(s) to suffer no material economic, legal or regulatory disadvantage, and
provided further that nothing in this Section 3.01(e) shall affect or postpone any of the Obligations of the Loan Parties or the rights of such Lender pursuant to Section 3.01(a) or (c). 

(f) Each Lender that is entitled to an exemption from or reduction of withholding tax under the law of the jurisdiction in which the
Borrower is located, or any treaty to which such jurisdiction is a party, with respect to any payments under this Agreement or any other Loan Document shall (i) deliver to the Borrower (with a copy to the Administrative Agent), at the time or
times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation and (ii) complete any procedural formalities, in each case, that are prescribed by applicable law as will permit such
payments to be made without withholding or at a reduced rate, provided that such Lender is legally entitled to complete, execute and deliver such documentation or complete such procedural formalities. 

Section 3.02 Illegality. 

(a) If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for
any Lender or its Applicable Lending Office to make, maintain or fund Eurocurrency Rate Loans, or to determine or charge interest rates based upon the LIBOR Rate, or any Governmental Authority has imposed material restrictions on the authority of
such Lender to purchase or sell, or to take deposits of, Dollars in the London interbank market, then, on notice thereof by such Lender to the Borrower through the Administrative Agent, any obligation of such Lender to make or continue Eurocurrency
Rate Loans or to convert Base Rate Loans to Eurocurrency Rate Loans shall be suspended until such Lender notifies the Administrative Agent and the Borrower that the circumstances giving rise to such determination no longer exist. Upon receipt of
such notice, the Borrower shall, upon demand from such Lender (with a copy to the Administrative Agent), prepay or, if applicable, convert all Eurocurrency Rate Loans of such Lender to Base Rate Loans, either on the last day of the Interest Period
therefor, if such Lender may lawfully continue to maintain such Eurocurrency Rate Loans to such day, or promptly, if such Lender may not lawfully continue to maintain such Eurocurrency Rate Loans. Upon any such prepayment or conversion, the Borrower
shall also pay accrued interest on the amount so prepaid or converted. Each Lender agrees to designate a different Applicable Lending Office if such designation will avoid the need for any such notice and will not, in the good faith judgment of such
Lender, otherwise be materially disadvantageous to such Lender. 

  
 -55-

 (b) If any provision of this Agreement or any of the other Loan Documents would obligate the
Borrower to make any payment of interest with respect to any of the Revolving Credit Exposure or other amount payable to the Administrative Agent or any Revolving Credit Lender in an amount or calculated at a rate which would be prohibited by any
Law then, notwithstanding such provision, such amount or rates shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not be so prohibited by any applicable law or so
result in a receipt by the Administrative Agent or such Revolving Credit Lender of interest with respect to its Revolving Credit Exposure at a criminal rate, such adjustment to be effected, to the extent necessary, as follows: 

(i) first, by reducing the amount or rates of interest required to be paid to the Administrative Agent or the
affected Revolving Credit Lender under Section 2.08; and 
 (ii) thereafter, by reducing any
fees, commissions, premiums and other amounts required to be paid to the Administrative Agent or the affected Revolving Credit Lender which would constitute interest with respect to the Revolving Credit Exposure for purposes of any applicable law.

 Section 3.03 Inability to Determine Rates. If the Required Lenders determine that
for any reason in connection with any request for a Eurocurrency Rate Loan or a conversion to or continuation thereof that (a) adequate and reasonable means do not exist for determining the LIBOR Rate for any requested Interest Period with
respect to a proposed Eurocurrency Rate Loan or (b) the LIBOR Rate for any requested Interest Period with respect to a proposed Eurocurrency Rate Loan does not adequately and fairly reflect the cost to such Lenders of funding such Loan or that
Dollar deposits, as applicable, are not being offered to banks in the London or European, as applicable, interbank eurodollar market for the applicable amount and the Interest Period of such Eurocurrency Loan the Administrative Agent will promptly
so notify the Borrower and each Lender. Thereafter, the obligation of the Lenders to make or maintain Eurocurrency Rate Loans in the relevant currency shall be suspended until the Administrative Agent (upon the instruction of the Required Lenders)
revokes such notice. Upon receipt of such notice, the Borrower may revoke any pending request for a Borrowing of, conversion to or continuation of Eurocurrency Rate Loans or, failing that, will be deemed to have converted such request into a request
for a Borrowing of Base Rate Loans, in the amount specified therein. 
 Section 3.04
Increased Cost and Reduced Return; Capital Adequacy; Reserves on Eurocurrency Rate Loans. 
 (a) If any Lender determines
that as a result of the introduction of or any Change in Law or a change in the interpretation of any Law, in each case after the Closing Date, or such Lender’s compliance therewith, there shall be any increase in the cost to such Lender of
agreeing to make or making, funding or maintaining any Loan (other than a Base Rate Loan) or issuing or participating in Letters of Credit, or a reduction in the amount received or receivable by such Lender in connection with any of the foregoing
(excluding for purposes of this Section 3.04(a) any such increased costs or reduction in amount resulting from (i) Taxes or Other Taxes covered by Section 3.01, (ii) the imposition of, or any change in the rate of,
any taxes imposed on or measured by net income (including branch profits) and franchise (and similar) taxes imposed in lieu of net income taxes payable by such Lender, or (iii) reserve requirements contemplated by Section 3.04(c),
then from time to time within fifteen (15) days after demand by such Lender setting forth in reasonable detail such increased costs (with a copy of such demand to the Administrative Agent given in accordance with Section 3.06), the
Borrower shall pay to such Lender such additional amounts as will compensate such Lender for such increased cost or reduction. 

  
 -56-

 (b) If any Lender determines that the introduction of any Law regarding capital adequacy or
any change therein or in the interpretation thereof, in each case after the Closing Date, or compliance by such Lender (or its Applicable Lending Office) therewith, has the effect of reducing the rate of return on the capital of such Lender or any
corporation controlling such Lender as a consequence of such Lender’s obligations hereunder (taking into consideration its policies with respect to capital adequacy and such Lender’s desired return on capital), then from time to time upon
demand of such Lender setting forth in reasonable detail the charge and the calculation of such reduced rate of return (with a copy of such demand to the Administrative Agent given in accordance with Section 3.06), the Borrower shall pay
to such Lender such additional amounts as will compensate such Lender for such reduction within fifteen (15) days after receipt of such demand. 
 (c) The Borrower shall pay to each Lender, (i) as long as such Lender shall be required to maintain reserves with respect to liabilities or assets consisting of or including Eurocurrency funds or
deposits, additional interest on the unpaid principal amount of each Eurocurrency Rate Loan equal to the actual costs of such reserves allocated to such Loan by such Lender (as determined by such Lender in good faith, which determination shall be
conclusive in the absence of manifest error), and (ii) as long as such Lender shall be required to comply with any reserve ratio requirement or analogous requirement of any other central banking or financial regulatory authority imposed in
respect of the maintenance of the Commitments or the funding of the Eurocurrency Rate Loans, such additional costs (expressed as a percentage per annum and rounded upwards, if necessary, to the nearest five decimal places) equal to the actual costs
allocated to such Commitment or Loan by such Lender (as determined by such Lender in good faith, which determination shall be conclusive absent manifest error) which in each case shall be due and payable on each date on which interest is payable on
such Loan, provided the Borrower shall have received at least fifteen (15) days’ prior notice (with a copy to the Administrative Agent) of such additional interest or cost from such Lender. If a Lender fails to give notice fifteen
(15) days prior to the relevant Interest Payment Date, such additional interest or cost shall be due and payable fifteen (15) days from receipt of such notice. 
 (d) Subject to Section 3.06(b), failure or delay on the part of any Lender to demand compensation pursuant to this Section 3.04 shall not constitute a waiver of such Lender’s
right to demand such compensation. 
 (e) If any Lender requests compensation under this Section 3.04, then such
Lender will, if requested by the Borrower, use commercially reasonable efforts to designate another Applicable Lending Office for any Loan affected by such event; provided that such efforts are made on terms that, in the reasonable judgment
of such Lender, cause such Lender and its Applicable Lending Office(s) to suffer no material economic, legal or regulatory disadvantage; provided further that nothing in this Section 3.04(e) shall affect or postpone any of the
Obligations of the Borrower or the rights of such Lender pursuant to Section 3.04(a), (b) or (c). 
 Section 3.05 Funding Losses. Upon demand of any Lender (with a copy to the Administrative Agent) from time to time, the Borrower shall promptly compensate such
Lender for and hold such Lender harmless from any loss, cost or expense incurred by it as a result of: 
 (i) any
continuation conversion, payment or prepayment of any Loan other than a Base Rate Loan on a day other than the last day of the Interest Period for such Loan (whether voluntary, mandatory, automatic, by reason of acceleration, or otherwise); or

 (ii) any failure by the Borrower (for a reason other than the failure of such Lender to make a Loan) to
prepay, borrow, continue or convert any Loan other than a Base Rate Loan on the date or in the amount notified by the Borrower; 

  
 -57-

 including any loss or expense arising from the liquidation or reemployment of funds obtained by it to
maintain such Loan or from fees payable to terminate the deposits from which such funds were obtained. 
 For purposes of calculating amounts
payable by the Borrower to the Lenders under this Section 3.05, each Lender shall be deemed to have funded each Eurocurrency Rate Loan made by it at the LIBOR Rate (with respect to any Eurocurrency Rate Loan denominated in Dollars) for
such Loan by a matching deposit or other borrowing in the London or European, as applicable, interbank eurodollar market for a comparable amount and for a comparable period, whether or not such Eurocurrency Rate Loan was in fact so funded.

 Section 3.06 Matters Applicable to All Requests for Compensation. 

(a) Any Agent or any Lender claiming compensation under this Article III shall deliver a certificate to the Borrower setting
forth the additional amount or amounts to be paid to it hereunder which shall be conclusive in the absence of manifest error. In determining such amount, such Agent or such Lender may use any reasonable averaging and attribution methods. 

(b) With respect to any Lender’s claim for compensation under Section 3.01, Section 3.02,
Section 3.03 or Section 3.04, the Borrower shall not be required to compensate such Lender for any amount incurred more than one hundred and eighty (180) days prior to the date that such Lender notifies the Borrower of
the event that gives rise to such claim; provided that if the circumstance giving rise to such claim is retroactive, then such 180-day period referred to above shall be extended to include the period of retroactive effect thereof. If any
Lender requests compensation by the Borrower under Section 3.04, the Borrower may, by notice to such Lender (with a copy to the Administrative Agent), suspend the obligation of such Lender to make or continue Eurocurrency Rate Loans from
one Interest Period to another, or to convert Base Rate Loans into Eurocurrency Rate Loans, until the event or condition giving rise to such request ceases to be in effect (in which case the provisions of Section 3.06(c) shall be
applicable); provided that such suspension shall not affect the right of such Lender to receive the compensation so requested. 
 (c) If the obligation of any Lender to make or continue any Eurocurrency Rate Loan from one Interest Period to another, or to convert Base Rate Loans into Eurocurrency Rate Loans shall be suspended
pursuant to Section 3.06(b) hereof, such Lender’s Eurocurrency Rate Loans shall be automatically converted into Base Rate Loans on the last day(s) of the then current Interest Period(s) for such Eurocurrency Rate Loans (or, in the
case of an immediate conversion required by Section 3.02, on such earlier date as required by Law) and, unless and until such Lender gives notice as provided below that the circumstances specified in Section 3.01,
Section 3.02, Section 3.03 or Section 3.04 hereof that gave rise to such conversion no longer exist: 
 (i) to the extent that such Lender’s Eurocurrency Rate Loans have been so converted, all payments and prepayments of principal that would otherwise be applied to such Lender’s Eurocurrency Rate
Loans shall be applied instead to its Base Rate Loans; and 
 (ii) all Loans that would otherwise be made or
continued from one Interest Period to another by such Lender as Eurocurrency Rate Loans shall be made or continued instead as Base Rate Loans, and all Base Rate Loans of such Lender that would otherwise be converted into Eurocurrency Rate Loans
shall remain as Base Rate Loans. 
 (d) If any Lender gives notice to the Borrower (with a copy to the Administrative Agent)
that the circumstances specified in Section 3.01, Section 3.02, Section 3.03 or Section 3.04 hereof that gave rise to the conversion of such Lender’s Eurocurrency Rate Loans pursuant to this
Section 3.06 no longer exist (which such Lender agrees to do promptly upon such circumstances ceasing to exist) at a time when Eurocurrency Rate Loans made by other Lenders are outstanding, such Lender’s Base Rate Loans shall be

  
 -58-

 
automatically converted to Eurocurrency Rate Loans, on the first day(s) of the next succeeding Interest Period(s) for such outstanding Eurocurrency Rate Loans, to the extent necessary so that,
after giving effect thereto, all Loans held by the Lenders holding Eurocurrency Rate Loans and by such Lender are held pro rata (as to principal amounts, interest rate basis, and Interest Periods) in accordance with their respective
Commitments. 
 Section 3.07 Replacement of Lenders Under Certain Circumstances.

 (a) If at any time (i) any Lender requests reimbursement for amounts owing pursuant to Section 3.01 or
Section 3.04 as a result of any condition described in such Sections or any Lender ceases to make Eurocurrency Rate Loans as a result of any condition described in Section 3.02 or Section 3.04, (ii) any
Lender becomes a Defaulting Lender or (iii) any Lender becomes a Non-Consenting Lender, then the Borrower may, on ten (10) Business Days’ prior written notice to the Administrative Agent and such Lender, replace such Lender by
requiring such Lender to (and such Lender shall be obligated to) assign pursuant to Section 10.07(b) (with the assignment fee to be paid by the Borrower in such instance) all of its rights and obligations under this Agreement (or, with
respect to clause (iii) above, all of its rights and obligations with respect to the Loans or Commitments that is the subject of the related consent, waiver or amendment) to one or more Eligible Assignees; provided that neither
the Administrative Agent nor any Lender shall have any obligation to the Borrower to find a replacement Lender or other such Person; and provided further that (A) in the case of any such assignment resulting from a claim for
compensation under Section 3.04 or payments required to be made pursuant to Section 3.01, such assignment will result in a reduction in such compensation or payments and (B) in the case of any such assignment resulting
from a Lender becoming a Non-Consenting Lender, the applicable Eligible Assignees shall have agreed to the applicable departure, waiver or amendment of the Loan Documents. 
 (b) Any Lender being replaced pursuant to Section 3.07(a) above shall (i) execute and deliver an Assignment and Assumption with respect to such Lender’s Commitment and outstanding
Loans, and (ii) deliver Notes, if any, evidencing such Loans to the Borrower or Administrative Agent. Pursuant to such Assignment and Assumption, (A) the assignee Lender shall acquire all or a portion, as the case may be, of the assigning
Lender’s Commitment, (B) all obligations of the Borrower owing to the assigning Lender relating to the Loans and participations so assigned shall be paid in full by the assignee Lender to such assigning Lender concurrently with such
assignment and assumption and (C) upon such payment and, if so requested by the assignee Lender, the assignor Lender shall deliver to the assignee Lender the appropriate Note or Notes executed by the Borrower, the assignee Lender shall become a
Lender hereunder and the assigning Lender shall cease to constitute a Lender hereunder with respect to such assigned Loans, Commitments and participations, except with respect to indemnification provisions under this Agreement, which shall survive
as to such assigning Lender. 
 (c) [Reserved]. 
 (d) In the event that (i) the Borrower or the Administrative Agent has requested that the Lenders consent to a departure or waiver of any provisions of the Loan Documents or agree to any amendment
thereto, (ii) the consent, waiver or amendment in question requires the agreement of all affected Lenders in accordance with the terms of Section 10.01 or all the Lenders with respect to the Loans and (iii) the Required Lenders
have agreed to such consent, waiver or amendment, then any Lender who does not agree to such consent, waiver or amendment shall be deemed a “Non-Consenting Lender.” 
 Section 3.08 Survival. All of the Borrower’s obligations under this Article III shall survive termination of the Aggregate Commitments and
repayment of all other Obligations hereunder. 

  
 -59-

 ARTICLE IV 

Conditions Precedent 
 Section 4.01 Conditions of Initial Borrowing. The obligation of each Lender to make its initial Borrowing hereunder is subject to satisfaction of the following
conditions precedent except as otherwise agreed between the Borrower and the Administrative Agent: 
 (a) The
Administrative Agent’s receipt of the following, each of which shall be originals or facsimiles (followed promptly by originals) unless otherwise specified, each properly executed by a Responsible Officer of the signing Loan Party: 

(i) executed counterparts of this Agreement from the Borrower and the Guaranty from each of the Persons listed on
Schedule 1; 
 (ii) a Note executed by the Borrower in favor of each Lender that has requested a Note at
least five (5) Business Days in advance of the Closing Date; 
 (iii) [Reserved]; 

(iv) such certificates (including a certificate substantially in the form of Exhibit J) of resolutions or
other action, incumbency certificates and/or other certificates of Responsible Officers and/or shareholders of each Loan Party as the Administrative Agent may reasonably require evidencing the identity, authority and capacity of each Responsible
Officer thereof authorized to act as a Responsible Officer in connection with this Agreement and the other Loan Documents to which such Loan Party is a party or is to be a party on the Closing Date; 

(v) an opinion from Kirkland & Ellis LLP, New York counsel to the Loan Parties, substantially in the form of
Exhibit H; 
 (vi) a certificate attesting to the Solvency of the Borrower and its Subsidiaries
(taken as a whole) on the Closing Date after giving effect to the Transactions, from the chief financial officer of the Borrower; and 
 (vii) if applicable under the laws of the jurisdiction of incorporation or organization of the relevant Loan Party, good standing certificates or certificates of status (to the extent such concept exists
in the relevant jurisdiction) from the jurisdiction of incorporation, organization or formation of each Loan Party. 
 (b) All fees and out-of-pocket expenses required to be paid hereunder and invoiced at least 3 Business Days prior to the Closing Date shall have been paid in full or will be paid on the Closing Date or
out of the initial Borrowing. 
 (c) Prior to or substantially simultaneously with the initial Borrowing,
(i) the Equity Contribution shall have been consummated and (ii) the Acquisition shall have been consummated in all material respects in accordance with the terms of the Purchase Agreement as in effect on May 12, 2011, without giving
effect to any modifications, amendments, consents or waivers by the Borrower thereto that are material and adverse to the Lenders or the Lead Arranger as reasonably determined by the Lead Arranger, without the prior consent of the Lead Arranger
(such consent not to be unreasonably withheld, delayed or conditioned). 

  
 -60-

 (d) The Administrative Agent and the Lead Arranger shall have received all
documentation and other information about the Borrower and the Guarantors as has been reasonably requested in writing at least 10 days prior to the Closing Date by the Administrative Agent or the Lead Arranger that they reasonably determine is
required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including without limitation the USA PATRIOT Act. 

Section 4.02 Conditions to All Borrowings. The obligation of each Lender to honor any Request
for Borrowing (other than a Committed Loan Notice requesting only a conversion of Loans to the other Type, or a continuation of Eurocurrency Rate Loans) is subject to the following conditions precedent: 

(a) The representations and warranties of the Borrower and each other Loan Party contained in Article V or any
other Loan Document (provided that in the case of any initial Borrowings on the Closing Date, the representations contained in Section 5.01(a), Section 5.01(b)(ii), Section 5.02(a),
Section 5.12, Section 5.15 and Section 5.16 are the only representations being made on the Closing Date) shall be true and correct in all material respects on and as of the date of such Borrowing; provided
that to the extent that such representations and warranties specifically refer to an earlier date, they shall be true and correct in all material respects as of such earlier date; provided further that any representation and warranty that
is qualified as to “materiality,” “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates. 

(b) In the case of each Borrowing after the initial Borrowings, no Default shall exist, or would result from such proposed
Borrowing or from the application of the proceeds therefrom. 
 (c) [Reserved.] 

(d) [Reserved]. 
 Each Request for Borrowing (other than a Committed Loan Notice requesting only a conversion of Loans to the other Type or a continuation of Eurocurrency Rate Loans) submitted by the Borrower shall be
deemed to be a representation and warranty that the conditions specified in Section 4.02(a) and (b) have been satisfied on and as of the date of the applicable Borrowing. 

Section 4.03 Closing Date. This Agreement shall become effective on the date (the
“Closing Date”) upon which the Administrative Agent shall have received executed counterparts of this Agreement from each of the Persons listed on Schedule 1 and each of the Lenders. 

ARTICLE V 
 Representations and Warranties 
 Borrower
represents and warrants to the Agents and the Lenders that: 
 Section 5.01 Existence,
Qualification and Power; Compliance with Laws. Each Loan Party and each other Restricted Subsidiary (a) is a Person duly incorporated, organized or formed, and validly existing and, if applicable under the laws of the jurisdiction of
incorporation or organization of the Relevant Loan Party, in good standing under the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority to (i) own or lease its assets and carry on its
business and (ii) execute, deliver and perform its obligations under the Loan Documents to which it is a 

  
 -61-

 
party, (c) is duly qualified and, if applicable, in good standing under the Laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business
requires such qualification, (d) is in compliance with all Laws, orders, writs, injunctions and orders and (e) has all requisite governmental licenses, authorizations, consents and approvals to operate its business as currently conducted;
except in each case referred to in clause (b)(i), (c), (d) or (e), to the extent that failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 Section 5.02 Authorization; No Contravention. The execution, delivery and
performance by each Loan Party of each Loan Document to which such Person is a party, and the consummation of the Transactions, are within such Loan Party’s corporate or other powers, have been duly authorized by all necessary corporate or
other organizational action, and do not and will not (a) contravene the terms of any of such Person’s Organization Documents, (b) conflict with or result in any breach or contravention of, or the creation of any Lien under (other than
as permitted by Section 7.01), or require any payment to be made under (i) any Contractual Obligation to which such Person is a party or affecting such Person or the properties of such Person or any of its Subsidiaries or (ii) any
material order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject; or (c) violate any material Law; except with respect to any conflict, breach or contravention or
payment (but not creation of Liens) or any order, writ or decree referred to in clause (b), to the extent that such conflict, breach, contravention or payment or any order, writ or decree could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. 
 Section 5.03 Governmental
Authorization; Other Consents. No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery
or performance by, or enforcement against, any Loan Party of this Agreement or any other Loan Document, or for the consummation of the Transactions, except for (i) the approvals, consents, exemptions, authorizations, actions, notices and
filings which have been duly obtained, taken, given or made and are in full force and effect and (ii) those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

Section 5.04 Binding Effect. This Agreement and each other Loan Document has been duly executed
and delivered by each Loan Party that is party thereto. This Agreement and each other Loan Document constitutes a legal, valid and binding obligation of such Loan Party, enforceable against each Loan Party that is party thereto in accordance with
its terms, except as such enforceability may be limited by Debtor Relief Laws, general principles of equity and the making of registrations, filings, stampings and/or notifications of the Loan Documents as required under local law for the validity
or enforceability thereof. 
 Section 5.05 Financial Statements; No Material Adverse
Effect. 
 (a) The Audited Financial Statements fairly present in all material respects the financial condition of the
Borrower as of the dates thereof and their results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the periods covered thereby, except as otherwise disclosed to the Administrative Agent prior to
the Closing Date. 
 (b) Since the Closing Date, there has been no event or circumstance, either individually or in the
aggregate, that has had or could reasonably be expected to have a Material Adverse Effect. 
 Each Lender and the Administrative
Agent hereby acknowledges and agrees that the Borrower and its Subsidiaries may be required to restate historical financial statements as the result of the 

  
 -62-

 
implementation of changes in GAAP or the interpretation thereof, and that such restatements will not result in a Default under the Loan Documents (including any effect on any conditions required
to be satisfied on the Closing Date) to the extent that the restatements do not reveal any material omission, misstatement or other material inaccuracy in the reported information from actual results for any relevant prior period. 

Section 5.06 Litigation. Except as set forth on Schedule 5.06, there are no actions,
suits, proceedings, claims or disputes pending or, to the knowledge of the Borrower, threatened in writing or contemplated, at law, in equity, in arbitration or before any Governmental Authority, by or against the Borrower or any Restricted
Subsidiary or against any of their properties or revenues that either individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. 
 Section 5.07 Ownership of Property; Liens. Each Loan Party and each of its Subsidiaries has good and defensible title in fee simple to, or valid leasehold
interests in, or easements or other limited property interests in, all real property necessary in the ordinary conduct of its business, free and clear of all Liens except for minor defects in title that do not materially interfere with its ability
to conduct its business or to utilize such assets for their intended purposes and Liens permitted by Section 7.01 and except where the failure to have such title or other interest could not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. 
 Section 5.08 Environmental Compliance.

 (a) There are no pending or, to the knowledge of Borrower, threatened claims, actions, suits, or proceedings by or against
the Borrower or any Subsidiary alleging potential liability or responsibility for violation of, or otherwise relating to, any applicable Environmental Law that could, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. 
 (b) Except as could not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect, (i) there are no and never have been any underground or aboveground storage tanks or any surface impoundments, septic tanks, pits, sumps or lagoons in which Hazardous Materials are being or have been treated, stored or disposed on any
property currently owned, leased or operated by any Loan Party or any other Subsidiary or, to its knowledge, on any property formerly owned or operated by any Loan Party or any other Restricted Subsidiary; (ii) there is no asbestos or
asbestos-containing material on any property currently owned or operated by any Loan Party or any other Subsidiary; and (iii) Hazardous Materials have not been released, discharged or disposed of by any of the Loan Parties or any other
Subsidiary at any location in a manner which would give rise to liability under applicable Environmental Laws. 
 (c) The
properties currently or formerly owned, leased or operated by the Borrower and its Subsidiaries do not contain any Hazardous Materials in amounts or concentrations which (i) constitute a violation of, (ii) require remedial action under, or
(iii) could give rise to liability under, applicable Environmental Laws, which violations, remedial actions and liabilities, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. 

(d) The Borrower or any of its Subsidiaries are not undertaking, or have not completed, either individually or together with other
potentially responsible parties, any investigation or assessment or remedial or response action relating to any actual or threatened release, discharge or disposal of Hazardous Materials at any site or location, either voluntarily or pursuant to the
order of any Governmental Authority or the requirements of any applicable Environmental Law except for such investigation or assessment or remedial or response action that, individually or in the aggregate, could not reasonably be expected to result
in a Material Adverse Effect. 

  
 -63-

 (e) All Hazardous Materials transported from any property currently or formerly owned or
operated by any Loan Party or any other Subsidiary for off-site disposal have been disposed of in a manner not reasonably expected to result, individually or in the aggregate, in a Material Adverse Effect. 

(f) Except as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Effect, none of the
Loan Parties nor any other Subsidiary has contractually assumed any liability or obligation under or relating to any applicable Environmental Law. 
 (g) Except as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Effect, the Loan Parties and each other Subsidiary and their respective businesses,
operations and properties are and have been in compliance with all applicable Environmental Laws. 

Section 5.09 Taxes. The Borrower and each Restricted Subsidiary have timely filed all national,
provincial, state, municipal, foreign and other material tax returns and reports required to be filed, and have timely paid all federal, provincial, state, municipal, foreign and other material taxes, assessments, fees and other governmental charges
levied or imposed upon them or their properties, income or assets otherwise due and payable, except those which are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in
accordance with GAAP and, except as could not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. 
 Section 5.10 Compliance with ERISA. 

(a) Except as set forth in Schedule 5.10(a) or as could not, either individually or in the aggregate, reasonably be expected to
result in a Material Adverse Effect, each Plan is in compliance in with the applicable provisions of ERISA, the Code and other federal or state Laws. 
 (b) (i) No ERISA Event has occurred or is reasonably expected to occur; (ii) neither any Loan Party nor any ERISA Affiliate has incurred, or reasonably expects to incur, any liability (and no event
has occurred which, with the giving of notice under Section 4219 of ERISA, would result in such liability) under Section 4201 et seq. or 4243 of ERISA with respect to a Multiemployer Plan; and (iii) neither any Loan Party nor any
ERISA Affiliate has engaged in a transaction that could be subject to Section 4069 or 4212(c) of ERISA, except, with respect to each of the foregoing clauses of this Section 5.10, as could not reasonably be expected, individually or
in the aggregate, to result in a Material Adverse Effect. 
 Section 5.11 Subsidiaries;
Equity Interests. As of the Closing Date, neither the Borrower nor any other Loan Party has any Subsidiaries other than those specifically disclosed in Schedule 5.11, and all of the outstanding Equity Interests in the Borrower and the
Material Subsidiaries have been validly issued, are fully paid and nonassessable and all Equity Interests owned by the Borrower or any other Loan Party are owned free and clear of all Liens except any nonconsensual Lien that is permitted under
Section 7.01. As of the Closing Date, Schedule 5.11 (a) sets forth the name and jurisdiction of organization of each Subsidiary and (b) sets forth the ownership interest of the Borrower and any of their Subsidiaries in
each of their Subsidiaries, including the percentage of such ownership. 
 Section 5.12
Margin Regulations; Investment Company Act. 
 (a) No Loan Party is engaged nor will it engage, principally or as one of
its important activities, in the business of purchasing or carrying margin stock (within the meaning of Regulation U issued by the FRB), or extending credit for the purpose of purchasing or carrying margin stock, and no proceeds of any Borrowings
will be used for any purpose that violates Regulation U. 

  
 -64-

 (b) None of the Borrower or any Loan Party is or is required to be registered as an
“investment company” under the Investment Company Act of 1940, as amended. 

Section 5.13 Disclosure. No report, financial statement, certificate or other written
information furnished by or on behalf of any Loan Party to any Agent or any Lender in connection with the transactions contemplated hereby and the negotiation of this Agreement or delivered hereunder or any other Loan Document (as modified or
supplemented by other information so furnished) on or before the Closing Date when taken as a whole contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not materially misleading; provided that with respect to projected financial information and pro forma financial information, the Borrower represents only that such information was
prepared in good faith based upon assumptions believed to be reasonable at the time of preparation; it being understood that such projections may vary from actual results and that such variances may be material. 

Section 5.14 Intellectual Property; Licenses, Etc. Each of the Loan Parties and the other
Restricted Subsidiaries own, license or possess the right to use, all of the trademarks, service marks, trade names, domain names, copyrights, patents, patent rights, technology, software, know-how database rights, design rights and other
intellectual property rights (collectively, “IP Rights”) that are reasonably necessary for the operation of their respective businesses as currently conducted, and, to the knowledge of Borrower, without violation of the rights of
any Person, except to the extent such violations, either individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Borrower, no such IP Rights infringe upon any rights held by any
Person except for such infringements, individually or in the aggregate, which could not reasonably be expected to have a Material Adverse Effect. No claim or litigation regarding any such IP Rights, is pending or, to the knowledge of the Borrower,
threatened against any Loan Party or Subsidiary, which, either individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. 
 Section 5.15 Solvency. On the Closing Date after giving effect to the Transactions, the Borrower, together with its Subsidiaries, on a consolidated basis, is
Solvent. 
 Section 5.16 Designation of Senior Debt. The Borrower shall, and shall
cause its Subsidiaries to, designate any of the Indebtedness under the Loan Documents as “Designated Senior Indebtedness” (or any similar term) under the terms of any Subordinated Indebtedness. 

ARTICLE VI 
 Affirmative Covenants 
 So long as any Lender
shall have any Commitment hereunder, any Loan or other Obligation hereunder which is accrued and payable shall remain unpaid or unsatisfied, the Borrower shall, and shall (except in the case of the covenants set forth in Section 6.01,
Section 6.02 and Section 6.03) cause each Restricted Subsidiary to: 

Section 6.01 Financial Statements. Deliver to the Administrative Agent for prompt further
distribution to each Lender: 
 (a) as soon as available, but in any event within ninety (90) days after the
end of each fiscal year of the Borrower, a consolidated balance sheet of Borrower and its Subsidiaries as at the end of such fiscal year, and the related consolidated statements of income or operations, stockholders’ equity and cash flows for
such fiscal year, setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and prepared in accordance 

  
 -65-

 
with GAAP, audited and accompanied by a report and opinion of an independent registered public accounting firm of internationally recognized standing, which report and opinion shall be prepared
in accordance with generally accepted auditing standards and shall not be subject to any “going concern” or like qualification or exception or any qualification or exception as to the scope of such audit; 

(b) as soon as available, but in any event, within forty-five (45) days after the end of each of the first three
(3) fiscal quarters of each fiscal year of the Borrower (commencing with the first full fiscal quarter ended after the Closing Date), a consolidated balance sheet of Borrower and its Subsidiaries as at the end of such fiscal quarter, and the
related (i) consolidated statements of income or operations for such fiscal quarter and for the portion of the fiscal year then ended and (ii) consolidated statements of cash flows for the portion of the fiscal year then ended, setting
forth in each case in comparative form the figures for the corresponding fiscal quarter of the previous fiscal year and the corresponding portion of the previous fiscal year, all in reasonable detail and certified by a Responsible Officer of the
Borrower as fairly presenting in all material respects the financial condition, results of operations, stockholders’ equity and cash flows of Borrower and its Subsidiaries in accordance with GAAP (it being agreed that the financial statements
provided pursuant to this clause (b) shall not include non-cash items that are customarily accounted for on an annual basis in accordance with GAAP or any purchase accounting adjustments), subject only to normal year-end adjustments and
the absence of footnotes; 
 (c) as soon as available, the audited financial statements of the Borrower for the
fiscal year ending December 31, 2010; and 
 (d) simultaneously with the delivery of each set of
consolidated financial statements referred to in Section 6.01(a) and (b) above the related consolidating financial statements reflecting the adjustments necessary to eliminate the accounts of Unrestricted Subsidiaries (if
any) from such consolidated financial statements. 
 Notwithstanding the foregoing, the obligations in paragraphs (a) and
(b) of this Section 6.01 may be satisfied with respect to financial information of Parent and its Subsidiaries by furnishing (A) the applicable financial statements of any direct or indirect parent of Parent that holds all of
the Equity Interests of the Borrower or (B) Borrower’s (or any direct or indirect parent thereof, as applicable), Form 10-K or 10-Q (or the equivalent in another jurisdiction), as applicable, filed with the SEC (or the equivalent in
another jurisdiction); provided that with respect to each of clauses (A) and (B), (i) to the extent such information relates to a parent of the Borrower, such information is accompanied by consolidating information
that explains in reasonable detail the differences between the information relating to the Borrower (or such parent), on the one hand, and the information relating to the Borrower and its Restricted Subsidiaries on a standalone basis, on the other
hand and (ii) to the extent such information is in lieu of information required to be provided under Section 6.01(a), such materials are accompanied by a report and opinion an independent registered public accounting firm of
internationally recognized standing, which report and opinion shall be prepared in accordance with generally accepted auditing standards. 
 Section 6.02 Certificates; Other Information. Deliver to the Administrative Agent for prompt further distribution to each Lender: 

(a) no later than five (5) days after the delivery of the financial statements referred to in
Section 6.01(a) and (b), a duly completed Compliance Certificate signed by a Responsible Officer of the Borrower; 

  
 -66-

 (b) promptly after the same are publicly available, copies of all annual,
regular, periodic and special reports and registration statements which the Borrower files with the SEC or with any Governmental Authority that may be substituted therefor or is the equivalent thereof in another jurisdiction (other than amendments
to any registration statement (to the extent such registration statement, in the form it became effective, is delivered), exhibits to any registration statement and, if applicable, any registration statement on Form S-8 or the equivalent) and in any
case not otherwise required to be delivered to the Administrative Agent pursuant hereto; 
 (c) promptly after
the furnishing thereof, copies of any material requests or material notices received by any Loan Party or any of its Subsidiaries from any Governmental Authority (other than in the ordinary course of business) that could reasonably be expected to
result in a Material Adverse Effect; 
 (d) together with the delivery of the financial statements pursuant to
Section 6.01(a) and each accompanying Compliance Certificate, (x) a list of Subsidiaries that identifies each Subsidiary as a Material Subsidiary or an Immaterial Subsidiary as of the date of delivery of such Compliance Certificate
or a confirmation that there is no change in such information since the later of the Closing Date or the date of the last such list and (y) such other information required by the Compliance Certificate; 

(e) no later than ninety (90) days following the first day of each fiscal year of the Borrower, a budget for such
fiscal year in form customarily prepared by the Borrower; and 
 (f) promptly, such additional information
regarding the business, legal, financial or corporate affairs of any Loan Party or any Material Subsidiary, or compliance with the terms of the Loan Documents, as the Administrative Agent or any Lender through the Administrative Agent may from time
to time reasonably request. 
 Documents required to be delivered pursuant to Section 6.01(a) and (b) or
Section 6.02(c) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which Borrower or the Company posts such documents, or provides a link thereto on Borrower or the
Company’s website on the Internet at the website address listed on Schedule 10.02; or (ii) on which such documents are posted on Borrower’s behalf on IntraLinks/IntraAgency or another relevant website, if any, to which each
Lender and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent); provided that: (i) upon written request by the Administrative Agent, Borrower shall deliver
paper copies of such documents to the Administrative Agent for further distribution to each Lender until a written request to cease delivering paper copies is given by the Administrative Agent and (ii) Borrower shall notify (which may be by
facsimile or electronic mail) the Administrative Agent of the posting of any such documents and provide to the Administrative Agent by electronic mail electronic versions (i.e., soft copies) of such documents. Notwithstanding the foregoing,
Borrower shall deliver originally executed Compliance Certificates to the Administrative Agent (in addition to the electronic copies pursuant to the foregoing). Each Lender shall be solely responsible for timely accessing posted documents or
requesting delivery of paper copies of such documents from the Administrative Agent and maintaining its copies of such documents. 
 Section 6.03 Notices. Promptly after a Responsible Officer obtains actual knowledge thereof, notify the Administrative Agent: 

(a) of the occurrence of any Default, which notice shall specify the nature thereof, the period of existence thereof and
what action the Borrower proposes to take with respect thereto; and 

  
 -67-

 (b) any litigation or governmental proceeding (including without limitation
pursuant to any applicable Environmental Laws) pending against the Borrower or any of the Subsidiaries that could reasonably be expected to be determined adversely and, if so determined, to result in a Material Adverse Effect. 

Section 6.04 Reserved. 

Section 6.05 Maintenance of Existence. (a) Preserve, renew and maintain in full force and
effect its legal existence under the Laws of the jurisdiction of its organization and (b) take all reasonable action to maintain all rights, privileges (including its good standing), permits, licenses and franchises necessary or desirable in
the normal conduct of its business, except in the case of clauses (a) and (b), (i) to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect or (ii) pursuant to a transaction
permitted by Section 7.04 or Section 7.05. 
 Section 6.06
Maintenance of Properties. Except if the failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (a) maintain, preserve and protect all of its material properties and
equipment necessary in the operation of its business in good working order, repair and condition, ordinary wear and tear excepted and casualty or condemnation excepted, and (b) make all necessary renewals, replacements, modifications,
improvements, upgrades, extensions and additions thereof or thereto in accordance with prudent industry practice. 
 
Section 6.07 Maintenance of Insurance. Maintain with financially sound and reputable insurance companies, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by
Persons engaged in the same or similar business, of such types and in such amounts (after giving effect to any self-insurance reasonable and customary for similarly situated Persons engaged in the same or similar businesses as the Borrower and its
Restricted Subsidiaries) as are customarily carried under similar circumstances by such other Persons. 
 
Section 6.08 Compliance with Laws. Comply in all respects with the requirements of all Laws and all orders, writs, injunctions, decrees and judgments applicable to it or to its business or property (including without limitation
Environmental Laws, ERISA and the USA PATRIOT Act), except if the failure to comply therewith could not, individually or in the aggregate reasonably be expected to have a Material Adverse Effect. 

Section 6.09 Books and Records. Maintain proper books of record and account, in which entries
that are full, true and correct in all material respects and are in conformity with GAAP consistently applied shall be made of all material financial transactions and matters involving the assets and business of the Borrower or such Subsidiary, as
the case may be. 
 Section 6.10 Inspection Rights. Permit representatives and
independent contractors of the Administrative Agent and each Lender to visit and inspect any of its properties and to discuss its affairs, finances and accounts with its directors, officers, and independent public accountants, all at the reasonable
expense of the Borrower and at such reasonable times during normal business hours and as often as may be reasonably desired, upon reasonable advance notice to the Borrower; provided that excluding any such visits and inspections during the
continuation of an Event of Default, only the Administrative Agent on behalf of the Lenders may exercise rights of the Administrative Agent and the Lenders under this Section 6.10 and the Administrative Agent shall not exercise such
rights more often than two (2) times during any calendar year absent the existence of an Event of Default and only one (1) such time shall be at the Borrower’s expense; provided further that when an Event of Default
exists, the Administrative Agent or any Lender (or any of their respective representatives or independent contractors) may do any of the foregoing at the expense of Borrower at any time during normal business

  
 -68-

 
hours and upon reasonable advance notice. The Administrative Agent and the Lenders shall give Borrower the opportunity to participate in any discussions with the Borrower’s independent
public accountants. Notwithstanding anything to the contrary in this Section 6.10, none of the Borrower or any Restricted Subsidiary will be required to disclose or permit the inspection or discussion of, any document, information or
other matter (i) that constitutes non-financial trade secrets or non-financial proprietary information, (ii) in respect of which disclosure to the Administrative Agent or any Lender (or their respective representatives or contractors) is
prohibited by Law or any binding agreement or (iii) that is subject to attorney client or similar privilege or constitutes attorney work product. 
 Section 6.11 Covenant to Guarantee Obligations. At the Borrower’s expense, take all action necessary or reasonably requested by the Administrative Agent to
ensure that the Guarantee Requirement continues to be satisfied, including: 
 (a) upon the formation or
acquisition of any new direct or indirect wholly-owned Subsidiary (in each case, other than an Unrestricted Subsidiary or an Excluded Subsidiary) by any Loan Party, the designation in accordance with Section 6.14 of any existing direct
or indirect wholly-owned Subsidiary as a Restricted Subsidiary, or any Immaterial Subsidiary becoming a Material Subsidiary: 
 (i) within thirty (30) days after such formation, acquisition, designation or occurrence or such longer period as the Administrative Agent may agree in its reasonable discretion. 

(b) [Reserved]. 
 (c) After the Closing Date, if (x) any Wholly Owned Subsidiary that is a Restricted Subsidiary or (y) any non-Wholly Owned Subsidiary that is a Restricted Subsidiary which has Guarantee
Obligations in respect of any capital markets debt securities of the Borrower or any Restricted Subsidiary, in either case, other than a Guarantor, shall, in either case, have a Guarantee Obligations in respect of any Indebtedness of the Borrower or
any other Guarantor then: 
 (i) within 30 days of the incurrence of such Guarantee Obligation, the Borrower
shall cause such Restricted Subsidiary to execute and deliver to the Administrative Agent a supplemental document providing for a senior Guarantee by such Restricted Subsidiary (unless such Restricted Subsidiary’s Guarantee Obligations in
respect of Indebtedness of the Borrower or any other Guarantor is by its express terms subordinated in right of payment to the Loans or such Restricted Subsidiary’s Guarantee) providing that such Restricted Subsidiary’s Guarantee
Obligation is subordinated in right of payment to such Guarantee substantially to the same extent as such Indebtedness is subordinated to the Loans or such Guarantor’s Guarantee; and 

(ii) such Restricted Subsidiary shall waive and will not in any manner whatsoever claim or take the benefit or advantage
of any rights of reimbursement, indemnity or subrogation or any other rights against the Borrower or any other Restricted Subsidiary as a result of any payment by such Restricted Subsidiary under its Guarantee Obligations until payment in full of
the Obligations under this Agreement; 
 provided that this Section 6.11(c) shall not be applicable to any Guarantee
Obligation of a Subsidiary that existed at the time such Person became a Restricted Subsidiary and was not incurred in connection with, or in contemplation of, such Person becoming a Restricted Subsidiary. The Borrower may elect, in its sole
discretion, to cause any Subsidiary that is not otherwise required 

  
 -69-

 
to be a Guarantor to become a Guarantor, in which case, such Subsidiary shall only be required to comply with the 30-day period described above. 

Section 6.12 Use of Proceeds. Use the proceeds of any Borrowing, whether directly or
indirectly, in a manner consistent with the uses set forth in the preliminary statements to this Agreement. 
 
Section 6.13 [Reserved]. 
 Section 6.14 Designation of Subsidiaries.

 (a) Subject to Section 6.14(b) below, the board of directors of the Borrower may at any time designate any
Restricted Subsidiary as an Unrestricted Subsidiary or any Unrestricted Subsidiary as a Restricted Subsidiary. The designation of any Restricted Subsidiary as an Unrestricted Subsidiary shall constitute an Investment by the Borrower therein at the
date of designation in an amount equal to the sum of (i) the net book value of the Loan Parties’ equity interest in such Subsidiary plus (ii) the excess over book value of the fair market value of any internally developed
intellectual property of such Subsidiary the fair market value and the net book value of Borrower’s investment therein. The designation of any Unrestricted Subsidiary as a Restricted Subsidiary shall constitute the incurrence at the time of
designation of any Indebtedness or Liens of such Subsidiary existing at such time. 
 (b) The Borrower may not
(x) designate any Restricted Subsidiary as an Unrestricted Subsidiary, or (y) designate an Unrestricted Subsidiary as a Restricted Subsidiary, in each case unless: 

(i) no Default or Event of Default exists or would result therefrom; and 

(ii) in the case of clause (x) only, (A) the Subsidiary to be so designated does not (directly, or
indirectly through its Subsidiaries) own any Equity Interests or Indebtedness of, or own or hold any Lien on any property of, the Borrower or any Restricted Subsidiary, and (B) neither the Borrower nor any Restricted Subsidiary shall at any
time be directly or indirectly liable for any Indebtedness that provides that the holder thereof may (with the passage of time or notice or both) declare a default thereon or cause the payment thereof to be accelerated or payable prior to its stated
maturity upon the occurrence of a default with respect to any Indebtedness, Lien or other obligation of any Unrestricted Subsidiary (including any right to take enforcement action against such Unrestricted Subsidiary). 

Section 6.15 Payment of Taxes. The Borrower will pay and discharge, and will cause each of the
Restricted Subsidiaries to pay and discharge, all taxes, assessments and governmental charges or levies imposed upon it or upon its income or profits, or upon any properties belonging to it, in each case on a timely basis, and all lawful claims
which, if unpaid, may reasonably be expected to become a lien or charge upon any properties of the Borrower or any of the Restricted Subsidiaries not otherwise permitted under this Agreement; provided that neither the Borrower nor any of the
Restricted Subsidiaries shall be required to pay any such tax, assessment, charge, levy or claim which is being contested in good faith and by proper proceedings if it has maintained adequate reserves with respect thereto in accordance with GAAP or
which would not reasonably be expected to constitute a Material Adverse Effect. 

Section 6.16 Post-Closing Obligations. The Borrower shall cause to be delivered to the
Administrative Agent, on or prior to the earlier of (a) twenty (20) Business Days after the execution of this Agreement or (b) the date of the initial Borrowing, the opinion of Reed Smith LLP, special Pennsylvania counsel to the Loan
Parties, in form and substance reasonably satisfactory to the Administrative Agent. 

  
 -70-

 ARTICLE VII 

Negative Covenants 
 So long as any Lender shall have any Commitment hereunder, any Loan or other Obligation hereunder which is accrued and payable shall remain unpaid or unsatisfied, the Borrower shall not, nor shall it
permit any Restricted Subsidiary to, directly or indirectly: 
 Section 7.01 Liens.
Create, incur, assume or permit to exist any Lien (other than Permitted Liens) upon any of its property or assets (including Capital Stock of a Restricted Subsidiary of the Borrower), whether owned on the Closing Date or acquired after that date,
which Lien secures any Indebtedness (such Lien, the “Initial Lien”), without effectively providing that the Loans hereunder shall be secured equally and ratably with (or prior to in the case of Subordinated Indebtedness) the
obligations so secured for so long as such obligations are so secured. Any Lien created for the benefit of the Secured Parties pursuant to the preceding sentence shall provide by its terms that such Lien shall be automatically and unconditionally
released and discharged upon the release and discharge of the Initial Lien. 
 Section 7.02
[RESERVED] 
 Section 7.03 Indebtedness. Incur any Indebtedness (including Acquired
Indebtedness); provided, however, that the Borrower and any of the Restricted Subsidiaries may Incur Indebtedness if on the date of such Incurrence and after giving pro forma effect thereto (including pro forma application of
the proceeds thereof), the Fixed Charge Coverage Ratio for the Borrower and its Restricted Subsidiaries is greater than 2.50 to 1.00. 
 Notwithstanding anything contained herein to the contrary, the Borrower and any Restricted Subsidiary may Incur the following Indebtedness: 

(a) Indebtedness Incurred pursuant to any Credit Facility (including this Agreement and letters of credit or bankers’ acceptances
issued or created under any Credit Facility), and any Refinancing Indebtedness in respect thereof and Guarantees in respect of such Indebtedness in a maximum aggregate principal amount at any time outstanding not exceed (i) $125,000,000, plus
(ii) $75,000,000, plus (iii) in the case of any refinancing of any Indebtedness permitted under this clause or any portion thereof, the aggregate amount of fees, underwriting discounts, premiums and other costs and expenses Incurred in
connection with such refinancing; 
 (b)(i) Guarantee Obligations of the Borrower or any Restricted Subsidiary of Indebtedness
of the Borrower or any Guarantor so long as the Incurrence of such Indebtedness is permitted under the terms hereof or (ii) without limiting the covenants set forth in Section 7.01, Indebtedness arising by reason of any Lien granted
by or applicable to such Person securing Indebtedness of the Borrower or any Restricted Subsidiary so long as the Incurrence of such Indebtedness and the granting of such Liens are permitted under the terms of this Agreement; 

(c) Indebtedness of the Borrower owing to and held by any Restricted Subsidiary or Indebtedness of a Restricted Subsidiary owing to and
held by the Borrower or any Restricted Subsidiary; provided, however, that (i) any subsequent issuance or transfer of Capital Stock or any other event which results in any such Indebtedness being beneficially held by a Person
other than the Borrower or a Restricted Subsidiary of the Borrower; and (ii) any sale or other transfer of any such Indebtedness to a Person other than the Borrower or a Restricted Subsidiary of the Borrower, in each case shall be deemed

  
 -71-

 
to constitute an Incurrence of such Indebtedness by the Borrower or such Restricted Subsidiary, as the case may be; 
 (d) Indebtedness represented by (i) the Senior Notes, including any Guarantee Obligations in respect thereof, (ii) Refinancing Indebtedness Incurred in respect of any Indebtedness described in
this clause or clauses (e), (g), or (k) of this Section or Incurred pursuant to the first paragraph of this Section 7.03, (iii) Management Advances, and (iv) any Indebtedness (other than Indebtedness described in clauses
(a), (c), or (d)(i)) outstanding on the date hereof; 
 (e) Indebtedness of (x) the Borrower or a Restricted Subsidiary
Incurred or issued to finance an acquisition or (y) Persons that are acquired by the Borrower or any Restricted Subsidiary or merged into or consolidated with the Borrower or a Restricted Subsidiary in accordance with the terms of this
Agreement; provided that after giving effect to such acquisition, merger or consolidation, either (i) the Borrower would be permitted to Incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test set
forth in the first paragraph of this Section 7.03; or (ii) the Fixed Charge Coverage Ratio of the Borrower and the Restricted Subsidiary would not be lower than immediately prior to such acquisition, merger or consolidation;

 (f) Hedging Obligations (excluding Hedging Obligations entered into for speculative purposes) for the purpose of limiting
interest rate risk, exchange rate risk or commodity pricing risk (as determined in good faith by the Board of Directors or senior management of the Borrower); 
 (g) Indebtedness represented by Capitalized Lease Obligations or Purchase Money Obligations, and in each case any Refinancing Indebtedness in respect thereof, in an aggregate outstanding principal amount
which, when taken together with the principal amount of all other Indebtedness Incurred pursuant to this clause and then outstanding, does not exceed the greater of (i) $75,000,000 and (ii) 3.75% of Total Assets at the time of Incurrence;

 (h) Indebtedness in respect of (i) workers’ compensation claims, self-insurance obligations, performance,
indemnity, surety, judgment, appeal, advance payment, customs, value added or other tax or other guarantees or other similar bonds, instruments or obligations and completion guarantees and warranties provided by the Borrower or a Restricted
Subsidiary or relating to liabilities, obligations or guarantees Incurred in the ordinary course of business, (ii) letters of credit, bankers’ acceptances, guarantees or other similar instruments or obligations issued or relating to
liabilities or obligations Incurred in the ordinary course of business, (iii) the financing of insurance premiums in the ordinary course of business and (iv) any customary Cash Management Services, cash pooling or netting or setting off
arrangements in the ordinary course of business; 
 (i) Indebtedness arising from agreements providing for guarantees,
indemnification, obligations in respect of earn-outs or other adjustments of purchase price or, in each case, similar obligations, in each case, Incurred or assumed in connection with the acquisition or disposition of any business or assets or
Person or any Capital Stock of a Subsidiary (other than Guarantee Obligations in respect of Indebtedness Incurred by any Person acquiring or disposing of such business or assets or such Subsidiary for the purpose of financing such acquisition or
disposition); provided that the maximum liability of the Borrower and its Restricted Subsidiaries in respect of all such Indebtedness shall at no time exceed the gross proceeds, including the fair market value of non-cash proceeds (measured
at the time received and without giving effect to any subsequent changes in value), actually received by the Borrower and its Restricted Subsidiaries in connection with such disposition; 

(j)(i) Indebtedness arising from the honoring by a bank or other financial institution of a check, draft or similar instrument drawn
against insufficient funds in the ordinary course of business; 

  
 -72-

 
provided, however, that such Indebtedness is extinguished within five (5) Business Days of Incurrence; (ii) Customer deposits and advance payments received in the ordinary
course of business from customers for goods or services purchased in the ordinary course of business; (iii) Indebtedness owed on a short-term basis of no longer than 30 days to banks and other financial institutions Incurred in the
ordinary course of business of the Borrower and its Restricted Subsidiaries with such banks or financial institutions that arises in connection with ordinary banking arrangements to manage cash balances of the Borrower and its Restricted
Subsidiaries; and (iv) Indebtedness Incurred by a Restricted Subsidiary in connection with bankers acceptances, discounted bills of exchange or the discounting or factoring of receivables for credit management purposes, in each case Incurred or
undertaken in the ordinary course of business on arm’s length commercial terms on a recourse basis; 
 (k) Indebtedness in
an aggregate outstanding principal amount which, when taken together with any Refinancing Indebtedness in respect thereof and the principal amount of all other Indebtedness Incurred pursuant to this clause (k) and then outstanding, will not
exceed $35,000,000; 
 (l) Indebtedness in an aggregate outstanding principal amount which, when taken together with any
Refinancing Indebtedness in respect thereof and the principal amount of all other Indebtedness Incurred pursuant to this clause and then outstanding, will not exceed 100% of the Net Cash Proceeds received by the Borrower from the issuance or sale
(other than to a Restricted Subsidiary) of its Capital Stock (other than Disqualified Stock, Designated Preferred Stock or an Excluded Contribution) or otherwise contributed to the equity (other than through the issuance of Disqualified Stock,
Designated Preferred Stock or an Excluded Contribution) of the Borrower, in each case, subsequent to the Closing Date; provided, however, that (i) any such Net Cash Proceeds that are so received or contributed shall be excluded
for purposes of making Restricted Payments under Section 7.06(a), (b), (c) or (d) and clauses (a), (b), (d) and (f) of the definition of “Permitted
Payment” to the extent the Borrower and its Restricted Subsidiaries Incur Indebtedness in reliance thereon and (ii) any Net Cash Proceeds that are so received or contributed shall be excluded for purposes of Incurring Indebtedness pursuant
to this clause to the extent the Borrower or any of its Restricted Subsidiaries makes a Restricted Payment pursuant to Section 7.06(a), (b), (c) or (d) and clauses (a), (b),
(d) and (f) of the definition of “Permitted Payment” in reliance thereon; 
 (m) Indebtedness
consisting of promissory notes issued by the Borrower or any of its Subsidiaries to any current or former employee, director or consultant of the Borrower, any of its Subsidiaries or any of its Parents (or permitted transferees, assigns, estates, or
heirs of such employee, director or consultant), to finance the purchase or redemption of Capital Stock of the Borrower or any of its Parents permitted by Section 7.06; and 

(n) Indebtedness of the Borrower or any of its Restricted Subsidiaries consisting of (i) the financing of insurance premiums or
(ii) take-or-pay obligations contained in supply arrangements, in each case Incurred in the ordinary course of business. 

Notwithstanding any contained herein a Restricted Subsidiary that is not a Guarantor may not Incur Indebtedness (other than Indebtedness
Incurred pursuant to the foregoing clause (a)(i) and any Refinancing Indebtedness in respect of Consolidated Priority Debt) if, after giving pro forma effect thereto, the Consolidated Priority Debt Leverage Ratio at the time of Incurrence would be
greater than 1.50 to 1.0. 
 For purposes of determining compliance with, and the outstanding principal amount of any particular
Indebtedness Incurred pursuant to and in compliance with, this Section: 

  
 -73-

 (1) in the event that Indebtedness meets the criteria of more than one of the types of
Indebtedness described in this Section, the Borrower, in its sole discretion, will classify, and may from time to time reclassify, such item of Indebtedness and only be required to include the amount and type of such Indebtedness in the foregoing
clauses (a) through (n) or the first paragraph of this Section; 
 (2) all or any portion of any item of Indebtedness
may later be classified as having been Incurred pursuant to any type of Indebtedness described in the first and second paragraphs of this covenant so long as such Indebtedness is permitted to be Incurred pursuant to such provision at the time of
reclassification; 
 (3) all Indebtedness outstanding on the Closing Date under the Packing Credit Facility and this Agreement
shall be deemed initially Incurred on the Closing Date under clause (a)(i) of this Section; 
 (4) Guarantee Obligations or
obligations in respect of letters of credit, bankers’ acceptances or other similar instruments relating to, or Liens securing, Indebtedness that is otherwise included in the determination of a particular amount of Indebtedness shall not be
included; 
 (5) if obligations in respect of letters of credit, bankers’ acceptances or other similar instruments are
Incurred pursuant to this Agreement and are being treated as Incurred pursuant to clauses (a), (k) or (l) of this Section or the first paragraph above and the letters of credit, bankers’ acceptances or other similar instruments
relate to other Indebtedness, then such other Indebtedness shall not be included; 
 (6) the principal amount of any
Disqualified Stock of the Borrower or a Restricted Subsidiary, or Preferred Stock of a Restricted Subsidiary, will be equal to the greater of the maximum mandatory redemption or repurchase price (not including, in either case, any redemption or
repurchase premium) or the liquidation preference thereof; 
 (7) Indebtedness permitted by this covenant need not be permitted
solely by reference to one provision permitting such Indebtedness but may be permitted in part by one such provision and in part by one or more other provisions of this covenant permitting such Indebtedness; and 

(8) the amount of Indebtedness issued at a price that is less than the principal amount thereof will be equal to the amount of the
liability in respect thereof determined on the basis of GAAP. 
 Accrual of interest, accrual of dividends, the accretion of
accreted value, the accretion or amortization of original issue discount, the payment of interest in the form of additional Indebtedness, the payment of dividends in the form of additional shares of Preferred Stock or Disqualified Stock or the
reclassification of commitments or obligations not treated as Indebtedness due to a change in GAAP, will not be deemed to be an Incurrence of Indebtedness for purposes of the covenant described under this Section. The amount of any Indebtedness
outstanding as of any date shall be (x) the accreted value thereof in the case of any Indebtedness issued with original issue discount and (y) the principal amount, or liquidation preference thereof, in the case of any other Indebtedness.

 If at any time an Unrestricted Subsidiary becomes a Restricted Subsidiary, any Indebtedness of such Subsidiary shall be
deemed to be Incurred by a Restricted Subsidiary of the Borrower as of such date (and, if such Indebtedness is not permitted to be Incurred as of such date under this Section, the Borrower shall be in breach of the covenant contained in this
Section 7.03). Notwithstanding any other provision in this Section 7.03, the maximum amount of Indebtedness that the Borrower or a Restricted Subsidiary may Incur pursuant to this Section shall not be deemed to be exceeded solely as
a result of fluctuations in the exchange rate of currencies. The principal amount of any Indebtedness Incurred to refinance other 

  
 -74-

 
Indebtedness, if Incurred in a different currency from the Indebtedness being refinanced, shall be calculated based on the currency exchange rate applicable to the currencies in which such
Refinancing Indebtedness is denominated that is in effect on the date of such refinancing. The Borrower will not, and will not permit any Guarantor to, directly or indirectly, Incur any Indebtedness (including Acquired Indebtedness) that is
subordinated or junior in right of payment to any Indebtedness of the Borrower or such Guarantor, as the case may be, unless such Indebtedness is expressly subordinated in right of payment to the Loans or such Guarantor’s Guarantee Obligations
to the extent and in the same manner as such Indebtedness is subordinated to other Indebtedness of the Borrower or such Guarantor, as the case may be, provided that for purposes of this Agreement, (1) unsecured Indebtedness shall not be
treated as subordinated or junior to Secured Indebtedness merely because it is unsecured and (2) senior Indebtedness shall not be treated as subordinated or junior to any other senior Indebtedness merely because it has a junior priority with
respect to the same collateral or is secured by different collateral. 
 Section 7.04
Fundamental Changes. Consolidate with or merge with or into, or sell, convey, assign, lease, transfer or otherwise Dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now
owned or hereafter acquired) to or in favor of any Person, unless: 
  

	 	(a)	With regards to the Borrower, 

 (i) the resulting, surviving or transferee Person (the “Successor Borrower”) will be a Person organized and existing under the laws of the United States of America, any State of the
United States or the District of Columbia and the Successor Borrower (if not the Borrower) will expressly assume, by an assumption agreement, executed and delivered to the Administrative Agent, in form reasonably satisfactory to the Administrative
Agent, all the obligations of the Borrower hereunder; 
 (ii) immediately after giving effect to such transaction
(and treating any Indebtedness that becomes an obligation of the Successor Borrower or any Subsidiary of the Successor Borrower as a result of such transaction as having been Incurred by the Successor Borrower or such Subsidiary at the time of such
transaction), no Default or Event of Default shall have occurred and be continuing; 
 (iii) immediately after
giving effect to such transaction, either (x) the Successor Borrower would be able to Incur at least an additional $1.00 of Indebtedness pursuant to Section 7.03 or (y) the Fixed Charge Coverage Ratio would not be lower than it
was immediately prior to giving effect to such transaction; and 
 (iv) the Borrower shall have delivered to the
Administrative Agent an Officer’s Certificate and an opinion in form and substance reasonably satisfactory to the Administrative Agent, each to the effect that such consolidation, merger or transfer complies with this Agreement. 

For purposes of this Section 7.04(a), the sale, lease, conveyance, assignment, transfer, or other disposition of all or
substantially all of the properties and assets of one or more Subsidiaries of the Borrower, which properties and assets, if held by the Borrower instead of such Subsidiaries, would constitute all or substantially all of the properties and assets of
the Borrower on a consolidated basis, shall be deemed to be the transfer of all or substantially all of the properties and assets of the Borrower. 

  
 -75-

 The Successor Borrower will succeed to, and be substituted for, and may exercise every right
and power of, the Borrower hereunder but in the case of a lease of all or substantially all its assets, the predecessor company will not be released from its obligations under this Agreement. 

Notwithstanding the foregoing clauses (ii) and (iii) (which do not apply to transactions referred to in this sentence),
(a) any Restricted Subsidiary of the Borrower may consolidate or otherwise combine with, merge into or transfer all or part of its properties and assets to the Borrower and (b) any Restricted Subsidiary may consolidate or otherwise combine
with, merge into or transfer all or part of its properties and assets to any other Restricted Subsidiary. Notwithstanding the preceding clauses (ii) and (iii) (which do not apply to the transactions referred to in this sentence), the
Borrower may consolidate or otherwise combine with or merge into an Affiliate incorporated or organized for the purpose of changing the legal domicile of the Borrower, reincorporating the Borrower in another jurisdiction, or changing the legal form
of the Borrower so long as the amount of Indebtedness is not increased thereby. The foregoing provisions (other than the requirements of the foregoing clause (ii)) shall not apply to the formation or organization of a new Subsidiary as a Restricted
Subsidiary of the Borrower. 
  

	 	(b)	With regards to the Guarantors, 

 (i) the other Person is the Borrower or any Restricted Subsidiary that is a Guarantor or becomes a Guarantor concurrently with the transaction; or 

(ii)(x) either (1) a Guarantor is the continuing Person or (2) the resulting, surviving or transferee Person
expressly assumes all of the obligations of the Guarantor hereunder; and (y) immediately after giving effect to the transaction, no Default has occurred and is continuing; or 

(iii) the transaction constitutes a sale or other disposition (including by way of consolidation or merger) of the
Guarantor or the sale or disposition of all or substantially all the assets of the Guarantor (in each case other than to the Borrower or a Restricted Subsidiary) otherwise permitted by this Agreement. 

Section 7.05 Dispositions. Make any Disposition unless: 

(a) the Borrower or any Restricted Subsidiary, as the case may be, receives consideration (including by way of relief from, or by any
other Person assuming responsibility for, any liabilities, contingent or otherwise) at least equal to the fair market value (such fair market value to be determined on the date of contractually agreeing to such Disposition), in each case, as
determined in good faith by the Board of Directors of the Borrower, of the shares and assets subject to such Disposition (including, for the avoidance of doubt, if such Disposition is a Permitted Asset Swap); 

(b) in any such Disposition, or series of related Dispositions (except to the extent the Disposition is a Permitted Asset Swap), at least
75% of the consideration from such Disposition (including by way of relief from, or by any other Person assuming responsibility for, any liabilities, contingent or otherwise) received by the Borrower or any Restricted Subsidiary, as the case may be,
is in the form of cash or Cash Equivalents; 
 (c) an amount equal to 100% of the Net Available Cash from such Disposition is
applied by the Borrower and the Restricted Subsidiaries (i) to prepay, repay or purchase any Indebtedness of a Non-Guarantor or Secured Indebtedness (in each case, other than Indebtedness owed to the Borrower or any Restricted Subsidiary)
within 365 days from the later of (x) the date of such Disposition and (y) the receipt of such Net Available Cash; provided, however, that, in connection with any prepayment, repayment or purchase of Indebtedness pursuant to
this clause (i), the Borrower or such Restricted 

  
 -76-

 
Subsidiary will retire such Indebtedness and will cause the related commitment (if any) to be reduced in an amount equal to the principal amount so prepaid, repaid or purchased; or (ii) to
prepay, repay or purchase Pari Passu Indebtedness at a price of no more than 100% of the principal amount of such Pari Passu Indebtedness plus accrued and unpaid interest to the date of such prepayment, repayment or purchase; provided,
however, that any such reinvestment in Additional Assets made pursuant to a definitive binding agreement or a commitment approved by the Board of Directors of the Borrower that is executed or approved within such time will satisfy this
requirement, so long as such investment is consummated within 180 days of such 365th day; provided that, pending the final application of any such Net Available Cash in accordance with clause (i) or clause (ii) above, the Borrower
and its Restricted Subsidiaries may temporarily reduce Indebtedness or otherwise use such Net Available Cash in any manner not prohibited by this Agreement; and 
 (d) with respect to any Disposition of property or assets from a Loan Party or iGate Global Solutions Limited to a Non-Guarantor, the amount received in respect of such Disposition is equal to the fair
market value on the date of the Disposition of the assets or property to such Non-Guarantor. 
 For the purposes of
Section 7.05(b), the following will be deemed to be cash: (1) the assumption by the transferee of Indebtedness or other liabilities contingent or otherwise of the Borrower or a Restricted Subsidiary (other than Subordinated
Indebtedness of the Borrower or a Guarantor) and the release of the Borrower or such Restricted Subsidiary from all liability on such Indebtedness or other liability in connection with such Disposition; (2) securities, notes or other
obligations received by the Borrower or any Restricted Subsidiary of the Borrower from the transferee that are converted by the Borrower or such Restricted Subsidiary into cash or Cash Equivalents within 180 days following the closing of such
Disposition; (3) Indebtedness (other than Subordinated Indebtedness) of any Restricted Subsidiary that is no longer a Restricted Subsidiary as a result of such Disposition, to the extent that the Borrower and each other Restricted Subsidiary
are released from any Guarantee Obligations in respect of payment of such Indebtedness in connection with such Disposition; (4) consideration consisting of Indebtedness of the Borrower (other than Subordinated Indebtedness) received after the
Closing Date from Persons who are not the Borrower or any Restricted Subsidiary; and (5) any Designated Non-Cash Consideration received by the Borrower or any Restricted Subsidiary in such Dispositions having an aggregate fair market value,
taken together with all other Designated Non-Cash Consideration received pursuant to this covenant that is at that time outstanding, not to exceed the greater of $25,000,000 and 1.25% of Total Assets (with the fair market value of each item of
Designated Non-Cash Consideration being measured at the time received and without giving effect to subsequent changes in value). 
 For the avoidance of doubt, the Borrower shall not be permitted to purchase any Senior Notes pursuant to this Section 7.05. In addition, notwithstanding anything to the contrary in this
Agreement, the Borrower shall not, and shall not permit any of its Subsidiaries to, sell, transfer, convey or otherwise dispose of any Equity Interests in Patni Computers Systems Limited unless, after giving effect thereto, the Borrower owns,
directly or indirectly, not less than 51% of the Equity Interests thereof, unless otherwise consented to by the Lenders in accordance with Section 10.01. 
 Section 7.06 Restricted Payments. (a) Declare or pay any dividend or make any distribution on or in respect of the Borrower’s or any Restricted
Subsidiary’s Capital Stock (including any payment in connection with any merger or consolidation involving the Borrower or any of its Restricted Subsidiaries) except (i) dividends or distributions payable in Capital Stock of the Borrower
(other than Disqualified Stock) or in options, warrants or other rights to purchase such Capital Stock of the Borrower and (ii) dividends or distributions payable to the Borrower or a Restricted Subsidiary (and, in the case of any such
Restricted Subsidiary making such dividend or distribution, to holders of its Capital Stock other than the Borrower or another Restricted Subsidiary on no more than a pro rata basis); (b) purchase, redeem, retire or otherwise acquire for
value any Capital Stock of the Borrower or any Parent of the Borrower held by 

  
 -77-

 
Persons other than the Borrower or a Restricted Subsidiary of the Borrower; (c) purchase, repurchase, redeem, defease or otherwise acquire or retire for value, prior to scheduled maturity,
scheduled repayment or scheduled sinking fund payment, any Subordinated Indebtedness (other than (x) any such purchase, repurchase, redemption, defeasance or other acquisition or retirement or in anticipation of satisfying a sinking fund
obligation, principal installment or final maturity, in each case, due within one year of the date of purchase, repurchase, redemption, defeasance or other acquisition or retirement and (y) any Indebtedness Incurred pursuant to
Section 7.03(c)); or (d) make any Restricted Investment (any such dividend, distribution, purchase, redemption, repurchase, defeasance, other acquisition, retirement or Restricted Investment referred to in clauses (a) through
(d) are referred to herein as a “Restricted Payment”), if at the time the Borrower or such Restricted Subsidiary makes such Restricted Payment: 
 (1) a Default shall have occurred and be continuing (or would result immediately thereafter therefrom); 
 (2) the Borrower is not able to Incur an additional $1.00 of Indebtedness pursuant to Section 7.03 after giving effect, on a pro forma basis, to such Restricted Payment; or 

(3) the aggregate amount of such Restricted Payment and all other Restricted Payments made subsequent to the Closing Date (and not
returned or rescinded) (including Permitted Payments permitted pursuant to clauses (a), (f), (i) and (j) in the definition of “Permitted Payments”) would exceed the sum of (without duplication) (i) 50% of Consolidated
Net Income for the period (treated as one accounting period) from the first day of the first fiscal quarter commencing after January 1, 2011 to the end of the most recent fiscal quarter ending prior to the date of such Restricted Payment for
which internal consolidated financial statements of the Borrower are available (or, in the case such Consolidated Net Income is a deficit, minus 100% of such deficit); (ii) 100% of the aggregate Net Cash Proceeds, and the fair market value of
property or assets or marketable securities, received by the Borrower from the issue or sale of its Capital Stock (other than Disqualified Stock or Designated Preferred Stock) subsequent to the Closing Date or otherwise contributed to the equity
(other than through the issuance of Disqualified Stock or Designated Preferred Stock) of the Borrower subsequent to the Closing Date (other than (x) Net Cash Proceeds or property or assets or marketable securities received from an issuance or
sale of such Capital Stock to a Restricted Subsidiary or an employee stock ownership plan or trust established by the Borrower or any Subsidiary of the Borrower for the benefit of its employees to the extent funded by the Borrower or any Restricted
Subsidiary, (y) Net Cash Proceeds or property or assets or marketable securities to the extent that any Restricted Payment has been made from such proceeds in reliance on clause (f) of the definition of “Permitted Payment” and
(z) Excluded Contributions); (iii) 100% of the aggregate Net Cash Proceeds, and the fair market value, as determined in good faith by the Board of Directors of the Borrower, of property or assets or marketable securities, received by the
Borrower or any Restricted Subsidiary from the issuance or sale (other than to the Borrower or a Restricted Subsidiary of the Borrower or an employee stock ownership plan or trust established by the Borrower or any Subsidiary of the Borrower for the
benefit of their employees to the extent funded by the Borrower or any Restricted Subsidiary) by the Borrower or any Restricted Subsidiary subsequent to the Closing Date of any Indebtedness, Disqualified Stock or Designated Preferred Stock that has
been converted into or exchanged for Capital Stock of the Borrower (other than Disqualified Stock or Designated Preferred Stock) plus the amount of any cash, and the fair market value of property or assets or marketable securities (other than the
securities so converted or exchanged), received by the Borrower or any Restricted Subsidiary upon such conversion or exchange; (iv) 100% of the aggregate amount received in cash and the fair market value, as determined in good faith by the
Board of Directors of the Borrower, of marketable securities or other property received by means of: (a) the sale or other Disposition (other than to the Borrower or a Restricted Subsidiary) of Restricted Investments made by the Borrower or its
Restricted Subsidiaries and repurchases and redemptions of such Restricted Investments from the Borrower or its Restricted Subsidiaries and repayments of loans or advances, and releases of guarantees,

  
 -78-

 
which constitute Restricted Investments by the Borrower or its Restricted Subsidiaries (other than in each case to the extent such Restricted Investment was made pursuant to clauses (j) and
(o) in the definition of “Permitted Payments” or (b) a dividend from an Unrestricted Subsidiary; and (v) in the case of the re-designation of an Unrestricted Subsidiary as a Restricted Subsidiary or the merger or
consolidation of an Unrestricted Subsidiary into the Issuer or a Restricted Subsidiary or the transfer of all or substantially all of the assets of an Unrestricted Subsidiary to the Issuer or a Restricted Subsidiary, the fair market value of the
Investment in such Unrestricted Subsidiary (or the assets transferred), as determined in good faith by the Board of Directors of the Borrower at the time of the re-designation of such Unrestricted Subsidiary as a Restricted Subsidiary or at the time
of such merger or consolidation or transfer of assets (after taking into consideration any Indebtedness associated with the Unrestricted Subsidiary so designated or merged or consolidated or Indebtedness associated with the assets so transferred),
other than to the extent of the amount of the Investment in such Unrestricted Subsidiary made by the Issuer or a Restricted Subsidiary pursuant to clauses (j) and (o) in the definition of “Permitted Payments” or to the extent of
the amount of the Investment that constituted a Permitted Investment. 
 Notwithstanding anything contained herein to the
contrary, the foregoing provisions will not prohibit any Permitted Payments. The amount of all Restricted Payments (other than cash) shall be the fair market value on the date of such Restricted Payment of the asset(s) or securities proposed to be
paid, transferred or issued by the Borrower or such Restricted Subsidiary, as the case may be, pursuant to such Restricted Payment. The fair market value of any cash Restricted Payment shall be its face amount, and the fair market value of any
non-cash Restricted Payment, property or assets other than cash shall be determined conclusively by the Board of Directors of the Borrower acting in good faith. 
 Section 
7.07 [RESERVED]. 
 Section 7.08 Transactions with Affiliates. Enter into or
conduct any transaction (including the purchase, sale, lease or exchange of any property or the rendering of any service) with any Affiliate of the Borrower (an “Affiliate Transaction”) involving aggregate value in excess of
$10,000,000 unless: 
 (a) the terms of such Affiliate Transaction taken as a whole are not materially less favorable to the
Borrower or such Restricted Subsidiary, as the case may be, than those that could be obtained in a comparable transaction at the time of such transaction or the execution of the agreement providing for such transaction in arm’s length dealings
with a Person who is not such an Affiliate; and 
 (b) in the event such Affiliate Transaction involves an aggregate value in
excess of $25,000,000, the terms of such transaction have been approved by a majority of the members of the Board of Directors. 

Any Affiliate Transaction shall be deemed to have satisfied the requirements set forth in Section 7.08(b) if such Affiliate
Transaction is approved by a majority of the Disinterested Directors, if any. The provisions of this Section 7.08 shall not apply to: 
 (1) any Restricted Payment permitted to be made pursuant to Section 7.06 or any Permitted Investment (other than clauses (1)(b) and (2) of the definition thereof); 

(2) any issuance or sale of Capital Stock, options, other equity-related interests or other securities, or other payments, awards or
grants in cash, securities or otherwise pursuant to, or the funding of, or entering into, or maintenance of, any employment, consulting, collective bargaining or benefit plan, program, agreement or arrangement, related trust or other similar
agreement and other compensation arrangements, options, warrants or other rights to purchase Capital Stock of the Borrower, any Restricted Subsidiary or any Parent, restricted stock plans, long-term incentive plans, stock appreciation rights plans,

  
 -79-

 
participation plans or similar employee benefits or consultants’ plans (including valuation, health, insurance, deferred compensation, severance, retirement, savings or similar plans,
programs or arrangements) or indemnities provided on behalf of officers, employees, directors or consultants approved by the Board of Directors of the Borrower, in each case in the ordinary course of business; 

(3) any Management Advances and any waiver or transaction with respect thereto; 

(4) any transaction between or among the Borrower and any Restricted Subsidiary (or entity that becomes a Restricted Subsidiary as a
result of such transaction), or between or among Restricted Subsidiaries; 
 (5) the entry into and performance of obligations
of the Borrower or any of its Restricted Subsidiaries under the terms of any transaction arising out of, and any payments pursuant to or for purposes of funding, any agreement or instrument in effect as of or on the Closing Date, as these agreements
and instruments may be amended, modified, supplemented, extended, renewed or refinanced from time to time in accordance with the other terms of this Section or to the extent not more disadvantageous to the Lenders in any material respect;

 (6) any customary transaction with a Securitization Subsidiary effected as part of a Qualified Securitization Financing;

 (7) transactions with customers, clients, suppliers or purchasers or sellers of goods or services, in each case in the
ordinary course of business, which are fair to the Borrower or the relevant Restricted Subsidiary in the reasonable determination of the Board of Directors or the senior management of the Borrower or the relevant Restricted Subsidiary, or are on
terms no less favorable than those that could reasonably have been obtained at such time from an unaffiliated party; 
 (8) any
transaction between or among the Borrower or any Restricted Subsidiary and any Affiliate of the Borrower or an Associate or similar entity that would constitute an Affiliate Transaction solely because the Borrower or a Restricted Subsidiary owns an
equity interest in or otherwise controls such Affiliate, Associate or similar entity; provided that such transaction would not otherwise be prohibited by this Agreement; 

(9) issuances or sales of Capital Stock (other than Disqualified Stock or Designated Preferred Stock) of the Borrower or options,
warrants or other rights to acquire such Capital Stock and the granting of registration and other customary rights in connection therewith or any contribution to capital of the Borrower or any Restricted Subsidiary (other than Disqualified Stock,
Designated Preferred Stock or Excluded Contributions); 
 (10) without duplication in respect of payments made pursuant to
clause (11) of this Section, (a) payments by the Borrower or any Restricted Subsidiary to any Permitted Holder (whether directly or indirectly) of annual customary management, consulting, monitoring or advisory fees and related expenses
and (b) customary payments by the Borrower or any Restricted Subsidiary to any Permitted Holder (whether directly or indirectly) for financial advisory, financing, underwriting or placement services or in respect of other investment banking
activities, including in connection with acquisitions or divestitures, which payments are approved by a majority of the Board of Directors in good faith; provided, however, that such payments, pursuant to this clause (10) do not exceed
$2,500,000 per calendar year; 

  
 -80-

 (11) payment to any Permitted Holder of all reasonable out of pocket expenses Incurred by
such Permitted Holder in connection with its direct or indirect investment in the Borrower and their Subsidiaries; 
 (12) the
Transactions and the payment of all fees and expenses related to the Transactions; 
 (13) transactions in which the Borrower or
any Restricted Subsidiary, as the case may be, delivers to the Administrative Agent a letter from an Independent Financial Advisor stating that such transaction is fair to the Borrower or such Restricted Subsidiary from a financial point of view or
meets the requirements of Section 7.08(a); 
 (14) the existence of, or the performance by the Borrower or any
Restricted Subsidiaries of its obligations under the terms of, any equity holders agreement (including any registration rights agreement or purchase agreements related thereto) to which it is party as of the Closing Date and any similar agreement
that it may enter into thereafter; provided, however, that the existence of, or the performance by the Borrower or any Restricted Subsidiary of its obligations under any future amendment to the equity holders’ agreement or under
any similar agreement entered into after the Closing Date will only be permitted under this clause to the extent that the terms of any such amendment or new agreement are not otherwise disadvantageous to the Lenders in any material respects; and

 (15) any purchases by the Borrower’s Affiliates of Indebtedness or Disqualified Stock of the Borrower or any of its
Restricted Subsidiaries the majority of which Indebtedness or Disqualified Stock is purchased by Persons who are not the Borrower’s Affiliates; provided that such purchases by the Borrower’s Affiliates are on the same terms as such
purchases by such Persons who are not the Borrower’s Affiliates. 
 Section 7.09
Limitation on Restrictions on Distributions from Restricted Subsidiaries. Create or otherwise cause or permit to exist or become effective any consensual encumbrance or consensual restriction on the ability of any Restricted Subsidiary to
(a) pay dividends or make any other distributions in cash or otherwise on its Capital Stock or pay any Indebtedness or other obligations owed to the Borrower or any Restricted Subsidiary; (b) make any loans or advances to the Borrower or
any Restricted Subsidiary; or (c) sell, lease or transfer any of its property or assets to the Borrower or any Restricted Subsidiary; provided that (x) the priority of any Preferred Stock in receiving dividends or liquidating
distributions prior to dividends or liquidating distributions being paid on common stock and (y) the subordination of (including the application of any standstill requirements to) loans or advances made to the Borrower or any Restricted
Subsidiary to other Indebtedness Incurred by the Borrower or any Restricted Subsidiary shall not be deemed to constitute such an encumbrance or restriction. 
 Notwithstanding anything contained herein, the following shall not be prohibited by this Section 7.09: 
 (1) any encumbrance or restriction pursuant to (a) any Credit Facility or the documents governing the Senior Notes or (b) any other agreement or instrument, in each case, in effect at or entered
into on the Closing Date; 
 (2) any encumbrance or restriction pursuant to an agreement or instrument of a Person or relating
to any Capital Stock or Indebtedness of a Person, entered into on or before the date on which such Person was acquired by or merged, consolidated or otherwise combined with or into the Borrower or any Restricted Subsidiary, or was designated as a
Restricted Subsidiary or on which such agreement or instrument is assumed by the Borrower or any Restricted Subsidiary in connection with an acquisition of assets (other than Capital Stock or Indebtedness Incurred as consideration in, or to provide
all or any 

  
 -81-

 
portion of the funds utilized to consummate, the transaction or series of related transactions pursuant to which such Person became a Restricted Subsidiary or was acquired by the Borrower or was
merged, consolidated or otherwise combined with or into the Borrower or any Restricted Subsidiary or entered into in contemplation of or in connection with such transaction) and outstanding on such date; provided that, for the purposes of
this clause, if another Person is the Successor Borrower, any Subsidiary thereof or agreement or instrument of such Person or any such Subsidiary shall be deemed acquired or assumed by the Borrower or any Restricted Subsidiary when such Person
becomes the Successor Borrower; 
 (3) any encumbrance or restriction (a) that restricts in a customary manner the
subletting, assignment or transfer of any property or asset that is subject to a lease, license or similar contract, or the assignment or transfer of any lease, license or other contract; (b) contained in mortgages, pledges, charges or other
security agreements permitted under this Agreement or securing Indebtedness of the Borrower or a Restricted Subsidiary permitted under this Agreement to the extent such encumbrances or restrictions restrict the transfer of the property or assets
subject to such mortgages, pledges, charges or other security agreements; or (c) pursuant to customary provisions restricting dispositions of real property interests set forth in any reciprocal easement agreements of the Borrower or any
Restricted Subsidiary; 
 (4) any encumbrance or restriction pursuant to Purchase Money Obligations and Capitalized Lease
Obligations permitted under this Agreement, in each case, that impose encumbrances or restrictions on the property so acquired or any encumbrance; 
 (5) any encumbrance or restriction with respect to a Restricted Subsidiary (or any of its property or assets) imposed pursuant to an agreement entered into for the direct or indirect sale or disposition
to a Person of all or substantially all the Capital Stock or assets of such Restricted Subsidiary (or the property or assets that are subject to such restriction) pending the closing of such sale or disposition; 

(6) customary provisions in leases, licenses, joint venture agreements and other similar agreements and instruments entered into in the
ordinary course of business; 
 (7) encumbrances or restrictions arising or existing by reason of applicable law or any
applicable rule, regulation or order, or required by any regulatory authority; 
 (8) any encumbrance or restriction on cash or
other deposits or net worth imposed by customers under agreements entered into in the ordinary course of business; 
 (9) any
encumbrance or restriction pursuant to Hedging Obligations; 
 (10) restrictions created in connection with any Qualified
Securitization Financing that, in the good faith determination of the Borrower, are necessary or advisable to effect such Securitization Facility and that apply to such Securitization Subsidiary; 

(11) any encumbrance or restriction arising pursuant to an agreement or instrument relating to any Indebtedness permitted to be Incurred
subsequent to the Closing Date pursuant to Section 7.03 if the encumbrances and restrictions contained in any such agreement or instrument taken as a whole are not materially less favorable to the Lenders than (a) the encumbrances
and restrictions contained in this Agreement, together with the security documents associated therewith as in effect on the Closing Date or (b) in comparable financings (as determined in good faith by the Borrower) and where, in the case of
clause (b), either (i) the Borrower determines at the time of issuance of such Indebtedness that such encumbrances or restrictions will not adversely affect, in any material respect, the Borrower’s ability to

  
 -82-

 
make principal or interest payments on the Indebtedness, including the Senior Notes, or (ii) such encumbrance or restriction applies only during the continuance of a default in respect of a
payment or financial maintenance covenant relating to such Indebtedness; 
 (12) any encumbrance or restriction existing by
reason of any lien permitted under Section 7.01; or 
 (13) any encumbrance or restriction pursuant to an agreement
or instrument effecting a refinancing of Indebtedness Incurred pursuant to, or that otherwise refinances, an agreement or instrument referred to in clauses (1) or (2) of this paragraph or this clause (an “Initial
Agreement”) or contained in any amendment, supplement or other modification to an agreement referred to in clauses (1) or (2) of this paragraph or this clause (13); provided, however, that the encumbrances and
restrictions with respect to such Restricted Subsidiary contained in any such agreement or instrument are no less favorable in any material respect to the Lenders taken as a whole than the encumbrances and restrictions contained in the Initial
Agreement or Initial Agreements to which such refinancing or amendment, supplement or other modification relates (as determined in good faith by the Borrower). 
 ARTICLE VIII 

Events of Default and Remedies 

Section 8.01 Events of Default. Any of the following events referred to in any of clauses
(a) through (m) inclusive of this Section 8.01 shall constitute an “Event of Default”: 
 (a) Non-Payment. Any Loan Party fails to pay (i) when and as required to be paid herein, any amount of principal of any Loan or (ii) within five (5) Business Days after the same
becomes due, any interest on any Loan or any other amount payable hereunder or with respect to any other Loan Document; or 
 (b) Specific Covenants. The Borrower, the Company or any Restricted Subsidiary fails to perform or observe any term, covenant or agreement contained in any of Section 6.03(a) or
Section 6.05 (solely with respect to the Borrower), Section 6.12, Section 6.14 or Article VII (other than Section 7.08); or 

(c) Other Defaults. The Borrower, the Company or any Restricted Subsidiary fails to perform or observe any other
covenant or agreement (not specified in Section 8.01(a) or (b) above) contained in any Loan Document on its part to be performed or observed and such failure continues for thirty (30) days after receipt by Borrower of
written notice thereof by the Administrative Agent or the Required Lenders; or 
 (d) Representations and
Warranties. Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of any Loan Party herein, in any other Loan Document, or in any document required to be delivered in connection herewith or
therewith shall be incorrect or misleading in any material respect when made or deemed made unless the circumstances giving rise to the foregoing are capable of being remedied and such representation, warranty, certification or statement of fact is
corrected within thirty (30) days after receipt by Borrower of written notice thereof by the Administrative Agent or the Required Lenders; or 
 (e) Cross-Default. Any Loan Party or any Restricted Subsidiary (A) fails to make any payment beyond the applicable grace period with respect thereto, if any (whether by scheduled maturity,
required prepayment, acceleration, demand, or otherwise) in respect of any 

  
 -83-

 
Indebtedness (other than Indebtedness hereunder) having an aggregate principal amount of not less than the Threshold Amount, or (B) fails to observe or perform any other agreement or
condition relating to any such Indebtedness, or any other event occurs (other than, with respect to Indebtedness consisting of Swap Contracts, termination events or equivalent events, pursuant to the terms of such Swap Contracts), the effect of
which default or other event is to cause, or to permit the holder or holders of such Indebtedness (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, with the giving of notice if required, all such
Indebtedness to become due or to be repurchased, prepaid, defeased or redeemed (automatically or otherwise), or an offer to repurchase, prepay, defease or redeem all such Indebtedness to be made, prior to its stated maturity; provided that
this clause (e)(B) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Indebtedness, if such sale or transfer is permitted hereunder and under the
documents providing for such Indebtedness; provided further that such failure is unremedied and is not waived by the holders of such Indebtedness; or 

(f) Insolvency Proceedings, Etc. Any Loan Party or any Material Subsidiary (or group of Restricted Subsidiaries
that together would constitute a Material Subsidiary) institutes or consents to the institution of any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any
receiver, interim receiver, receiver and manager, trustee, custodian, conservator, liquidator, rehabilitator, administrator, administrative receiver, compulsory manager or similar officer in any jurisdiction for it or for all or any material part of
its property; or any receiver, interim receiver, receiver and manager, trustee, custodian, conservator, liquidator, rehabilitator, administrator, administrative receiver, compulsory manager or similar officer in any jurisdiction is appointed without
the application or consent of such Person and the appointment continues undischarged or unstayed for sixty (60) calendar days; or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material part of its
property is instituted without the consent of such Person and continues undismissed or unstayed for sixty (60) calendar days; or an order for relief is entered in any such proceeding; or 

(g) Inability to Pay Debts; Attachment. (i) The Borrower, the Company or any Material Subsidiary (or any group
of Restricted Subsidiaries that together would constitute a Material Subsidiary) becomes unable to, admits in writing its inability to or fails generally to pay its debts in excess of the Threshold Amount as they become due, or (ii) any writ or
warrant of attachment or execution or similar process is issued or levied against all or any material part of the property, taken as a whole, of the Borrower, the Company or the Restricted Subsidiaries and such judgment or order shall not have been
satisfied, vacated or fully bonded within sixty (60) days after its issue or levy; or 
 (h)
Judgments. There is entered against any Loan Party or any Restricted Subsidiary a final judgment or order for the payment of money in an aggregate amount exceeding the Threshold Amount (to the extent not covered by independent third-party
insurance) and such judgment or order shall not have been satisfied, vacated, discharged or stayed or bonded pending an appeal for a period of sixty (60) consecutive days; or 

(i) ERISA. (i) An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which has resulted
or could reasonably be expected to result in liability of any Loan Party or ERISA Affiliate under Title IV of ERISA in an aggregate amount which could reasonably be expected to result in a Material Adverse Effect, (ii) any Loan Party or any
ERISA Affiliate fails to pay when due, after the expiration of any applicable grace period, any installment payment with respect to its Withdrawal Liability under Section 4201 of ERISA under a

  
 -84-

 
Multiemployer Plan in an aggregate amount which could reasonably be expected to result in a Material Adverse Effect, (iii) any Loan Party or any ERISA Affiliate shall have been notified by
the sponsor of a Multiemployer Plan that such Multiemployer Plan is in reorganization or is being terminated, within the meaning of Title IV of ERISA, and as a result of such reorganization or termination the aggregate annual contributions of the
Loan Parties and the ERISA Affiliates to all Multiemployer Plans that are then in reorganization or being terminated have been or will be increased over the amounts contributed to such Multiemployer Plans for the plan years of such Multiemployer
Plans immediately preceding the plan year in which such reorganization or termination occurs by an aggregate amount which could reasonably be expected to result in a Material Adverse Effect; or (iv) a termination, withdrawal or noncompliance
with applicable law or plan terms or termination, withdrawal or other event similar to an ERISA Event occurs with respect to a Foreign Plan that could reasonably be expected to result in a Material Adverse Effect; or 

(j) [Reserved].; or 
 (k) Change of Control. There occurs any Change of Control; or 
 (l) [Reserved]. 
 Section 8.02
Remedies upon Event of Default. If any Event of Default occurs and is continuing, the Administrative Agent may and, at the request of the Required Lenders, shall take any or all of the following actions: 

(a) declare the commitment of each Lender to make Loans to be terminated, whereupon such commitments and obligation shall
be terminated; 
 (b) declare the unpaid principal amount of all outstanding Loans, all interest accrued and
unpaid thereon, and all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the
Borrower; and 
 (c) [Reserved]. 

(d) exercise on behalf of itself and the Lenders all rights and remedies available to it and the Lenders under the Loan
Documents or applicable Law; 
 provided that upon the occurrence of an Event of Default under Section 8.01(f) or
(g) with respect to the Borrower, the obligation of each Lender to make Loans shall automatically terminate, the unpaid principal amount of all outstanding Loans and all interest and other amounts as aforesaid shall automatically become
due and payable, in each case without further act of the Administrative Agent or any Lender. 

Section 8.03 Exclusion of Immaterial Subsidiaries. Solely for the purpose of determining whether
a Default has occurred under clause (f) or (g) of Section 8.01, any reference in any such clause to any Restricted Subsidiary or Loan Party shall be deemed not to include any Immaterial Subsidiary affected by any
event or circumstances referred to in any such clause unless the Billings of such Immaterial Subsidiary together with the Billings of all other Immaterial Subsidiaries affected by such event or circumstance referred to in such clause, shall exceed
5% of the aggregate Billings for the most recently completed Test Period of Borrower and the Restricted Subsidiaries. 

  
 -85-

 Section 8.04 Application of Funds. If the
circumstances described in Section 2.12(g) have occurred, or after the exercise of remedies provided for in Section 8.02, including in any bankruptcy or insolvency proceeding, any amounts received on account of the
Obligations shall be applied by the Administrative Agent in the following order: 
 First, to payment of
that portion of the Obligations constituting fees, indemnities, expenses and other amounts (other than principal and interest, but including Attorney Costs payable under Section 10.04 and amounts payable under Article III)
payable to each Agent in its capacity as such; 
 Second, to payment of that portion of the Obligations
constituting fees, indemnities and other amounts (other than principal and interest) payable to the Lenders (including Attorney Costs payable under Section 10.04 and amounts payable under Article III), ratably among them in
proportion to the amounts described in this clause Second payable to them; 
 Third, to payment of
that portion of the Obligations constituting accrued and unpaid interest (including, but not limited to, post-petition interest), ratably among the Lenders in proportion to the respective amounts described in this clause Third payable to
them; 
 Fourth, to payment of that portion of the Obligations constituting unpaid principal, or face
amounts of the Loans, ratably among the Secured Parties in proportion to the respective amounts described in this clause Fourth held by them; 
 Fifth, to the payment of all other Obligations of the Loan Parties that are due and payable to the Administrative Agent and the other Secured Parties on such date, ratably based upon the respective
aggregate amounts of all such Obligations owing to the Administrative Agent and the other Secured Parties on such date; and 
 Last, the balance, if any, after all of the Obligations have been indefeasibly paid in full, to the Borrower or as otherwise required by Law. 

ARTICLE IX 
 Administrative Agent and Other Agents 
 
Section 9.01 Appointment and Authorization of Agents. 
 (a) Each Lender hereby irrevocably appoints, designates
and authorizes the Administrative Agent to take such action on its behalf under the provisions of this Agreement and each other Loan Document and to exercise such powers and perform such duties as are expressly delegated to it by the terms of this
Agreement or any other Loan Document, together with such powers as are reasonably incidental thereto. Notwithstanding any provision to the contrary contained elsewhere herein or in any other Loan Document, the Administrative Agent shall have no
duties or responsibilities, except those expressly set forth herein, nor shall the Administrative Agent have or be deemed to have any fiduciary relationship with any Lender or participant, and no implied covenants, functions, responsibilities,
duties, obligations or liabilities shall be read into this Agreement or any other Loan Document or otherwise exist against the Administrative Agent. Without limiting the generality of the foregoing sentence, the use of the term “agent”
herein and in the other Loan Documents with reference to any Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead, such term is used merely as a matter
of market custom, and is intended to create or reflect only an administrative relationship between independent contracting parties. 

  
 -86-

 (b) [RESERVED]. 
 (c) [Reserved]. 
 Section 9.02 [Reserved].

 Section 9.03 Delegation of Duties. The Agents may execute any of its duties under
this Agreement or any other Loan Document by or through Affiliates, agents, employees or attorneys-in-fact, such sub-agents as shall be deemed necessary by the Agents, and shall be entitled to advice of counsel, both internal and external, and other
consultants or experts concerning all matters pertaining to such duties. The Agents shall not be responsible for the negligence or misconduct of any agent or sub-agent or attorney-in-fact that it selects in the absence of gross negligence or willful
misconduct. 
 Section 9.04 Liability of Agents. No Agent-Related Person shall
(a) be liable to any Lender for any action taken or omitted to be taken by any of them under or in connection with this Agreement or any other Loan Document or the transactions contemplated hereby (except for its own gross negligence or willful
misconduct, as determined by the final judgment of a court of competent jurisdiction, in connection with its duties expressly set forth herein), or (b) be responsible in any manner to any Lender or participant for any recital, statement,
representation or warranty made by any Loan Party or any officer thereof, contained herein or in any other Loan Document, or in any certificate, report, statement or other document referred to or provided for in, or received by the Administrative
Agent under or in connection with, this Agreement or any other Loan Document, or the validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Loan Document, or for any failure of any Loan Party or any other
party to any Loan Document to perform its obligations hereunder or thereunder. No Agent-Related Person shall be under any obligation to any Lender or participant to ascertain or to inquire as to the observance or performance of any of the agreements
contained in, or conditions of, this Agreement or any other Loan Document, or to inspect the properties, books or records of any Loan Party or any Affiliate thereof. 
 Section 9.05 Reliance by Agents. 
 (a)
Each Agent shall be entitled to rely, and shall be fully protected in relying, upon any writing, communication, signature, resolution, representation, notice, consent, certificate, affidavit, letter, telegram, facsimile, telex or telephone message,
electronic mail message, statement or other document or conversation believed by it to be genuine and correct and to have been signed, sent or made by the proper Person or Persons, and upon advice and statements of legal counsel (including counsel
to any Loan Party), independent accountants and other experts selected by such Agent. Each Agent shall be fully justified in failing or refusing to take any action under any Loan Document unless it shall first receive such advice or concurrence of
the Required Lenders as it deems appropriate and, if it so requests, it shall first be indemnified to its satisfaction by the Lenders against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any
such action. Each Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement or any other Loan Document in accordance with a request or consent of the Required Lenders (or such greater number of Lenders
as may be expressly required hereby in any instance) and such request and any action taken or failure to act pursuant thereto shall be binding upon all the Lenders. 
 (b) For purposes of determining compliance with the conditions specified in Section 4.01, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted
or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed
Closing Date specifying its objection thereto. 

  
 -87-

 Section 9.06 Notice of Default. The
Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default, except with respect to defaults in the payment of principal, interest and fees required to be paid to the Administrative Agent for the account of
the Lenders, unless the Administrative Agent shall have received written notice from a Lender or the Borrower referring to this Agreement, describing such Default and stating that such notice is a “notice of default.” The Administrative
Agent will notify the Lenders of its receipt of any such notice. The Administrative Agent shall take such action with respect to any Event of Default as may be directed by the Required Lenders in accordance with Article VIII; provided
that unless and until the Administrative Agent has received any such direction, the Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Event of Default as it shall
deem advisable or in the best interest of the Lenders. 
 Section 9.07 Credit Decision;
Disclosure of Information by Agents. Each Lender acknowledges that no Agent-Related Person has made any representation or warranty to it, and that no act by any Agent hereafter taken, including any consent to and acceptance of any assignment or
review of the affairs of any Loan Party or any Affiliate thereof, shall be deemed to constitute any representation or warranty by any Agent-Related Person to any Lender as to any matter, including whether Agent-Related Persons have disclosed
material information in their possession. Each Lender represents to each Agent that it has, independently and without reliance upon any Agent-Related Person and based on such documents and information as it has deemed appropriate, made its own
appraisal of and investigation into the business, prospects, operations, property, financial and other condition and creditworthiness of the Loan Parties and its Subsidiaries, and all applicable bank or other regulatory Laws relating to the
transactions contemplated hereby, and made its own decision to enter into this Agreement and to extend credit to the Borrower and the other Loan Parties hereunder. Each Lender also represents that it will, independently and without reliance upon any
Agent-Related Person and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Loan
Documents, and to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of the Borrower and the other Loan Parties. Except for notices,
reports and other documents expressly required to be furnished to the Lenders by any Agent herein, such Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, prospects,
operations, property, financial and other condition or creditworthiness of any of the Loan Parties or any of their respective Affiliates which may come into the possession of any Agent-Related Person. 

Section 9.08 Indemnification of Agents and Expense Reimbursement. Whether or not the
transactions contemplated hereby are consummated, the Lenders shall indemnify upon demand each Agent-Related Person (to the extent not reimbursed by or on behalf of any Loan Party and without limiting the obligation of any Loan Party to do so),
pro rata, and hold harmless each Agent-Related Person from and against any and all Indemnified Liabilities incurred by it; provided that no Lender shall be liable for the payment to any Agent-Related Person of any portion of such
Indemnified Liabilities resulting from such Agent-Related Person’s own gross negligence or willful misconduct, as determined by the final judgment of a court of competent jurisdiction; provided that no action taken in accordance with the
directions of the Required Lenders (or such other number or percentage of the Lenders as shall be required by the Loan Documents) shall be deemed to constitute gross negligence or willful misconduct for purposes of this Section 9.08. In
the case of any investigation, litigation or proceeding giving rise to any Indemnified Liabilities, this Section 9.08 applies whether any such investigation, litigation or proceeding is brought by any Lender or any other Person. Without
limitation of the foregoing, each Lender shall reimburse the Administrative Agent upon demand for its ratable share of any costs or out-of-pocket expenses (including Attorney Costs) incurred by the Administrative Agent in connection with the
preparation, execution, delivery, administration, modification, amendment or enforcement (whether 

  
 -88-

 
through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or responsibilities under, this Agreement, any other Loan Document, or any document contemplated by
or referred to herein, to the extent that the Administrative Agent is not reimbursed for such expenses by or on behalf of the Borrower, provided that such reimbursement by the Lenders shall not affect the Borrower’s continuing
reimbursement obligations with respect thereto, if any. The undertaking in this Section 9.08 shall survive termination of the Aggregate Commitments, the payment of all other Obligations and the resignation of the Administrative Agent.

 Section 9.09 Agents in Their Individual Capacities. DBS and its Affiliates may
make loans to, issue letters of credit for the account of, accept deposits from, acquire Equity Interests in and generally engage in any kind of banking, trust, financial advisory, underwriting or other business with each of the Loan Parties and
their respective Affiliates as though DBS were not the Administrative Agent hereunder and without notice to or consent of the Lenders. The Lenders acknowledge that, pursuant to such activities, DBS or its Affiliates may receive information regarding
any Loan Party or any Affiliate of a Loan Party (including information that may be subject to confidentiality obligations in favor of such Loan Party or such Affiliate) and acknowledge that the Administrative Agent shall be under no obligation to
provide such information to them. With respect to its Loans, DBS shall have the same rights and powers under this Agreement as any other Lender and may exercise such rights and powers as though it were not the Administrative Agent. 

Section 9.10 Successor Agents. The Administrative Agent may resign as the Administrative Agent
upon thirty (30) days’ notice to the Lenders and Borrower. If the Administrative Agent resigns under this Agreement, the Required Lenders shall appoint from among the Lenders a successor agent for the Lenders, which appointment of a
successor agent shall require the consent of Borrower at all times other than during the existence of an Event of Default under Section 8.01(f) or (g) (which consent of Borrower shall not be unreasonably withheld or delayed).
If no successor agent is appointed prior to the Closing Date of the resignation of the Administrative Agent, the Administrative Agent may appoint, after consulting with the Lenders and Borrower, a successor agent from among the Lenders. Upon the
acceptance of its appointment as successor agent hereunder, the Person acting as such successor agent shall succeed to all the rights, powers and duties of the retiring Administrative Agent and the term “Administrative Agent,” shall mean
such successor administrative agent and/or supplemental administrative agent, as the case may be, and the retiring Administrative Agent’s appointment, powers and duties as the Administrative Agent shall be terminated. After the retiring
Administrative Agent’s resignation hereunder as the Administrative Agent, the provisions of this Article IX and Section 10.04 and Section 10.05 shall inure to its benefit as to any actions taken or omitted to
be taken by it while it was the Administrative Agent under this Agreement. If no successor agent has accepted appointment as the Administrative Agent by the date which is thirty (30) days following the retiring Administrative Agent’s
notice of resignation, the retiring Administrative Agent’s resignation shall nevertheless thereupon become effective and the Lenders shall perform all of the duties of the Administrative Agent hereunder until such time, if any, as the Required
Lenders appoint a successor agent as provided for above. Upon the acceptance of any appointment as the Administrative Agent hereunder by a successor and upon the execution and filing or recording of such instruments or notices, as may be necessary
or desirable, or as the Required Lenders may reasonably request, in order to otherwise ensure that the Guarantee Requirement is satisfied, the Administrative Agent shall thereupon succeed to and become vested with all the rights, powers, discretion,
privileges, and duties of the retiring Administrative Agent, and the retiring Administrative Agent shall be discharged from its duties and obligations under the Loan Documents. 

Section 9.11 Administrative Agent May File Proofs of Claim. In case of the pendency of any
receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to any Loan Party, the Administrative Agent (irrespective of whether the principal of any Loan shall then
be due and payable as herein expressed or by declaration or otherwise 

  
 -89-

 
and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise: 

(a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans
and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation,
expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under Section 2.09 and Section 10.04)
allowed in such judicial proceeding; and 
 (b) to collect and receive any monies or other property payable or
deliverable on any such claims and to distribute the same; and 
 (c) any custodian, receiver, assignee, trustee,
liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of
such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Agents and their respective agents and counsel, and any other amounts due to the
Administrative Agent under Section 2.09 and Section 10.04. 
 Nothing contained herein shall be deemed
to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or to authorize the
Administrative Agent to vote in respect of the claim of any Lender in any such proceeding. 

Section 9.12 Guaranty Matters. The Lenders irrevocably agree: 

(a) that any Subsidiary Guarantor shall be automatically released from its obligations under the Guaranty if such Person
ceases to be a Restricted Subsidiary as a result of a transaction or designation permitted hereunder; and 
 (b)
if any Subsidiary Guarantor shall cease to be a Material Subsidiary (as certified in writing by a Responsible Officer), such Subsidiary shall be automatically released from its obligations under any Guaranty. 

Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent’s
authority to release any Guarantor from its obligations under the Guaranty pursuant to this Section 9.12. In each case as specified in this Section 9.12, the Administrative Agent will promptly (and each Lender irrevocably
authorizes the Administrative Agent to), at the Borrower’s expense, execute and deliver to the applicable Loan Party such documents as such Loan Party may reasonably request to evidence the release of such Guarantor from its obligations under
the Guaranty, in each case in accordance with the terms of the Loan Documents and this Section 
9.12. 
 Section 9.13 Other Agents; Arrangers and Managers. None of the Lenders or
other Persons identified on the facing page or signature pages of this Agreement as a “syndication agent” shall have any right, power, obligation, liability, responsibility or duty under this Agreement other than those applicable to all
Lenders as such. Without limiting the foregoing, none of the Lenders or other Persons so identified shall have or be deemed to have any fiduciary relationship with any Lender. Each Lender acknowledges

  
 -90-

 
that it has not relied, and will not rely, on any of the Lenders or other Persons so identified in deciding to enter into this Agreement or in taking or not taking action hereunder. 

Section 9.14 Appointment of Supplemental Administrative Agents. 

(a) It is the purpose of this Agreement and the other Loan Documents that there shall be no violation of any Law of any jurisdiction
denying or restricting the right of banking corporations or associations to transact business as agent or trustee in such jurisdiction. It is recognized that in case of litigation under this Agreement or any of the other Loan Documents, and in
particular in case of the enforcement of any of the Loan Documents, or in case the Administrative Agent deems that by reason of any present or future Law of any jurisdiction it may not exercise any of the rights, powers or remedies granted herein or
in any of the other Loan Documents or take any other action which may be desirable or necessary in connection therewith, the Administrative Agent is hereby authorized to appoint an additional individual or institution selected by the Administrative
Agent in its sole discretion as a separate trustee, co-trustee, administrative agent, collateral agent, administrative sub-agent or administrative co-agent (any such additional individual or institution being referred to herein individually as a
“Supplemental Administrative Agent” and collectively as “Supplemental Administrative Agents”). 
 (b) [Reserved]. 
 (c) Should any instrument in writing from any Loan Party be
required by any Supplemental Administrative Agent so appointed by the Administrative Agent for more fully and certainly vesting in and confirming to him or it such rights, powers, privileges and duties, the Borrower shall, or shall cause such Loan
Party to, execute, acknowledge and deliver any and all such instruments promptly upon request by the Administrative Agent. In case any Supplemental Administrative Agent, or a successor thereto, shall die, become incapable of acting, resign or be
removed, all the rights, powers, privileges and duties of such Supplemental Administrative Agent, to the extent permitted by Law, shall vest in and be exercised by the Administrative Agent until the appointment of a new Supplemental Administrative
Agent. 
 Section 9.15 Withholding Tax. 

(a) To the extent required by any applicable law, the Administrative Agent may withhold from any payment to any Lender an amount equal to
any applicable withholding tax. If any Governmental Authority asserts a claim that the Administrative Agent did not properly withhold tax from any amount paid to or for the account of any Lender for any reason (including because the appropriate form
was not delivered or was not properly executed, or because such Lender failed to notify the Administrative Agent of a change in circumstances that rendered the exemption from, or reduction of, withholding tax ineffective), such Lender shall
indemnify and hold harmless the Administrative Agent (to the extent that the Administrative Agent has not already been reimbursed by the Borrower and without limiting or expanding the obligation of the Borrower to do so) for all amounts paid,
directly or indirectly, by the Administrative Agent as tax or otherwise, including any penalties, additions to tax or interest thereto, together with all expenses incurred, including legal expenses and any out-of-pocket expenses, whether or not such
tax was correctly or legally imposed or asserted by the relevant Government Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error.

 (b) Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such
Lender under this Agreement or any other Loan Document against any amount due to the Administrative Agent under this Section 9.15. The agreements in this Section 9.15 shall survive the resignation and/or replacement of the
Administrative Agent, any assignment of rights by, or the replacement of, a Lender, the termination of the Facility and the repayment, satisfaction or 

  
 -91-

 
discharge of all Obligations. Unless required by applicable Laws, at no time shall the Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender any refund of
Taxes withheld or deducted from funds paid for the account of such Lender. 
 ARTICLE X

 Miscellaneous 
 Section 10.01 Amendments, Etc. Except as otherwise set forth in this Agreement, no amendment or waiver of any provision of this Agreement or any other Loan
Document, and no consent to any departure by the Borrower or any other Loan Party therefrom, shall be effective unless in writing signed by the Required Lenders and the Borrower or the applicable Loan Party, as the case may be, and each such waiver
or consent shall be effective only in the specific instance and for the specific purpose for which given; provided that no such amendment, waiver or consent shall: 

(a) extend or increase the Commitment of any Lender without the written consent of each Lender directly affected thereby
(it being understood that a waiver of any condition precedent set forth in Section 4.02 or the waiver of any Default, mandatory prepayment or mandatory reduction of the Commitments shall not constitute an extension or increase of any
Commitment of any Lender); 
 (b) postpone any date scheduled for, or reduce the amount of, any payment of
principal or interest under Section 2.07 or Section 2.08 without the written consent of each Lender directly affected thereby; 
 (c) reduce the principal of, or the rate of interest specified herein on, any Loan or (subject to clause (iii) of the second proviso to this Section 10.01) any fees or other
amounts payable hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby; provided that only the consent of the Required Lenders shall be necessary to amend the definition of
“Default Rate” or to waive any obligation of the Borrower to pay interest at the Default Rate; 
 (d)
change any provision of this Section 10.01, the definition of “Required Lenders” or “Pro Rata Share” or Section 2.06(c) or Section 8.04 without the written consent of each Lender affected
thereby; 
 (e) [Reserved]; or 

(f) release all or substantially all of the value of the Guarantees in any transaction or series of related transactions,
without the written consent of each Lender; provided that any transaction permitted under Section 7.04 or Section 7.05 shall not be subject to this clause (f) to the extent such transaction does not result
in the release of all or substantially all of the Guarantees; 
 and provided further that (i) no amendment, waiver or consent
shall, unless in writing and signed by the Administrative Agent in addition to the Lenders required above, affect the rights or duties of, or any fees or other amounts payable to, the Administrative Agent under this Agreement or any other Loan
Document and (ii) Section 10.07(h) may not be amended, waived or otherwise modified without the consent of each Granting Lender all or any part of whose Loans are being funded by an SPC at the time of such amendment, waiver or other
modification. Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent 

  
 -92-

 
hereunder, except that the Commitment of such Lender may not be increased or extended without the consent of such Lender (it being understood that any Commitments or Loans held or deemed held by
any Defaulting Lender shall be excluded for a vote of the Lenders hereunder requiring any consent of the Lenders). 

Notwithstanding the foregoing, this Agreement may be amended (or amended and restated) with the written consent of the Required Lenders,
the Administrative Agent and the Borrower (a) to add one or more additional credit facilities to this Agreement and to permit the extensions of credit from time to time outstanding thereunder and the accrued interest and fees in respect thereof
to share ratably in the benefits of this Agreement and the other Loan Documents with the Revolving Credit Loans, and the accrued interest and fees in respect thereof and (b) to include appropriately the Lenders holding such credit facilities in
any determination of the Required Lenders. 
 Notwithstanding anything to the contrary contained in this
Section 10.01, any guarantees, and related documents executed by Subsidiaries in connection with this Agreement may be in a form reasonably determined by the Administrative Agent. 

Section 10.02 Notices and Other Communications; Facsimile Copies. 

(a) General. Unless otherwise expressly provided herein, all notices and other communications provided for hereunder or under any
other Loan Document shall be in writing (including by facsimile transmission). All such written notices shall be mailed, faxed or delivered to the applicable address, facsimile number or electronic mail address, and all notices and other
communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows: 
 (i) if to the Borrower or the Administrative Agent, to the address, facsimile number, electronic mail address or telephone number specified for such Person on Schedule 10.02 or to such other
address, facsimile number, electronic mail address or telephone number as shall be designated by such party in a notice to the other parties (a copy of any notice sent the Borrower shall also be sent to Borrower and the Company); and 

(ii) if to any other Lender, to the address, facsimile number, electronic mail address or telephone number specified in
its Administrative Questionnaire or to such other address, facsimile number, electronic mail address or telephone number as shall be designated by such party in a written notice to the Borrower and the Administrative Agent. 

All such notices and other communications shall be deemed to be given or made upon the earlier to occur of (i) actual receipt by the relevant party
hereto and (ii) (A) if delivered by hand or by courier, when signed for by or on behalf of the relevant party hereto; (B) if delivered by mail, four (4) Business Days after deposit in the mails, postage prepaid; (C) if
delivered by facsimile, when sent and receipt has been confirmed by telephone; and (D) if delivered by electronic mail (which form of delivery is subject to the provisions of Section 10.02(b)), when delivered; provided that
notices and other communications to the Administrative Agent pursuant to Article II shall not be effective until actually received by such Person during the person’s normal business hours. In no event shall a voice mail message be
effective as a notice, communication or confirmation hereunder. 
 (b) Effectiveness of Facsimile Documents and
Signatures. Loan Documents may be transmitted and/or signed by facsimile or other electronic communication. The effectiveness of any such documents and signatures shall, subject to applicable Law, have the same force and effect as manually
signed originals and shall be binding on all Loan Parties, the Agents and the Lenders. 

  
 -93-

 (c) Reliance by Agents and Lenders. The Administrative Agent and the Lenders shall be
entitled to rely and act upon any notices (including telephonic Committed Loan Notices) purportedly given by or on behalf of the Borrower even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded
or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Borrower shall indemnify each Agent-Related Person and each Lender from all losses,
costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower in the absence of gross negligence or willful misconduct. All telephonic notices to the Administrative Agent
may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording. 
 (d) Notice
to Other Loan Parties. The Borrower agrees that notices to be given to any other Loan Party under this Agreement or any other Loan Document may be given to the Borrower in accordance with the provisions of this Section 10.02 with the
same effect as if given to such other Loan Party in accordance with the terms hereunder or thereunder. 
 
Section 10.03 No Waiver; Cumulative Remedies. No failure by any Lender or the Administrative Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder or under any other Loan
Document shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
The rights, remedies, powers and privileges herein provided, and provided under each other Loan Document, are cumulative and not exclusive of any rights, remedies, powers and privileges provided by Law. 

Section 10.04 Attorney Costs and Expenses. The Borrower agree (a) if the Closing Date
occurs, to pay or reimburse the Administrative Agent and the Lead Arranger for all reasonable and documented out-of-pocket costs and expenses incurred in connection with the preparation, syndication, execution, delivery and administration of this
Agreement and the other Loan Documents, and any amendment, waiver, consent or other modification of the provisions hereof and thereof (whether or not the transactions contemplated thereby are consummated), including all Attorney Costs of
Shearman & Sterling LLP and one local and foreign counsel in each relevant jurisdiction (to the extent consented to by the Borrower (such consent not to be unreasonably withheld or delayed)), and (b) to pay or reimburse the
Administrative Agent for all reasonable and documented out-of-pocket costs and expenses incurred in connection with the enforcement of any rights or remedies under this Agreement or the other Loan Documents (including all costs and expenses incurred
in connection with any workout or restructuring in respect of the Loans, all such costs and expenses incurred during any legal proceeding, including any proceeding under any Debtor Relief Law, and including all Attorney Costs of a single lead
counsel to the Administrative Agent and one local counsel in each relevant jurisdiction). The foregoing costs and expenses shall include all reasonable search, filing, recording and title insurance charges and fees related thereto, and other
reasonable and documented out-of-pocket expenses incurred by any Agent. The agreements in this Section 10.04 shall survive the termination of the Aggregate Commitments and repayment of all other Obligations. All amounts due under this
Section 10.04 shall be paid within ten (10) Business Days of receipt by the Borrower of an invoice relating thereto setting forth such expenses in reasonable detail. If any Loan Party fails to pay when due any costs, expenses or
other amounts payable by it hereunder or under any Loan Document, such amount may be paid on behalf of such Loan Party by the Administrative Agent in its sole discretion. 
 Section 10.05 Indemnification by the Borrower. Whether or not the transactions contemplated hereby are consummated, the Borrower shall indemnify and hold
harmless each Agent-Related Person, each Lender and their respective Affiliates, directors, officers, employees, advisors, agents and other representatives of the foregoing (collectively the “Indemnitees”) from and against any and
all losses, 

  
 -94-

 
claims, damages, liabilities and reasonable and documented or invoiced out-of-pocket fees and expenses (including reasonable Attorney Costs of one counsel for all Indemnitees and, if necessary,
one firm of local counsel in each appropriate jurisdiction (which may include a single special counsel acting in multiple jurisdictions) for all Indemnitees (and, in the case of an actual or perceived conflict of interest, where the Indemnitee
affected by such conflict informs the Borrower of such conflict and thereafter retains its own counsel, of another firm of counsel for such affected Indemnitee)) of any such Indemnitee in any way relating to or arising out of or in connection with
(a) the execution, delivery, enforcement, performance or administration of any Loan Document or any other agreement, letter or instrument delivered in connection with the transactions contemplated thereby or the consummation of the transactions
contemplated thereby, (b) any Commitment, Loan or the use or proposed use of the proceeds therefrom, or (c) any actual or alleged presence or release of Hazardous Materials on, at, under or from any property currently or formerly owned or
operated by the Borrower, any Subsidiary or any other Loan Party, or any Environmental Liability related in any way to the Borrower, any Subsidiary or any other Loan Party, or (d) any actual or prospective claim, litigation, investigation or
proceeding relating to any of the foregoing, whether based on contract, tort or any other theory (including any investigation of, preparation for, or defense of any pending or threatened claim, investigation, litigation or proceeding) (all the
foregoing, collectively, the “Indemnified Liabilities”), in all cases, whether or not caused by or arising, in whole or in part, out of the negligence of the Indemnitee; provided that such indemnity shall not, as to any
Indemnitee, be available to the extent that such liabilities, obligations, losses, damages, penalties, claims, demands, actions, judgments, suits, costs, expenses or disbursements resulted from (x) the gross negligence, bad faith or willful
misconduct of such Indemnitee or of any of its affiliates, controlling persons, directors, officers, employees, agents, advisors, or members of any of the foregoing, (y) a material breach of the Loan Documents by such Indemnitee or of any of
its affiliates, controlling persons, directors, officers, employees, agents, advisors, or members of any of the foregoing, or (z) disputes between and among Indemnitees. No Indemnitee shall be liable for any damages arising from the use by
others of any information or other materials obtained through IntraLinks or other similar information transmission systems in connection with this Agreement, nor shall any Indemnitee or any Loan Party have any liability for any special, punitive,
indirect or consequential damages relating to this Agreement or any other Loan Document or arising out of its activities in connection herewith or therewith (whether before or after the Closing Date). In the case of an investigation, litigation or
other proceeding to which the indemnity in this Section 10.05 applies, such indemnity shall be effective whether or not such investigation, litigation or proceeding is brought by any Loan Party, its directors, partners, stockholders or
creditors or an Indemnitee or any other Person, whether or not any Indemnitee is otherwise a party thereto and whether or not any of the transactions contemplated hereunder or under any of the other Loan Documents is consummated. All amounts due
under this Section 10.05 shall be paid within ten (10) Business Days after demand therefor; provided, however, that such Indemnitee shall promptly refund such amount to the extent that there is a final judicial or
arbitral determination that such Indemnitee was not entitled to indemnification or contribution rights with respect to such payment pursuant to the express terms of this Section 10.05. The agreements in this Section 10.05
shall survive the resignation of the Administrative Agent, the replacement of any Lender, the termination of the Aggregate Commitments and the repayment, satisfaction or discharge of all the other Obligations. 

Section 10.06 Payments Set Aside. To the extent that any payment by or on behalf of the
Borrower is made to any Agent or any Lender, or any Agent or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set
aside or required (including pursuant to any settlement entered into by such Agent or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or otherwise,
then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and
(b) each Lender severally agrees to pay to the Administrative Agent upon demand its applicable share of any 

  
 -95-

 
amount so recovered from or repaid by any Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Effective Rate.

 Section 10.07 Successors and Assigns. 

(a) The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors
and assigns permitted hereby, except that, except as otherwise provided herein (including without limitation as permitted under Section 7.04), the Borrower may not assign or otherwise transfer any of its rights or obligations hereunder
without the prior written consent of each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an Eligible Assignee, (ii) by way of participation in accordance with the provisions
of Section 10.07(e), (iii) by way of pledge or assignment of a security interest subject to the restrictions of Section 10.07(g) or (iv) to an SPC in accordance with the provisions of Section 10.07(h)
(and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors
and assigns permitted hereby, Participants to the extent provided in Section 10.07(e) and, to the extent expressly contemplated hereby, the Indemnitees) any legal or equitable right, remedy or claim under or by reason of this Agreement.

 (b)(i) Subject to the conditions set forth in paragraph (b)(ii) below, any Lender may assign to one or more assignees
(“Assignees”) all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment and the Loans with the prior written consent (such consent not to be unreasonably withheld or delayed)
of: 
 (A) the Borrower, provided that no consent of the Borrower shall be required for an assignment to a
Revolving Credit Lender, an Affiliate of a Revolving Credit Lender, an Approved Fund relating thereto; and 
 (B)
the Administrative Agent. 
 (ii) Assignments shall be subject to the following additional conditions: 

(A) except in the case of an assignment to a Lender or an Affiliate of a Lender or an Approved Fund or an assignment of
the entire remaining amount of the assigning Lender’s Commitment or Loans, the amount of the Commitment or Loans of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to
such assignment is delivered to the Administrative Agent) shall be an integral multiple of $2,500,000 unless the Borrower and the Administrative Agent otherwise consent or, if less, all of such Lender’s remaining Loans and Commitments,
provided that (1) no such consent of the Borrower shall be required if an Event of Default under Section 8.01(a) or, with respect to the Borrower only, Section 8.01(f) or (g), has occurred and is continuing
and (2) such amounts shall be aggregated in respect of each Lender and its Affiliates or Approved Funds, if any; 
 (B) the parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption; and 

(C) the Assignee, if it shall not be a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire
and any documentation required by Section 3.01(f). 
 (c) Subject to acceptance and recording thereof by the
Administrative Agent pursuant to Section 10.07(d) and receipt by the Administrative Agent from the parties to each assignment of a 

  
 -96-

 
processing and recordation fee of $3,500 (which may be waived by the Administrative Agent in its sole discretion), from and after the effective date specified in each Assignment and Assumption,
the Eligible Assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder
shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and
obligations under this Agreement, such Lender shall cease to be a party hereto but shall continue to be entitled to the benefits of Section 3.01, 3.04, 3.05, 10.04 and 10.05 with respect to facts and circumstances
occurring prior to the Closing Date of such assignment). Upon request, and the surrender by the assigning Lender of its Note (if any), the Borrower (at its expense) shall execute and deliver a Note to the assignee Lender. Any assignment or transfer
by a Lender of rights or obligations under this Agreement that does not comply with this clause (c) shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance
with Section 10.07(e). For greater certainty, any assignment by a Lender pursuant to this Section 10.07 shall not in any way constitute or be deemed to constitute a novation, discharge, recession, extinguishment or
substitution of the existing Indebtedness and any Indebtedness so assigned shall continue to be the same obligation and not a new obligations. 
 (d) The Administrative Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at the Administrative Agent’s Office a copy of each Assignment and Assumption delivered to it
and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and related interest amounts) of the Loans, owing to, each Lender pursuant to the terms hereof from time to time (the
“Register”). The entries in the Register shall be conclusive, absent manifest error, and the Borrower, the Agents and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a
Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by the Borrower, any Agent and any Lender, at any reasonable time and from time to time upon reasonable prior
notice. 
 (e) Any Lender may at any time, without the consent of, or notice to, the Borrower or the Administrative Agent, sell
participations to any Person (other than a natural person) (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of its Commitment and/or the
Loans; provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and
(iii) the Borrower, the Agents and the other Lenders shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement. Any agreement or instrument pursuant to which a
Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and the other Loan Documents and to approve any amendment, modification or waiver of any provision of this Agreement or the other
Loan Documents; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, waiver or other modification described in Section 10.01(a),
(b), (c), (e) or (f) that directly and adversely affects such Participant. Subject to Section 10.07(f), the Borrower agrees that each Participant shall be entitled to the benefits of
Section 3.01 (subject to the requirements of Section 3.01(e) and Section 3.01(f)), 3.04 and 3.05 (through the applicable Lender) to the same extent as if it were a Lender and had acquired its
interest by assignment pursuant to Section 10.07(b). To the extent permitted by applicable Law, each Participant also shall be entitled to the benefits of Section 10.09 as though it were a Lender; provided that such
Participant agrees to be subject to Section 2.13 as though it were a Lender. 

  
 -97-

 (f) A Participant shall not be entitled to receive any greater payment under
Section 3.01, 3.04 or 3.05 than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the
Borrower’s prior written consent. 
 (g) Any Lender may at any time pledge or assign a security interest in all or any
portion of its rights under this Agreement (including under its Note, if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment
shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto. 
 (h) Notwithstanding anything to the contrary contained herein, any Lender (a “Granting Lender”) may grant to a special purpose funding vehicle identified as such in writing from time to
time by the Granting Lender to the Administrative Agent and the Borrower (an “SPC”) the option to provide all or any part of any Loan that such Granting Lender would otherwise be obligated to make pursuant to this Agreement;
provided that (i) nothing herein shall constitute a commitment by any SPC to fund any Loan and (ii) if an SPC elects not to exercise such option or otherwise fails to make all or any part of such Loan, the Granting Lender shall be
obligated to make such Loan pursuant to the terms hereof. Each party hereto hereby agrees that (i) neither the grant to any SPC nor the exercise by any SPC of such option shall increase the costs or expenses or otherwise increase or change the
obligations of the Borrower under this Agreement (including its obligations under Section 3.01, 3.04 or 3.05), (ii) no SPC shall be liable for any indemnity or similar payment obligation under this Agreement for which
a Lender would be liable and such liability shall remain with the Granting Lender, and (iii) the Granting Lender shall for all purposes, including the approval of any amendment, waiver or other modification of any provision of any Loan
Document, remain the lender of record hereunder. The making of a Loan by an SPC hereunder shall utilize the Commitment of the Granting Lender to the same extent, and as if, such Loan were made by such Granting Lender. Notwithstanding anything to the
contrary contained herein, any SPC may (i) with notice to, but without prior consent of the Borrower and the Administrative Agent, assign all or any portion of its right to receive payment with respect to any Loan to the Granting Lender and
(ii) disclose on a confidential basis any non-public information relating to its funding of Loans to any rating agency, commercial paper dealer or provider of any surety or Guarantee Obligation or credit or liquidity enhancement to such SPC.

 (i) Notwithstanding anything to the contrary contained herein, (1) any Lender may in accordance with applicable Law
create a security interest in all or any portion of the Loans owing to it and the Note, if any, held by it and (2) any Lender that is a Fund may create a security interest in all or any portion of the Loans owing to it and the Note, if any,
held by it to the trustee for holders of obligations owed, or securities issued, by such Fund as security for such obligations or securities; provided that unless and until such trustee actually becomes a Lender in compliance with the other
provisions of this Section 10.07, (i) no such pledge shall release the pledging Lender from any of its obligations under the Loan Documents and (ii) such trustee shall not be entitled to exercise any of the rights of a Lender
under the Loan Documents even though such trustee may have acquired ownership rights with respect to the pledged interest through foreclosure or otherwise. 
 (j) [Reserved]. 
 (k) The Borrower shall cause any Loans assigned to it pursuant
to this Agreement to be cancelled to the extent permitted by applicable law and not giving rise to adverse tax consequences the Borrower or the Subsidiaries. Notwithstanding anything in this Agreement or any other Loan Document to the contrary, the
Borrower shall not have any rights to receive information required to be delivered to the Lenders hereunder (including rights to participate in calls or meetings with other Lenders), other than

  
 -98-

 
the right to receive notices of Borrowings, notices of prepayments and other administrative notices in respect of its Loans or Commitments required to be delivered to Lenders pursuant to
Article II. 
 Section 10.08 Confidentiality. Each of the Agents and the
Lenders agrees to maintain the confidentiality of the Information and to not use or disclose such information, except that Information may be disclosed (a) to its Affiliates and its and its Affiliates’ directors, officers, employees,
trustees, investment advisors and agents, including accountants, legal counsel and other advisors (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to
keep such Information confidential); (b) to the extent requested by any Governmental Authority; (c) to the extent required by applicable Laws or regulations or by any subpoena or similar legal process; (d) to any other party to this
Agreement; (e) subject to an agreement containing provisions substantially the same as those of this Section 10.08 (or as may otherwise be reasonably acceptable to the Borrower), to any pledgee referred to in
Section 10.07(g) or Section 10.07(i), counterparty to a Swap Contract, Eligible Assignee of or Participant in, or any prospective Eligible Assignee of or Participant in, any of its rights or obligations under this Agreement;
(f) with the written consent of the Borrower; (g) to the extent such Information becomes publicly available other than as a result of a breach of this Section 10.08; (h) to any Governmental Authority or examiner regulating
any Lender; (i) to any rating agency when required by it (it being understood that, prior to any such disclosure, such rating agency shall undertake to preserve the confidentiality of any Information relating to the Loan Parties received by it
from such Lender); or (j) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or
thereunder. In addition, the Agents and the Lenders may disclose the existence of this Agreement and information about this Agreement to market data collectors, similar service providers to the lending industry, and service providers to the Agents
and the Lenders in connection with the administration and management of this Agreement, the other Loan Documents, the Commitments, and the Borrowings. For the purposes of this Section 10.08, “Information” means all
information received from any Loan Party or its Affiliates or its Affiliates’ directors, officers, employees, trustees, investment advisors or agents, relating to the Borrower or any of their subsidiaries or their business, other than any such
information that is publicly available to any Agent or any Lender prior to disclosure by any Loan Party other than as a result of a breach of this Section 10.08, including, without limitation, information delivered pursuant to
Section 6.01, 6.02 or 6.03 hereof. 
 Section 10.09 Setoff.
In addition to any rights and remedies of the Lenders provided by Law, upon the occurrence and during the continuance of any Event of Default and upon the consent of the Administrative Agent (not to be unreasonably limited or delayed), each Lender
and its Affiliates is authorized at any time and from time to time, without prior notice to the Borrower or any other Loan Party, any such notice being waived by the Borrower (on its own behalf and on behalf of each Loan Party and its Subsidiaries)
to the fullest extent permitted by applicable Law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held by, and other Indebtedness at any time owing by, such Lender and its Affiliates,
to or for the credit or the account of the respective Loan Parties and their Subsidiaries against any and all Obligations then due and owing to such Lender and its Affiliates hereunder or under any other Loan Document, now or hereafter existing,
irrespective of whether or not such Agent or such Lender or Affiliate shall have made demand under this Agreement or any other Loan Document and although such Obligations may be denominated in a currency different from that of the applicable deposit
or Indebtedness. Each Lender agrees promptly to notify the Borrower and the Administrative Agent after any such set-off and application made by such Lender; provided that the failure to give such notice shall not affect the validity of such
set-off and application. The rights of the Administrative Agent and each Lender under this Section 10.09 are in addition to other rights and remedies (including other rights of setoff) that the Administrative Agent and such Lender may
have. 

  
 -99-

 Section 10.10 Counterparts. This Agreement and
each other Loan Document may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery by telecopier of an executed counterpart of a signature
page to this Agreement and each other Loan Document shall be effective as delivery of an original executed counterpart of this Agreement and such other Loan Document. The Agents may also require that any such documents and signatures delivered by
telecopier be confirmed by a manually signed original thereof; provided that the failure to request or deliver the same shall not limit the effectiveness of any document or signature delivered by telecopier. 

Section 10.11 Integration. This Agreement, together with the other Loan Documents and the Fee
Letter, comprises the complete and integrated agreement of the parties on the subject matter hereof and thereof and supersedes all prior agreements, written or oral, on such subject matter. In the event of any conflict between the provisions of this
Agreement and those of any other Loan Document, the provisions of this Agreement shall control; provided that the inclusion of supplemental rights or remedies in favor of the Agents or the Lenders in any other Loan Document shall not be
deemed a conflict with this Agreement. Each Loan Document was drafted with the joint participation of the respective parties thereto and shall be construed neither against nor in favor of any party, but rather in accordance with the fair meaning
thereof. 
 Section 10.12 Survival of Representations and Warranties. All
representations and warranties made hereunder and in any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof. Such
representations and warranties have been or will be relied upon by each Agent and each Lender, regardless of any investigation made by any Agent or any Lender or on their behalf and notwithstanding that any Agent or any Lender may have had notice or
knowledge of any Default at the time of any Borrowing, and shall continue in full force and effect as long as any Loan or any other Obligation hereunder shall remain unpaid or unsatisfied. 

Section 10.13 Severability. If any provision of this Agreement or the other Loan Documents is
held to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby. The invalidity of a provision in a
particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 
 
Section 10.14 GOVERNING LAW. 
 (a) THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE
LAW OF THE STATE OF NEW YORK. 
 (b) ANY LEGAL ACTION OR PROCEEDING ARISING UNDER ANY LOAN DOCUMENT OR IN ANY WAY CONNECTED WITH
OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO ANY LOAN DOCUMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, MAY BE BROUGHT IN THE COURTS OF THE STATE
OF NEW YORK SITTING IN NEW YORK CITY OR OF THE UNITED STATES FOR THE SOUTHERN DISTRICT OF SUCH STATE, AND BY EXECUTION AND DELIVERY OF THIS AGREEMENT, THE BORROWER, EACH AGENT AND EACH LENDER CONSENTS, FOR ITSELF AND IN RESPECT OF ITS PROPERTY, TO
THE NON-EXCLUSIVE JURISDICTION OF THOSE COURTS. THE BORROWER, EACH AGENT AND EACH LENDER IRREVOCABLY WAIVES ANY OBJECTION, INCLUDING ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON THE GROUNDS OF FORUM NON CONVENIENS, WHICH IT MAY NOW OR HEREAFTER
HAVE TO 

  
 -100-

 
THE BRINGING OF ANY ACTION OR PROCEEDING IN SUCH JURISDICTION IN RESPECT OF ANY LOAN DOCUMENT OR OTHER DOCUMENT RELATED THERETO. 

Section 10.15 WAIVER OF RIGHT TO TRIAL BY JURY. EACH PARTY TO THIS AGREEMENT HEREBY EXPRESSLY
WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER ANY LOAN DOCUMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO ANY LOAN
DOCUMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF
ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 10.15 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO
THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. 
 Section 10.16 Binding Effect. This
Agreement shall become effective when it shall have been executed by the Borrower and the Administrative Agent shall have been notified by each Lender that each such Lender has executed it and thereafter shall be binding upon and inure to the
benefit of the Borrower, each Agent and each Lender and their respective successors and assigns, except that the Borrower shall not have the right to assign its rights hereunder or any interest herein without the prior written consent of the Lenders
except as permitted by Section 7.04. 
 Section 10.17 Judgment Currency.
If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder or any other Loan Document in one currency into another currency, the rate of exchange used shall be that at which in accordance with normal
banking procedures the Administrative Agent could purchase the first currency with such other currency on the Business Day preceding that on which final judgment is given. The obligation of the Borrower in respect of any such sum due from it to the
Administrative Agent or the Lenders hereunder or under the other Loan Documents shall, notwithstanding any judgment in a currency (the “Judgment Currency”) other than that in which such sum is denominated in accordance with the
applicable provisions of this Agreement (the “Agreement Currency”), be discharged only to the extent that on the Business Day following receipt by the Administrative Agent of any sum adjudged to be so due in the Judgment Currency,
the Administrative Agent may in accordance with normal banking procedures purchase the Agreement Currency with the Judgment Currency. If the amount of the Agreement Currency so purchased is less than the sum originally due to the Administrative
Agent from the Borrower in the Agreement Currency, the Borrower agrees, as a separate obligation and notwithstanding any such judgment, to indemnify the Administrative Agent or the Person to whom such obligation was owing against such loss. If the
amount of the Agreement Currency so purchased is greater than the sum originally due to the Administrative Agent in such currency, the Administrative Agent agrees to return the amount of any excess to the Borrower (or to any other Person who may be
entitled thereto under applicable Law). 
 Section 10.18 Lender Action. Each Lender
agrees that it shall not take or institute any actions or proceedings, judicial or otherwise, for any right or remedy against any Loan Party or any other obligor under any of the Loan Documents (including the exercise of any right of setoff, rights
on account of any banker’s lien or similar claim or other rights of self-help), or institute any actions or proceedings, or otherwise commence any remedial procedures, with respect to any property of any such Loan Party, without the prior
written consent of the Administrative Agent. The provision of this Section 10.18 are for the sole benefit of the Lenders and shall not afford any right to, or constitute a defense available to, any Loan Party. 

  
 -101-

 Section 10.19 USA PATRIOT Act. Each Lender hereby
notifies the Borrower that pursuant to the requirements of the USA PATRIOT Act, it is required to obtain, verify and record information that identifies the Borrower, which information includes the name and address of the Borrower and other
information that will allow such Lender to identify the Borrower in accordance with the USA PATRIOT Act. 
 [THE REMAINDER OF
THIS PAGE IS INTENTIONALLY LEFT BLANK.] 

  
 -102-

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first above written. 
  

			
	iGATE CORPORATION, as Borrower
		
	By:	 	 /s/ Sujit Sircar

		 	Name: Sujit Sircar
		 	Title: CFO

  
 S-1

 
			
	 DBS BANK LTD., SINGAPORE,
 as Administrative Agent

		
	By:	 	 /s/ Probal Banerjee

		 	Name: Probal Banerjee
		 	Title: Senior Vice President

  
 S-2

 Administrative Agent’s Office, Certain Addresses for Notice 

  
 Annex-I-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]